Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
28000.0 | 2023-08-30 00:00:00 UTC | Abeona Therapeutics Plans To Proceed With BLA Submission To FDA For EB-101; Stock Up In Pre-market | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-plans-to-proceed-with-bla-submission-to-fda-for-eb-101-stock-up-in-pre | nan | nan | (RTTNews) - Abeona Therapeutics Inc. (ABEO) said Wednesday that it plans to proceed with the submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for EB-101, its investigational autologous, engineered cell therapy, for patients with recessive dystrophic epidermolysis bullosa after the recent completion of a pre-BLA meeting with the FDA.
In Wednesday pre-market trade, ABEO was trading at $4.43 up $0.32 or 7.97%.
At the meeting, Abeona reached alignment with the FDA that the EB-101 clinical efficacy and safety data appear adequate to support a BLA submission.
The Agency also agreed that retroviral vector manufactured at Abeona and Indiana University appear comparable based on the data that Abeona provided in its briefing book.
The FDA requested that Abeona include within its BLA submission additional background and data supporting the scientific rationale underlying its EB-101 potency and identity assays so that they can be fully evaluated by the Agency post-submission.
The Agency also requested that supplemental data pertaining to certain chemistry, manufacturing, and controls and clinical topics be included in the BLA package.
Abeona believes that it has the necessary supporting data in-hand to generate these additional reports, including those regarding potency and identity, to address the Agency's requests.
EB-101 has been granted Regenerative Medicine Advanced Therapy, Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations by the FDA.
For More Such Health News, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abeona Therapeutics Inc. (ABEO) said Wednesday that it plans to proceed with the submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for EB-101, its investigational autologous, engineered cell therapy, for patients with recessive dystrophic epidermolysis bullosa after the recent completion of a pre-BLA meeting with the FDA. The FDA requested that Abeona include within its BLA submission additional background and data supporting the scientific rationale underlying its EB-101 potency and identity assays so that they can be fully evaluated by the Agency post-submission. Abeona believes that it has the necessary supporting data in-hand to generate these additional reports, including those regarding potency and identity, to address the Agency's requests. | In Wednesday pre-market trade, ABEO was trading at $4.43 up $0.32 or 7.97%. The FDA requested that Abeona include within its BLA submission additional background and data supporting the scientific rationale underlying its EB-101 potency and identity assays so that they can be fully evaluated by the Agency post-submission. Abeona believes that it has the necessary supporting data in-hand to generate these additional reports, including those regarding potency and identity, to address the Agency's requests. | (RTTNews) - Abeona Therapeutics Inc. (ABEO) said Wednesday that it plans to proceed with the submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for EB-101, its investigational autologous, engineered cell therapy, for patients with recessive dystrophic epidermolysis bullosa after the recent completion of a pre-BLA meeting with the FDA. At the meeting, Abeona reached alignment with the FDA that the EB-101 clinical efficacy and safety data appear adequate to support a BLA submission. The FDA requested that Abeona include within its BLA submission additional background and data supporting the scientific rationale underlying its EB-101 potency and identity assays so that they can be fully evaluated by the Agency post-submission. | (RTTNews) - Abeona Therapeutics Inc. (ABEO) said Wednesday that it plans to proceed with the submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for EB-101, its investigational autologous, engineered cell therapy, for patients with recessive dystrophic epidermolysis bullosa after the recent completion of a pre-BLA meeting with the FDA. The FDA requested that Abeona include within its BLA submission additional background and data supporting the scientific rationale underlying its EB-101 potency and identity assays so that they can be fully evaluated by the Agency post-submission. In Wednesday pre-market trade, ABEO was trading at $4.43 up $0.32 or 7.97%. |
28001.0 | 2023-07-03 00:00:00 UTC | Health Care Sector Update for 07/03/2023: DERM, HLN, ABEO | ABEO | https://www.nasdaq.com/articles/health-care-sector-update-for-07-03-2023%3A-derm-hln-abeo | nan | nan | Health care stocks were lower on Monday afternoon with the NYSE Health Care Index falling 1.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.8%.
The iShares Biotechnology ETF (IBB) was decreasing 0.2%.
In company news, Journey Medical (DERM) shares jumped 27% after the company said it expects to release topline results from two phase 3 trials evaluating DFD-29 for the treatment of moderate to severe papulopustular rosacea next week.
Haleon (HLN) is looking into divesting some quit-smoking products and is working with an adviser for the identification of potential buyers, Bloomberg reported Monday. Haleon shares were shedding 2%.
Abeona Therapeutics (ABEO) shares jumped 9.2% after the company said it raised $25 million from some existing investors, mainly to fund the start of launch preparations ahead of the Biologics License Application submission for EB-101 and potential approval.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics (ABEO) shares jumped 9.2% after the company said it raised $25 million from some existing investors, mainly to fund the start of launch preparations ahead of the Biologics License Application submission for EB-101 and potential approval. In company news, Journey Medical (DERM) shares jumped 27% after the company said it expects to release topline results from two phase 3 trials evaluating DFD-29 for the treatment of moderate to severe papulopustular rosacea next week. Haleon (HLN) is looking into divesting some quit-smoking products and is working with an adviser for the identification of potential buyers, Bloomberg reported Monday. | Abeona Therapeutics (ABEO) shares jumped 9.2% after the company said it raised $25 million from some existing investors, mainly to fund the start of launch preparations ahead of the Biologics License Application submission for EB-101 and potential approval. Health care stocks were lower on Monday afternoon with the NYSE Health Care Index falling 1.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.8%. In company news, Journey Medical (DERM) shares jumped 27% after the company said it expects to release topline results from two phase 3 trials evaluating DFD-29 for the treatment of moderate to severe papulopustular rosacea next week. | Abeona Therapeutics (ABEO) shares jumped 9.2% after the company said it raised $25 million from some existing investors, mainly to fund the start of launch preparations ahead of the Biologics License Application submission for EB-101 and potential approval. Health care stocks were lower on Monday afternoon with the NYSE Health Care Index falling 1.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.8%. In company news, Journey Medical (DERM) shares jumped 27% after the company said it expects to release topline results from two phase 3 trials evaluating DFD-29 for the treatment of moderate to severe papulopustular rosacea next week. | Abeona Therapeutics (ABEO) shares jumped 9.2% after the company said it raised $25 million from some existing investors, mainly to fund the start of launch preparations ahead of the Biologics License Application submission for EB-101 and potential approval. Health care stocks were lower on Monday afternoon with the NYSE Health Care Index falling 1.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.8%. The iShares Biotechnology ETF (IBB) was decreasing 0.2%. |
28002.0 | 2023-01-05 00:00:00 UTC | Steven Cohen's Point72 Discloses 5.3% Pulmonx Stake As BofA Downgrades The Stock | ABEO | https://www.nasdaq.com/articles/steven-cohens-point72-discloses-5.3-pulmonx-stake-as-bofa-downgrades-the-stock | nan | nan | On Wednesday evening after the closure of US equity markets, a 13G filing with the SEC revealed Steven Cohen's hedge fund Point72 had disclosed a 5.3% stake in lunch disease focused biopharma company Plumonx (US:LUNG). The filing came only one day after BofA’s latest recommendation downgrade on Tuesday which pushed the stock down 11%.
The trade comes after Pulmonx’s stock has shown solid recovery momentum with shares up more than 60% from all-time lows reached in early November following third quarter results. Even with the last two months of momentum, the stock continues to trade 75% below its share price from the start of 2022. Pulmonx, along with the rest of the small/mid-cap biotech sector has re-rated lower over 2022 as discount rates pushed down valuations for the sector.
In the latest filing, Point72 disclosed the ownership of 1,971,810 shares which makes the fund the 6th largest institutional holder on the register. The purchase has contributed to the above average Fintel fund sentiment score of 69.24 which ranks the LUNG in the top 20% when screened against 36,181 other global securities.
Pulmonx has a total of 264 institutions on the register that collectively own 42.7 million LUNG shares. Some of the other largest shareholders on the register include: Primecap Management Co, Deerfield Management, Champlain Investment Partners, Morgan Stanley, TimesSquare Capital Management, and Jefferies Group LLC
On Tuesday morning, Bank of America’s equity research arm BofA downgraded the stock to an ‘underperform’ recommendation from ‘neutral’ as the stock had rallied above the firm's $8 price target. The BofA analysts noted to clients that they had been cautious about how long it would take for Pulmonx’s management to develop market and growth expectations.
The firm highlighted that the valuation for the stock is consistent with small cap medtech peers growing at similar rates and decoded to waiting on the sidelines watching for signs of market acceleration again in a non-Covid environment. This institution and many other sell-side firms lowered forward forecasts for Pulmonx when the company provided updated guidance during the third quarter results.
The new FY22 guidance included a downgrade in product revenue guidance from $55 to $60 million to a new range of $51.5 to $52.5 million. At the same time, Pulmonx upgraded operating expense guidance from $98 to $100 million upwards to $100 to $105 million.
Fintel’s sell-side analysis page for LUNG also highlighted that Citigroup upgraded the stock from ‘neutral’ to ‘buy’ during December whilst decreasing its target price from $14 to $10.
Fintel’s consensus price target of $11.95 for LUNG suggests the stock could experience a further 44.83% capital upside from current levels.
This latest trade is only one of many during the quarter for the hedge fund. Point72 Asset Management currently has a total of 1,369 total holdings as per the latest SEC filings.
Some of the other new positions added during the quarter during November included a 7.1% stake in Marinus Pharmaceuticals Inc (US:MRNS), a 9.99% stake in Abeona Therapeutics Inc (US:ABEO), a 5.1% stake in Health Catalyst Inc (US:HCAT) and a 4.9% stake in Gritstone Oncology (US:GRTS).
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some of the other new positions added during the quarter during November included a 7.1% stake in Marinus Pharmaceuticals Inc (US:MRNS), a 9.99% stake in Abeona Therapeutics Inc (US:ABEO), a 5.1% stake in Health Catalyst Inc (US:HCAT) and a 4.9% stake in Gritstone Oncology (US:GRTS). On Wednesday evening after the closure of US equity markets, a 13G filing with the SEC revealed Steven Cohen's hedge fund Point72 had disclosed a 5.3% stake in lunch disease focused biopharma company Plumonx (US:LUNG). The firm highlighted that the valuation for the stock is consistent with small cap medtech peers growing at similar rates and decoded to waiting on the sidelines watching for signs of market acceleration again in a non-Covid environment. | Some of the other new positions added during the quarter during November included a 7.1% stake in Marinus Pharmaceuticals Inc (US:MRNS), a 9.99% stake in Abeona Therapeutics Inc (US:ABEO), a 5.1% stake in Health Catalyst Inc (US:HCAT) and a 4.9% stake in Gritstone Oncology (US:GRTS). On Wednesday evening after the closure of US equity markets, a 13G filing with the SEC revealed Steven Cohen's hedge fund Point72 had disclosed a 5.3% stake in lunch disease focused biopharma company Plumonx (US:LUNG). The filing came only one day after BofA’s latest recommendation downgrade on Tuesday which pushed the stock down 11%. | Some of the other new positions added during the quarter during November included a 7.1% stake in Marinus Pharmaceuticals Inc (US:MRNS), a 9.99% stake in Abeona Therapeutics Inc (US:ABEO), a 5.1% stake in Health Catalyst Inc (US:HCAT) and a 4.9% stake in Gritstone Oncology (US:GRTS). On Wednesday evening after the closure of US equity markets, a 13G filing with the SEC revealed Steven Cohen's hedge fund Point72 had disclosed a 5.3% stake in lunch disease focused biopharma company Plumonx (US:LUNG). Some of the other largest shareholders on the register include: Primecap Management Co, Deerfield Management, Champlain Investment Partners, Morgan Stanley, TimesSquare Capital Management, and Jefferies Group LLC On Tuesday morning, Bank of America’s equity research arm BofA downgraded the stock to an ‘underperform’ recommendation from ‘neutral’ as the stock had rallied above the firm's $8 price target. | Some of the other new positions added during the quarter during November included a 7.1% stake in Marinus Pharmaceuticals Inc (US:MRNS), a 9.99% stake in Abeona Therapeutics Inc (US:ABEO), a 5.1% stake in Health Catalyst Inc (US:HCAT) and a 4.9% stake in Gritstone Oncology (US:GRTS). Pulmonx has a total of 264 institutions on the register that collectively own 42.7 million LUNG shares. Some of the other largest shareholders on the register include: Primecap Management Co, Deerfield Management, Champlain Investment Partners, Morgan Stanley, TimesSquare Capital Management, and Jefferies Group LLC On Tuesday morning, Bank of America’s equity research arm BofA downgraded the stock to an ‘underperform’ recommendation from ‘neutral’ as the stock had rallied above the firm's $8 price target. |
28003.0 | 2022-11-29 00:00:00 UTC | Philips (PHG) Showcases New AI-Based Solutions at the RSNA | ABEO | https://www.nasdaq.com/articles/philips-phg-showcases-new-ai-based-solutions-at-the-rsna | nan | nan | Koninklijke Philips PHG recently released its latest portfolio of smart diagnostic systems and transformative workflow solutions powered by AI at the Radiological Society of North America’s (RSNA) annual meeting in 2022.
Radiology plays an important role in guiding patients to the right treatment procedure. However, with massive increasing staff shortages and workloads, radiologists are finding it extremely difficult to manage and interpret the huge volume of data captured to provide quality care for each patient.
In a recent survey commissioned by Philips, 24% of radiology specialists stated that managing the sheer volume of data is the biggest issue faced by them in the healthcare industry, while nearly 65% stated that the staff is unable to handle the data overload efficiently.
In order to deal with these issues Philips has launched new solutions such as the Philips Imaging Orchestrator – ROCC (Radiology Operations Command Center) and Philips Ultrasound Collaboration Live. These solutions will help to virtualize radiology, and help in solving the staff shortage issue.
Philips is also launching other solutions such as the Philips Advanced Visualization Workspace to automate reporting procedures.
Koninklijke Philips N.V. Price and Consensus
Koninklijke Philips N.V. price-consensus-chart | Koninklijke Philips N.V. Quote
Philips Investing Heavily in AI Solutions to Boost Prospects
Philips has been unable to meet the rising demand for its various products such as image guided therapy, ultrasound and hospital patient Monitoring system products and connected care business solutions with proper supply due to the severe global shortage of chips, which has disrupted the manufacturing of life-saving medical devices and the supply chain system.
The chip shortage is happening at a time when black swan events such as the Covid-19 pandemic is still prevalent, while wars between nations like Russia and Ukraine are posing a severe threat to people’s lives.
Headwinds caused primarily due to global supply chain challenges, COVID lockdowns in China the Russia-Ukraine war impacted Philips’ top-line growth negatively in the third quarter of 2022, which grew in the low single digits. Additionally, adjusted EBITDA was hurt by lower sales volume as the rising inflation reduced demand for its products in high-margin businesses like patient monitoring, ultrasound and image-guided therapy systems, even though there is a positive review in the market regarding Philips’ new solutions.
Due to the current macro-economic scenario, growth prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Aclaris Therapeutics ACRS, Abeona Therapeutics ABEO and Agenus AGEN.
Philips currently has a Zacks Rank # 4 (Sell). Shares of PHG have plunged 60.9% in the year-to-date period compared with the Zacks Medical-Products industry and the Medical sector’s decline of 44.8% and 18.6%, respectively.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
ACER’s shares have fallen 48.7% in the year-to-date period compared with the Zacks Medical - Drugs industry’s decline of 30.3%.
Abeona’s stock has tanked 54.2% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 19.6%.
Agenus’ shares have slumped 16.7% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 19.5%.
However, the pandemic exposed various issues in healthcare and highlighted how new trending technologies like AI and virtual care solutions are required to support patients in these trying times effectively.
Effective crisis management has given rise to healthcare companies like Philips integrating the benefits of the cloud and software as a service (SaaS) in the healthcare industry.
The development of Philips’ latest AI-based products will aid in providing diagnosis faster and through virtual sessions to patients who have no access to hospitals.
The development of its AI-based solutions separates the company’s services from its peers and is likely to aid the company in winning market share, as the healthcare industry bounces back in the long run.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report
Agenus Inc. (AGEN) : Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO) : Free Stock Analysis Report
Aclaris Therapeutics, Inc. (ACRS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Due to the current macro-economic scenario, growth prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Aclaris Therapeutics ACRS, Abeona Therapeutics ABEO and Agenus AGEN. Abeona’s stock has tanked 54.2% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 19.6%. Click to get this free report Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report Agenus Inc. (AGEN) : Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO) : Free Stock Analysis Report Aclaris Therapeutics, Inc. (ACRS) : Free Stock Analysis Report To read this article on Zacks.com click here. | Due to the current macro-economic scenario, growth prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Aclaris Therapeutics ACRS, Abeona Therapeutics ABEO and Agenus AGEN. Click to get this free report Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report Agenus Inc. (AGEN) : Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO) : Free Stock Analysis Report Aclaris Therapeutics, Inc. (ACRS) : Free Stock Analysis Report To read this article on Zacks.com click here. Abeona’s stock has tanked 54.2% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 19.6%. | Click to get this free report Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report Agenus Inc. (AGEN) : Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO) : Free Stock Analysis Report Aclaris Therapeutics, Inc. (ACRS) : Free Stock Analysis Report To read this article on Zacks.com click here. Due to the current macro-economic scenario, growth prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Aclaris Therapeutics ACRS, Abeona Therapeutics ABEO and Agenus AGEN. Abeona’s stock has tanked 54.2% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 19.6%. | Due to the current macro-economic scenario, growth prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Aclaris Therapeutics ACRS, Abeona Therapeutics ABEO and Agenus AGEN. Abeona’s stock has tanked 54.2% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 19.6%. Click to get this free report Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report Agenus Inc. (AGEN) : Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO) : Free Stock Analysis Report Aclaris Therapeutics, Inc. (ACRS) : Free Stock Analysis Report To read this article on Zacks.com click here. |
28004.0 | 2022-11-04 00:00:00 UTC | Orin Hirschman Takes Large Position in ABEO / Abeona Therapeutics | ABEO | https://www.nasdaq.com/articles/orin-hirschman-takes-large-position-in-abeo-abeona-therapeutics | nan | nan | Orin Hirschman has filed a 13G form with the SEC disclosing ownership of 791,818 shares of Abeona Therapeutics (ABEO). This represents 6.1% of the company.
The company recently released topline results for a key study, reporting:
The pivotal Phase 3 VIITAL study evaluated the efficacy, safety and tolerability of EB-101 in 43 large chronic wound pairs in 11 subjects with RDEB. The large chronic wounds randomized and treated in VIITAL measured greater than 20 cm2 of surface area and had remained open for a minimum of six months and a maximum of 21 years (mean 6.2 years). The co-primary endpoints of the study were: 1) the proportion of RDEB wound sites with greater than or equal to 50% healing from baseline, comparing randomized treated with matched untreated (control) wound sites at the six-month timepoint, as determined by direct investigator assessment; and 2) pain reduction associated with wound dressing change assessed by the mean differences in scores of the Wong-Baker FACES scale between randomized treated and matched untreated (control) wounds at the six-month timepoint.
What are other large shareholders doing?
Adage Capital Partners Gp, L.l.c. holds 8,007,272 shares representing 134.57% ownership of the company. No change in the last quarter.
Renaissance Technologies Llc holds 2,398,166 shares representing 40.30% ownership of the company. In it's prior filing, the firm reported owning 2,325,816 shares, representing an increase of 3.02%. The firm decreased its portfolio allocation in ABEO by 31.32% over the last quarter.
Vanguard Group Inc holds 2,270,677 shares representing 38.16% ownership of the company. In it's prior filing, the firm reported owning 2,231,277 shares, representing an increase of 1.74%. The firm decreased its portfolio allocation in ABEO by 20.21% over the last quarter.
Knoll Capital Management, LLC holds 2,215,740 shares representing 37.24% ownership of the company. No change in the last quarter.
BlackRock Inc. holds 1,394,102 shares representing 23.43% ownership of the company. In it's prior filing, the firm reported owning 1,694,624 shares, representing a decrease of 21.56%. The firm decreased its portfolio allocation in ABEO by 35.11% over the last quarter.
What is the overall institutional sentiment?
There are 55 funds or institutions reporting positions in Abeona Therapeutics Inc. This is a decrease of 27 owner(s) or 32.93%.
Average portfolio weight of all funds dedicated to Abeona Therapeutics Inc is 0.0055%, a decrease of 56.2150%. Total shares owned by institutions decreased in the last three months by 33.29% to 21,846,763 shares.
Based on this information, institutional sentiment is bearish.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Orin Hirschman has filed a 13G form with the SEC disclosing ownership of 791,818 shares of Abeona Therapeutics (ABEO). The firm decreased its portfolio allocation in ABEO by 31.32% over the last quarter. The firm decreased its portfolio allocation in ABEO by 20.21% over the last quarter. | Orin Hirschman has filed a 13G form with the SEC disclosing ownership of 791,818 shares of Abeona Therapeutics (ABEO). The firm decreased its portfolio allocation in ABEO by 31.32% over the last quarter. The firm decreased its portfolio allocation in ABEO by 20.21% over the last quarter. | Orin Hirschman has filed a 13G form with the SEC disclosing ownership of 791,818 shares of Abeona Therapeutics (ABEO). The firm decreased its portfolio allocation in ABEO by 31.32% over the last quarter. The firm decreased its portfolio allocation in ABEO by 20.21% over the last quarter. | The firm decreased its portfolio allocation in ABEO by 31.32% over the last quarter. The firm decreased its portfolio allocation in ABEO by 20.21% over the last quarter. Orin Hirschman has filed a 13G form with the SEC disclosing ownership of 791,818 shares of Abeona Therapeutics (ABEO). |
28005.0 | 2022-09-19 00:00:00 UTC | Philips (PHG) to Showcase New Innovations & Cardiac Solutions | ABEO | https://www.nasdaq.com/articles/philips-phg-to-showcase-new-innovations-cardiac-solutions | nan | nan | Koninklijke Philips PHG recently announced that it will showcase latest innovations and cardiology solutions designed to deliver cardiac care for patients at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting.
Some of the latest innovations to be showcased by the company at TCT 2022 are Philips 3D Intracardiac Echocardiography Catheter and Philips live fluoroscopy-echo fusion imaging solution and Philips Laser System – Nexcimer.
Philips 3D Intracardiac is designed to offer 2D and 3D live-image guidance for a wide range of procedures in structural heart disease and electrophysiology. The Philips live fluoroscopy-echo fusion imaging solution provides live fusion imaging plus new anatomical modeling and transeptal guidance during minimally-invasive structural heart disease procedures.
Philips is building its imaging solutions to deliver better cardiac solutions to further benefit from its tried-and-tested strategic operational decision to build new products to attract more customers. PHG is consistently benefiting from strong demand for Image-Guided Therapy, Diagnostic Imaging, Ultrasound and Hospital Patient Monitoring system products as it is innovating an array of products in these verticals.
Koninklijke Philips N.V. Price and Consensus
Koninklijke Philips N.V. price-consensus-chart | Koninklijke Philips N.V. Quote
Philips Designing Products to Drive Top Line
Philips’ top-line growth in the second quarter of 2022 was negatively impacted by global supply shortages and lockdowns in China due to the resurgence of the COVID-19 pandemic in Shanghai and adjoined areas. Due to the lockdowns, production in various factories in China was halted, severely affecting the supply capabilities of Philips.
Additionally, adjusted EBITDA was hurt by lower sales volume as the rising inflation reduced demand for its products in high-margin businesses like patient monitoring, ultrasound and image-guided therapy systems, even though there is positive review in the market regarding Philips’ new solutions.
Philips also trimmed its guidance for the third quarter of 2022 as management expects these macroeconomic challenges — affecting the business operations — to persist. PHG expects 2022 comparable sales growth between 1% and 3% (down from previous guidance of 3% to 5%). Adjusted EBITA margin is expected to be 10%, driven by 6-9% comparable sales growth in the second half of 2022.
Due to the current macroeconomic scenario, prospects are sluggish in the healthcare market worldwide. This is evident from the depreciating share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and Agenus AGEN.
Philips currently has a Zacks Rank # 4 (Sell). Shares of PHG have plunged 61.5% in the year-to-date period compared with the Zacks Medical-Products industry and the Medical sector’s decline of 48.2% and 23.9%, respectively. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
ACER’s shares have fallen 43.3% in the year-to-date period compared with the Zacks Medical - Drugs industry’s decline of 29.8%.
Abeona’ stock has tanked 86.8% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%.
Agenus’s shares have slumped 59.3% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 38.8%.
However, Philips is stepping up its pricing structure to benefit against competitors, and manufacturing products that have high market demand and creating supply chain resilience. Philips recently expanded its global network of partners in developing the Philips Spectral Angio CT suite. PHG has partnered with the Leiden University Medical Center in the Netherlands, which will help it realize its goal to build the world’s first spectral detector angio CT solution. Philips is also developing AI-based products, which will aid in providing diagnosis faster. The development of its AI-based solutions and expansion of cardiac solutions will boost Philips’ top-line growth in the long run.
FREE Report: The Metaverse is Exploding! Don’t You Want to Cash In?
Rising gas prices. The war in Ukraine. America's recession. Inflation. It's no wonder why the metaverse is so popular and growing every day. Becoming Spider Man and fighting Darth Vader is infinitely more appealing than spending over $5 per gallon at the pump. And that appeal is why the metaverse can provide such massive gains for investors. But do you know where to look? Do you know which metaverse stocks to buy and which to avoid? In a new FREE report from Zacks' leading stock specialist, we reveal how you could profit from the internet’s next evolution. Even though the popularity of the metaverse is spreading like wildfire, investors like you can still get in on the ground floor and cash in. Don't miss your chance to get your piece of this innovative $30 trillion opportunity - FREE.
>>Yes, I want to know the top metaverse stocks for 2022>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Koninklijke Philips N.V. (PHG): Free Stock Analysis Report
Agenus Inc. (AGEN): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Acer Therapeutics Inc. (ACER): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This is evident from the depreciating share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and Agenus AGEN. Abeona’ stock has tanked 86.8% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | This is evident from the depreciating share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and Agenus AGEN. Abeona’ stock has tanked 86.8% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | This is evident from the depreciating share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and Agenus AGEN. Abeona’ stock has tanked 86.8% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | This is evident from the depreciating share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and Agenus AGEN. Abeona’ stock has tanked 86.8% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report |
28006.0 | 2022-09-09 00:00:00 UTC | Philips (PHG) Expands Partnership to Build Angio CT Solution | ABEO | https://www.nasdaq.com/articles/philips-phg-expands-partnership-to-build-angio-ct-solution | nan | nan | Koninklijke Philips PHG recently announced the expansion of its global network of partners in developing the Philips Spectral Angio CT suite and its use in clinical research. PHG’s partnership with the Leiden University Medical Center in the Netherlands is one of its most recent deals, which will help it realize its goal to build the world’s first spectral detector angio CT solution.
To build the technology, Philips will combine its Spectral CT 7500 system and its Image-Guided Therapy System – Azurion with FlexArm into a single solution. This will help interventionalists with an immediate access to two key imaging modalities to simultaneously perform procedures requiring both CT and angio guidance.
Leiden University Medical Center will help perform the clinical research to show how Philips’ spectral detector angio CT solution could potentially offer new treatment opportunities to the patient.
Philips is building the latest Angio CT solution to further benefit from its tried-and-tested strategic operational decision to build new products to attract more customers. PHG is consistently benefiting from strong demand for Image-Guided Therapy, Diagnostic Imaging, Ultrasound and Hospital Patient Monitoring system products as it is innovating an array of products in these verticals.
Koninklijke Philips N.V. Price and Consensus
Koninklijke Philips N.V. price-consensus-chart | Koninklijke Philips N.V. Quote
Philips Develops New Products to Fight Market Slump
Philips’ top-line growth in the second quarter of 2022 was negatively impacted by global supply shortages and lockdowns in China due to the resurgence of the COVID-19 pandemic in Shanghai and adjoined areas. Due to the lockdowns, production in various factories in China was halted, severely affecting the supply capabilities of Philips.
Additionally, adjusted EBITDA was hurt by lower sales volume as the rising inflation reduced demand for its products in high-margin businesses like patient monitoring, ultrasound and image-guided therapy systems, even though there is a positive review in the market regarding Philips’ new solutions.
Due to the current macroeconomic scenario, prospects are sluggish in the healthcare market worldwide. This is evident from the depreciating share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and the General Electric GE subsidiary GE Healthcare.
Philips’ potential looks tepid in the near term. The stock currently has a Zacks Rank # 4 (Sell). Shares of PHG have plunged 53.9% in the year-to-date period compared with the Zacks Medical-Products industry and the Medical sector’s decline of 43.8% and 21.7%, respectively. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
ACER’s shares have fallen 39% in the year-to-date period compared with the Zacks Medical - Drugs industry’s decline of 24.4%.
Abeona’ stock has tanked 55.7% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%.
General Electric’s shares have slumped 23.6% in the year-to-date period compared with the Zacks Diversified Operations industry’s decline of 19.4%.
Philips also trimmed its guidance for the third quarter of 2022 as management expects these macroeconomic challenges — affecting the business operations — to persist. PHG expects 2022 comparable sales growth between 1% and 3% (down from previous guidance between 3% and 5%). Adjusted EBITA margin is expected to be 10%, driven by 6-9% comparable sales growth in the second half of 2022.
However, the Russia-Ukraine war and the pandemic exposed various issues in healthcare, highlighting how new, trending technologies like AI and virtual care solutions are required to support patients in these trying times, effectively.
To align with the changing market demands, Philips is developing AI-based products, which will aid in providing diagnosis faster. Also, with its expansion of clinical network, PHG is helping provide better care to patients in critical departments like interventional oncology.
The development of its AI-based solutions and expansion of clinical networks will aid in Philips top line growth in the long run.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
General Electric Company (GE): Free Stock Analysis Report
Koninklijke Philips N.V. (PHG): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Acer Therapeutics Inc. (ACER): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This is evident from the depreciating share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and the General Electric GE subsidiary GE Healthcare. Abeona’ stock has tanked 55.7% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | This is evident from the depreciating share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and the General Electric GE subsidiary GE Healthcare. Abeona’ stock has tanked 55.7% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | This is evident from the depreciating share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and the General Electric GE subsidiary GE Healthcare. Abeona’ stock has tanked 55.7% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | This is evident from the depreciating share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and the General Electric GE subsidiary GE Healthcare. Abeona’ stock has tanked 55.7% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report |
28007.0 | 2022-09-07 00:00:00 UTC | Philips (PHG) Alerts Users of Health Hazards of Therapy Masks | ABEO | https://www.nasdaq.com/articles/philips-phg-alerts-users-of-health-hazards-of-therapy-masks | nan | nan | Koninklijke Philips’ PHG subsidiary Philips Respironics recently issued a warning for users of CPAP or Bi-Level PAP therapy masks with magnetic headgear that the devices should not be used near other patients, household members, caregivers and bed partners who have metallic implanted devices or metallic objects (such as metallic splinters) in the body.
The metallic implanted devices, which might be affected by the headgear’s magnetic field are pacemakers, implantable cardioverter defibrillators (ICD), neurostimulators, embolic coils, ocular implants, aneurysm clips, etc.
To date, PHG has distributed more than 17 million masks containing magnetic clips and as of Aug 30, 2022, Philips Respironics received 14 patient reports with complaints that the mask magnets impacted their medical devices, causing disturbances, such as pacemaker interference, failure, seizures, irregular blood pressure, change in heartbeat and cognitive issues.
The complaints raised even though are very few. However, the issues raised are quite serious and after the Philips Respironics recall of its’ certain bi-level positive airway pressure machines as the U.S. Food and Drug Administration stated the health hazards of using it, the newly arised situation is a headwind.
Philip’s top-line growth is facing major headwinds due to decreasing demand for its products. Further, the recent news is expected to make investors wary of the stock.
Koninklijke Philips N.V. Price and Consensus
Koninklijke Philips N.V. price-consensus-chart | Koninklijke Philips N.V. Quote
Global Macroeconomic Challenges: Major Bane for Price Growth
Philips top-line growth in the second quarter of 2022 was negatively impacted by global supply shortages and lockdowns in China due to the resurgence of the COVID-19 pandemic in Shanghai and adjoined areas. Additionally, adjusted EBITDA was negatively impacted by lower sales volumes as rising inflation reduced demand for its products in high-margin businesses like patient monitoring, ultrasound and image-guided therapy systems.
Demand for Connected Care declined 13% in the last reported quarter, induced primarily by a substantial decrease in sleep and respiratory care product sales. News of certain health hazards caused by therapy masks are further going to make buyers pessimistic of the product.
Due to the current macro-economic scenario, prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and the General Electric GE subsidiary GE Healthcare.
Philips’ prospects look tepid in the near-term. The stock currently has a Zacks Rank # 4 (Sell). Shares of PHG have fallen 53.9% in the year-to-date period compared with the Zacks Medical-Products industry and the Medical sector’s decline of 43.8% and 21.7%, respectively. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Meanwhile, ACER shares have fallen 39% in the year-to-date period compared with the Zacks Medical - Drugs industry’s decline of 24.4%.
Abeona’ stock has plunged 55.7% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%.
General Electric’s shares have slumped 23.6% in the year-to-date period compared with the Zacks Diversified Operations industry’s decline of 19.4%.
However, the Russia-Ukraine war and the pandemic exposed various issues in healthcare and highlighted how new, trending technologies like AI and virtual care solutions are required to support patients in these trying times effectively.
To align with the changing market demands, Philips is developing AI-based products, which will aid in providing diagnosis faster.
The development of its AI-based solutions separates PHG’s services from its peers and is likely to aid it in winning market share as the healthcare industry bounces back in the long run.
Want to Know the #1 Semiconductor Stock for 2022?
Few people know how promising the semiconductor market is. Over the last couple of years, disruptions to the supply chain have caused shortages in several industries. The absence of one single semiconductor can stop all operations in certain industries.
This year, companies that create and produce this essential material will have incredible pricing power. For a limited time, Zacks is revealing the top semiconductor stock for 2022. You'll find it in our new Special Report, One Semiconductor Stock Stands to Gain the Most.
Today, it's yours free with no obligation.
>>Give me access to my free special report.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
General Electric Company (GE): Free Stock Analysis Report
Koninklijke Philips N.V. (PHG): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Acer Therapeutics Inc. (ACER): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Due to the current macro-economic scenario, prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and the General Electric GE subsidiary GE Healthcare. Abeona’ stock has plunged 55.7% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | Due to the current macro-economic scenario, prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and the General Electric GE subsidiary GE Healthcare. Abeona’ stock has plunged 55.7% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | Due to the current macro-economic scenario, prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and the General Electric GE subsidiary GE Healthcare. Abeona’ stock has plunged 55.7% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | Due to the current macro-economic scenario, prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Acer Therapeutics ACER, Abeona Therapeutics ABEO and the General Electric GE subsidiary GE Healthcare. Abeona’ stock has plunged 55.7% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report |
28008.0 | 2022-07-29 00:00:00 UTC | Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up | ABEO | https://www.nasdaq.com/articles/ultragenyxs-rare-q2-earnings-miss-estimates-revenues-up | nan | nan | Ultragenyx Pharmaceutical Inc. RARE incurred a loss of $2.26 per share in second-quarter 2022, wider than the Zacks Consensus Estimate of a loss of $1.72. The company reported a loss of $1.45 per share in the year-ago quarter.
Ultragenyx’s total revenues of $89.34 million in the second quarter, up 2.7% year over year. The top line surpassed the Zacks Consensus Estimate of $89 million.
Shares of Ultragenyx have lost 38.3% in the year so far compared with the industry's decline of 18.1%.
Image Source: Zacks Investment Research
Ultragenyx markets three drugs, namely Crysvita, Mepsevii and Dojolvi. Crysvita is approved for treating X-linked hypophosphatemia, an inherited disorder; and tumor-induced osteomalacia, an ultra-rare disease. Mepsevii is approved to treat Mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome. Dojolvi was approved in June 2020 for all forms of long-chain fatty acid oxidation disorders (LC-FAOD).
Quarter in Detail
Crysvita’s total revenues were $69.4 million, up 40.1% year over year, driven by increased demand for approved indications. Crysvita revenues in Ultragenyx territories rose 43.3% to $64 million in the second quarter and included $51.6 million from the North America profit share territory and $12.4 million of net product sales for the drug in other regions. Total royalty revenues related to the sales of Crysvita in the European region were $5.4 million. Ultragenyx sold its Crysvita rights in the European territory to Royalty Pharma in December 2019.
Mepsevii product revenues were $4.9 million in the second quarter compared with $5.4 million reported in the year-ago quarter. Dojolvi product revenues were $13.5 million compared with $10 million in the year-ago quarter, driven by strong new patient demand.
Operating expenses increased 36% to $230.9 million in the second quarter due to pipeline advancements.
2022 Guidance
Ultragenyx reaffirmed the guidance it had provided earlier this year. The company expectsCrysvita revenues in the range of $250-$260 million in Ultragenyx territories. Dojolvi revenues are expected to be $55-$65 million
Pipeline Updates
In May, Ultragenyx announced positive long-term safety and efficacy data from the phase I/II studies of its candidates DTC401 and DTC301 for the potential treatment of Glycogen Storage Disease Type Ia (GSDIa) and the potential treatment of Ornithine Transcarbamylase (OTC) deficiency, respectively. Results to date exhibited ongoing durability of both safety and response for both the gene therapy programs.
In April, Ultragenyx dosed the first patient in a pivotal phase II/III study evaluating its fully human monoclonal antibody, setrusumab (UX143), for the treatment of osteogenesis imperfecta (“OI”) in patients aged between five to less than 26 years.
In the second half of 2022, the company expects to provide a dosing update on the phase II portion of the Orbit study and transition to phase III.
Other Updates
Ultragenyx recently sold 30% of the royalty interests it receives from partner Kyowa Kirin on future sales of its rare disease drug, Crysvita, in the United States and Canada. In return, RARE will receive $500 million without diluting capital. This money will be used by Ultragenyx to fund its ongoing clinical studies as well as planned commercial activities.
In May, Ultragenyx entered into an exclusive license agreement with New York-based biopharmaceutical company, Abeona Therapeutics Inc. ABEO, wherein it will acquire global rights of the latter’s gene therapy candidate ABO-102 (now UX111). The AAV gene therapy candidate, UX111, is currently being evaluated in the open-label, global phase I/II Transpher A study for the treatment of patients with Sanfilippo syndrome type A (MPS IIIA), a rare, fatal lysosomal storage disease.
Ultragenyx is evaluating UX701, an AAV type-9 gene therapy product candidate, in a seamless phase I/II/III study for the treatment of Wilson disease — a larger rare metabolic disease.
Ultragenyx Pharmaceutical Inc. Price, Consensus and EPS Surprise
Ultragenyx Pharmaceutical Inc. price-consensus-eps-surprise-chart | Ultragenyx Pharmaceutical Inc. Quote
Zacks Rank & Stocks to Consider
Ultragenyx currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector is BioNTech BNTX and Scholar Rock SRRK, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BioNTech’s earnings estimates for 2022 have declined from $34.82 to $33.51 in the past 30 days. Shares of BioNTech have declined 35.4% year to date. Earnings of BNTX beat earnings estimates in all the last four quarters, witnessing a surprise of 56.87%, on average.
Scholar Rock’s loss estimates for 2022 have narrowed from $2.59 to $2.48 in the past 30 days. Shares of SRRK have declined 70.1% year to date. Earnings of BNTX beat earnings estimates in two of the trailing four quarters and missed the same in the remaining two occasions, witnessing a surprise of 13.12%, on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Scholar Rock Holding Corporation (SRRK): Free Stock Analysis Report
BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In May, Ultragenyx entered into an exclusive license agreement with New York-based biopharmaceutical company, Abeona Therapeutics Inc. ABEO, wherein it will acquire global rights of the latter’s gene therapy candidate ABO-102 (now UX111). Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report Other Updates Ultragenyx recently sold 30% of the royalty interests it receives from partner Kyowa Kirin on future sales of its rare disease drug, Crysvita, in the United States and Canada. | In May, Ultragenyx entered into an exclusive license agreement with New York-based biopharmaceutical company, Abeona Therapeutics Inc. ABEO, wherein it will acquire global rights of the latter’s gene therapy candidate ABO-102 (now UX111). Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report Dojolvi product revenues were $13.5 million compared with $10 million in the year-ago quarter, driven by strong new patient demand. | In May, Ultragenyx entered into an exclusive license agreement with New York-based biopharmaceutical company, Abeona Therapeutics Inc. ABEO, wherein it will acquire global rights of the latter’s gene therapy candidate ABO-102 (now UX111). Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report Ultragenyx’s total revenues of $89.34 million in the second quarter, up 2.7% year over year. | In May, Ultragenyx entered into an exclusive license agreement with New York-based biopharmaceutical company, Abeona Therapeutics Inc. ABEO, wherein it will acquire global rights of the latter’s gene therapy candidate ABO-102 (now UX111). Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report The company reported a loss of $1.45 per share in the year-ago quarter. |
28009.0 | 2022-07-13 00:00:00 UTC | Philips (PHG) Expands AI Portfolio With SmartSpeed Solution | ABEO | https://www.nasdaq.com/articles/philips-phg-expands-ai-portfolio-with-smartspeed-solution | nan | nan | Koninklijke Philips (PHG) recently announced that its latest AI-powered MR acceleration software SmartSpeed has received U.S. Food and Drug Administration’s (FDA) 510(k) clearance. The new software will be showcased as part of an AI-powered precision diagnosis portfolio at the European Congress of Radiology (ECR).
The rising global aging population, high levels of clinical burnout and increasing shortage of staff are putting radiology departments under increasing pressure to improve performance, productivity and profitability.
Philips SmartSpeed increases image resolution by 65% and scans three times faster compared to conventional MR scans available in the market currently.
It helps in improving diagnostic decisions as it supports 97% of current clinical protocols like advanced contrasts and diffusion-weighted imaging and quantitative imaging such as T1 or T2 mapping brain, liver, heart of musculoskeletal.
Koninklijke Philips N.V. Price and Consensus
Koninklijke Philips N.V. price-consensus-chart | Koninklijke Philips N.V. Quote
Philips Banks on AI-based Solutions to Drive Top Line
Philips has been unable to meet the rising demand with proper supply due to the severe global shortage of chips, which has disrupted the manufacturing of life-saving medical devices and the supply chain system.
The chip shortage is happening at a time when chronic diseases are on the rise again, while wars and economic issues globally are posing a severe threat to people’s lives.
Due to the current macro-economic scenario, growth prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Aclaris Therapeutics ACRS, Abeona Therapeutics ABEO and General Electric GE subsidiary GE Healthcare.
Philips’ short-term growth looks tepid, and its shares currently have a Zacks Rank # 4 (Sell). The company's shares have fallen 55% in the year-to-date (YTD) period compared with the Zacks Medical-Products industry and the Medical sector’s decline of 32.1% and 18.1%, respectively.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Aclaris shares have fallen 8.7% in the YTD period, compared with the Zacks Medical - Drugs industry’s decline of 21.4%.
Abeona shares have plunged 34.5% in the YTD period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 20.6%.
General Electric shares have slumped 38.9% in the YTD period compared with the Zacks Diversified Operations industry’s decline of 29.7%.
However, the Russia-Ukraine war and the pandemic have exposed various issues in healthcare and highlighted how new trending technologies like AI and virtual care solutions are required to support patients in these trying times effectively.
Effective crisis management has given rise to healthcare companies like Philips integrating the benefits of the cloud and software as a service (SaaS) in the healthcare industry.
The development of Philips’ latest AI-based products will aid in providing diagnosis faster, even through virtual sessions to patients who have no access to hospitals.
Philips SmartSpeed is the latest addition to the company’s AI-driven, smart, connected imaging and smart workflow solutions that help in solving the problems plaguing the healthcare industry, especially the radiology staff. The latest AI- software helps in achieving the company’s quadruple aim of improving diagnostic outcomes and enhancing patient and staff experiences while simultaneously reducing healthcare costs overall amid rising inflation.
The development of its AI-based solutions separates the company’s services from its peers and is likely to aid the company in winning market share as the healthcare industry bounces back in the long run.
Zacks' Top Picks to Cash in on Electric Vehicles
Big money has already been made in the Electric Vehicle (EV) industry. But, the EV revolution has not hit full throttle yet. There is a lot of money to be made as the next push for future technologies ramps up. Zacks’ Special Report reveals 5 picks investors
See 5 EV Stocks With Extreme Upside Potential >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
General Electric Company (GE): Free Stock Analysis Report
Koninklijke Philips N.V. (PHG): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Aclaris Therapeutics, Inc. (ACRS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Due to the current macro-economic scenario, growth prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Aclaris Therapeutics ACRS, Abeona Therapeutics ABEO and General Electric GE subsidiary GE Healthcare. Abeona shares have plunged 34.5% in the YTD period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 20.6%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | Due to the current macro-economic scenario, growth prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Aclaris Therapeutics ACRS, Abeona Therapeutics ABEO and General Electric GE subsidiary GE Healthcare. Abeona shares have plunged 34.5% in the YTD period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 20.6%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | Due to the current macro-economic scenario, growth prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Aclaris Therapeutics ACRS, Abeona Therapeutics ABEO and General Electric GE subsidiary GE Healthcare. Abeona shares have plunged 34.5% in the YTD period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 20.6%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | Due to the current macro-economic scenario, growth prospects are sluggish in the healthcare market worldwide, as evident from the negative share price movement of Philips and its peers operating in the broader medical sector, including Aclaris Therapeutics ACRS, Abeona Therapeutics ABEO and General Electric GE subsidiary GE Healthcare. Abeona shares have plunged 34.5% in the YTD period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 20.6%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report |
28010.0 | 2022-07-08 00:00:00 UTC | Pre-market Movers: DBD, SRG, ISIG, UPST, CSSE… | ABEO | https://www.nasdaq.com/articles/pre-market-movers%3A-dbd-srg-isig-upst-csse... | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.50 A.M. ET).
In the Green
Diebold Nixdorf, Incorporated (DBD) is up over 60% at $4 Seritage Growth Properties (SRG) is up over 42% at $8.68 Insignia Systems, Inc. (ISIG) is up over 27% at $10.36 Chicken Soup for the Soul Entertainment, Inc. (CSSE) is up over 17% at $9.15 Brickell Biotech, Inc. (BBI) is up over 17% at $4.45 United Maritime Corp (USEA) is up over 16% at $8.23 TransMedics Group, Inc. (TMDX) is up over 12% at $39.00 Rafael Holdings, Inc. (RFL) is up over 12% at $2.31 Nine Energy Service, Inc. (NINE) is up over 11% at $2.71 OppFi Inc. (OPFI) is up over 10% at $3.95 Evoqua Water Technologies Corp. (AQUA) is up over 6% at $37.11
In the Red
Upstart Holdings, Inc. (UPST) is down over 18% at $27.60 Grove Collaborative Holdings, Inc. (GROV) is down over 10% at $6.62 Wayfair Inc. (W) is down over 8% at $53.26 Abeona Therapeutics Inc. (ABEO) is down over 8% at $4.13 Zevia PBC (ZVIA) is down over 7% at $3.32 GameStop Corp. (GME) is down over 6% at $127.00 PPL Corporation (PPL) is down over 6% at $25.40 UWM Holdings Corporation (UWMC) is down over 6% at $3.61 Genfit S.A. (GNFT) is down over 6% at $3.35
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green Diebold Nixdorf, Incorporated (DBD) is up over 60% at $4 Seritage Growth Properties (SRG) is up over 42% at $8.68 Insignia Systems, Inc. (ISIG) is up over 27% at $10.36 Chicken Soup for the Soul Entertainment, Inc. (CSSE) is up over 17% at $9.15 Brickell Biotech, Inc. (BBI) is up over 17% at $4.45 United Maritime Corp (USEA) is up over 16% at $8.23 TransMedics Group, Inc. (TMDX) is up over 12% at $39.00 Rafael Holdings, Inc. (RFL) is up over 12% at $2.31 Nine Energy Service, Inc. (NINE) is up over 11% at $2.71 OppFi Inc. (OPFI) is up over 10% at $3.95 Evoqua Water Technologies Corp. (AQUA) is up over 6% at $37.11 In the Red Upstart Holdings, Inc. (UPST) is down over 18% at $27.60 Grove Collaborative Holdings, Inc. (GROV) is down over 10% at $6.62 Wayfair Inc. (W) is down over 8% at $53.26 Abeona Therapeutics Inc. (ABEO) is down over 8% at $4.13 Zevia PBC (ZVIA) is down over 7% at $3.32 GameStop Corp. (GME) is down over 6% at $127.00 PPL Corporation (PPL) is down over 6% at $25.40 UWM Holdings Corporation (UWMC) is down over 6% at $3.61 Genfit S.A. (GNFT) is down over 6% at $3.35 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.50 A.M. ET). | In the Green Diebold Nixdorf, Incorporated (DBD) is up over 60% at $4 Seritage Growth Properties (SRG) is up over 42% at $8.68 Insignia Systems, Inc. (ISIG) is up over 27% at $10.36 Chicken Soup for the Soul Entertainment, Inc. (CSSE) is up over 17% at $9.15 Brickell Biotech, Inc. (BBI) is up over 17% at $4.45 United Maritime Corp (USEA) is up over 16% at $8.23 TransMedics Group, Inc. (TMDX) is up over 12% at $39.00 Rafael Holdings, Inc. (RFL) is up over 12% at $2.31 Nine Energy Service, Inc. (NINE) is up over 11% at $2.71 OppFi Inc. (OPFI) is up over 10% at $3.95 Evoqua Water Technologies Corp. (AQUA) is up over 6% at $37.11 In the Red Upstart Holdings, Inc. (UPST) is down over 18% at $27.60 Grove Collaborative Holdings, Inc. (GROV) is down over 10% at $6.62 Wayfair Inc. (W) is down over 8% at $53.26 Abeona Therapeutics Inc. (ABEO) is down over 8% at $4.13 Zevia PBC (ZVIA) is down over 7% at $3.32 GameStop Corp. (GME) is down over 6% at $127.00 PPL Corporation (PPL) is down over 6% at $25.40 UWM Holdings Corporation (UWMC) is down over 6% at $3.61 Genfit S.A. (GNFT) is down over 6% at $3.35 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.50 A.M. ET). | In the Green Diebold Nixdorf, Incorporated (DBD) is up over 60% at $4 Seritage Growth Properties (SRG) is up over 42% at $8.68 Insignia Systems, Inc. (ISIG) is up over 27% at $10.36 Chicken Soup for the Soul Entertainment, Inc. (CSSE) is up over 17% at $9.15 Brickell Biotech, Inc. (BBI) is up over 17% at $4.45 United Maritime Corp (USEA) is up over 16% at $8.23 TransMedics Group, Inc. (TMDX) is up over 12% at $39.00 Rafael Holdings, Inc. (RFL) is up over 12% at $2.31 Nine Energy Service, Inc. (NINE) is up over 11% at $2.71 OppFi Inc. (OPFI) is up over 10% at $3.95 Evoqua Water Technologies Corp. (AQUA) is up over 6% at $37.11 In the Red Upstart Holdings, Inc. (UPST) is down over 18% at $27.60 Grove Collaborative Holdings, Inc. (GROV) is down over 10% at $6.62 Wayfair Inc. (W) is down over 8% at $53.26 Abeona Therapeutics Inc. (ABEO) is down over 8% at $4.13 Zevia PBC (ZVIA) is down over 7% at $3.32 GameStop Corp. (GME) is down over 6% at $127.00 PPL Corporation (PPL) is down over 6% at $25.40 UWM Holdings Corporation (UWMC) is down over 6% at $3.61 Genfit S.A. (GNFT) is down over 6% at $3.35 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.50 A.M. ET). | In the Green Diebold Nixdorf, Incorporated (DBD) is up over 60% at $4 Seritage Growth Properties (SRG) is up over 42% at $8.68 Insignia Systems, Inc. (ISIG) is up over 27% at $10.36 Chicken Soup for the Soul Entertainment, Inc. (CSSE) is up over 17% at $9.15 Brickell Biotech, Inc. (BBI) is up over 17% at $4.45 United Maritime Corp (USEA) is up over 16% at $8.23 TransMedics Group, Inc. (TMDX) is up over 12% at $39.00 Rafael Holdings, Inc. (RFL) is up over 12% at $2.31 Nine Energy Service, Inc. (NINE) is up over 11% at $2.71 OppFi Inc. (OPFI) is up over 10% at $3.95 Evoqua Water Technologies Corp. (AQUA) is up over 6% at $37.11 In the Red Upstart Holdings, Inc. (UPST) is down over 18% at $27.60 Grove Collaborative Holdings, Inc. (GROV) is down over 10% at $6.62 Wayfair Inc. (W) is down over 8% at $53.26 Abeona Therapeutics Inc. (ABEO) is down over 8% at $4.13 Zevia PBC (ZVIA) is down over 7% at $3.32 GameStop Corp. (GME) is down over 6% at $127.00 PPL Corporation (PPL) is down over 6% at $25.40 UWM Holdings Corporation (UWMC) is down over 6% at $3.61 Genfit S.A. (GNFT) is down over 6% at $3.35 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.50 A.M. ET). |
28011.0 | 2022-06-29 00:00:00 UTC | Pfizer (PFE) Discloses Autoimmune Drug Deal With Priovant | ABEO | https://www.nasdaq.com/articles/pfizer-pfe-discloses-autoimmune-drug-deal-with-priovant | nan | nan | Pfizer PFE has finally unveiled Priovant Therapeutics, a company formed in collaboration with Roivant Sciences ROIV last September to develop and market novel therapies for autoimmune diseases. Pfizer holds a 25% equity ownership stake in Priovant.
As part of the collaboration with Roivant Sciences in September, Pfizer out-licensed global development rights for an oral and topical formulation of brepocitinib, apotential first-in-class dual inhibitor of TYK2 and JAK1 to Priovant. PFE has out-licensed the commercial rights for brepocitinib in the United States and Japan to Priovant. PFE will retain ex-U.S. commercial rights for the drug.
Pfizer has also licensed similar rights to a selective TYK2 inhibitor, ropsacitinib, to Priovant.
Although Pfizer had mentioned the licensing deal and the formation of the new company on the third-quarter 2021 conference call last November, it did not disclose the name or details of Roivant Sciences or Priovant Therapeutics at the time.
Shares of Pfizer have lost 14.2% in the year so far against the industry’s 3.9% rise.
Image Source: Zacks Investment Research
Priovant Therapeutics is developing the oral formulation of brepocitinib as a franchise for multiple orphan and specialty autoimmune disease, which not only has high morbidity and mortality but also does not have many safe and effective treatment options. A dual inhibition of TYK2 and JAK1 is expected to provide greater efficacy than inhibiting either one alone.
An oral formulation of brepocitinibis currently being evaluated in registration-enabling clinical studies in two indications. A recently initiated phase III VALOR study, which is currently enrolling participants, is evaluating the drug as a potential treatment for dermatomyositis. A phase IIb study is evaluating oral brepocitinib in systemic lupus erythematosus (“SLE”). Data from this study is expected in second-half 2023.
The oral formulation of brepocitinib has been evaluated in 14 completed early-stage and mid-stage studies. These include five phase II studies wherein treatment with the drug in psoriatic arthritis, plaque psoriasis, ulcerative colitis, alopecia areata and hidradenitis suppurativa indications generated statistically significant and clinically meaningful results compared to those who were administered a placebo. The safety profile of the drug was also consistent with that of an approved JAK inhibitor.
Per Pfizer, Roivant’s expertise in late-stage inflammation and immunology drug development will be beneficial to this partnership. PFE also expects the collaboration with ROIV to allow it to focus on diversifying its pipeline against inflammatory diseases.
Pfizer Inc. Price
Pfizer Inc. price | Pfizer Inc. Quote
Zacks Rank & Stocks to Consider
Pfizer currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO andSesen Bio SESN. While Sesen Bio sports a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Sesen Bio’s 2022 bottom line have declined from a loss of 46 cents to 44 cents in the past 60 days. Share prices of Sesen Bio have risen 0.5% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 69.9%. In the last reported quarter, Sesen Bio delivered an earnings surprise of 100%.
Estimates for Abeona Therapeutics’ 2022 bottom line have narrowed from a loss of 33 cents to 31 cents in the past 60 days. Shares of Abeona Therapeutics have plunged 45.3% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and matched the same twice, with the average negative surprise being 8.2%. In the last reported quarter, Abeona Therapeutics missed earnings estimates by 25%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
SESEN BIO, INC. (SESN): Free Stock Analysis Report
Roivant Sciences Ltd. (ROIV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A couple of better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO andSesen Bio SESN. While Sesen Bio sports a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Estimates for Abeona Therapeutics’ 2022 bottom line have narrowed from a loss of 33 cents to 31 cents in the past 60 days. | While Sesen Bio sports a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). A couple of better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO andSesen Bio SESN. Estimates for Abeona Therapeutics’ 2022 bottom line have narrowed from a loss of 33 cents to 31 cents in the past 60 days. | While Sesen Bio sports a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). A couple of better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO andSesen Bio SESN. Estimates for Abeona Therapeutics’ 2022 bottom line have narrowed from a loss of 33 cents to 31 cents in the past 60 days. | In the last reported quarter, Abeona Therapeutics missed earnings estimates by 25%. A couple of better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO andSesen Bio SESN. While Sesen Bio sports a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). |
28012.0 | 2022-06-24 00:00:00 UTC | F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm | ABEO | https://www.nasdaq.com/articles/f-star-fstx-stock-rises-on-buyout-offer-from-sino-biopharm | nan | nan | F-star Therapeutics, Inc. FSTX announced that it has signed a definitive agreement with invoX Pharma, a wholly-owned subsidiary of China-based Sino Biopharmaceutical, wherein the latter will acquire all the issued and outstanding shares of the former in an all-cash transaction value of $7.12 per share.
Following the acquisition, FSTX’s equity stake will be valued at $161 million. The acquisition price of $7.12 per share represents a premium of 11.6% to F-star’s closing price on Jun 23.
Shares of F-star Therapeutics rose 59.8% on Jun 23, following the deal announcement. The stock has risen 26.7% in the year so far against the industry’s 23% decline.
Image Source: Zacks Investment Research
Though F-star has no marketed drug in its portfolio, it is evaluating multiple pipeline candidates across clinical studies that have been developed using its proprietary antibody discovery platform. This technology pioneers the use of tetravalent (2+2) bispecific antibodies that enable the simultaneous targeting of two different antigens and a unique set of pharmacology to deliver focused, potent and safe immune activation in the tumor microenvironment.
F-star Therapeutics is currently evaluating four clinical programs in its pipeline. The most advanced candidate in the company’s pipeline is FS118, a dual checkpoint inhibitor targeting PD-L1 and LAG-3. The candidate is currently being evaluated in a phase II proof-of-concept study for treating head & neck cancer as well as non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).
The other three candidates, namely FS222 (A CD137 stimulator and PD-L1 inhibitor), FS120 (a conditional OX40/CD137 dual agonist) and SB11285 (a STING agonist) are being evaluated in early-stage studies targeting multiple oncology indications.
Per invoX, the acquisition of F-star Therapeutics will help expand Sino Biopharmaceutical’s R&D platform outside of China. invoX has a core focus on developing therapeutics, targeting oncology and respiratory indications. F-star’s proprietary platform is expected to complement Sino Biopharmaceutical’s existing R&D platforms and pipeline outside of China.
The acquisition deal was unanimously approved by the board of directors of both companies. The transaction, expected to be completed by second-half 2022, is subject to customary closing conditions and clearance from the regulatory authorities.
Fstar Therapeutics, Inc. Price
Fstar Therapeutics, Inc. price | Fstar Therapeutics, Inc. Quote
Zacks Rank & Stock to Consider
F-star Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes and Sesen Bio each sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Sesen Bio’s 2022 bottom line have declined from a loss of 33 cents to 32 cents in the past 60 days. Shares of Sesen Bio have risen 1.2% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark once, with the average surprise being 69.9%. In the last reported quarter, Sesen Bio delivered an earnings surprise of 100%.
Estimates for Alkermes’ 2022 bottom line have narrowed from a loss of 10 cents to 3 cents in the past 60 days. Shares of Alkermes have risen 27.1% year to date.
Earnings of Alkermes beat estimates in each of the trailing four quarters, with the average surprise being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Estimates for Abeona Therapeutics’ 2022 bottom line have narrowed from a loss of 33 cents to 31 cents in the past 30 days. Shares of Abeona Therapeutics have plunged 44.6% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and matched the same twice, with the average negative surprise being 8.2%. In the last reported quarter, Abeona Therapeutics missed earnings estimates by 25%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
SESEN BIO, INC. (SESN): Free Stock Analysis Report
Fstar Therapeutics, Inc. (FSTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes and Sesen Bio each sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Estimates for Abeona Therapeutics’ 2022 bottom line have narrowed from a loss of 33 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes and Sesen Bio each sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Estimates for Abeona Therapeutics’ 2022 bottom line have narrowed from a loss of 33 cents to 31 cents in the past 30 days. | While Alkermes and Sesen Bio each sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. | In the last reported quarter, Abeona Therapeutics missed earnings estimates by 25%. Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes and Sesen Bio each sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). |
28013.0 | 2022-06-22 00:00:00 UTC | Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug | ABEO | https://www.nasdaq.com/articles/acer-therapeutics-acer-gets-crl-for-urea-cycle-disorders-drug | nan | nan | Acer Therapeutics ACER announced that the FDA has issued a complete response letter (“CRL”) to its new drug application (“NDA”), which seeks approval for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders (UCDs).
Per the FDA, the CRL was issued as Acer Therapeutics’ third-party contract packaging manufacturer facility was not ready for inspection. Hence, the regulatory body’s field investigator was unable to complete the inspection of this facility. A satisfactory inspection is required to be carried out by the regulatory body before approving the drug in its current form, cited the CRL.
Though the FDA did not raise any approvability concerns related to the efficacy, safety or pharmacokinetics of ACER-001, it did request ACER to provide additional existing non-clinical information in the resubmission of the NDA. This information, requested by the FDA, was identified in the CRL as “not an approvability issue.”
Shares of Acer Therapeutics fell 21% on Jun 21, following the above announcement. The stock has declined 39% so far this year compared with the industry’s 25.4% fall.
Image Source: Zacks Investment Research
Based on the response received in the CRL, Acer Therapeutics is currently collaborating with its third-party contract packaging manufacturer to ensure that the FDA’s queries are resolved. ACER plans to resubmit the NDA during early-to-mid of third-quarter 2022.
Apart from UCD, Acer Therapeutics is also developing ACER-001 to treat various other inborn errors of metabolism, including maple syrup urine disease. The drug is yet to be approved by any regulatory authority worldwide for any indication.
With no marketed drugs in its portfolio, ACER is highly dependent on its pipeline candidates for growth. Other than ACER-001, the company currently has two other candidates in clinical development. One of them is Edsivo (celiprolol), which is expected to enter a pivotal phase III study by the end of second-quarter 2022 to treat patients with COL3A1-positivevascular Ehlers-Danlos Syndrome (vEDS). Another candidate is ACER-801 (osanetant), which is being evaluated in an ongoing phase IIa study for the treatment of moderate-to-severe Vasomotor symptoms in post-menopausal women. Data from this mid-stage study is expected later this year.
Acer Therapeutics Inc. Price
Acer Therapeutics Inc. price | Acer Therapeutics Inc. Quote
Zacks Rank & Stocks to Consider
Acer Therapeutics currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes and Sesen Bio each sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Sesen Bio’s 2022 bottom line have declined from a loss of 33 cents to 32 cents in the past 60 days. Shares of Sesen Bio have risen 8.8% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark once, with the average surprise being 69.9%. In the last reported quarter, Sesen Bio delivered an earnings surprise of 100%.
Estimates for Alkermes’ 2022 bottom line have narrowed from a loss of 10 cents to 3 cents in the past 60 days. Shares of Alkermes have risen 18.9% year to date.
Earnings of Alkermes beat estimates in each of the trailing four quarters, with the average surprise being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Estimates for Abeona Therapeutics’ 2022 bottom line have narrowed from a loss of 33 cents to 31 cents in the past 30 days. Shares of Abeona Therapeutics have plunged 50.3% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and matched the same twice, with the average negative surprise being 8.2%. In the last reported quarter, Abeona Therapeutics missed earnings estimates by 25%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Acer Therapeutics Inc. (ACER): Free Stock Analysis Report
SESEN BIO, INC. (SESN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes and Sesen Bio each sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Estimates for Abeona Therapeutics’ 2022 bottom line have narrowed from a loss of 33 cents to 31 cents in the past 30 days. | While Alkermes and Sesen Bio each sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. Estimates for Abeona Therapeutics’ 2022 bottom line have narrowed from a loss of 33 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes and Sesen Bio each sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Estimates for Abeona Therapeutics’ 2022 bottom line have narrowed from a loss of 33 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes and Sesen Bio each sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Estimates for Abeona Therapeutics’ 2022 bottom line have narrowed from a loss of 33 cents to 31 cents in the past 30 days. |
28014.0 | 2022-06-17 00:00:00 UTC | ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids | ABEO | https://www.nasdaq.com/articles/obsevas-obsv-yselty-gets-eu-nod-to-treat-uterine-fibroids | nan | nan | ObsEva SA OBSV recently announced that the European Commission (EC) has granted marketing authorization to its oral GnRH receptor antagonist, linzagolix, for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women of reproductive age. The drug will be marketed under the trade name Yselty.
The approval follows a positive review by the Committee for Medicinal Products for Human Use (CHMP), which recommended the approval of the oral drug in all member states. The decisions by both EC and CHMP are based on data from two phase III PRIMOSE studies. Pooled week 24 data from both these studies show that treatment with a 200 mg dose of the drug with hormonal ABT achieved a responder rate of 84.5% in participants, while a 100 mg dose without ABT achieved a responder rate of 56.5%.
The EC decision makes Yselty the first and currently the only approved GnRH receptor antagonist that offers women with UF flexible dosing options with and without hormonal add-back therapy (ABT). Yselty is the first oral GnRH antagonist to provide therapeutic alternatives for women who are unable to take hormone therapy.
Shares of ObsEva were up 11% in pre-market trading on Jun 17 following the announcement. In the year so far, the stock has decreased 8% compared with the industry’s decline of 30.4%.
Image Source: Zacks Investment Research
The company has filed a new drug application (NDA) with the FDA, which is currently under review. A final decision on the NDA is expected by Sep 13, 2022.
ObsEva has signed a strategic licensing agreement with London-based Theramex to commercialize Yselty outside of the United States, Canada and Asia. Per the agreement, ObsEva will be eligible to receive royalties of a mid-thirties percentage on commercial sales of the drug. The agreement makes OBSV eligible to receive potential milestone payments.
We remind investors that ObsEva acquired the in-license rights of linzagolix from Japan-based pharma company Kissei in 2015. The rights include global (excluding Asia) commercial rights for the product.
ObsEva SA Price
ObsEva SA price | ObsEva SA Quote
Zacks Rank & Other Stocks to Consider
ObsEva currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 13 cents to 3 cents in the past 60 days. Shares of Alkermes have risen 3.4% year to date.
Earnings of Alkermes beat estimates in each of the trailing four quarters, the average surprise being 350.5%. In the last reported quarter, ALKS delivered an earnings surprise of 1,100%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. Shares of Abeona Therapeutics have plunged 42.6% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and matched the same twice, the average negative surprise being 8.2%. In the last reported quarter, ABEO missed on earnings by 25%.
Sesen Bio’s loss per share estimates for 2022 has declined from 33 cents to 32 cents in the past 60 days. Shares of Sesen Bio have fallen 19.9% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark once, the average surprise being 69.9%. In the last reported quarter, SESN delivered an earnings surprise of 100%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
ObsEva SA (OBSV): Free Stock Analysis Report
SESEN BIO, INC. (SESN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2. | While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2. Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. |
28015.0 | 2022-06-16 00:00:00 UTC | Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study | ABEO | https://www.nasdaq.com/articles/clovis-clvs-up-19.4-on-upbeat-data-from-solid-tumor-study | nan | nan | Shares of Clovis Oncology, Inc. CLVS rallied 19.4% on Jun 15 after management reported initial data from the phase I/II LuMIERE study on FAP-2286, which demonstrates preliminary evidence of activity as a treatment and imaging agent across a wide range of solid tumors.
Data from the first two dose cohorts of the phase I portion of the LuMIERE study showed that nine patients treated with FAP-2286, labelled with lutetium-177 (177Lu-FAP-2286) demonstrated a manageable safety profile and encouraging evidence of activity. A confirmed partial response was also reported in one heavily pre-treated patient who completed six administrations of 177Lu-FAP-2286. In fact, no serious adverse event was observed in the study participants who were treated with 177Lu-FAP-2286.
Management plans to use the data from the phase I portion to determine the recommended dose and schedule in the phase II portion of the LuMIERE study. Clovis plans to start the phase II portion later this year.
The phase I/II LuMIERE study is evaluating the safety, pharmacokinetics, dosimetry and preliminary antitumor activity of FAP-2286 for treating solid tumors. CLVS is currently enrolling participants in the third dose cohort of this study.
Shares of Clovis have declined 64.3% in the year so far compared with the industry’s 30.2% fall.
Image Source: Zacks Investment Research
An investigator initiated phase I study is also evaluating the safety and tumor uptake of FAP-2286 labeled with gallium-68 (68Ga-FAP-2286) as a novel imaging agent to identify metastatic cancer in patients with solid tumors. Clovis plans to use data from the study to begin phase II expansion cohorts for the treatment of multiple tumors by fourth-quarter 2022.
FAP-2286 is the lead candidate in Clovis’ targeted radionuclide therapy development program. Per management, the candidate is also the first peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP) to enter clinical development. FAP is a promising theranostic target with expression across many types of solid tumors.
Per management, this initial data supports Clovis’ hypothesis that FAP-2286 not only targets the tumor but also avoids off-target tissues. This data supports the potential clinical utility of the candidate to treat advanced solid tumors.
Clovis Oncology, Inc. Price
Clovis Oncology, Inc. price | Clovis Oncology, Inc. Quote
Zacks Rank & Stocks to Consider
Clovis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 13 cents to 3 cents in the past 60 days. Shares of ALKS have risen 18.8% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. Shares of ABEO have plunged 52% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and met the same on the remaining two occasions, the average negative surprise being 8.2%. In the last reported quarter, Abeona Therapeutics missed on earnings by 25%.
Sesen Bio’s loss per share estimates for 2022 have declined from 33 cents to 32 cents in the past 60 days. Shares of SESN have fallen 22.5% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 69.9%. In the last reported quarter, Sesen Biodelivered an earnings surprise of 100%.
Special Report: The Top 5 IPOs for Your Portfolio
Today, you have a chance to get in on the ground floor of one of the best investment opportunities of the year. As the world continues to benefit from an ever-evolving internet, a handful of innovative tech companies are on the brink of reaping immense rewards - and you can put yourself in a position to cash in. One is set to disrupt the online communication industry. Brilliantly designed for creating online communities, this stock is poised to explode when made public. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity.
>>See Zacks’ Hottest IPOs Now
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
SESEN BIO, INC. (SESN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2 (Buy). Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. In the last reported quarter, Abeona Therapeutics missed on earnings by 25%. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2 (Buy). |
28016.0 | 2022-06-13 00:00:00 UTC | FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy | ABEO | https://www.nasdaq.com/articles/fda-committee-endorses-bluebirds-blue-thalassemia-therapy | nan | nan | bluebird bio BLUE announced that the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) has unanimously recommended approval of its gene therapy candidate betibeglogene autotemcel (beti-cel) to treat beta-thalassemia, a severe genetic blood disorder.
The CTGTAC voted 13-0, unanimously recommending the benefits of treatment with beti-cel to outweigh the risks.
bluebird bio’s biologics license application (BLA) filed with the FDA seeks approval for beti-cel to treat patients with beta-thalassemia who require regular red blood cell (RBC) transfusions. The filing was granted a priority review by the FDA last November and the regulatory agency’s final decision on the gene therapy is expected by Aug 19, 2022.
Shares of bluebird bio have plunged 62.7% in the year so far compared with the industry’s 27.5% decline.
Image Source: Zacks Investment Research
The CTGTAC’s positive recommendation was based on data from multiple clinical studies, namely the ongoing phase III HGB-207 and HGB-212 studies, and the completed phase I/II HGB-204 and HGB-205 studies that evaluate beti-cel in beta thalassemia patients across all ages and genotypes.
Based on the late-stage clinical studies conducted by bluebird bio on beti-cel, 89% of evaluable patients achieved transfusion independence, which is defined as no longer needing RBC transfusions for at least 12 months while maintaining an average hemoglobin (hb) of at least 9g/dL.
Beti-cel involves adding functional copies of a modified form of the beta-globin gene into thalassemia patients’ own hematopoietic (blood) stem cells to enable the formation of normal RBCs in patients, without the need for transfusions.
Since last week, some good news has been driving BLUE’s prospects. Apart from the above recommendation for beti-cel, the CTGTAC unanimously recommended approval for another bluebird bio’s regulatory filing, which seeks approval for elivaldogene autotemcel (eli-cel) to treat cerebral adrenoleukodystrophy (CALD), a rare neurodegenerative disease.The CTGTAC voted 15-0, recommending the benefits of treatment with eli-cel to offset the risks. A final decision from the FDA is expected by Sep 16, 2022.
bluebird bio is currently facing the risk of a severe cash crunch. In fact, management expressed concerns over BLUE’s capacity to continue as a going concern due to the pressure on its existing cash balance, which is expected to dry up in the near future.
Presently, BLUE has no approved/marketed drug in its portfolio. A tentative approval for either beti-cel or eli-cel will provide bluebird bio with its first FDA-approved drug.
An approval of either or both beti-cel and eli-cel will also make bluebird bio eligible for priority review vouchers (PRVs) from the FDA. BLUE anticipates selling these vouchers to boost its cash resources.
bluebird bio, Inc. Price
bluebird bio, Inc. price | bluebird bio, Inc. Quote
Zacks Rank & Stocks to Consider
bluebird bio carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While both Alkermes and Sesen Bio sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 60 days. Shares of ALKS have risen 18.1% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, ALKS delivered an earnings surprise of 1,100%.
Sesen Bio’s loss per share estimates for 2022 have declined from 33 cents to 32 cents in the past 60 days. Shares of SESN have fallen 10.5% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 69.9%. In the last reported quarter, SESN delivered an earnings surprise of 100%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. Shares of ABEO have plunged 49.6% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and met the same on the remaining two occasions, the average negative surprise being 8.2%. In the last reported quarter, ABEO missed on earnings by 25%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
bluebird bio, Inc. (BLUE): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
SESEN BIO, INC. (SESN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While both Alkermes and Sesen Bio sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | While both Alkermes and Sesen Bio sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While both Alkermes and Sesen Bio sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While both Alkermes and Sesen Bio sport a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. |
28017.0 | 2022-06-10 00:00:00 UTC | FDA Committee Recommends bluebird's (BLUE) CALD Therapy | ABEO | https://www.nasdaq.com/articles/fda-committee-recommends-bluebirds-blue-cald-therapy | nan | nan | bluebird bio BLUE announced that the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) has unanimously recommended approval of its gene therapy candidate elivaldogene autotemcel (eli-cel) to treat cerebral adrenoleukodystrophy (CALD), a rare neurodegenerative disease.
The CTGTAC voted 15-0, unanimously recommending the benefits of treatment with eli-cel to outweigh the risks. The FDA Committee also voted 13-1, concluding the safety data from lovo-cel, another gene therapy developed for treating sickle-cell disease, is not relevant to review for eli-cel.
If approved by the regulatory agency, eli-cel will be the first approved gene therapy to treat early active CALD, in the United States.
bluebird bio’s biologics license application (BLA) filed with the FDA seeks approval for eli-cel to treat early CALD in patients less than 18 years of age, who do not have a matched sibling hematopoietic stem cell (HSC) donor. The filing was granted priority review by the FDA last December and the regulatory agency’s final decision on the gene therapy is expected by Sep 16, 2022.
Shares of bluebird bio have plunged 62.7% in the year so far compared with the industry’s 25.4% decline.
Image Source: Zacks Investment Research
The CTGTAC’s positive recommendation was based on data from the completed phase II/III Starbeam study (ALD-102) wherein 90.6% of the patients achieved the primary endpoint of Major Functional Disabilities-free survival at 24 months. bluebird bio also filed data for subjects dosed in the ongoing phase III ALD-104 study, which completed enrolmentand treatment of all patients.
CALD is a rare, progressive and irreversible neurodegenerative disorder affecting young children. It involves the breakdown of myelin, the protective sheath that nerve cells need for neurologic function. Patients who do not receive treatment for CALD die within five years of symptom onset. Currently, allogeneic hematopoietic stem cell transplant (allo-HSCT) is the only effective treatment option but it carries a significant risk for patients.
Eli-cel is developed to treat the underlying cause of CALD and stabilize the neurologic function. The therapy aims to stop the progression of CALD and preserve as much neurological function as possible.
The CTGTAC is also set to give its recommendation on another bluebird bio regulatory filing, seeking approval for betibeglogene autotemcel (beti-cel) as a potential treatment for β-thalassemia. The meeting will be scheduled on Jun 10.
Presently, BLUE has no approved/marketed drug in its portfolio. A tentative approval for either beti-cel or eli-cel will provide bluebird bio with its first FDA-approved drug.
bluebird bio is currently facing the risk of a severe cash crunch. In fact, management expressed concerns over BLUE’s capacity to continue as a going concern due to the pressure on its existing cash balance, which is expected to dry up in the near future.
An approval of either or both beti-cel and eli-cel will also make bluebird bio eligible for priority review vouchers (PRVs) from the FDA. BLUE anticipates selling these vouchers to boost its cash resources.
In a separate press release, bluebird bio also announced that the NASDAQ halted trading BLUE’s common shares on Jun 9 and 10. This is likely to take into account for the impact of the CTGTAC’s recommendations on BLUE’s share price. Shares are expected to rise once trading resumes on Jun 11 after the FDA committee’s positive recommendation.
bluebird bio, Inc. Price
bluebird bio, Inc. price | bluebird bio, Inc. Quote
Zacks Rank & Stocks to Consider
bluebird bio carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Sesen Bio sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Alkermes carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sesen Bio’s loss per share estimates for 2022 have declined from 33 cents to 32 cents in the past 60 days. Shares of SESN have inched up 1.7% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 69.9%. In the last reported quarter, SESN delivered an earnings surprise of 100%.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 60 days. Shares of ALKS have risen 20.9% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, ALKS delivered an earnings surprise of 1,100%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. The same for 2023 has narrowed from 15 cents to 13 cents in the same time frame. Shares of ABEO have plunged 49.6% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and met the same on the remaining two occasions, the average negative surprise being 8.2%. In the last reported quarter, ABEO missed on earnings by 25%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
bluebird bio, Inc. (BLUE): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
SESEN BIO, INC. (SESN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Sesen Bio sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Alkermes carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | While Sesen Bio sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Alkermes carry a Zacks Rank #2 (Buy). Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Sesen Bio sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Alkermes carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Sesen Bio sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Alkermes carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. |
28018.0 | 2022-06-06 00:00:00 UTC | AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half | ABEO | https://www.nasdaq.com/articles/astrazeneca-azn-breast-cancer-drug-cuts-risk-of-death-to-half | nan | nan | AstraZeneca AZN announced detailed positive data from the pivotal phase III DESTINY-Breast04 study, which evaluated its antibody drug conjugate (ADC) drug Enhertu, in previously treated patients with HER2-low unresectable and/or metastatic breast cancer with hormone receptor (HR) positive or HR-negative disease.
The DESTINY-Breast04 study achieved its primary endpoint of progression free survival (PFS) in patients with HER2-low metastatic breast cancer with HR-positive disease. Enhertu demonstrated a 49% reduction in the risk of disease progression or death over the physician’s choice of chemotherapy. A median PFS of 10.1 months was observed in patients administered Enhertu compared to 5.4 months concerning those who were administered chemotherapy.
The study also showed a clinically meaningful overall survival (OS), a key secondary endpoint, in the above patient group. Data from the study showed a 36% in the risk of death in HR-positive disease patients who were administered Enhertu, based on OS. A median OS of 23.9 months was observed in patients administered Enhertu compared to 17.5 months in those administered chemotherapy.
Overall, the study showed a consistent efficacy of Enhertu in all study participants pertaining to both HR-positive and HR-negative diseases. The study met the key secondary endpoint of PFS in all study participants (both HR-positive and HR-negative disease patients), wherein there was 50% reduction in the risk of disease progression or death observed between Enhertu and chemotherapy. Based on the OS endpoint, there was 36% reduction in risk of death in the patients administered Enhertu over those administered chemotherapy.
In the year so far, shares of AstraZeneca have risen 12.8% compared with the industry’s 4.1% increase.
Image Source: Zacks Investment Research
Based on these results, AstraZeneca believes that a HER2-directed therapy like Enhertu has the potential to redefine treatment for approximately half the patients with breast cancer, thereby providing a survival benefit to those with low HER2 expression.
We remind investors that Enhertu is already approved by the FDA to treat certain patients with HER2-positive breast cancer as well as specific patients with HER2-positive stomach cancer (called gastric or gastroesophageal junction adenocarcinoma). The drug is developed by AstraZeneca in collaboration with Daiichi Sankyo.
Both AstraZeneca and Daiichi Sankyo are also exploring the potential of Enhertu in earlier lines of treatment as well as in new breast cancer settings.
AstraZeneca is highly focused on strengthening its oncology business. In first-quarter 2022, AZN generated $3.6 billion worth of total revenues from its Oncology business, reflecting a 25% year-over-year rise in the constant exchange rate, driven by a solid performance of newer medicines, such as Tagrisso, Lynparza, Imfinzi and Calquence. AZN is working to further strengthen this portfolio through label expansions and advancing oncology pipeline candidates.
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 60 days. Shares of ALKS have risen 26% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, ALKS delivered an earnings surprise of 1,100%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. The same for 2023 has narrowed from 15 cents to 13 cents in the same time frame. Shares of ABEO have plunged 52.7% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and met the same on the remaining two occasions, the average negative surprise being 8.2%. In the last reported quarter, ABEO missed on earnings by 25%.
Sesen Bio’s loss per share estimates for 2022 have declined from 33 cents to 32 cents in the past 60 days. Shares of SESN have dropped 30.4% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 69.9%. In the last reported quarter, SESN delivered an earnings surprise of 100%.
Free: Top Stocks for the $30 Trillion Metaverse Boom
The metaverse is a quantum leap for the internet as we currently know it - and it will make some investors rich. Just like the internet, the metaverse is expected to transform how we live, work and play. Zacks has put together a new special report to help readers like you target big profits. The Metaverse - What is it? And How to Profit with These 5 Pioneering Stocks reveals specific stocks set to skyrocket as this emerging technology develops and expands.
Download Zacks’ Metaverse Report now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Alkermes plc (ALKS): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
SESEN BIO, INC. (SESN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Sesen Bio carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 31 cents in the past 30 days. |
28019.0 | 2022-06-01 00:00:00 UTC | BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug | ABEO | https://www.nasdaq.com/articles/biomarin-bmrn-delays-fda-re-submission-for-hemophilia-drug | nan | nan | Shares of BioMarin Pharmaceutical Inc. BMRN were down 7.2% on May 31 after management decided to delay the re-submission of the biologics license application (BLA) for its investigational gene-therapy candidate valoctocogene roxaparvovec or valrox to treat adults with severe hemophilia A.
Per management, the BLA was earlier planned to be re-filed in June 2022. The process will now be completed by September-end. This decision by management is based on the FDA’s request for additional information and analyses of data on the candidate. The BLA will be supported by a two-year follow-up safety and efficacy data from the phase III GENEr8-1 study. The regulatory agency has not requested any additional pre-clinical and/or clinical studies.
BioMarin reported a six-year and a five-year post-treatment follow-up of the 6e13 vg/kg and 4e13 vg/kg cohorts from the open-label phase I/II study on valoctocogene roxaparvovec, which showed a consistent and a durable bleed control following a one-time treatment with the said candidate.
In the 6e13 vg/kg dose cohort, patients administered with valrox achieved a mean cumulative annualized bleed rate (ABR) reduction of 95% and a Factor VIII use reduction of 96% through six years. In the 4e13 vg/kg dose cohort, patients treated with valrox achieved a mean cumulative ABR reduction of 91% and a Factor VIII use reduction of 93% through five years.
Data from all these studies indicates that a one-time treatment with this gene-therapy candidate generated a sustained hemostatic efficacy. A potential approval of the candidate is expected to change the treatment paradigm.
Shares of BioMarin have declined 15% in the year-to-date period compared with the industry’s 23.6% decrease.
Image Source: Zacks Investment Research
BioMarin has already submitted a regulatory filing with the European Medicines Agency (EMA) seeking approval for valrox in hempphilia A, which is currently undergoing review. A recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) is expected by mid-2022.
BMRN had previously submitted a BLA in 2019 for valoctocogene roxaparvovec to address hemophilia A. However, the FDA issued a complete response letter (CRL) to the BLA ahead of the PDUFA date in August 2020. This was due to the regulatory agency’s dissatisfaction with the available data. As a result, it asked for a two-year follow-up info on the annualized bleed rates from the GENEr8-1 study only to provide additional evidence of a durable effect.
BioMarin Pharmaceutical Inc. Price
BioMarin Pharmaceutical Inc. price | BioMarin Pharmaceutical Inc. Quote
Zacks Rank & Stocks to Consider
BioMarin currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same sector are Abeona Therapeutics ABEO, Aeglea BioTherapeutics AGLE and Sesen Bio SESN. While Sesen Bio currently sports a Zacks Rank #1 (Strong Buy), both Abeona Therapeutics and Aeglea BioTherapeutics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sesen Bio’s loss per share estimates for 2022 have declined from 33 cents to 31 cents in the past 30 days. Shares of SESN have decreased 24.8% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 69.9%. In the last reported quarter, SESN delivered an earnings surprise of 100%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 28 cents in the past 30 days. The same for 2023 has narrowed from 15 cents to 13 cents in the same time frame. Shares of ABEO have plunged 50.1% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and met the same on the remaining two occasions, the average negative surprise being 8.2%. In the last reported quarter, ABEO missed on earnings by 25%.
Aeglea BioTherapeutics’ loss per share estimates for 2022 have narrowed from $1.43 to $1.16 in the past 30 days. The same for 2023 has narrowed from $1.49 to $1.04 in the past 30 days. Shares of AGLE have plunged 66.7% year to date.
Earnings of Aeglea BioTherapeutics beat estimates in two of the last four quarters and missed the mark on the other two occasions, the average surprise being 9.5%. In the last reported quarter, AGLE witnessed a negative earnings surprise of 5.7%.
How to Profit from the Hot Electric Vehicle Industry
Global electric car sales in 2021 more than doubled their 2020 numbers. And today, the electric vehicle (EV) technology and very nature of the business is changing quickly. The next push for future technologies is happening now and investors who get in early could see exceptional profits.
See Zacks' Top Stocks to Profit from the EV Revolution >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Aeglea BioTherapeutics, Inc. (AGLE): Free Stock Analysis Report
SESEN BIO, INC. (SESN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the same sector are Abeona Therapeutics ABEO, Aeglea BioTherapeutics AGLE and Sesen Bio SESN. While Sesen Bio currently sports a Zacks Rank #1 (Strong Buy), both Abeona Therapeutics and Aeglea BioTherapeutics carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 28 cents in the past 30 days. | While Sesen Bio currently sports a Zacks Rank #1 (Strong Buy), both Abeona Therapeutics and Aeglea BioTherapeutics carry a Zacks Rank #2 (Buy). Some better-ranked stocks in the same sector are Abeona Therapeutics ABEO, Aeglea BioTherapeutics AGLE and Sesen Bio SESN. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 28 cents in the past 30 days. | While Sesen Bio currently sports a Zacks Rank #1 (Strong Buy), both Abeona Therapeutics and Aeglea BioTherapeutics carry a Zacks Rank #2 (Buy). Some better-ranked stocks in the same sector are Abeona Therapeutics ABEO, Aeglea BioTherapeutics AGLE and Sesen Bio SESN. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 28 cents in the past 30 days. | Some better-ranked stocks in the same sector are Abeona Therapeutics ABEO, Aeglea BioTherapeutics AGLE and Sesen Bio SESN. While Sesen Bio currently sports a Zacks Rank #1 (Strong Buy), both Abeona Therapeutics and Aeglea BioTherapeutics carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 28 cents in the past 30 days. |
28020.0 | 2022-05-31 00:00:00 UTC | Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe | ABEO | https://www.nasdaq.com/articles/amicus-fold-galafold-aids-growth-overdependence-a-woe | nan | nan | Amicus Therapeutics FOLD is focused on developing a diverse set of novel treatments for patients living with rare metabolic diseases.
Currently, FOLD has only one marketed medicine in its portfolio called Galafold (migalastat), an oral precision medicine for patients living with Fabry disease, having amenable genetic variants.
A rare genetic disorder, Fabry disease is caused by various mutations of the enzyme alpha-galactosidase A (alpha-Gal A). Migalastat is a potent, orally available inhibitor of alpha-Gal A.
Galafold has shown a solid uptake since its launch. The product is approved in more than 40 countries, including the United States, Europe and Japan. The drug’s sales have been rising consistently year over year. Amicus recorded sales worth $305 million in 2021. For 2022, Galafold sales are estimated in the range of at least $350-$365 million, suggesting growth of around 20% from the year-ago reported figure.
Last August, Galafold received approval for label expansion in the European Union (EU) for the long treatment of adolescents with Fabry disease. The drug also has a strong IP portfolio in the United States, providing it protection through 2038.
Shares of Amicus have plunged 31.2% so far this year compared with the industry’s 22.1% decline.
Image Source: Zacks Investment Research
Amicus also developed its lead pipeline candidate, AT-GAA, as a potential treatment for Pompe disease. The candidate consists of two components, such as cipaglucosidase alfa, an engineered enzyme to enhance lysosomal uptake into cells, and miglustat, a stabilizer of the engineered enzyme. AT-GAA was granted a Breakthrough Therapy designation (BTD) by the FDA in 2019, the first ever such tag granted to an investigational product for Pompe disease.
Amicus has already filed regulatory applications for AT-GAA, comprising a biologics license application (BLA) for cipaglucosidase alfa and a new drug application (NDA) for miglustat, to treat Pompe disease. The filings in both the United States and the EU are based on data from the phase I/II and phase III PROPEL studies as well as the long-term open-label extension study evaluating AT-GAA to address Pompe disease.
Although initially, the FDA decisions on both regulatory filings were expected by mid-2022, the FDA extended the review periods by three months after FOLD submitted additional clinical data on the candidate. The FDA’s decision on the NDA is expected later this year in August while a decision on the BLA is expected by October.Amicus expects the extension to provide it with additional time to allow completion of the pre-license approval inspections required at the WuXi Biologics manufacturing site in China.
As part of Amicus’ long-term commitment toward providing multiple solutions to address the significant unmet needs of the Pompe disease community, it is advancing a next-generation gene therapy as a potential cure for Pompe disease.
Other than AT-GAA, Amicus is developing several gene-therapy programs. While many of these programs are currently being evaluated in preclinical studies, a clinical gene-therapy program is being developed for CLN3, a form of Batten disease, in a phase I/II study. The program is advancing well. In first-quarter 2020, the FDA granted a Fast Track designation to the CLN3 Batten disease gene therapy AT-GTX-502 to treat pediatric patients below the age of 18 years.
Both Fabry disease and Pompe disease are rare indications with high market potential. The incidence of Fabry disease increased tenfold in recent years. Many types of genetic mutations may result in misfolded alpha-Gal A and therefore, may also respond to treatment with monotherapy Galafold. Thus, approximately 35-50% of the Fabry disease patient population may benefit from Galafold as a standalone treatment. However, the entire Fabry disease patient population has potential to gain from Galafold in combination with ERT.
Like Fabry disease, Pompe is a lysosomal disorder, stemming from a deficiency in an enzyme called GAA. Per reported estimates of the Acid Maltase Deficiency Association, the United Pompe Foundation and the Lysosomal Disease Program at Massachusetts General Hospital, there are 5,000-10,000 patients with Pompe disease worldwide.
Amicus also suffered its fair share of setbacks. In first-quarter 2022, FOLD decided to discontinue the CLN6 Batten Disease gene-therapy program development. The decision was based on the review of a long-term extension study data, which determined that any initial stabilization of disease progression at the two-year time point was not maintained. Such setbacks do not bode well for the stock.
Amicus Therapeutics, Inc. Price
Amicus Therapeutics, Inc. price | Amicus Therapeutics, Inc. Quote
Zacks Rank & Key Picks
Amicus currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Sesen Bio currently sports a Zacks Rank #1 (Strong Buy), both Alkermes and Abeo Therapeutics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sesen Bio’s loss per share estimates for 2022 have declined from 33 cents to 32 cents in the past 30 days. Shares of SESN have declined 35.6% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 69.9%. In the last reported quarter, Sesen Bio delivered an earnings surprise of 100%.
Alkermes’ loss per share estimates for 2022 have narrowed from 6 cents to 3 cents in the past 30 days. Shares of ALKS have risen 31.3% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. The same for 2023 has narrowed from 15 cents to 13 cents in the past 30 days. Shares of ABEO have declined 50.2% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and met the same on the remaining two occasions, the average negative surprise being 8.2%. In the last reported quarter, Abeona Therapeutics missed on earnings by 25%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Amicus Therapeutics, Inc. (FOLD): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
SESEN BIO, INC. (SESN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the same sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Sesen Bio currently sports a Zacks Rank #1 (Strong Buy), both Alkermes and Abeo Therapeutics carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. | While Sesen Bio currently sports a Zacks Rank #1 (Strong Buy), both Alkermes and Abeo Therapeutics carry a Zacks Rank #2 (Buy). Some better-ranked stocks in the same sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the same sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Sesen Bio currently sports a Zacks Rank #1 (Strong Buy), both Alkermes and Abeo Therapeutics carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the same sector are Abeona Therapeutics ABEO, Alkermes ALKS and Sesen Bio SESN. While Sesen Bio currently sports a Zacks Rank #1 (Strong Buy), both Alkermes and Abeo Therapeutics carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. |
28021.0 | 2022-05-26 00:00:00 UTC | Verrica (VRCA) Down 64% as Molluscum Drug Gets CRL From FDA | ABEO | https://www.nasdaq.com/articles/verrica-vrca-down-64-as-molluscum-drug-gets-crl-from-fda | nan | nan | Verrica Pharmaceuticals VRCA announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA), which seeks approval for its lead product candidate, VP-102, to treat molluscum contagiosum (molluscum), a highly contagious skin disease.
Per the CRL, the FDA identified deficiencies at a general reinspection of Sterling Pharmaceuticals Services, LLC. Sterling is VRCA’s contract manufacturing organization (CMO), which manufactures the latter’s bulk solution of VP-102.
Last week, Verrica was notified that Sterling is currently being classified under an OAI (Official Action Indicated) status, based on an FDA-conducted inspection earlier this February. The FDA’s internal policies prevent it from approving an NDA and communicating the drug’s label if the CMO is placed under an OAI status.
Per Verrica, the CRL did not identify any other deficiency apart from the one mentioned above. In fact, none of the deficiencies pertain to manufacturing operations for VP-102. There were also no open questions on VP-102’s regulatory filing mentioned in the CRL.
Per management, Sterling was placed under the OAI status on the possible grounds of manufacturing higher-risk sterile ophthalmic products for the United States government.
Based on the response received in the CRL, Verrica plans to file for a Type A meeting request with the FDA officials by the end of this week. VRCA will also coordinate with Sterling and the FDA to quickly resolve the deficiencies highlighted in the CRL. VRCA is also planning to engage an additional CMO to manufacture VP-102’s bulk solution.
Shares of Verrica plunged 63.9% on May 25 following the above announcement. The stock has slumped 78.1% so far this year compared with the industry’s 25.5% decline.
Image Source: Zacks Investment Research
If approved, VP-102 will be the first FDA-approved drug for treating molluscum. Currently, there are no approved medications to treat the said indication. Management plans to market the drug under the trade name Ycanth.
The NDA filing with the FDA was based on positive data from two pivotal phase III studies, namely CAMP-1 and CAMP-2, which evaluated the safety and efficacy of VP-102 over placebo in participants aged two years and above and diagnosed with molluscum. Both studies achieved their primary endpoint of complete clearance of all treatable molluscum lesions at the end of the regime.
This is the second CRL received by Verrica for the VP-102 NDA. The first CRL was received last September regarding a deficiency identified by the FDA following a general inspection of Sterling. Like the current CRL, the previous one also did not identify any flaws pertaining to the manufacturing of VP-102. Following the receipt of the first CRL, the FDA classified Sterling as the Voluntary Action Indicated (VAI).
Per the FDA, a CMO classified as VAI means that objectionable conditions or practices were found but the agency is not yet prepared to take or recommend any administrative or regulatory action.
Apart from mollusum, Verrica is developing VP-102 to treat common warts and external genital warts. VRCA also successfully completed two separate mid-stage studies evaluating the candidate for these indications.
Verrica Pharmaceuticals Inc. Price
Verrica Pharmaceuticals Inc. price | Verrica Pharmaceuticals Inc. Quote
Zacks Rank & Other Stocks to Consider
Verrica currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN, each of which has a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. The same for 2023 has narrowed from 15 cents to 13 cents in the past 30 days. Shares of ABEO have declined 54.5% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and met the same on the remaining two occasions, the average negative surprise being 8.2%. In the last reported quarter, Abeona Therapeutics missed on earnings by 25%.
Alkermes’ loss per share estimates for 2022 have narrowed from 10 cents to 3 cents in the past 30 days. Shares of ALKS have risen 24% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Angion Biomedica’s loss per share estimates for 2023 have narrowed from $2.19 to $2.07 in the past 30 days. Shares of ANGN have plunged 56.6% in the year-to-date period.
Earnings of Angion Biomedica beat estimates in three of the last four quarters and missed the mark once, the average surprise being 58.1%. In the last reported quarter, Angion Biomedica missed on earnings by 9.1%.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?
Last year's 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys
Access Zacks Top 10 Stocks for 2022 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Angion Biomedica Corp. (ANGN): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Verrica Pharmaceuticals Inc. (VRCA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN, each of which has a Zacks Rank of 2 at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. Shares of ABEO have declined 54.5% in the year-to-date period. | Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN, each of which has a Zacks Rank of 2 at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. Shares of ABEO have declined 54.5% in the year-to-date period. | Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN, each of which has a Zacks Rank of 2 at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. Shares of ABEO have declined 54.5% in the year-to-date period. | Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN, each of which has a Zacks Rank of 2 at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. Shares of ABEO have declined 54.5% in the year-to-date period. |
28022.0 | 2022-05-25 00:00:00 UTC | Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease | ABEO | https://www.nasdaq.com/articles/aerie-aeri-starts-late-stage-study-to-treat-dry-eye-disease | nan | nan | Aerie Pharmaceuticals AERI announced that it has started dosing patients in the phase III COMET-2 study with AR-15512, its investigational ophthalmic solution, for the treatment of signs and symptoms of dry eye disease (DED).
While the primary efficacy assessment of the COMET-2 study is tear production, which will be measured by the unanesthetized Schirmer test (sign), the key secondary measure is dry eye symptoms, based on the Symptom Assessment iN Dry Eye (SANDE) questionnaire. The study will also evaluate participants based on other assessments at multiple timepoints throughout the study tenure.
Top-line data from the study is expected in the second half of 2023.
The COMET-2 study will evaluate the safety and efficacy of AR-15512, a TRMP8 agonist, in patients with DED. The study will randomize participants to either receive AR-15512 (0.003%) or AR-15512 vehicle, dosed twice daily in each eye, for three months.
Shares of Aerie have declined 19.5% in the year so far compared with the industry’s 25.8% decrease.
Image Source: Zacks Investment Research
The initiation of the COMET-2 study is based on data from the phase IIb COMET-1 study, which evaluated AR-15512 in DED patients. While the study did achieve a statistical significance over multiple pre-specified symptoms and sign endpoints, it did not achieve all pre-determined primary endpoints with statistical significance.
The COMET-2 study is one of the three studies in the phase III registrational program, seeking approval for AR-15512 to address DED. Aerie plans to start the COMET-3 study, which is identical to the COMET-2 study, in third-quarter 2022. Management also aims to begin the phase III COMET-4 study, which is also a 12-month safety study, in fourth-quarter 2022.
AERI expects data from these three studies to support a potential new drug application (NDA), seeking approval for AR-15512 to treat DED. Aerie expects to file the NDA in 2024.
Aerie Pharmaceuticals, Inc. Price
Aerie Pharmaceuticals, Inc. price | Aerie Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Aerie currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN, each of which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. The same for 2023 has narrowed from 15 cents to 13 cents in the past 30 days. Shares of ABEO have declined 54.7% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and met the same on the remaining two occasions, the average negative surprise being 8.2%. In the last reported quarter, Abeona Therapeutics missed on earnings by 25%.
Alkermes’ loss per share estimates for 2022 have narrowed from 10 cents to 3 cents in the past 30 days. Shares of ALKS have risen 21.9% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Angion Biomedica’s loss per share estimates for 2023 have narrowed from $2.19 to $2.07 in the past 30 days. Shares of ANGN have plunged 57.6% in the year-to-date period.
Earnings of Angion Biomedica beat estimates in three of the last four quarters and missed the mark once, the average surprise being 58.1%. In the last reported quarter, Angion Biomedica missed on earnings by 9.1%.
Zacks’ Top Picks to Cash in on Artificial Intelligence
This world-changing technology is projected to generate $100s of billions by 2025. From self-driving cars to consumer data analysis, people are relying on machines more than we ever have before. Now is the time to capitalize on the 4th Industrial Revolution. Zacks’ urgent special report reveals 6 AI picks investors need to know about today.
See 6 Artificial Intelligence Stocks With Extreme Upside Potential>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Angion Biomedica Corp. (ANGN): Free Stock Analysis Report
Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN, each of which has a Zacks Rank #2 (Buy) at present. Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and met the same on the remaining two occasions, the average negative surprise being 8.2%. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN, each of which has a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. Shares of ABEO have declined 54.7% in the year-to-date period. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN, each of which has a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. Shares of ABEO have declined 54.7% in the year-to-date period. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN, each of which has a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. Shares of ABEO have declined 54.7% in the year-to-date period. |
28023.0 | 2022-05-23 00:00:00 UTC | Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal | ABEO | https://www.nasdaq.com/articles/athersys-athx-down-as-ischemic-stroke-study-fails-to-meet-goal | nan | nan | Shares of Athersys ATHX were down 65.5% on Friday (May 20) after management announced top-line data from the phase II/III TREASURE study, which evaluated its investigational stem cell treatment, MultiStem (invimestrocel), in patients with ischemic stroke. The study was conducted in Japan by ATHX’s partner Healios K.K.
The study failed to achieve its primary endpoint of Excellent Outcome at 90 days, with statistical significance. However, it did demonstrate an overall and consistent improvement in essentially all measured functional outcomes over time through one year, supporting the long-term impact on and continued improvement in the quality of life of participants treated in the study.
We note that the TREASURE study evaluated a single dose of MultiStem cells against placebo, administered via intravenous infusion, in 206 patients with moderate to moderate-severe ischemic stroke. Participants in the study were randomized to receive either of the two within 18-36 hours of their moderate or moderate-severe ischemic stroke.
Shares of Athersys have plunged 71.1% this year so far compared with the industry’s 23.6% fall.
Image Source: Zacks Investment Research
Athersys is also conducting a phase III MASTERS-2 study in the United States, Europe and the Asia-Pacific, evaluating the MultiStem treatment against placebo in the same patient group. However, compared to the currently enrolling MASTERS-2 study, the TREASURE study evaluated a substantially older study group with a median age of 78 years and moderately greater stroke severity.
One of the reasons for the TREASURE study’s failure to achieve its primary endpoint, as suggested by ATHX, was the presence of the older demographic, which caused slower and less robust recovery in patients enrolled in the TREASURE study.
Athersys expects data from the MASTERS-2 study to have a higher potential to achieve its primary endpoint, i.e. modified Rankin Score (mRS) shift. This main goal is based on the data from the TREASURE study, which enrolled patients representative of the currently recruited participants in the MASTERS-2 study.
Per Athersys, despite not meeting its primary endpoint, the TREASURE study provides new information on the MultiStem treatment in older patients (aged 80 years and above). While the MASTERS-2 study is enrolling this age group as a limited proportion of subjects, the previously conducted phase II MASTERS-1 study did not evaluate the treatment in this particular age bracket.
Athersys, Inc. Price
Athersys, Inc. price | Athersys, Inc. Quote
Zacks Rank & Key Picks
Athersys currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN. While Alkermes sports a Zacks Rank #1 (Strong Buy), both Abeona Therapeutics and Angion Biomedica carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 13 cents to 3 cents in the past 30 days. Shares of ALKS have risen 29% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. The same for 2023 has narrowed from 15 cents to 13 cents in the past 30 days. Shares of ABEO have declined 53.7% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and met the same on the remaining two occasions, the average negative surprise being 8.2%. In the last reported quarter, Abeona Therapeutics missed on earnings by 25%.
Angion Biomedica’s loss per share estimates for 2023 have narrowed from $2.19 to $2.02 in the past 30 days. Shares of ANGN have plunged 55.9% in the year-to-date period.
Earnings of Angion Biomedica beat estimates in three of the last four quarters and missed the mark once, the average surprise being 58.1%. In the last reported quarter, Angion Biomedica missed on earnings by 9.1%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Angion Biomedica Corp. (ANGN): Free Stock Analysis Report
Athersys, Inc. (ATHX): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN. While Alkermes sports a Zacks Rank #1 (Strong Buy), both Abeona Therapeutics and Angion Biomedica carry a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN. While Alkermes sports a Zacks Rank #1 (Strong Buy), both Abeona Therapeutics and Angion Biomedica carry a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN. While Alkermes sports a Zacks Rank #1 (Strong Buy), both Abeona Therapeutics and Angion Biomedica carry a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Angion Biomedica ANGN. While Alkermes sports a Zacks Rank #1 (Strong Buy), both Abeona Therapeutics and Angion Biomedica carry a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 33 cents to 31 cents in the past 30 days. |
28024.0 | 2022-05-19 00:00:00 UTC | Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops | ABEO | https://www.nasdaq.com/articles/enantas-enta-rsv-drug-fails-to-meet-study-goal-stock-drops | nan | nan | Shares of Enanta Pharmaceuticals ENTA were down 15.1% in after-hours trading on Wednesday (May 18) after management announced top-line data from the phase IIb RSVP study, which evaluated its potent N-protein inhibitor candidate EDP-938 against placebo in otherwise healthy adults with community-acquired Respiratory Syncytial Virus (RSV).
Though EDP-398 demonstrated a favorable safety profile and was well-tolerated by the study participants, the RSVP study failed to achieve its primary endpoint of reduction in total symptom score (TSS) compared to placebo. The study also did not achieve any secondary endpoint.
However, the study did achieve a statistically significant difference in the number of subjects achieving undetectable RSV RNA at the end of treatment with EDP-938.
Per Enanta, the RSVP study is currently the only study that achieved a statistically significant antiviral effect in otherwise healthy adults with community-acquired RSV.
Based on the above analysis, Enanta will continue to evaluate EDP-398 to treat RSV infections in both the ongoing and planned clinical studies. ENTA is currently enrolling patients in two mid-stage studies that are evaluating the candidate in pediatric patients and adult hematopoietic cell transplant recipients, respectively. ENTA also intends to start a phase IIb study by this year-end on the candidate in a high-risk adult population, including elderly patients.
Shares of Enanta have declined 43% this year so far compared with the industry’s 27% fall.
Image Source: Zacks Investment Research
ENTA is also on track to start a phase I study later this year to evaluate EDP-323, an investigational oral direct-acting antiviral, designed to target RSV L-protein. Enanta plans to develop EDP-323, both as a monotherapy and in combination with other RSV drugs like EDP-398, to expand the scope of RSV treatment in broad patient groups.
Many other companies are also preparing their own pipeline candidates targeting RSV infections.
Last month, Pfizer PFE announced that it entered into a definitive agreement to acquire the closely-held biotech company ReViral, which is developing therapeutics for RSV. The acquisition will add some promising RSV candidates to PFE’s portfolio, including sisunatovir, an oral therapy that showed significantly reduced viral load in a phase II RSV human challenge study in healthy adults. The same is also being evaluated in a phase II study in infants.
Another candidate is in phase I study for inhibition of RSV replication targeting the viral N protein. Pfizer believes that if these RSV candidates are successfully developed, they have the potential to generate annual revenues of more than $1.5 billion.
Pfizer is also developing its own RSV vaccine candidate PF-06928316 or RSVpreF in ongoing late-stage clinical studies.
Enanta Pharmaceuticals, Inc. Price
Enanta Pharmaceuticals, Inc. price | Enanta Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Enanta Pharmaceuticals currently carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO and Alkermes ALKS each of which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abeona Therapeutics’ loss per share estimates for 2023 have narrowed from 15 cents to 13 cents in the past 30 days. Shares of ABEO have declined 51.8% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the trailing four quarters and met the same on the remaining two occasions, the average negative surprise being 8.2%. In the last reported quarter, Abeona Therapeutics missed on earnings by 25%.
Alkermes’ loss per share estimates for 2022 have narrowed from 13 cents to 3 cents in the past 30 days. Shares of ALKS have risen 24.1% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
Alkermes plc (ALKS): Free Stock Analysis Report
Enanta Pharmaceuticals, Inc. (ENTA): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Two better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO and Alkermes ALKS each of which has a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2023 have narrowed from 15 cents to 13 cents in the past 30 days. Shares of ABEO have declined 51.8% in the year-to-date period. | Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report Two better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO and Alkermes ALKS each of which has a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2023 have narrowed from 15 cents to 13 cents in the past 30 days. | Two better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO and Alkermes ALKS each of which has a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2023 have narrowed from 15 cents to 13 cents in the past 30 days. Shares of ABEO have declined 51.8% in the year-to-date period. | Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report Two better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO and Alkermes ALKS each of which has a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2023 have narrowed from 15 cents to 13 cents in the past 30 days. |
28025.0 | 2022-05-18 00:00:00 UTC | Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate | ABEO | https://www.nasdaq.com/articles/ultragenyx-rare-acquires-rights-of-aav-gene-therapy-candidate | nan | nan | Ultragenyx Pharmaceutical Inc. RARE announced that it has entered into an exclusive license agreement with New York-based biopharmaceutical company, Abeona Therapeutics Inc. ABEO, wherein it will acquire global rights of the latter’s gene therapy candidate ABO-102 (now UX111).
The AAV gene therapy candidate, UX111, is currently being evaluated in the open-label, global phase I/II Transpher A study for the treatment of patients with Sanfilippo syndrome type A (MPS IIIA), a rare, fatal lysosomal storage disease. Currently, there is no approved therapy for the given indication.
Per the latest agreement, Ultragenyx will undertake the responsibility of the ABO-102 program while ABEO will be entitled to receive tiered royalties of up to 10% on net sales and milestone payments upon potential approval of the product.
Shares of Ultragenyx have declined 35.3% so far this year compared with the industry’s decrease of 24.9%.
Image Source: Zacks Investment Research
The phase I/II Transpher A study is investigating ABO-102 for treating patients with MPS IIIA. The primary endpoints of the study are neurodevelopment and safety.
Per the press release, Abeona has completed a Type B meeting, which was a success, with the FDA regarding the Transpher A study. The findings from the study are likely to support regulatory filing and approval of ABO-102 for MPS IIIA.
Till date, data from the study have shown that treatment with a single intravenous dose of ABO-102 has the potential to offer children with MPS IIIA sustained neurocognitive development when treated at early stages of their disease.
If successfully developed and upon potential approval, ABO-102 might serve an area of highly unmet medical need and offer a transformative therapy for children with MPS IIIA.
The FDA has already granted Regenerative Medicine Advanced Therapy, Fast Track, Rare Pediatric Disease and Orphan Drug designations to ABO-102 for the treatment of MPS IIIA.
The above deal looks a good strategic fit for Ultragenyx, given that it already has some gene therapy candidates in its pipeline that are being developed for various indications.
Zacks Rank & Stocks to Consider
Ultragenyx currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Applied Therapeutics, Inc. APLT and AegleaBio Therapeutics, Inc. AGLE, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Applied Therapeutics’ loss per share estimates have narrowed 27.1% for 2022 and 20.2% for 2023 over the past 60 days.
Earnings of Applied Therapeutics have surpassed the Zacks Consensus Estimate in one of the trailing four quarters, met the same once and missed the same on the other two occasions. APLT delivered an earnings surprise of -0.67% on average.
AegleaBio Therapeutics’ loss per share estimates have narrowed 23.2% for 2022 and 30.6% for 2023 over the past 60 days.
Earnings of AegleaBio Therapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AGLE delivered an earnings surprise of 9.47% on average.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Aeglea BioTherapeutics, Inc. (AGLE): Free Stock Analysis Report
Applied Therapeutics Inc. (APLT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ultragenyx Pharmaceutical Inc. RARE announced that it has entered into an exclusive license agreement with New York-based biopharmaceutical company, Abeona Therapeutics Inc. ABEO, wherein it will acquire global rights of the latter’s gene therapy candidate ABO-102 (now UX111). Per the latest agreement, Ultragenyx will undertake the responsibility of the ABO-102 program while ABEO will be entitled to receive tiered royalties of up to 10% on net sales and milestone payments upon potential approval of the product. Per the press release, Abeona has completed a Type B meeting, which was a success, with the FDA regarding the Transpher A study. | Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. RARE announced that it has entered into an exclusive license agreement with New York-based biopharmaceutical company, Abeona Therapeutics Inc. ABEO, wherein it will acquire global rights of the latter’s gene therapy candidate ABO-102 (now UX111). Per the latest agreement, Ultragenyx will undertake the responsibility of the ABO-102 program while ABEO will be entitled to receive tiered royalties of up to 10% on net sales and milestone payments upon potential approval of the product. | Ultragenyx Pharmaceutical Inc. RARE announced that it has entered into an exclusive license agreement with New York-based biopharmaceutical company, Abeona Therapeutics Inc. ABEO, wherein it will acquire global rights of the latter’s gene therapy candidate ABO-102 (now UX111). Per the latest agreement, Ultragenyx will undertake the responsibility of the ABO-102 program while ABEO will be entitled to receive tiered royalties of up to 10% on net sales and milestone payments upon potential approval of the product. Per the press release, Abeona has completed a Type B meeting, which was a success, with the FDA regarding the Transpher A study. | Ultragenyx Pharmaceutical Inc. RARE announced that it has entered into an exclusive license agreement with New York-based biopharmaceutical company, Abeona Therapeutics Inc. ABEO, wherein it will acquire global rights of the latter’s gene therapy candidate ABO-102 (now UX111). Per the latest agreement, Ultragenyx will undertake the responsibility of the ABO-102 program while ABEO will be entitled to receive tiered royalties of up to 10% on net sales and milestone payments upon potential approval of the product. Per the press release, Abeona has completed a Type B meeting, which was a success, with the FDA regarding the Transpher A study. |
28026.0 | 2022-05-17 00:00:00 UTC | Philips' (PHG) Launches a Range of New Products at EuroPCR 2022 | ABEO | https://www.nasdaq.com/articles/philips-phg-launches-a-range-of-new-products-at-europcr-2022 | nan | nan | Koninklijke Philips PHG recently announced several new innovative additions to its existing healthcare solutions portfolio. The new additions include ultra-low contrast percutaneous coronary intervention (ULC-PCI), Dynamic Coronary Roadmap Software, EchoNavigator 2.0, iFR Co-registration and IVUS Co-registration.
Among these introductions, the most exciting solutions are the ULC-PCI and EchoNavigator 2.0. While ULC-PCI will help interventionists perform percutaneous coronary intervention with greater confidence and clarity and at a much more reduced cost, EchoNavigator 4.0 will aid in complex heart disease treatment such as heart valve repair or therapy.
Philips’ ULC-PCI solutions integrate with its image-guided therapy system Azurion and co-registers instantaneous blood flow measurements and intravascular ultrasound (IVUS) images onto real-time fluoroscopy to help diagnose and confirm the success of PCI, limiting the use of too much-iodinated contrast media and reducing healthcare costs.
Exposure to contrast media during PCI procedures increases the risk of suffering contrast-induced nephropathy (CIN), especially among patients suffering from coronary artery disease (CAD) and chronic kidney disease (CKD). CIN is a hospital-acquired life-threatening kidney injury, which results in an average increase in length of hospital stay of 3.6 days and an additional healthcare cost of $9,448 per patient.
Philips’ EchoNavigator provides advanced image-guided therapy solutions for the treatment of structural heart disease. Structural heart diseases such as mitral regurgitation are a common phenomenon among people above the age of 75 years. Worldwide more than 156 million people suffer from this disease and have to go through complex open-heart surgery. However, with the help of EchoNavigator, treatment of such diseases can be performed using image-guided minimally invasive catheter-based procedures that cause far less trauma, thus making the new product a very attractive solution among doctors.
Koninklijke Philips N.V. Price and Consensus
Koninklijke Philips N.V. price-consensus-chart | Koninklijke Philips N.V. Quote
Supply Chain Issues Impact Near-Term Profitability
Philips witnessed solid demand for patient monitors, hospital ventilators, computed tomography and portable ultrasound systems amid the COVID-19 outbreak. The company has been benefiting from strong demand for Image-Guided Therapy, Diagnostic Imaging, Ultrasound and Hospital Patient Monitoring system.
However, rising supply chain issues due to the pandemic had negatively impacted the company’s top line in the first quarter of 2022. The supply chain management issues are still prevalent globally and pose a significant threat to the company’s near-term profitability.
As a result of the pandemic, growth prospects are sluggish in the healthcare market worldwide. Rising raw material prices are hampering Philips’ ability to maintain competitiveness in the markets it operates.
Philips Respironics voluntarily recalled ventilators, bi-level positive airway pressure and positive airway pressure machines due to potential health hazards. This impacted sales negatively in the first quarter of 2022.
Comparable sales decreased 4% on a year-over-year basis to €3.92 billion in the first quarter of 2022.
The company’s earnings had declined by 46.4% to 15 cents in the first quarter. The slowdown in the economy has hurt the medical sector.
Philips currently carries a Zacks Rank # 3 (Hold). The company's shares have fallen 29.5% in the year-to-date period compared with the Zacks Medical-Products industry and the Medical sector’s decline of 11% and 80.4%, respectively.
Stocks to Consider
While Philips is reeling from the effects of an economic slowdown and global supply chain issues, here are some better-ranked stocks worth considering in the broader Medical sector.
AMN Healthcare Services AMN sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN shares have fallen 26.9% in the year-to-date period, compared with the Zacks Medical Services industry’s decline of 35.1%.
Aclaris Therapeutics ACRS carries a Zacks Rank #2 (Buy).
Aclaris shares have fallen 24.1% in the year-to-date period, compared with the Zacks Medical - Drugs industry’s decline of 26.1%.
Abeona Therapeutics ABEO carries a Zacks Rank #2.
Abeona shares have plunged 46.6% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25%.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Koninklijke Philips N.V. (PHG): Free Stock Analysis Report
AMN Healthcare Services Inc (AMN): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Aclaris Therapeutics, Inc. (ACRS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics ABEO carries a Zacks Rank #2. Abeona shares have plunged 46.6% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | Abeona Therapeutics ABEO carries a Zacks Rank #2. Abeona shares have plunged 46.6% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | Abeona Therapeutics ABEO carries a Zacks Rank #2. Abeona shares have plunged 46.6% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | Abeona Therapeutics ABEO carries a Zacks Rank #2. Abeona shares have plunged 46.6% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry’s decline of 25%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report |
28027.0 | 2022-05-17 00:00:00 UTC | AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug | ABEO | https://www.nasdaq.com/articles/abbvie-abbv-buys-option-rights-to-nextgen-inflammation-drug | nan | nan | AbbVie ABBV announced that it signed a deal with precision medicines biotech, Cugene, for CUG252, a potential best-in-class Treg-selective IL-2 mutein for the potential treatment of autoimmune and inflammatory diseases.
Per the deal, AbbVie will get an option to license worldwide rights for certain IL-2 muteins, including a next-generation inflammatory candidate, CUG252, from Cugene. CUG252 is being evaluated in a phase I study in healthy volunteers while Cugene plans to conduct a phase Ib study in patients with autoimmune/inflammatory disease during the option period.
AbbVie’s stock has risen 14.7% this year so far compared with an increase of 2.1% for the industry.
Image Source: Zacks Investment Research
For the deal, AbbVie will make an upfront payment of $48.5 million to Cugene while also being entitled to make future development and regulatory milestone payments. If AbbVie chooses to exercise the option, it will have to make an option exercise payment and will then take care of all future clinical development and commercialization activities for CUG252.
The deal builds on AbbVie’s strong position in immunology with a blockbuster drug like Humira and its new immunology medicines, Skyrizi and Rinvoq, in its portfolio. Skyrizi and Rinvoq demonstrated differentiated clinical profiles versus Humira and are already contributing meaningful revenues, including $4.6 billion in combined sales in 2021. With new indications coming in the next couple of years, sales of these drugs could be higher and have the potential to replace Humira when generics are launched in 2023.
Zacks Rank and Stocks to Consider
AbbVie currently has a Zacks Rank #3 (Hold).
Some better-ranked biotech stocks are Alkermes ALKS, Sesen Bio SESN and Abeona Therapeutics ABEO. While Alkermes and Sesen Bio have a Zacks Rank #1, Abeona Therapeutics has a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Alkermes’ 2022 loss per share has narrowed from 13 cents to 3 cents in the past 30 days. Shares of ALKS have risen 24.3% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%.
The consensus estimate for Sesen Bio’s 2022 loss per share has declined from 33 cents to 32 cents in the past 30 days. Shares of SESN have declined 49.2% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 69.9%.
The consensus estimate for Abeona Therapeutics’ 2022 loss has narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 46.6% in the year-to-date period.
Earnings of Abeona Therapeutics missed estimates in two of the last four quarters and met the mark on two occasions, the average negative surprise being 8.17%.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
SESEN BIO, INC. (SESN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked biotech stocks are Alkermes ALKS, Sesen Bio SESN and Abeona Therapeutics ABEO. While Alkermes and Sesen Bio have a Zacks Rank #1, Abeona Therapeutics has a Zacks Rank of 2. The consensus estimate for Abeona Therapeutics’ 2022 loss has narrowed from 34 cents to 33 cents in the past 30 days. | Some better-ranked biotech stocks are Alkermes ALKS, Sesen Bio SESN and Abeona Therapeutics ABEO. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report While Alkermes and Sesen Bio have a Zacks Rank #1, Abeona Therapeutics has a Zacks Rank of 2. | While Alkermes and Sesen Bio have a Zacks Rank #1, Abeona Therapeutics has a Zacks Rank of 2. Some better-ranked biotech stocks are Alkermes ALKS, Sesen Bio SESN and Abeona Therapeutics ABEO. The consensus estimate for Abeona Therapeutics’ 2022 loss has narrowed from 34 cents to 33 cents in the past 30 days. | While Alkermes and Sesen Bio have a Zacks Rank #1, Abeona Therapeutics has a Zacks Rank of 2. Some better-ranked biotech stocks are Alkermes ALKS, Sesen Bio SESN and Abeona Therapeutics ABEO. The consensus estimate for Abeona Therapeutics’ 2022 loss has narrowed from 34 cents to 33 cents in the past 30 days. |
28028.0 | 2022-05-13 00:00:00 UTC | Abeona Therapeutics Posts Q1 Net Loss Of $20.79 Mln | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-posts-q1-net-loss-of-%2420.79-mln | nan | nan | (RTTNews) - Abeona Therapeutics Inc. (ABEO), a biotech firm focused on cell and gene therapies, on Friday posted a wider net loss for the first quarter, amidst increased research and development or R&D and administrative expenses, and non-cash impairment charges. However, per share loss narrowed on higher share count at the end of the latest quarter.
For the quarter ended in March, the Dallas-headquartered company reported a net loss of $20.791 million or $0.14 per share, compared with $16.00 million or $0.17 per share loss reported for the same period a year ago.
The net loss includes a $6.2 million in non-cash impairment charges resulting from the disposition of the ABO-102 and ABO-101 development programs as Abeona targets resources on its EB-101 pivotal program and preclinical eye gene therapy initiatives, the company said in a statement.
Operating loss was at $20.591 million, higher than $14.597 million of previous year.
R&D, general and administrative expenses were reported at $10.545 million and $ 4.224 million, respectively, compared with $8.317 million and $6.280 million, reported for the first quarter of 2021.
License and other revenues in the quarter were $0.3 million with no such revenues comparable with last year.
Vish Seshadri, CEO of Abeona, said: "During the quarter, we took significant steps to preserve our capital with the goal to fund operations over the next 12 months with existing cash resources... Furthermore, we have initiated steps toward regaining compliance with Nasdaq listing requirements."
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abeona Therapeutics Inc. (ABEO), a biotech firm focused on cell and gene therapies, on Friday posted a wider net loss for the first quarter, amidst increased research and development or R&D and administrative expenses, and non-cash impairment charges. The net loss includes a $6.2 million in non-cash impairment charges resulting from the disposition of the ABO-102 and ABO-101 development programs as Abeona targets resources on its EB-101 pivotal program and preclinical eye gene therapy initiatives, the company said in a statement. Vish Seshadri, CEO of Abeona, said: "During the quarter, we took significant steps to preserve our capital with the goal to fund operations over the next 12 months with existing cash resources... | The net loss includes a $6.2 million in non-cash impairment charges resulting from the disposition of the ABO-102 and ABO-101 development programs as Abeona targets resources on its EB-101 pivotal program and preclinical eye gene therapy initiatives, the company said in a statement. (RTTNews) - Abeona Therapeutics Inc. (ABEO), a biotech firm focused on cell and gene therapies, on Friday posted a wider net loss for the first quarter, amidst increased research and development or R&D and administrative expenses, and non-cash impairment charges. Vish Seshadri, CEO of Abeona, said: "During the quarter, we took significant steps to preserve our capital with the goal to fund operations over the next 12 months with existing cash resources... | The net loss includes a $6.2 million in non-cash impairment charges resulting from the disposition of the ABO-102 and ABO-101 development programs as Abeona targets resources on its EB-101 pivotal program and preclinical eye gene therapy initiatives, the company said in a statement. (RTTNews) - Abeona Therapeutics Inc. (ABEO), a biotech firm focused on cell and gene therapies, on Friday posted a wider net loss for the first quarter, amidst increased research and development or R&D and administrative expenses, and non-cash impairment charges. Vish Seshadri, CEO of Abeona, said: "During the quarter, we took significant steps to preserve our capital with the goal to fund operations over the next 12 months with existing cash resources... | (RTTNews) - Abeona Therapeutics Inc. (ABEO), a biotech firm focused on cell and gene therapies, on Friday posted a wider net loss for the first quarter, amidst increased research and development or R&D and administrative expenses, and non-cash impairment charges. The net loss includes a $6.2 million in non-cash impairment charges resulting from the disposition of the ABO-102 and ABO-101 development programs as Abeona targets resources on its EB-101 pivotal program and preclinical eye gene therapy initiatives, the company said in a statement. Vish Seshadri, CEO of Abeona, said: "During the quarter, we took significant steps to preserve our capital with the goal to fund operations over the next 12 months with existing cash resources... |
28029.0 | 2022-05-12 00:00:00 UTC | AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals | ABEO | https://www.nasdaq.com/articles/abbvies-abbv-rinvoq-meets-crohns-disease-study-goals | nan | nan | AbbVie, Inc. ABBV announced top-line data from the phase III maintenance study, U-ENDURE, which evaluated its JAK inhibitor drug Rinvoq (upadacitinib) for moderate-to-severe Crohn’s disease (CD).
This study achieved its co-primary endpoints of clinical remission and endoscopic response at week 52. The study also achieved its secondary endpoint of endoscopic remission at week 52.
The U-ENDURE study evaluated the safety and efficacy of two doses of upadacitinib (15 mg and 30mg) against placebo in adult participants with moderate-to-severe CD, who resposnded to indiction treatment with the drug in the phase III U-EXCEED and U-EXCEL induction studies.
The co-primary endpoint of clinical remission was defined by the Crohn's Disease Activity Index (CDAI) or by stool frequency and abdominal pain score (SF/AP). Both CDAI and SF/AP were used to accommodate the regulatory differences in the United States and Europe. The FDA considers CDAI while the EMA considers SF/AP.
Per CDAI, patients in the U-ENDURE study who received upadacitinib, achieved a clinical remission of 37% and 48% with the 15 mg and 30 mg dose, respectively. Patients administered with placebo only achieved a 15% clinical remission based on CDAI. Per the SF/AP score, patients having received 15mg dose of the drug achieved a clinical remission of 36% while those who received 30mg dose achieved 46% clinical remission. Patients in the placebo group achieved clinical remission of 14% based on the SF/AP score.
Patients administered with upadacitinib achieved an endoscopic response of 28% for the 15mg dose of the drug and 40% for the 30mg dose. Participants in the placebo group achieved a response of 7%.
Participants administered with the 15 mg and 30mg doses of the drug achieved 19% and 29% endoscopic remission, respectively, while those in the placebo group achieved only 5% remission. The safety results of the drug in the maintenance study were also consistent with the safety profile observed in the induction studies.
Shares of AbbVie have gained 12.2% so far this year compared with the industry’s 0.6% rise.
Image Source: Zacks Investment Research
Rinvoq is already approved by the FDA for five indications, namely rheumatoid arthritis, active psoriatic arthritis (PsA), ulcerative colitis (UC), ankylosing spondylitis and atopic dermatitis.
ABBV also markets another blockbuster drug Skyrizi, an IL-23 inhibitor currently approved for two indications in the United States, which are plaque psoriasis and PsA. An FDA filing seeking label expansion for the CD indication is currently under review.
AbbVie is alert about strengthening its focus on Rinvoq and Skyrizi to gradually lower its dependence on Humira, ABBV’s blockbuster drug, sales of which are declining due to biosimilars eroding its yearly international sales. Humira biosimilars are expected to be launched in the United States in 2023.
Both Skyrizi and Rinvoq demonstrated differentiated clinical profiles compared to Humira. With many new indications coming in the next couple of years, AbbVie expects combined sales of these two drugs to be more than $15 billion by 2025.
Skyrizi generated sales worth $940 million in the first three months of 2022, while Rinvoq generated sales worth $465 million during the same period.
The targeted CD market is highly competitive. ABBV faces stiff competition from Johnson & Johnson JNJ, which markets its own drug Stelara that utilizes a different mechanism of action to treat the CD indication.
A blockbuster drug, J&J’s Stelara is a human IL-12 and IL-23 antagonist approved by the FDA for treating moderately-to-severely active CD. The drug is also approved for other indications, including UC and PsA. Evidently, Stelara is one of JNJ’s top-line drivers. During first-quarter 2022, J&J recorded revenues worth $2.3 billion from Stelara sales.
AbbVie Inc. Price
AbbVie Inc. price | AbbVie Inc. Quote
Zacks Rank & Stocks to Consider
AbbVie currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO and Alkermes ALKS. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 30 days. Shares of ALKS have rallied 13.5% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 59.5% in the year-to-date period.
Abeona Therapeutics has a mixed surprise history, with its earnings having surpassed expectations in one of the trailing four quarters, missing the mark in another and meeting the same on the remaining two occasions, the average surprise being 0.7%. In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?
Last year's 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys
Access Zacks Top 10 Stocks for 2022 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Alkermes plc (ALKS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO and Alkermes ALKS. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. | In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%. Better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO and Alkermes ALKS. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). | Better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO and Alkermes ALKS. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. | In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report Better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO and Alkermes ALKS. |
28030.0 | 2022-05-11 00:00:00 UTC | Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates | ABEO | https://www.nasdaq.com/articles/epizyme-epzm-q1-earnings-miss-revenues-lag-estimates | nan | nan | Epizyme, Inc. EPZM incurred a loss of 38 cents per share for first-quarter 2022, narrower than the year-ago period’s loss of 69 cents.
Adjusted loss (excluding gains on change in fair value of warrants to purchase common stock) for the first quarter was 39 cents, wider than the Zacks Consensus Estimate of a loss of 35 cents but narrower than the year-ago period’s loss of 69 cents.
Total revenues for the first quarter were $8.7 million, which missed the Zacks Consensus Estimate of $10.9 million but increased from the year-ago quarter’s $7.6 million.
Shares of Epizyme have plunged 76.3% so far this year compared with the industry’s 26.3% decline.
Image Source: Zacks Investment Research
Quarter in Detail
Tazverik (tazemetostat) received accelerated approval from the FDA in January 2020 to treat metastatic or locally-advanced Epithelioid Sarcoma (ES). In June 2020, the regulatory body approved the supplemental new drug application for Tazverik for two distinct follicular lymphoma (FL) indications.
The drug generated net product revenues worth $8.7 million in the first quarter. Commercial sales of the drug were $8.1 million, which grew 10% sequentially.
Adjusted research and development expenses declined to $27.8 million from $30.3 million in the year-ago quarter. Selling, general and administrative expenses also declined to $23.6 million from $31.5 million in the prior-year quarter.
Epizyme had $199.7 million of cash, cash equivalents and marketable securities as of Mar 31, 2022, compared with $176.8 million on Dec 31, 2021.
Recent Update
Since the FDA approval for Tazverik to treat both indications is under an accelerated pathway, Epizyme is also conducting confirmatory studies for ES and FL with Tazverik. A phase Ib/III confirmatory study (EZH-301) is evaluating Tazverik in combination with doxorubicin compared with doxorubicin plus placebo as a front-line treatment of ES.
Another phase Ib/III confirmatory study (EZH-302, SYMPHONY-1) is evaluating Tazverik combined with R2, clubbing Revlimid with Rituxan compared with R2 plus placebo for treating at least second-line FL patients. While data from the phase Ib portion of the study is expected later this year, Epizyme announced in March 2022 that it had dosed the first patient in the phase III portion of the study.
EPZM initiated a phase Ib/II basket study, ARIA (EZH-1501), during fourth-quarter 2021 to evaluate the safety and efficacy of tazemetostat across multiple new types of hematological malignancies. Epizyme already initiated a bispecific cohort of the study evaluating a combination of tazemetostat with Roche’s RHHBY mosunetuzumab in patients with R/R FL who received two or more prior lines of therapy. Preliminary data from the study is expected in second-half 2022.
Mosunetuzumab is Roche’s investigational CD20xCD3 T-cell engaging bispecific antibody. Epizyme entered into a clinical supply agreement with Roche for the bispecific cohort of the EZH-1501 study.
Our Take
Epizyme’s performance for the first quarter was dismal. Nevertheless, management’s efforts to increase the commercial adoption of Tazverik as well as develop tazemetostat for additional indications are encouraging. EPZM also has multiple pipeline readouts in 2022.
Zacks Rank & Stocks to Consider
Epizyme currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO and Alkermes ALKS. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 30 days. Shares of ALKS have rallied 15.9% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 52.5% in the year-to-date period.
Abeona Therapeutics has a mixed surprise history, with its earnings having surpassed expectations in one of the trailing four quarters, missing the mark in another and meeting the same on the remaining two occasions, the average surprise being 0.7%. In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%.
Special Report: The Top 5 IPOs for Your Portfolio
Today, you have a chance to get in on the ground floor of one of the best investment opportunities of the year. As the world continues to benefit from an ever-evolving internet, a handful of innovative tech companies are on the brink of reaping immense rewards - and you can put yourself in a position to cash in. One is set to disrupt the online communication industry. Brilliantly designed for creating online communities, this stock is poised to explode when made public. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity.
>>See Zacks’ Hottest IPOs Now
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Alkermes plc (ALKS): Free Stock Analysis Report
Epizyme, Inc. (EPZM): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO and Alkermes ALKS. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. | In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report Better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO and Alkermes ALKS. | Better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO and Alkermes ALKS. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. | In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%. Better-ranked stocks in the overall healthcare sector include Abeona Therapeutics ABEO and Alkermes ALKS. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, Abeona Therapeutics carries a Zacks Rank #2 (Buy). |
28031.0 | 2022-05-10 00:00:00 UTC | Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates | ABEO | https://www.nasdaq.com/articles/amicus-fold-q1-earnings-miss-galafold-sales-top-estimates | nan | nan | Amicus Therapeutics FOLD reported a loss of 30 cents per share for first-quarter 2022, wider than the Zacks Consensus Estimate of a loss of 24 cents as well as the year-ago loss of 25 cents.
Revenues increased 18.5% year over year to $78.7 million for the first quarter, beating the Zacks Consensus Estimate of $77 million. Revenues were entirely derived from the sales of Galafold (migalastat), approved for Fabry disease.
Shares of Amicus Therapeutics have slumped 46.1% in the year so far compared with the industry’s 28% decline.
Image Source: Zacks Investment Research
Quarter in Detail
Revenues for the first quarter were driven by strong new patient accruals, continued sustained patient compliance and adherence rates. While Amicus Therapeutics generated 31% of total revenues from within the United States, the remaining 69% was generated from the ex-U.S. sales of Galafold.
Operating expenses (adjusted basis) were $109 million, up 20.4% year over year.
As of Mar 31, 2022, Amicus Therapeutics had cash, cash equivalents and marketable securities of $411.2 million compared with $482.5 million on Dec 31, 2021.
Amicus Therapeutics expects cash resources and revenues to be enough to support operations and the ongoing research programs through self-sustainability.FOLD anticipates achieving profitability by 2023.
Maintains 2022 Guidance
For the full year, Amicus Therapeutics expects total Galafold revenues of at least $350-$365 million, driven by continued patient demand and commercial execution across all major markets, including the United States, the EU, the U.K. and Japan.
Adjusted operating expenses for the year are estimated in the range of $470-$485 million, driven by continued investments for the global Galafold launch, AT-GAA clinical studies and pre-launch activities.
Other Updates
The lead pipeline candidate in Amicus Therapeutics’ portfolio is AT-GAA, developed as a potential treatment of Pompe disease. The FDA accepted FOLD’s biologics license application (BLA) and the new drug application (NDA) for AT-GAA to treat Pompe disease. The FDA set PDUFA action dates of May 29, 2022, for the NDA and Jul 29, 2022, for the BLA.
In the EU, Amicus Therapeutics completed the marketing authorization application (MAA) submissions for AT-GAA in fourth-quarter 2021. A positive opinion on the MAA by the EMA’s Committee for Medicinal Products for Human Use (CHMP) is expected later this year.
The submissions in both the United States and the EU are based on data from the phase I/II and phase III PROPEL studies as well as the long-term open-label extension study evaluating AT-GAA for Pompe disease.
During the first quarter, Amicus Therapeutics decided to discontinue the CLN6 Batten Disease gene-therapy program development. The decision was based on the review of a long-term extension study data, which determined that any initial stabilization of disease progression at the two-year time point was not maintained.
Amicus Therapeutics, Inc. Price
Amicus Therapeutics, Inc. price | Amicus Therapeutics, Inc. Quote
Zacks Rank & Other Stocks to Consider
Amicus Therapeutics currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Vertex Pharmaceuticals VRTX. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Vertex Pharmaceuticals carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 30 days. Shares of ALKS have risen 14.4% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 54.2% in the year-to-date period.
Abeona Therapeutics has a mixed surprise history, with its earnings having surpassed expectations in one of the trailing four quarters, missing the mark in another and meeting the same on the remaining two occasions, the average surprise being 0.7%. In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%.
Vertex Pharmaceuticals’ earnings per share estimates for 2023 have increased from $15.31 to $15.33 in the past 30 days. VRTX has rallied 7% in the year so far.
Earnings of Vertex Pharmaceuticals beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 7.6%. In the last reported quarter, Vertex Pharmaceuticals missed earnings estimates by 2.2%.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Amicus Therapeutics, Inc. (FOLD): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Vertex Pharmaceuticals VRTX. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Vertex Pharmaceuticals carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. | While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Vertex Pharmaceuticals carry a Zacks Rank #2 (Buy). Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Vertex Pharmaceuticals VRTX. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. | While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Vertex Pharmaceuticals carry a Zacks Rank #2 (Buy). Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Vertex Pharmaceuticals VRTX. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. | Some other top-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Vertex Pharmaceuticals VRTX. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Vertex Pharmaceuticals carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. |
28032.0 | 2022-05-10 00:00:00 UTC | Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down | ABEO | https://www.nasdaq.com/articles/bausch-bhc-q1-earnings-and-revenues-miss-stock-down | nan | nan | Shares of Bausch Health Companies Inc. BHC are trading down in response to weak first-quarter 2022 results.
The stock has plunged 70.4% in the year so far compared with the industry’s decline of 30.4%.
Image Source: Zacks Investment Research
The company’s adjusted earnings per share of 72 cents missed the Zacks Consensus Estimate of $1.03 and decreased from $1.04 reported in the year-ago quarter.
Total revenues of $1.9 billion missed the Zacks Consensus Estimate of $2.1 billion and fell 5% year over year. Management stated that incremental macro pressures and a challenging supply chain environment affected the quarter.
Quarter in Detail
The company reported revenues in five segments – Salix, International, Diversified Products, Solta Medical and Bausch + Lomb.
Salix revenues came in at $464 million, down 2%. The decrease was primarily due to lower volumes on the loss of exclusivity of certain products, partially offset by increased sales of Xifaxan (rifaximin), Trulance (plecanatide) and Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), which grew 1%, 14% and 60%, respectively year over year.
International Rx revenues in the quarter were $244 million, down 20%.
Diversified Products revenues were $249 million, down 16% from the year-ago quarter, primarily due to decreased volumes.
Solta Medical reported revenues of $72 million, flat year over year, as an increase in net realized pricing was offset by a decline in volumes primarily due to inventory shortfalls resulting from the impact of lockdowns in China due to the new COVID-19 variant and microchip supply chain constraints.
Revenues from Bausch + Lomb were $889 million, up 1% year over year. Excluding the unfavorable impact of $29 million from foreign exchange and the impact of divestitures and discontinuations of $3 million, revenues increased organically by 5%, primarily due to higher sales in the global Vision Care business, including Lumify (brimonidine tartrate ophthalmic solution 0.025%), Biotrue Multi-Purpose Solution and Ocuvite/PreserVision and higher sales in the Global Surgical business.
Bausch Health Cos Inc. Price, Consensus and EPS Surprise
Bausch Health Cos Inc. price-consensus-eps-surprise-chart | Bausch Health Cos Inc. Quote
2022 Guidance Updated
Revenues are now expected in the $8.25-$8.40 billion range (earlier projection: $8.40-$8.60 billion).
Initial Public Offering of Bausch + Lomb
Bausch Health's eye health business, Bausch + Lomb, launched its initial public offering (IPO) and subsequently began trading under the ticker "BLCO" on May 6, 2022. The IPO is expected to close later in the day. The company expects to close the IPO with $630 million in gross proceeds to be applied for the repayment of Bausch Health's long-term debt on May 10, 2022.
Following the close of the IPO of the Bausch + Lomb eye health business, Bausch Health will operate as two companies.
The company has also planned to separate its Solta business.
Pipeline Progress
The company launched Xipere (triamcinolone acetonide injectable suspension), which uses the suprachoroidal space to treat patients suffering from macular edema associated with uveitis in the United States during the current quarter.
Enrollment is ongoing in the phase III study of rifaximin soluble solid dispersion to study the use of rifaximin to prevent hepatic encephalopathy. The company initiated phase II study to evaluate amiselimod (S1P modulator) for the treatment of mild to moderate ulcerative colitis.
Our Take
Bausch's first-quarter results were dismal amid incremental macro pressures and a challenging supply chain environment.
Zacks Rank & Stocks to Consider
Bausch currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare space are Abeona Therapeutics ABEO, Alkermes ALKS and Sarepta Therapeutics SRPT. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, the other stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 54.2% in the year-to-date period.
Abeona Therapeutics has a mixed surprise history. Its earnings surpassed expectations in one of the trailing four quarters, missing the mark in another and meeting the same in the remaining two occasions, the average surprise being 0.7%. In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 30 days. Shares of ALKS have risen 18.2% in the year-to-date period.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%.
Sarepta’s loss per share estimates for 2022 have narrowed by 28 cents in the past seven days. SRPT’s earnings having surpassed expectations in all of the trailing four quarters, the average surprise being 21.45%.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Bausch Health Cos Inc. (BHC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the healthcare space are Abeona Therapeutics ABEO, Alkermes ALKS and Sarepta Therapeutics SRPT. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 54.2% in the year-to-date period. | Some better-ranked stocks in the healthcare space are Abeona Therapeutics ABEO, Alkermes ALKS and Sarepta Therapeutics SRPT. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 54.2% in the year-to-date period. | Some better-ranked stocks in the healthcare space are Abeona Therapeutics ABEO, Alkermes ALKS and Sarepta Therapeutics SRPT. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 54.2% in the year-to-date period. | In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%. Some better-ranked stocks in the healthcare space are Abeona Therapeutics ABEO, Alkermes ALKS and Sarepta Therapeutics SRPT. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. |
28033.0 | 2022-05-09 00:00:00 UTC | Intercept (ICPT) Q1 Earnings Top, Ocaliva Sales Miss Estimates | ABEO | https://www.nasdaq.com/articles/intercept-icpt-q1-earnings-top-ocaliva-sales-miss-estimates | nan | nan | Intercept Pharmaceuticals, Inc. ICPT incurred a loss of 58 cents per share in first-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of 89 cents and the year-ago quarter’s loss of $1.22.
Total revenues of $88.6 million in the quarter missed the Zacks Consensus Estimate by 2.51%. The top line, however, registered 8% year over year growth.
Intercept’s shares have gained 20.3% in the year so far against the industry’s decrease of 25.2%.
Image Source: Zacks Investment Research
Quarter in Detail
Total revenues generated in the quarter comprised only Ocaliva (obeticholic acid or OCA) net sales. Net sales came in at $59.2 million in the United States and $29.4 million outside the country. Ex-U.S. sales of the drug were up 21% year over year, driven by new patient initiations, demonstrating encouraging growth.
OCA is approved under the brand name Ocaliva for treating primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA alone or as a monotherapy for adults intolerant to UDCA. While the approval to Ocaliva was granted by the FDA under accelerated pathway, the drug received conditional approval from the European Commission.
Selling, general and administrative expenses decreased to $50.0 million from $59.3 million in the prior-year quarter. The decline was primarily driven by ICPT’s ongoing efforts to manage its operational costs.
Research and development expenses decreased to $48.1 million from $50.8 million in the year-ago quarter.
As of Mar 31, 2022, Intercept had cash, cash equivalents, restricted cash and marketable securities of $406.9 million.
Other Updates
Intercept is currently in the process of compiling data from the post-marketing phase IV COBALT study. ICPT plans to submit data from this study to both the FDA and the EMA later this year to support the continued approval of Ocalvia for PBC indication.
ICPT is also on track to compile a new data package from the phase III REGENERATE study on fibrosis due to Nonalcoholic Steatohepatitis (NASH) to support a potential resubmission meeting with the FDA heads next month.
Intercept expects to report top-line results in the third quarter from the phase III REVERSE study, a late-stage program on compensated cirrhosis due to NASH.
Last week, Intercept announced that it entered into an agreement with Europe-based Advanz Pharma whereby the latter will acquire the international operations of the former, including the rights to commercialize Ocalvia for PBC indication in the ex-U.S. markets.
In return, ICPT will be eligible to receive up to $450 million, including $405 million as an upfront payment and another $45 million as contingent payments. As a result of inking this transaction deal, which is subject to customary conditions and regulatory approvals, Intercept decided to temporarily suspend its financial guidance for the current year. ICPT expects the transaction to be completed during the second quarter of 2022.
Intercept Pharmaceuticals, Inc. Price
Intercept Pharmaceuticals, Inc. price | Intercept Pharmaceuticals, Inc. Quote
Zacks Stock and Stocks to Consider
Intercept currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Vertex Pharmaceuticals VRTX, each of which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 51.2% in the year-to-date period.
Abeona Therapeutics has a mixed surprise history, with its earnings having surpassed expectations in one of the trailing four quarters, missing the mark in another and meeting the same on the remaining two occasions, the average surprise being 0.7%. In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 30 days. Shares of ALKS have risen 18.8% in the year-to-date period.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Vertex Pharmaceuticals’ earnings per share estimates for 2023 have increased from $15.31 to $15.33 in the past 30 days. VRTX has rallied 15.6% in the year so far.
Earnings of Vertex Pharmaceuticals beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 7.6%. In the last reported quarter, Vertex Pharmaceuticals missed earnings estimates by 2.2%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Vertex Pharmaceuticals VRTX, each of which has a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 51.2% in the year-to-date period. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Vertex Pharmaceuticals VRTX, each of which has a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 51.2% in the year-to-date period. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Vertex Pharmaceuticals VRTX, each of which has a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 51.2% in the year-to-date period. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Vertex Pharmaceuticals VRTX, each of which has a Zacks Rank #2 (Buy) at present. Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 51.2% in the year-to-date period. |
28034.0 | 2022-05-06 00:00:00 UTC | Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y | ABEO | https://www.nasdaq.com/articles/aerie-aeri-q1-loss-wider-than-expected-revenues-rise-y-y | nan | nan | Aerie Pharmaceuticals AERI reported adjusted loss per share of 66 cents for first-quarter 2022, wider than the Zacks Consensus Estimate of a loss of 65 cents but narrower than the year-ago quarter’s loss of 72 cents.
Revenues came in at $29.8 million, which increased from $23 million in the year-ago quarter. However, the reported revenues missed the Zacks Consensus Estimate of $30 million.
Shares of Aerie have risen 0.4% in the year so far against the industry’s 22.6% fall.
Image Source: Zacks Investment Research
Quarter in Detail
AERI earned product revenues of $29.8 million from the sales of its two glaucoma products, namely Rhopressa and Rocklatan. The figure was up 30% year over year.
We remind investors that Aerie’s first drug Rhopressa (netarsudil ophthalmic solution) was approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Aerie’s second drug Rocklatan, a once-daily, quadruple-action, fixed-dose combination of Rhopressa and Xalatan, was approved to reduce the elevated IOP in patients with open-angle glaucoma or ocular hypertension.
Total operating expenses for the reported quarter were $52.2 million compared with $42.2 million in the year-ago period.
2022 Guidance
AERI reiterated its financial guidance for 2022. Management expects net product revenues in the range of $130-$140 million, indicating a rise of 16-25% from the 2021 figure.
Pipeline Updates
Aerie announced data from the phase IIb COMET-1 study last September, which evaluated its investigational therapy AR-15512 in patients with dry eye disease. While the study achieved a statistical significance over multiple pre-specified symptoms and sign endpoints, it did not achieve all pre-determined primary endpoints with statistical significance. To complete the development of AR-15512, AERI plans to initiate a registrational phase III study in dry-eye disease during second-quarter 2022.
Aerie remains on track to file an investigational new drug (IND) application to start clinical studies for AR-14034, in wet age-related macular degeneration by second-half 2022. AERI also intends to file an IND application for AR-6121, a ROCK inhibitor-linked steroid, in the second half of 2022.
Following discussions with both the FDA and EMA authorities, Aerie expects to initiate phase III activities during the first half of 2022for its sustained-release retinal implant AR-1105 in patients with macular edema due to retinal vein occlusion.
Aerie Pharmaceuticals, Inc. Price
Aerie Pharmaceuticals, Inc. price | Aerie Pharmaceuticals, Inc. Quote
Zacks Rank & Key Picks
Aerie currently has a Zacks Rank #4 (Sell).
Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Amicus Therapeutics FOLD. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Amicus Therapeutics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 30 days. Shares of Alkermes have risen 20% in the year-to-date period.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, ALKS delivered an earnings surprise of 1,100%.
Amicus Therapeutics’ loss per share estimates for 2023 have narrowed from 19 cents to 16 cents in the past 30 days. Shares of FOLD have declined 42.7% in the year-to-date period.
Earnings of Amicus Therapeutics missed estimates in three of the last four quarters and beat the mark on one occasion, witnessing a negative surprise of 28%, on average. In the last reported quarter, FOLD delivered a negative earnings surprise of 107.1%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 46.2% in the year-to-date period.
Abeona Therapeutics has a mixed surprise history, with its earnings having surpassed expectations in one of the trailing four quarters, missing the mark in another and meeting the same on the remaining two occasions. The average earnings surprise was 0.7%. In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Amicus Therapeutics, Inc. (FOLD): Free Stock Analysis Report
Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Amicus Therapeutics FOLD. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Amicus Therapeutics carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Amicus Therapeutics FOLD. In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Amicus Therapeutics carry a Zacks Rank #2 (Buy). | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Amicus Therapeutics FOLD. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Amicus Therapeutics carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Amicus Therapeutics FOLD. In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Amicus Therapeutics carry a Zacks Rank #2 (Buy). |
28035.0 | 2022-05-06 00:00:00 UTC | ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates | ABEO | https://www.nasdaq.com/articles/chemocentryx-ccxi-q1-earnings-and-sales-miss-estimates | nan | nan | ChemoCentryx Inc. CCXI reported first-quarter 2022 loss of 55 cents per share, wider than the Zacks Consensus Estimate of a loss of 30 cents and the year-ago quarter’s loss of 43 cents.
Total revenues were recorded at $5.5 million, missing the Zacks Consensus Estimate of $25.7 million and declining from $10.4 million in the year-ago quarter.
Quarter in Detail
ChemoCentryx received an FDA approval last October for its lead candidate avacopan as an adjunctive treatment combined with the standard therapy for two main forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, namely granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). The drug is being marketed under the brand name Tavneos.
Tavneos generated net product sales of $5.4 million during the first quarter of 2022 entirely from its commercial sales in the United States. Sales rose more than five-fold from the fourth-quarter 2021 reading. In the year-ago quarter, ChemoCentryx did not record any revenues from product sales.
During the first quarter, CCXI received 248 new patient start forms (PSFs) for the drug, which is nearly 95% higher than the figure reported in the previous quarter. As of March-end, 277 patients continue to be treated with Tavneos, reflecting a 208% sequential rise.
Collaboration revenues recorded during the quarter were $0.1 million compared with $10.2 million in the year-ago quarter. This substantial decline was triggered by a milestone payment received from partner Vifor Pharma in the year-ago quarter due to the acceptance of a regulatory filing for Tavneos to address ANCA-associated vasculitis in Japan.
Research and development expenses were $17.5 million in the quarter compared with $23.4 million in the year-ago quarter. This decline was on account of a reduction in clinical expenses on completing the phase IIb TAVNEOS AURORA study evaluating Tavneos for the hidradenitis suppurativa (HS) indication.
Selling, general and administrative expenses increased to $26 million from $16.3 million due to higher employee-related expenses associated with commercialization planning efforts and the launch of Tavneos in the United States.
ChemoCentryxhad $371.8 million in cash, cash equivalents and investments as of Mar 31, 2022.
Recent Updates
In January 2022, Tavneos was approved in the EU combined with a rituximab or cyclophosphamide regimen for the treatment of adult patients with a severe, active GPA or an MPA. The EU approval triggered a $45 million milestone from ChemoCentryx’ partner Vifor Pharma. While this payment was received by CCXI during the quarter, its accounting treatment will recognize the same as collaboration revenues over a four-year period.
Shares of CCXI were up 13.2% in after-hours trading on May 5, possibly on the receipt of the milestone payment. Yet, the stock has plunged 50.9% in the year so far compared with the industry’s 22.6% decline.
Image Source: Zacks Investment Research
ChemoCentryx will get royalties in the teens-to-the-mid-20% range on the potential aggregate net sales from territories outside the United States, which are under Vifor’s coverage. Tavneos also received a regulatory nod in Canada last month for treating ANCA-associated vasculitis.
Management plans to initiate clinical development of avacopan in patients with lupus nephritis in the second half of the year. It plans to meet with the FDA officials to discuss the late-stage development of Tavneos in patients with Hurley Stage III (severe) HS during the second quarter, with the goal of initiating a phase III study in those patients during the second half of 2022.
ChemoCentryx, Inc. Price
ChemoCentryx, Inc. price | ChemoCentryx, Inc. Quote
Zacks Rank & Stocks to Consider
ChemoCentryx currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Amicus Therapeutics FOLD. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Amicus Therapeutics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 30 days. Shares of ALKS have risen 20% in the year-to-date period.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Amicus Therapeutics’ loss per share estimates for 2023 have narrowed from 19 cents to 16 cents in the past 30 days. Shares of FOLD have declined 42.7% in the year-to-date period.
Earnings of Amicus Therapeutics missed estimates in three of the last four quarters and beat the mark on one occasion, witnessing a negative surprise of 28%, on average. In the last reported quarter, Amicus Therapeutics delivered a negative earnings surprise of 107.1%.
Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. Shares of ABEO have declined 46.2% in the year-to-date period.
Abeona Therapeutics has a mixed surprise history, with its earnings having surpassed expectations in one of the trailing four quarters, missing the mark in another and meeting the same on the remaining two occasions. The average earnings surprise was 0.7%. In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Amicus Therapeutics, Inc. (FOLD): Free Stock Analysis Report
ChemoCentryx, Inc. (CCXI): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Amicus Therapeutics FOLD. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Amicus Therapeutics carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Amicus Therapeutics FOLD. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Amicus Therapeutics carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. | Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Amicus Therapeutics FOLD. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Amicus Therapeutics carry a Zacks Rank #2 (Buy). Abeona Therapeutics’ loss per share estimates for 2022 have narrowed from 34 cents to 33 cents in the past 30 days. | In the last reported quarter, Abeona Therapeutics missed earnings estimates by 7.7%. Some better-ranked stocks in the overall healthcare sector are Abeona Therapeutics ABEO, Alkermes ALKS and Amicus Therapeutics FOLD. While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, both Abeona Therapeutics and Amicus Therapeutics carry a Zacks Rank #2 (Buy). |
28036.0 | 2022-03-14 00:00:00 UTC | Philips' (PHG) Collaboration Live Gets Nod for Remote Diagnosis | ABEO | https://www.nasdaq.com/articles/philips-phg-collaboration-live-gets-nod-for-remote-diagnosis | nan | nan | Koninklijke Philips’ PHG Collaboration Live integrated tele-ultrasound receives the expanded U.S. Food & Drug Administration 510(k) clearance for remote diagnostic use on additional mobile platforms.
Collaboration Live is the medical industry’s first tele-ultrasound technology that lets clinicians collaborate, text, share screens with and transfer control to remote colleagues in real time.
Collaboration Live, which is available on Philips’ Ultrasound Systems EPIQ and Affiniti, helps clinicians to collaborate in real-time with colleagues to complete image acquisition and diagnosis regardless of location.
Ultrasound imaging brings clinicians in direct contact with patients. Amidst the ongoing pandemic, clinicians are facing impending risk of coming in contact with infected patients and in turn creating widespread staffing shortages.
This increases backlog of postponed exams and increases workload for clinicians working in hospitals and other medical institutions. However, with the expanded clearance, Philips’ Collaboration Live clinicians can consult or diagnose from their mobile devices, thus reducing the risk of contamination by coming in contact with infected patients.
Koninklijke Philips N.V. Price and Consensus
Koninklijke Philips N.V. price-consensus-chart | Koninklijke Philips N.V. Quote
Philips Rides on Solid Demand Amidst Pandemic
Philips witnessed solid demand for patient monitors, hospital ventilators, computed tomography and portable ultrasound systems due to the coronavirus outbreak. Moreover, increased interest in telehealth solutions like tele-ICU, tele-radiology and tele-pathology, which aid virtual working and collaboration of healthcare professionals, bodes well for Philips.
However due to the pandemic, rising supply chain issues had negatively impacted the company’s top-line growth in the fourth quarter of 2021. The supply chain management issues are still prevalent globally and potray significant threat to the company’s near-term profitability.
As a result of the pandemic, growth prospects are also sluggish in the healthcare market on a global scale. Rising raw material prices are also hurting Philips’ ability to sustain competitiveness in the markets it operates in.
Increased interest in telehealth solutions like tele-ICU, tele-radiology, tele-pathology, tele-dentistry services might act a key catalyst for the company’s growth in the healthcare market.
Collaboration Live, which is a part of the company’s Connected Care Business, accounted for 26.7% of sales in 2021. The Connected Care segment comprises the Monitoring & Analytics (41% of sales), Therapeutic Care (5% of sales), Population Health Management (4% of sales), Sleep & Respiratory Care (47% of sales) and Connected Care Informatics (3% of sales) businesses.
Zacks Rank and Stocks to Consider
Philips currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Philips’ shares have fallen 16.3% in the year-to-date period, underperforming the Zacks Medical-Products industry and the Medical sector’s declines of 11.9% and 11.5%, respectively.
Here are a few better-ranked stock worth considering in the broader Medical Sector.
AmerisourceBergen ABC carries a Zacks Rank #2 (Buy).
ABC shares have returned 8.8% in the year-to-date period, outperforming the Zacks Medical - Dental Supplies industry and the Medical sector’s declines of 8.5% and 11.5%, respectively.
Abeona Therapeutics ABEO carries a Zacks Rank #2 (Buy).
Abeona shares have fallen 16.2% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry and the Medical sector’s declines of 19.3% and 11.5%, respectively.
Acumen Pharmaceuticals ABOS also carry a Zacks Rank #2 (Buy).
Acumen shares have fallen 18.5% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry and the Medical sector’s declines of 19.3% and 11.5%, respectively.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?
Last year's 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys
Access Zacks Top 10 Stocks for 2022 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Koninklijke Philips N.V. (PHG): Free Stock Analysis Report
AmerisourceBergen Corporation (ABC): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Acumen Pharmaceuticals, Inc. (ABOS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics ABEO carries a Zacks Rank #2 (Buy). Abeona shares have fallen 16.2% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry and the Medical sector’s declines of 19.3% and 11.5%, respectively. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | Abeona shares have fallen 16.2% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry and the Medical sector’s declines of 19.3% and 11.5%, respectively. Abeona Therapeutics ABEO carries a Zacks Rank #2 (Buy). Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | Abeona Therapeutics ABEO carries a Zacks Rank #2 (Buy). Abeona shares have fallen 16.2% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry and the Medical sector’s declines of 19.3% and 11.5%, respectively. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report | Abeona Therapeutics ABEO carries a Zacks Rank #2 (Buy). Abeona shares have fallen 16.2% in the year-to-date period compared with the Zacks Medical - Biomedical and Genetics industry and the Medical sector’s declines of 19.3% and 11.5%, respectively. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report |
28037.0 | 2022-02-02 00:00:00 UTC | Pre-market Movers: MDJH, ELMS, EXC, PYPL, PHAR… | ABEO | https://www.nasdaq.com/articles/pre-market-movers%3A-mdjh-elms-exc-pypl-phar... | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.05 A.M. ET).
In the Green
MDJM Ltd (MDJH) is up over 73% at $2.92 Pharming Group N.V. (PHAR) is up over 13% at $10.01 Advanced Micro Devices, Inc. (AMD) is up over 11% at $129.86 Entasis Therapeutics Holdings Inc. (ETTX) is up over 11% at $1.61 Alphabet Inc. (GOOG) is up over 10% at $3038 Xilinx, Inc. (XLNX) is up over 10% at $219.49 Helbiz, Inc. (HLBZ) is up over 10% at $3.37 IceCure Medical Ltd (ICCM) is up over 10% at $2.85 Arbutus Biopharma Corporation (ABUS) is up over 9% at $3.19 Epizyme, Inc. (EPZM) is up over 9% at $1.35 Abeona Therapeutics Inc. (ABEO) is up over 7% at $0.30 AgriFORCE Growing Systems, Ltd. (AGRI) is up over 6% at $1.55
In the Red
Electric Last Mile Solutions, Inc. (ELMS) is down over 31% at $3.81 Exelon Corporation (EXC) is down over 27% at $41.79 PayPal Holdings, Inc. (PYPL) is down over 16% at $146.79 ION Geophysical Corporation (IO) is down over 11% at $0.53 BRF S.A. (BRFS) is down over 9% at $3.72 Indonesia Energy Corporation Limited (INDO) is down over 8% at $4.05 Encompass Health Corporation (EHC) is down over 7% at $57.00 FGI Industries Ltd. (FGI) is down over 7% at $4.44
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green MDJM Ltd (MDJH) is up over 73% at $2.92 Pharming Group N.V. (PHAR) is up over 13% at $10.01 Advanced Micro Devices, Inc. (AMD) is up over 11% at $129.86 Entasis Therapeutics Holdings Inc. (ETTX) is up over 11% at $1.61 Alphabet Inc. (GOOG) is up over 10% at $3038 Xilinx, Inc. (XLNX) is up over 10% at $219.49 Helbiz, Inc. (HLBZ) is up over 10% at $3.37 IceCure Medical Ltd (ICCM) is up over 10% at $2.85 Arbutus Biopharma Corporation (ABUS) is up over 9% at $3.19 Epizyme, Inc. (EPZM) is up over 9% at $1.35 Abeona Therapeutics Inc. (ABEO) is up over 7% at $0.30 AgriFORCE Growing Systems, Ltd. (AGRI) is up over 6% at $1.55 In the Red Electric Last Mile Solutions, Inc. (ELMS) is down over 31% at $3.81 Exelon Corporation (EXC) is down over 27% at $41.79 PayPal Holdings, Inc. (PYPL) is down over 16% at $146.79 ION Geophysical Corporation (IO) is down over 11% at $0.53 BRF S.A. (BRFS) is down over 9% at $3.72 Indonesia Energy Corporation Limited (INDO) is down over 8% at $4.05 Encompass Health Corporation (EHC) is down over 7% at $57.00 FGI Industries Ltd. (FGI) is down over 7% at $4.44 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.05 A.M. ET). | In the Green MDJM Ltd (MDJH) is up over 73% at $2.92 Pharming Group N.V. (PHAR) is up over 13% at $10.01 Advanced Micro Devices, Inc. (AMD) is up over 11% at $129.86 Entasis Therapeutics Holdings Inc. (ETTX) is up over 11% at $1.61 Alphabet Inc. (GOOG) is up over 10% at $3038 Xilinx, Inc. (XLNX) is up over 10% at $219.49 Helbiz, Inc. (HLBZ) is up over 10% at $3.37 IceCure Medical Ltd (ICCM) is up over 10% at $2.85 Arbutus Biopharma Corporation (ABUS) is up over 9% at $3.19 Epizyme, Inc. (EPZM) is up over 9% at $1.35 Abeona Therapeutics Inc. (ABEO) is up over 7% at $0.30 AgriFORCE Growing Systems, Ltd. (AGRI) is up over 6% at $1.55 In the Red Electric Last Mile Solutions, Inc. (ELMS) is down over 31% at $3.81 Exelon Corporation (EXC) is down over 27% at $41.79 PayPal Holdings, Inc. (PYPL) is down over 16% at $146.79 ION Geophysical Corporation (IO) is down over 11% at $0.53 BRF S.A. (BRFS) is down over 9% at $3.72 Indonesia Energy Corporation Limited (INDO) is down over 8% at $4.05 Encompass Health Corporation (EHC) is down over 7% at $57.00 FGI Industries Ltd. (FGI) is down over 7% at $4.44 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.05 A.M. ET). | In the Green MDJM Ltd (MDJH) is up over 73% at $2.92 Pharming Group N.V. (PHAR) is up over 13% at $10.01 Advanced Micro Devices, Inc. (AMD) is up over 11% at $129.86 Entasis Therapeutics Holdings Inc. (ETTX) is up over 11% at $1.61 Alphabet Inc. (GOOG) is up over 10% at $3038 Xilinx, Inc. (XLNX) is up over 10% at $219.49 Helbiz, Inc. (HLBZ) is up over 10% at $3.37 IceCure Medical Ltd (ICCM) is up over 10% at $2.85 Arbutus Biopharma Corporation (ABUS) is up over 9% at $3.19 Epizyme, Inc. (EPZM) is up over 9% at $1.35 Abeona Therapeutics Inc. (ABEO) is up over 7% at $0.30 AgriFORCE Growing Systems, Ltd. (AGRI) is up over 6% at $1.55 In the Red Electric Last Mile Solutions, Inc. (ELMS) is down over 31% at $3.81 Exelon Corporation (EXC) is down over 27% at $41.79 PayPal Holdings, Inc. (PYPL) is down over 16% at $146.79 ION Geophysical Corporation (IO) is down over 11% at $0.53 BRF S.A. (BRFS) is down over 9% at $3.72 Indonesia Energy Corporation Limited (INDO) is down over 8% at $4.05 Encompass Health Corporation (EHC) is down over 7% at $57.00 FGI Industries Ltd. (FGI) is down over 7% at $4.44 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.05 A.M. ET). | In the Green MDJM Ltd (MDJH) is up over 73% at $2.92 Pharming Group N.V. (PHAR) is up over 13% at $10.01 Advanced Micro Devices, Inc. (AMD) is up over 11% at $129.86 Entasis Therapeutics Holdings Inc. (ETTX) is up over 11% at $1.61 Alphabet Inc. (GOOG) is up over 10% at $3038 Xilinx, Inc. (XLNX) is up over 10% at $219.49 Helbiz, Inc. (HLBZ) is up over 10% at $3.37 IceCure Medical Ltd (ICCM) is up over 10% at $2.85 Arbutus Biopharma Corporation (ABUS) is up over 9% at $3.19 Epizyme, Inc. (EPZM) is up over 9% at $1.35 Abeona Therapeutics Inc. (ABEO) is up over 7% at $0.30 AgriFORCE Growing Systems, Ltd. (AGRI) is up over 6% at $1.55 In the Red Electric Last Mile Solutions, Inc. (ELMS) is down over 31% at $3.81 Exelon Corporation (EXC) is down over 27% at $41.79 PayPal Holdings, Inc. (PYPL) is down over 16% at $146.79 ION Geophysical Corporation (IO) is down over 11% at $0.53 BRF S.A. (BRFS) is down over 9% at $3.72 Indonesia Energy Corporation Limited (INDO) is down over 8% at $4.05 Encompass Health Corporation (EHC) is down over 7% at $57.00 FGI Industries Ltd. (FGI) is down over 7% at $4.44 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.05 A.M. ET). |
28038.0 | 2022-01-25 00:00:00 UTC | Here's Why Abeona Therapeutics (ABEO) Looks Ripe for Bottom Fishing | ABEO | https://www.nasdaq.com/articles/heres-why-abeona-therapeutics-abeo-looks-ripe-for-bottom-fishing | nan | nan | A downtrend has been apparent in Abeona Therapeutics (ABEO) lately. While the stock has lost 16.8% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.
While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this drug developer is a solid fundamental factor that enhances the prospects of a trend reversal for the stock.
What is a Hammer Chart and How to Trade It?
This is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a 'hammer.'
In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price.
When it occurs at the bottom of a downtrend, this pattern signals that the bears might have lost control over the price. And, the success of bulls in stopping the price from falling further indicates a potential trend reversal.
Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors.
Like every technical indicator, the hammer chart pattern has its limitations. Particularly, as the strength of a hammer depends on its placement on the chart, it should always be used in conjunction with other bullish indicators.
Here's What Makes the Trend Reversal More Likely for ABEO
There has been an upward trend in earnings estimate revisions for ABEO lately, which can certainly be considered a bullish indicator on the fundamental side. That's because a positive trend in earnings estimate revisions usually translates into price appreciation in the near term.
The consensus EPS estimate for the current year has increased 2.5% over the last 30 days. This means that the Wall Street analysts covering ABEO are majorly in agreement about the company's potential to report better earnings than what they predicted earlier.
If this is not enough, you should note that ABEO currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Moreover, a Zacks Rank of 2 for Abeona Therapeutics is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company's prospects are beginning to improve.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A downtrend has been apparent in Abeona Therapeutics (ABEO) lately. Here's What Makes the Trend Reversal More Likely for ABEO There has been an upward trend in earnings estimate revisions for ABEO lately, which can certainly be considered a bullish indicator on the fundamental side. This means that the Wall Street analysts covering ABEO are majorly in agreement about the company's potential to report better earnings than what they predicted earlier. | You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Moreover, a Zacks Rank of 2 for Abeona Therapeutics is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company's prospects are beginning to improve. Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report A downtrend has been apparent in Abeona Therapeutics (ABEO) lately. | If this is not enough, you should note that ABEO currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Moreover, a Zacks Rank of 2 for Abeona Therapeutics is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company's prospects are beginning to improve. A downtrend has been apparent in Abeona Therapeutics (ABEO) lately. | Here's What Makes the Trend Reversal More Likely for ABEO There has been an upward trend in earnings estimate revisions for ABEO lately, which can certainly be considered a bullish indicator on the fundamental side. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Moreover, a Zacks Rank of 2 for Abeona Therapeutics is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company's prospects are beginning to improve. A downtrend has been apparent in Abeona Therapeutics (ABEO) lately. |
28039.0 | 2021-12-25 00:00:00 UTC | Abeona Therapeutics Inc Shares Close the Day 11.0% Higher - Daily Wrap | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-inc-shares-close-the-day-11.0-higher-daily-wrap | nan | nan | Abeona Therapeutics Inc (ABEO) shares closed today 11.0% higher than it did at the end of yesterday. The stock is currently down 77.0% year-to-date, down 79.1% over the past 12 months, and down 92.5% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%.
Trading Activity
Shares traded as high as $0.37 and as low as $0.27 this week.
Shares closed 90.5% below its 52-week high and 33.9% above its 52-week low.
Trading volume this week was 70.7% lower than the 10-day average and 15.3% lower than the 30-day average.
Beta, a measure of the stock’s volatility relative to the overall market stands at 0.9.
Technical Indicators
The Relative Strength Index (RSI) on the stock was between 30 and 70.
MACD, a trend-following momentum indicator, indicates a downward trend.
The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance
The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis
The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis
The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis
Per Group Comparative Performance
The company's stock price performance year-to-date lags the peer average by 789.4%
The company's stock price performance over the past 12 months lags the peer average by 887.5%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc (ABEO) shares closed today 11.0% higher than it did at the end of yesterday. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. | Abeona Therapeutics Inc (ABEO) shares closed today 11.0% higher than it did at the end of yesterday. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 789.4% The company's stock price performance over the past 12 months lags the peer average by 887.5% | Abeona Therapeutics Inc (ABEO) shares closed today 11.0% higher than it did at the end of yesterday. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 789.4% The company's stock price performance over the past 12 months lags the peer average by 887.5% This story was produced by the Kwhen Automated News Generator. | Abeona Therapeutics Inc (ABEO) shares closed today 11.0% higher than it did at the end of yesterday. Shares closed 90.5% below its 52-week high and 33.9% above its 52-week low. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. |
28040.0 | 2021-12-17 00:00:00 UTC | Health Care Sector Update for 12/17/2021: GNFT,IPN.PA,CERN,ORCL,ABEO | ABEO | https://www.nasdaq.com/articles/health-care-sector-update-for-12-17-2021%3A-gnftipn.pacernorclabeo | nan | nan | Health care stocks were mixed this afternoon, with the NYSE Health Care Index falling 0.5%, while the SPDR Health Care Select Sector ETF (XLV) was up 0.1%.
The Nasdaq Biotechnology index was climbing by 2.5%.
In company news, Genfit (GNFT) soared over 60% after the French biopharmaceuticals company issued an exclusive license for its elafibranor liver medication to Paris-listed rival Ipsen (IPN.PA) in exchange for a 120 million euro ($135.4 million) upfront payment, a 28 million euro ($31.6 million) equity investment and up to 360 million euro ($406.3 million) in additional milestone payments. Separately, Genfit Friday said it was acquiring exclusive rights in the US, Canada and Europe to Genoscience Pharma's GNS561 drug candidate to treat cholangiocarcinoma through a 3 million euro ($3.39 million) equity stake in Genoscience.
Cerner (CERN) rose nearly 14% following reports Oracle (ORCL) is discussing a potential takeover of the digital medical-records company worth up to $30 billion, the Wall Street Journal reported, citing people familiar with the matter.
Abeona Therapeutics (ABEO) plunged over 39% after the biopharmaceuticals firm Friday priced a $17.5 million public offering of 44.7 million common shares at $0.39 apiece, or 20% under its last closing price. Investors also received an equal number of five-year warrants to buy an additional share, also exercisable at $0.39 per share.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics (ABEO) plunged over 39% after the biopharmaceuticals firm Friday priced a $17.5 million public offering of 44.7 million common shares at $0.39 apiece, or 20% under its last closing price. Separately, Genfit Friday said it was acquiring exclusive rights in the US, Canada and Europe to Genoscience Pharma's GNS561 drug candidate to treat cholangiocarcinoma through a 3 million euro ($3.39 million) equity stake in Genoscience. Cerner (CERN) rose nearly 14% following reports Oracle (ORCL) is discussing a potential takeover of the digital medical-records company worth up to $30 billion, the Wall Street Journal reported, citing people familiar with the matter. | Abeona Therapeutics (ABEO) plunged over 39% after the biopharmaceuticals firm Friday priced a $17.5 million public offering of 44.7 million common shares at $0.39 apiece, or 20% under its last closing price. Health care stocks were mixed this afternoon, with the NYSE Health Care Index falling 0.5%, while the SPDR Health Care Select Sector ETF (XLV) was up 0.1%. In company news, Genfit (GNFT) soared over 60% after the French biopharmaceuticals company issued an exclusive license for its elafibranor liver medication to Paris-listed rival Ipsen (IPN.PA) in exchange for a 120 million euro ($135.4 million) upfront payment, a 28 million euro ($31.6 million) equity investment and up to 360 million euro ($406.3 million) in additional milestone payments. | Abeona Therapeutics (ABEO) plunged over 39% after the biopharmaceuticals firm Friday priced a $17.5 million public offering of 44.7 million common shares at $0.39 apiece, or 20% under its last closing price. Health care stocks were mixed this afternoon, with the NYSE Health Care Index falling 0.5%, while the SPDR Health Care Select Sector ETF (XLV) was up 0.1%. In company news, Genfit (GNFT) soared over 60% after the French biopharmaceuticals company issued an exclusive license for its elafibranor liver medication to Paris-listed rival Ipsen (IPN.PA) in exchange for a 120 million euro ($135.4 million) upfront payment, a 28 million euro ($31.6 million) equity investment and up to 360 million euro ($406.3 million) in additional milestone payments. | Abeona Therapeutics (ABEO) plunged over 39% after the biopharmaceuticals firm Friday priced a $17.5 million public offering of 44.7 million common shares at $0.39 apiece, or 20% under its last closing price. Health care stocks were mixed this afternoon, with the NYSE Health Care Index falling 0.5%, while the SPDR Health Care Select Sector ETF (XLV) was up 0.1%. The Nasdaq Biotechnology index was climbing by 2.5%. |
28041.0 | 2021-12-17 00:00:00 UTC | Pre-market Movers: GNFT, ABEO, SPRB, IO, CERN… | ABEO | https://www.nasdaq.com/articles/pre-market-movers%3A-gnft-abeo-sprb-io-cern... | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.10 A.M. ET).
In the Green
Genfit SA (GNFT) is up over 44% at $4.80 Spruce Biosciences, Inc. (SPRB) is up over 20% at $2.99 Cerner Corporation (CERN) is up over 18% at $94.30 Moxian (BVI) Inc (MOXC) is up over 15% at $4.86 Adagio Therapeutics, Inc. (ADGI) is up over 11% at $15.78 E-Home Household Service Holdings Limited (EJH) is up over 9% at $1.80 Kiora Pharmaceuticals, Inc. (KPRX) is up over 9% at $0.95 ObsEva SA (OBSV) is up over 6% at $2.34
In the Red
Abeona Therapeutics Inc. (ABEO) is down over 25% at $0.37 ION Geophysical Corporation (IO) is down over 19% at $1.11 Rivian Automotive, Inc. (RIVN) is down over 9% at $99.03 UP Fintech Holding Limited (TIGR) is down over 9% at $4.39 Huadi International Group Co., Ltd. (HUDI) is down over 8% at $26.93 Jupai Holdings Limited (JP) is down over 8% at $0.96 Futu Holdings Limited (FUTU) is down over 7% at $34.43 Kaixin Auto Holdings (KXIN) is down over 5% at $1.60
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green Genfit SA (GNFT) is up over 44% at $4.80 Spruce Biosciences, Inc. (SPRB) is up over 20% at $2.99 Cerner Corporation (CERN) is up over 18% at $94.30 Moxian (BVI) Inc (MOXC) is up over 15% at $4.86 Adagio Therapeutics, Inc. (ADGI) is up over 11% at $15.78 E-Home Household Service Holdings Limited (EJH) is up over 9% at $1.80 Kiora Pharmaceuticals, Inc. (KPRX) is up over 9% at $0.95 ObsEva SA (OBSV) is up over 6% at $2.34 In the Red Abeona Therapeutics Inc. (ABEO) is down over 25% at $0.37 ION Geophysical Corporation (IO) is down over 19% at $1.11 Rivian Automotive, Inc. (RIVN) is down over 9% at $99.03 UP Fintech Holding Limited (TIGR) is down over 9% at $4.39 Huadi International Group Co., Ltd. (HUDI) is down over 8% at $26.93 Jupai Holdings Limited (JP) is down over 8% at $0.96 Futu Holdings Limited (FUTU) is down over 7% at $34.43 Kaixin Auto Holdings (KXIN) is down over 5% at $1.60 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.10 A.M. ET). | In the Green Genfit SA (GNFT) is up over 44% at $4.80 Spruce Biosciences, Inc. (SPRB) is up over 20% at $2.99 Cerner Corporation (CERN) is up over 18% at $94.30 Moxian (BVI) Inc (MOXC) is up over 15% at $4.86 Adagio Therapeutics, Inc. (ADGI) is up over 11% at $15.78 E-Home Household Service Holdings Limited (EJH) is up over 9% at $1.80 Kiora Pharmaceuticals, Inc. (KPRX) is up over 9% at $0.95 ObsEva SA (OBSV) is up over 6% at $2.34 In the Red Abeona Therapeutics Inc. (ABEO) is down over 25% at $0.37 ION Geophysical Corporation (IO) is down over 19% at $1.11 Rivian Automotive, Inc. (RIVN) is down over 9% at $99.03 UP Fintech Holding Limited (TIGR) is down over 9% at $4.39 Huadi International Group Co., Ltd. (HUDI) is down over 8% at $26.93 Jupai Holdings Limited (JP) is down over 8% at $0.96 Futu Holdings Limited (FUTU) is down over 7% at $34.43 Kaixin Auto Holdings (KXIN) is down over 5% at $1.60 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.10 A.M. ET). | In the Green Genfit SA (GNFT) is up over 44% at $4.80 Spruce Biosciences, Inc. (SPRB) is up over 20% at $2.99 Cerner Corporation (CERN) is up over 18% at $94.30 Moxian (BVI) Inc (MOXC) is up over 15% at $4.86 Adagio Therapeutics, Inc. (ADGI) is up over 11% at $15.78 E-Home Household Service Holdings Limited (EJH) is up over 9% at $1.80 Kiora Pharmaceuticals, Inc. (KPRX) is up over 9% at $0.95 ObsEva SA (OBSV) is up over 6% at $2.34 In the Red Abeona Therapeutics Inc. (ABEO) is down over 25% at $0.37 ION Geophysical Corporation (IO) is down over 19% at $1.11 Rivian Automotive, Inc. (RIVN) is down over 9% at $99.03 UP Fintech Holding Limited (TIGR) is down over 9% at $4.39 Huadi International Group Co., Ltd. (HUDI) is down over 8% at $26.93 Jupai Holdings Limited (JP) is down over 8% at $0.96 Futu Holdings Limited (FUTU) is down over 7% at $34.43 Kaixin Auto Holdings (KXIN) is down over 5% at $1.60 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.10 A.M. ET). | In the Green Genfit SA (GNFT) is up over 44% at $4.80 Spruce Biosciences, Inc. (SPRB) is up over 20% at $2.99 Cerner Corporation (CERN) is up over 18% at $94.30 Moxian (BVI) Inc (MOXC) is up over 15% at $4.86 Adagio Therapeutics, Inc. (ADGI) is up over 11% at $15.78 E-Home Household Service Holdings Limited (EJH) is up over 9% at $1.80 Kiora Pharmaceuticals, Inc. (KPRX) is up over 9% at $0.95 ObsEva SA (OBSV) is up over 6% at $2.34 In the Red Abeona Therapeutics Inc. (ABEO) is down over 25% at $0.37 ION Geophysical Corporation (IO) is down over 19% at $1.11 Rivian Automotive, Inc. (RIVN) is down over 9% at $99.03 UP Fintech Holding Limited (TIGR) is down over 9% at $4.39 Huadi International Group Co., Ltd. (HUDI) is down over 8% at $26.93 Jupai Holdings Limited (JP) is down over 8% at $0.96 Futu Holdings Limited (FUTU) is down over 7% at $34.43 Kaixin Auto Holdings (KXIN) is down over 5% at $1.60 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.10 A.M. ET). |
28042.0 | 2021-12-02 00:00:00 UTC | Pre-market Movers: TANH, GRAB, DWAC, VIR, SNOW… | ABEO | https://www.nasdaq.com/articles/pre-market-movers%3A-tanh-grab-dwac-vir-snow... | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).
In the Green
Grab Holdings Limited Class A Ordinary Shares (GRAB) is up over 42% at $15.65 Digital World Acquisition Corp. (DWAC) is up over 20% at $53.58 Vir Biotechnology, Inc. (VIR) is up over 19% at $56.01 Phunware, Inc. (PHUN) is up over 19% at $3.87 Snowflake Inc. (SNOW) is up over 15% at $358.00 4D pharma plc (LBPS) is up over 15% at $6.98 Arbutus Biopharma Corporation (ABUS) is up over 15% at $5.32 Remark Holdings, Inc. (MARK) is up over 15% at $1.38 RLX Technology Inc. (RLX) is up over 11% at $4.60 Outlook Therapeutics, Inc. (OTLK) is up over 9% at $1.41 Abeona Therapeutics Inc. (ABEO) is up over 8% at $0.65 Express, Inc. (EXPR) is up over 7% at $3.65 T2 Biosystems, Inc. (TTOO) is up over 7% at $0.64 trivago N.V. (TRVG) is up over 6% at $2.20
In the Red
Tantech Holdings Ltd (TANH) is down over 47% at $0.79 180 Life Sciences Corp. (ATNF) is down over 15% at $4.25 MDJM Ltd (MDJH) is down over 15% at $2.55 OceanPal Inc. (OP) is down over 14% at $5.60 NLS Pharmaceutics AG (NLSP) is down over 10% at $1.80 Cumberland Pharmaceuticals Inc. (CPIX) is down over 8% at $3.77 Skylight Health Group Inc. (SLHG) is down over 8% at $1.55 Palatin Technologies, Inc. (PTN) is down over 5% at $0.54 Clarus Therapeutics Holdings, Inc. (CRXT) is down over 4% at $4.75
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green Grab Holdings Limited Class A Ordinary Shares (GRAB) is up over 42% at $15.65 Digital World Acquisition Corp. (DWAC) is up over 20% at $53.58 Vir Biotechnology, Inc. (VIR) is up over 19% at $56.01 Phunware, Inc. (PHUN) is up over 19% at $3.87 Snowflake Inc. (SNOW) is up over 15% at $358.00 4D pharma plc (LBPS) is up over 15% at $6.98 Arbutus Biopharma Corporation (ABUS) is up over 15% at $5.32 Remark Holdings, Inc. (MARK) is up over 15% at $1.38 RLX Technology Inc. (RLX) is up over 11% at $4.60 Outlook Therapeutics, Inc. (OTLK) is up over 9% at $1.41 Abeona Therapeutics Inc. (ABEO) is up over 8% at $0.65 Express, Inc. (EXPR) is up over 7% at $3.65 T2 Biosystems, Inc. (TTOO) is up over 7% at $0.64 trivago N.V. (TRVG) is up over 6% at $2.20 In the Red Tantech Holdings Ltd (TANH) is down over 47% at $0.79 180 Life Sciences Corp. (ATNF) is down over 15% at $4.25 MDJM Ltd (MDJH) is down over 15% at $2.55 OceanPal Inc. (OP) is down over 14% at $5.60 NLS Pharmaceutics AG (NLSP) is down over 10% at $1.80 Cumberland Pharmaceuticals Inc. (CPIX) is down over 8% at $3.77 Skylight Health Group Inc. (SLHG) is down over 8% at $1.55 Palatin Technologies, Inc. (PTN) is down over 5% at $0.54 Clarus Therapeutics Holdings, Inc. (CRXT) is down over 4% at $4.75 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET). | In the Green Grab Holdings Limited Class A Ordinary Shares (GRAB) is up over 42% at $15.65 Digital World Acquisition Corp. (DWAC) is up over 20% at $53.58 Vir Biotechnology, Inc. (VIR) is up over 19% at $56.01 Phunware, Inc. (PHUN) is up over 19% at $3.87 Snowflake Inc. (SNOW) is up over 15% at $358.00 4D pharma plc (LBPS) is up over 15% at $6.98 Arbutus Biopharma Corporation (ABUS) is up over 15% at $5.32 Remark Holdings, Inc. (MARK) is up over 15% at $1.38 RLX Technology Inc. (RLX) is up over 11% at $4.60 Outlook Therapeutics, Inc. (OTLK) is up over 9% at $1.41 Abeona Therapeutics Inc. (ABEO) is up over 8% at $0.65 Express, Inc. (EXPR) is up over 7% at $3.65 T2 Biosystems, Inc. (TTOO) is up over 7% at $0.64 trivago N.V. (TRVG) is up over 6% at $2.20 In the Red Tantech Holdings Ltd (TANH) is down over 47% at $0.79 180 Life Sciences Corp. (ATNF) is down over 15% at $4.25 MDJM Ltd (MDJH) is down over 15% at $2.55 OceanPal Inc. (OP) is down over 14% at $5.60 NLS Pharmaceutics AG (NLSP) is down over 10% at $1.80 Cumberland Pharmaceuticals Inc. (CPIX) is down over 8% at $3.77 Skylight Health Group Inc. (SLHG) is down over 8% at $1.55 Palatin Technologies, Inc. (PTN) is down over 5% at $0.54 Clarus Therapeutics Holdings, Inc. (CRXT) is down over 4% at $4.75 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET). | In the Green Grab Holdings Limited Class A Ordinary Shares (GRAB) is up over 42% at $15.65 Digital World Acquisition Corp. (DWAC) is up over 20% at $53.58 Vir Biotechnology, Inc. (VIR) is up over 19% at $56.01 Phunware, Inc. (PHUN) is up over 19% at $3.87 Snowflake Inc. (SNOW) is up over 15% at $358.00 4D pharma plc (LBPS) is up over 15% at $6.98 Arbutus Biopharma Corporation (ABUS) is up over 15% at $5.32 Remark Holdings, Inc. (MARK) is up over 15% at $1.38 RLX Technology Inc. (RLX) is up over 11% at $4.60 Outlook Therapeutics, Inc. (OTLK) is up over 9% at $1.41 Abeona Therapeutics Inc. (ABEO) is up over 8% at $0.65 Express, Inc. (EXPR) is up over 7% at $3.65 T2 Biosystems, Inc. (TTOO) is up over 7% at $0.64 trivago N.V. (TRVG) is up over 6% at $2.20 In the Red Tantech Holdings Ltd (TANH) is down over 47% at $0.79 180 Life Sciences Corp. (ATNF) is down over 15% at $4.25 MDJM Ltd (MDJH) is down over 15% at $2.55 OceanPal Inc. (OP) is down over 14% at $5.60 NLS Pharmaceutics AG (NLSP) is down over 10% at $1.80 Cumberland Pharmaceuticals Inc. (CPIX) is down over 8% at $3.77 Skylight Health Group Inc. (SLHG) is down over 8% at $1.55 Palatin Technologies, Inc. (PTN) is down over 5% at $0.54 Clarus Therapeutics Holdings, Inc. (CRXT) is down over 4% at $4.75 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET). | In the Green Grab Holdings Limited Class A Ordinary Shares (GRAB) is up over 42% at $15.65 Digital World Acquisition Corp. (DWAC) is up over 20% at $53.58 Vir Biotechnology, Inc. (VIR) is up over 19% at $56.01 Phunware, Inc. (PHUN) is up over 19% at $3.87 Snowflake Inc. (SNOW) is up over 15% at $358.00 4D pharma plc (LBPS) is up over 15% at $6.98 Arbutus Biopharma Corporation (ABUS) is up over 15% at $5.32 Remark Holdings, Inc. (MARK) is up over 15% at $1.38 RLX Technology Inc. (RLX) is up over 11% at $4.60 Outlook Therapeutics, Inc. (OTLK) is up over 9% at $1.41 Abeona Therapeutics Inc. (ABEO) is up over 8% at $0.65 Express, Inc. (EXPR) is up over 7% at $3.65 T2 Biosystems, Inc. (TTOO) is up over 7% at $0.64 trivago N.V. (TRVG) is up over 6% at $2.20 In the Red Tantech Holdings Ltd (TANH) is down over 47% at $0.79 180 Life Sciences Corp. (ATNF) is down over 15% at $4.25 MDJM Ltd (MDJH) is down over 15% at $2.55 OceanPal Inc. (OP) is down over 14% at $5.60 NLS Pharmaceutics AG (NLSP) is down over 10% at $1.80 Cumberland Pharmaceuticals Inc. (CPIX) is down over 8% at $3.77 Skylight Health Group Inc. (SLHG) is down over 8% at $1.55 Palatin Technologies, Inc. (PTN) is down over 5% at $0.54 Clarus Therapeutics Holdings, Inc. (CRXT) is down over 4% at $4.75 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET). |
28043.0 | 2021-12-02 00:00:00 UTC | Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday | ABEO | https://www.nasdaq.com/articles/todays-biggest-pre-market-stock-movers%3A-10-top-gainers-and-losers-on-thursday-0 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Good morning, trader! We’re gearing up for another busy day of trading with the biggest pre-market stock movers for Thursday!
Source: ventdusud / Shutterstock.com
News moving stocks today include earnings reports, social media chatter, Omicron, and more.
Let’s get into that news below!
Pre-Market Stock Movers: 10 Top Gainers
Digital World Acquisition (NASDAQ:DWAC) stock is soaring more than 21% on reports the SPAC plans to raise $1 billion in fundraising for its merger with former President Donald Trump’s social media company.
Phunware (NASDAQ:PHUN) shares are heading over 18% higher due to its possible connection to Digital World Acquisition.
Abeona Therapeutics (NASDAQ:ABEO) stock is surging more than 16% on social media buzz from retail traders.
Arbutus Biopharma (NASDAQ:ABUS) shares are rising over 14% as it continues to rally on court ruling news.
Snowflake (NYSE:SNOW) stock is sitting almost 14% higher thanks to the release of its Q3 earnings report.
RLX Technology (NYSE:RLX) shares are climbing more than 12% as China prepares new regulations for e-ciggarettes.
Remark (NASDAQ:MARK) stock is gaining over 11% despite a lack of news this morning.
Express (NYSE:EXPR) shares are increasing nearly 11% with the release of its most recent earnings report.
T2 Biosystems (NASDAQ:TTOO) stock is getting a more than 10% boost after announcing its test can detect Covid-19 variant Omicron.
Vir Biotechnology (NASDAQ:VIR) shares are up over 9% on news that sotrovimab is still effective against Omicron.
7 Stocks to Buy to Hedge Against Rising Oil Prices
10 Top Losers
Tantech (NASDAQ:TANH) stock is plummeting 42% after announcing a proposed public offering.
MDJM (NASDAQ:MDJH) shares are diving more than 16% on no apparent news today.
180 Life Sciences (NASDAQ:ATNF) stock is taking an over 13% beating following a presentation including clinical data yesterday.
OceanPal (NASDAQ:OP) shares are pulling back more than 11% following a recent rally on their public debut.
Clarus Therapeutics (NASDAQ:CRXT) stock is falling over 10% as shares retreat after a rally earlier this week on patent news.
Cumberland (NASDAQ:CPIX) shares are decreasing more than 9% after rallying recently on FDA news.
NLS Pharmaceutics (NASDAQ:NLSP) stock is slipping over 9% following a recent rally on preclinical results.
Skylight Health Group (NASDAQ:SLHG) shares are dropping more than 9% after announcing the pricing for a public offering of its stock.
Pasithea Therapeutics (NASDAQ:KTTA) stock is dipping over 8% after closing its private placement.
Palatin Technologies (NYSEAMERICAN:PTN) shares close out our pre-market stock movers down more than 8% as they settle from a rally at the start of the week.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics (NASDAQ:ABEO) stock is surging more than 16% on social media buzz from retail traders. Source: ventdusud / Shutterstock.com News moving stocks today include earnings reports, social media chatter, Omicron, and more. Clarus Therapeutics (NASDAQ:CRXT) stock is falling over 10% as shares retreat after a rally earlier this week on patent news. | Abeona Therapeutics (NASDAQ:ABEO) stock is surging more than 16% on social media buzz from retail traders. Source: ventdusud / Shutterstock.com News moving stocks today include earnings reports, social media chatter, Omicron, and more. Pre-Market Stock Movers: 10 Top Gainers Digital World Acquisition (NASDAQ:DWAC) stock is soaring more than 21% on reports the SPAC plans to raise $1 billion in fundraising for its merger with former President Donald Trump’s social media company. | Abeona Therapeutics (NASDAQ:ABEO) stock is surging more than 16% on social media buzz from retail traders. Pre-Market Stock Movers: 10 Top Gainers Digital World Acquisition (NASDAQ:DWAC) stock is soaring more than 21% on reports the SPAC plans to raise $1 billion in fundraising for its merger with former President Donald Trump’s social media company. 7 Stocks to Buy to Hedge Against Rising Oil Prices 10 Top Losers Tantech (NASDAQ:TANH) stock is plummeting 42% after announcing a proposed public offering. | Abeona Therapeutics (NASDAQ:ABEO) stock is surging more than 16% on social media buzz from retail traders. Source: ventdusud / Shutterstock.com News moving stocks today include earnings reports, social media chatter, Omicron, and more. Let’s get into that news below! |
28044.0 | 2021-11-15 00:00:00 UTC | Pre-market Movers: CREX, BTB, EYPT, OXBR, MICT… | ABEO | https://www.nasdaq.com/articles/pre-market-movers%3A-crex-btb-eypt-oxbr-mict...-2021-11-15 | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.10 A.M. ET).
In the Green
Creative Realities, Inc. (CREX) is up over 104% at $2.99 Bit Brother Limited (BTB) is up over 62% at $4.30 EyePoint Pharmaceuticals, Inc. (EYPT) is up over 39% at $19.56 Oxbridge Re Holdings Limited (OXBR) is up over 15% at $4.12 MICT, Inc. (MICT) is up over 15% at $1.52 NanoViricides, Inc. (NNVC) is up over 13% at $5.32 Xeris Biopharma Holdings, Inc. (XERS) is up over 13% at $2.42 Abeona Therapeutics Inc. (ABEO) is up over 11% at $1.02 Arqit Quantum Inc. (ARQQ) is up over 9% at $24.67
In the Red
Wunong Net Technology Company Limited (WNW) is down over 11% at $4.11 Koninklijke Philips N.V. (PHG) is down over 10% at $42.80 BioXcel Therapeutics, Inc. (BTAI) is down over 10% at $31.05 AcelRx Pharmaceuticals, Inc. (ACRX) is down over 10% at $0.71 NuZee, Inc. (NUZE) is down over 8% at $4.73 Moving iMage Technologies, Inc. (MITQ) is down over 7% at $3.03 Stran & Company, Inc. (STRN) is down over 6% at $5.36 Astra Space, Inc. (ASTR) is down over 4% at $10.15 InterCure Ltd. (INCR) is down over 3% at $8.33
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green Creative Realities, Inc. (CREX) is up over 104% at $2.99 Bit Brother Limited (BTB) is up over 62% at $4.30 EyePoint Pharmaceuticals, Inc. (EYPT) is up over 39% at $19.56 Oxbridge Re Holdings Limited (OXBR) is up over 15% at $4.12 MICT, Inc. (MICT) is up over 15% at $1.52 NanoViricides, Inc. (NNVC) is up over 13% at $5.32 Xeris Biopharma Holdings, Inc. (XERS) is up over 13% at $2.42 Abeona Therapeutics Inc. (ABEO) is up over 11% at $1.02 Arqit Quantum Inc. (ARQQ) is up over 9% at $24.67 In the Red Wunong Net Technology Company Limited (WNW) is down over 11% at $4.11 Koninklijke Philips N.V. (PHG) is down over 10% at $42.80 BioXcel Therapeutics, Inc. (BTAI) is down over 10% at $31.05 AcelRx Pharmaceuticals, Inc. (ACRX) is down over 10% at $0.71 NuZee, Inc. (NUZE) is down over 8% at $4.73 Moving iMage Technologies, Inc. (MITQ) is down over 7% at $3.03 Stran & Company, Inc. (STRN) is down over 6% at $5.36 Astra Space, Inc. (ASTR) is down over 4% at $10.15 InterCure Ltd. (INCR) is down over 3% at $8.33 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.10 A.M. ET). | In the Green Creative Realities, Inc. (CREX) is up over 104% at $2.99 Bit Brother Limited (BTB) is up over 62% at $4.30 EyePoint Pharmaceuticals, Inc. (EYPT) is up over 39% at $19.56 Oxbridge Re Holdings Limited (OXBR) is up over 15% at $4.12 MICT, Inc. (MICT) is up over 15% at $1.52 NanoViricides, Inc. (NNVC) is up over 13% at $5.32 Xeris Biopharma Holdings, Inc. (XERS) is up over 13% at $2.42 Abeona Therapeutics Inc. (ABEO) is up over 11% at $1.02 Arqit Quantum Inc. (ARQQ) is up over 9% at $24.67 In the Red Wunong Net Technology Company Limited (WNW) is down over 11% at $4.11 Koninklijke Philips N.V. (PHG) is down over 10% at $42.80 BioXcel Therapeutics, Inc. (BTAI) is down over 10% at $31.05 AcelRx Pharmaceuticals, Inc. (ACRX) is down over 10% at $0.71 NuZee, Inc. (NUZE) is down over 8% at $4.73 Moving iMage Technologies, Inc. (MITQ) is down over 7% at $3.03 Stran & Company, Inc. (STRN) is down over 6% at $5.36 Astra Space, Inc. (ASTR) is down over 4% at $10.15 InterCure Ltd. (INCR) is down over 3% at $8.33 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.10 A.M. ET). | In the Green Creative Realities, Inc. (CREX) is up over 104% at $2.99 Bit Brother Limited (BTB) is up over 62% at $4.30 EyePoint Pharmaceuticals, Inc. (EYPT) is up over 39% at $19.56 Oxbridge Re Holdings Limited (OXBR) is up over 15% at $4.12 MICT, Inc. (MICT) is up over 15% at $1.52 NanoViricides, Inc. (NNVC) is up over 13% at $5.32 Xeris Biopharma Holdings, Inc. (XERS) is up over 13% at $2.42 Abeona Therapeutics Inc. (ABEO) is up over 11% at $1.02 Arqit Quantum Inc. (ARQQ) is up over 9% at $24.67 In the Red Wunong Net Technology Company Limited (WNW) is down over 11% at $4.11 Koninklijke Philips N.V. (PHG) is down over 10% at $42.80 BioXcel Therapeutics, Inc. (BTAI) is down over 10% at $31.05 AcelRx Pharmaceuticals, Inc. (ACRX) is down over 10% at $0.71 NuZee, Inc. (NUZE) is down over 8% at $4.73 Moving iMage Technologies, Inc. (MITQ) is down over 7% at $3.03 Stran & Company, Inc. (STRN) is down over 6% at $5.36 Astra Space, Inc. (ASTR) is down over 4% at $10.15 InterCure Ltd. (INCR) is down over 3% at $8.33 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.10 A.M. ET). | In the Green Creative Realities, Inc. (CREX) is up over 104% at $2.99 Bit Brother Limited (BTB) is up over 62% at $4.30 EyePoint Pharmaceuticals, Inc. (EYPT) is up over 39% at $19.56 Oxbridge Re Holdings Limited (OXBR) is up over 15% at $4.12 MICT, Inc. (MICT) is up over 15% at $1.52 NanoViricides, Inc. (NNVC) is up over 13% at $5.32 Xeris Biopharma Holdings, Inc. (XERS) is up over 13% at $2.42 Abeona Therapeutics Inc. (ABEO) is up over 11% at $1.02 Arqit Quantum Inc. (ARQQ) is up over 9% at $24.67 In the Red Wunong Net Technology Company Limited (WNW) is down over 11% at $4.11 Koninklijke Philips N.V. (PHG) is down over 10% at $42.80 BioXcel Therapeutics, Inc. (BTAI) is down over 10% at $31.05 AcelRx Pharmaceuticals, Inc. (ACRX) is down over 10% at $0.71 NuZee, Inc. (NUZE) is down over 8% at $4.73 Moving iMage Technologies, Inc. (MITQ) is down over 7% at $3.03 Stran & Company, Inc. (STRN) is down over 6% at $5.36 Astra Space, Inc. (ASTR) is down over 4% at $10.15 InterCure Ltd. (INCR) is down over 3% at $8.33 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.10 A.M. ET). |
28045.0 | 2021-11-15 00:00:00 UTC | Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday | ABEO | https://www.nasdaq.com/articles/todays-biggest-pre-market-stock-movers%3A-10-top-gainers-and-losers-on-monday-0 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Welcome back, trader! We’re getting right into the thick of it this week with a look at the biggest pre-market stock movers for Monday!
Source: Eric Urquhart/Shutterstock.com
Moving stocks today are earnings reports, acquisition news, clinical trial data, and more.
Let’s get right into those pre-market stock movers below!
Pre-Market Stock Movers: 10 Top Gainers
Creative Realities (NASDAQ:CREX) stock is rocketing more than 102% after announcing a merger deal with Reflect Systems.
Bit Brother (NASDAQ:BTB) shares are surging over 55% in what appears to be a short-squeeze of the stock.
EyePoint Pharmaceuticals (NASDAQ:EYPT) stock is soaring more than 45% after reporting positive data from a Phase 1 clinical trial.
Oxbridge Re Holdings (NASDAQ:OXBR) shares are rising over 16% with the release of its Q3 earnings report.
Abeona Therapeutics (NASDAQ:ABEO) stock is climbing more than 15% higher due to a likely rally from retail traders.
Xeris Biopharma Holdings (NASDAQ:XERS) shares are increasing over 13% as traders online discuss insider buying.
Nanoviricides (NYSEAMERICAN:NNVC) stock is gaining more than 11% after developing chewable gummies to treat Covid-19.
Arqit Quantum (NASDAQ:ARQQ) shares are getting an over 10% boost as it continues a rally from Friday.
MICT (NASDAQ:MICT) stock is jumping more than 10% despite a lack of pre-market news.
AcelRx Pharmaceuticals (NASDAQ:ACRX) shares are up over 10% on Q3 earnings and Lowell Therapeutics acquisition news.
7 Stocks to Buy With Stacks of Free Cash Flow
10 Top Losers
Wunong Net Technology (NASDAQ:WNW) stock is falling more than 10% following a rally on Friday.
Koninklijke Philips (NYSE:PHG) shares are taking an over 10% beating after providing an update on its mechanical ventilator recall.
BioXcel Therapeutics (NASDAQ:BTAI) stock is falling nearly 10% ahead of its presentation at the 12th Annual Jefferies Global Healthcare Conference on Wednesday.
Stran & Co (NASDAQ:STRN) shares are dropping more than 9% after the company revealed the closing of a public offering.
Nuzee (NASDAQ:NUZE) stock is decreasing over 8% on no apparent news.
Moving iMage Technologies (NYSEAMERICAN:MITQ) shares are declining roughly 7% after rallying higher on earnings last week.
Intercure (NASDAQ:INCR) stock is slipping 6% ahead of its Q3 earnings report on Tuesday.
Astra Space (NASDAQ:ASTR) shares are dipping close to 6% after Q3 earnings sent it higher last week.
Digital Ally (NASDAQ:DGLY) stock is losing more than 5% of its value following a rally on Friday.
EVgo (NASDAQ:EVGO) shares close out our pre-market stock movers down over 5% as it retreats from a rally last week.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics (NASDAQ:ABEO) stock is climbing more than 15% higher due to a likely rally from retail traders. Source: Eric Urquhart/Shutterstock.com Moving stocks today are earnings reports, acquisition news, clinical trial data, and more. BioXcel Therapeutics (NASDAQ:BTAI) stock is falling nearly 10% ahead of its presentation at the 12th Annual Jefferies Global Healthcare Conference on Wednesday. | Abeona Therapeutics (NASDAQ:ABEO) stock is climbing more than 15% higher due to a likely rally from retail traders. Source: Eric Urquhart/Shutterstock.com Moving stocks today are earnings reports, acquisition news, clinical trial data, and more. EVgo (NASDAQ:EVGO) shares close out our pre-market stock movers down over 5% as it retreats from a rally last week. | Abeona Therapeutics (NASDAQ:ABEO) stock is climbing more than 15% higher due to a likely rally from retail traders. Pre-Market Stock Movers: 10 Top Gainers Creative Realities (NASDAQ:CREX) stock is rocketing more than 102% after announcing a merger deal with Reflect Systems. 7 Stocks to Buy With Stacks of Free Cash Flow 10 Top Losers Wunong Net Technology (NASDAQ:WNW) stock is falling more than 10% following a rally on Friday. | Abeona Therapeutics (NASDAQ:ABEO) stock is climbing more than 15% higher due to a likely rally from retail traders. Source: Eric Urquhart/Shutterstock.com Moving stocks today are earnings reports, acquisition news, clinical trial data, and more. Moving iMage Technologies (NYSEAMERICAN:MITQ) shares are declining roughly 7% after rallying higher on earnings last week. |
28046.0 | 2021-10-05 00:00:00 UTC | Abeona Therapeutics Inc Shares Fall 4.0% Below Previous 52-Week Low - Market Mover | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-inc-shares-fall-4.0-below-previous-52-week-low-market-mover-2021-10-05 | nan | nan | Abeona Therapeutics Inc (ABEO) shares closed 4.0% lower than its previous 52 week low, giving the company a market cap of $106M. The stock is currently down 33.1% year-to-date, flat over the past 12 months, and down 82.5% over the past five years. This week, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 3.2%.
Trading Activity
Trading volume this week was 21.5% lower than the 20-day average.
Beta, a measure of the stock’s volatility relative to the overall market stands at 0.7.
Technical Indicators
The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
MACD, a trend-following momentum indicator, indicates a downward trend.
The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance
The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis
The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis
The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis
Per Group Comparative Performance
The company's stock price performance year-to-date lags the peer average by 1417.2%
The company's stock price performance over the past 12 months lags the peer average by -100.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc (ABEO) shares closed 4.0% lower than its previous 52 week low, giving the company a market cap of $106M. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.7. This story was produced by the Kwhen Automated News Generator. | Abeona Therapeutics Inc (ABEO) shares closed 4.0% lower than its previous 52 week low, giving the company a market cap of $106M. This week, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 3.2%. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1417.2% The company's stock price performance over the past 12 months lags the peer average by -100.0% | Abeona Therapeutics Inc (ABEO) shares closed 4.0% lower than its previous 52 week low, giving the company a market cap of $106M. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1417.2% The company's stock price performance over the past 12 months lags the peer average by -100.0% This story was produced by the Kwhen Automated News Generator. | Abeona Therapeutics Inc (ABEO) shares closed 4.0% lower than its previous 52 week low, giving the company a market cap of $106M. Trading Activity Trading volume this week was 21.5% lower than the 20-day average. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought. |
28047.0 | 2021-10-05 00:00:00 UTC | Tuesday Sector Laggards: Precious Metals, Drugs | ABEO | https://www.nasdaq.com/articles/tuesday-sector-laggards%3A-precious-metals-drugs-2021-10-05 | nan | nan | In trading on Tuesday, precious metals shares were relative laggards, down on the day by about 1.4%. Helping drag down the group were shares of Huadi International Group, down about 13.3% and shares of Alexco Resource off about 3.9% on the day.
Also lagging the market Tuesday are drugs shares, down on the day by about 0.8% as a group, led down by Abeona Therapeutics, trading lower by about 16% and Unity Biotechnology, trading lower by about 13.8%.
VIDEO: Tuesday Sector Laggards: Precious Metals, Drugs
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also lagging the market Tuesday are drugs shares, down on the day by about 0.8% as a group, led down by Abeona Therapeutics, trading lower by about 16% and Unity Biotechnology, trading lower by about 13.8%. In trading on Tuesday, precious metals shares were relative laggards, down on the day by about 1.4%. VIDEO: Tuesday Sector Laggards: Precious Metals, Drugs The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also lagging the market Tuesday are drugs shares, down on the day by about 0.8% as a group, led down by Abeona Therapeutics, trading lower by about 16% and Unity Biotechnology, trading lower by about 13.8%. In trading on Tuesday, precious metals shares were relative laggards, down on the day by about 1.4%. VIDEO: Tuesday Sector Laggards: Precious Metals, Drugs The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also lagging the market Tuesday are drugs shares, down on the day by about 0.8% as a group, led down by Abeona Therapeutics, trading lower by about 16% and Unity Biotechnology, trading lower by about 13.8%. Helping drag down the group were shares of Huadi International Group, down about 13.3% and shares of Alexco Resource off about 3.9% on the day. VIDEO: Tuesday Sector Laggards: Precious Metals, Drugs The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also lagging the market Tuesday are drugs shares, down on the day by about 0.8% as a group, led down by Abeona Therapeutics, trading lower by about 16% and Unity Biotechnology, trading lower by about 13.8%. In trading on Tuesday, precious metals shares were relative laggards, down on the day by about 1.4%. Helping drag down the group were shares of Huadi International Group, down about 13.3% and shares of Alexco Resource off about 3.9% on the day. |
28048.0 | 2021-07-22 00:00:00 UTC | Abeona Therapeutics' (NASDAQ:ABEO) Shareholders Are Down 89% On Their Shares | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-nasdaq%3Aabeo-shareholders-are-down-89-on-their-shares-2021-07-22 | nan | nan | As every investor would know, not every swing hits the sweet spot. But really bad investments should be rare. So take a moment to sympathize with the long term shareholders of Abeona Therapeutics Inc. (NASDAQ:ABEO), who have seen the share price tank a massive 89% over a three year period. That'd be enough to cause even the strongest minds some disquiet. The more recent news is of little comfort, with the share price down 54% in a year.
While a drop like that is definitely a body blow, money isn't as important as health and happiness.
Abeona Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.
In the last three years, Abeona Therapeutics saw its revenue grow by 74% per year, compound. That's well above most other pre-profit companies. So on the face of it we're really surprised to see the share price down 24% a year in the same time period. The share price makes us wonder if there is an issue with profitability. Ultimately, revenue growth doesn't amount to much if the business can't scale well. Unless the balance sheet is strong, the company might have to raise capital.
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
NasdaqCM:ABEO Earnings and Revenue Growth July 22nd 2021
This free interactive report on Abeona Therapeutics' balance sheet strength is a great place to start, if you want to investigate the stock further.
A Different Perspective
Abeona Therapeutics shareholders are down 54% for the year, but the market itself is up 37%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 8% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 4 warning signs for Abeona Therapeutics (1 shouldn't be ignored!) that you should be aware of before investing here.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | So take a moment to sympathize with the long term shareholders of Abeona Therapeutics Inc. (NASDAQ:ABEO), who have seen the share price tank a massive 89% over a three year period. NasdaqCM:ABEO Earnings and Revenue Growth July 22nd 2021 This free interactive report on Abeona Therapeutics' balance sheet strength is a great place to start, if you want to investigate the stock further. Abeona Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). | So take a moment to sympathize with the long term shareholders of Abeona Therapeutics Inc. (NASDAQ:ABEO), who have seen the share price tank a massive 89% over a three year period. NasdaqCM:ABEO Earnings and Revenue Growth July 22nd 2021 This free interactive report on Abeona Therapeutics' balance sheet strength is a great place to start, if you want to investigate the stock further. Abeona Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). | So take a moment to sympathize with the long term shareholders of Abeona Therapeutics Inc. (NASDAQ:ABEO), who have seen the share price tank a massive 89% over a three year period. Abeona Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). In the last three years, Abeona Therapeutics saw its revenue grow by 74% per year, compound. | Abeona Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). So take a moment to sympathize with the long term shareholders of Abeona Therapeutics Inc. (NASDAQ:ABEO), who have seen the share price tank a massive 89% over a three year period. In the last three years, Abeona Therapeutics saw its revenue grow by 74% per year, compound. |
28049.0 | 2021-04-22 00:00:00 UTC | Rock star Growth Puts Abeona Therapeutics (NASDAQ:ABEO) In A Position To Use Debt | ABEO | https://www.nasdaq.com/articles/rock-star-growth-puts-abeona-therapeutics-nasdaq%3Aabeo-in-a-position-to-use-debt-2021-04-22 | nan | nan | Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. Importantly, Abeona Therapeutics Inc. (NASDAQ:ABEO) does carry debt. But should shareholders be worried about its use of debt?
What Risk Does Debt Bring?
Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. If things get really bad, the lenders can take control of the business. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. The first step when considering a company's debt levels is to consider its cash and debt together.
How Much Debt Does Abeona Therapeutics Carry?
As you can see below, at the end of December 2020, Abeona Therapeutics had US$1.76m of debt, up from none a year ago. Click the image for more detail. However, its balance sheet shows it holds US$95.0m in cash, so it actually has US$93.3m net cash.
NasdaqCM:ABEO Debt to Equity History April 22nd 2021
How Healthy Is Abeona Therapeutics' Balance Sheet?
The latest balance sheet data shows that Abeona Therapeutics had liabilities of US$42.0m due within a year, and liabilities of US$6.69m falling due after that. Offsetting this, it had US$95.0m in cash and US$7.00m in receivables that were due within 12 months. So it actually has US$53.4m more liquid assets than total liabilities.
This surplus liquidity suggests that Abeona Therapeutics' balance sheet could take a hit just as well as Homer Simpson's head can take a punch. With this in mind one could posit that its balance sheet means the company is able to handle some adversity. Succinctly put, Abeona Therapeutics boasts net cash, so it's fair to say it does not have a heavy debt load! When analysing debt levels, the balance sheet is the obvious place to start. But ultimately the future profitability of the business will decide if Abeona Therapeutics can strengthen its balance sheet over time. So if you're focused on the future you can check out this free report showing analyst profit forecasts.
In the last year Abeona Therapeutics managed to produce its first revenue as a listed company, but given the lack of profit, shareholders will no doubt be hoping to see some strong increases.
So How Risky Is Abeona Therapeutics?
Statistically speaking companies that lose money are riskier than those that make money. And the fact is that over the last twelve months Abeona Therapeutics lost money at the earnings before interest and tax (EBIT) line. And over the same period it saw negative free cash outflow of US$36m and booked a US$84m accounting loss. However, it has net cash of US$93.3m, so it has a bit of time before it will need more capital. The good news for shareholders is that Abeona Therapeutics has dazzling revenue growth, so there's a very good chance it can boost its free cash flow in the years to come. High growth pre-profit companies may well be risky, but they can also offer great rewards. There's no doubt that we learn most about debt from the balance sheet. However, not all investment risk resides within the balance sheet - far from it. These risks can be hard to spot. Every company has them, and we've spotted 4 warning signs for Abeona Therapeutics you should know about.
When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the last year Abeona Therapeutics managed to produce its first revenue as a listed company, but given the lack of profit, shareholders will no doubt be hoping to see some strong increases. Importantly, Abeona Therapeutics Inc. (NASDAQ:ABEO) does carry debt. How Much Debt Does Abeona Therapeutics Carry? | Importantly, Abeona Therapeutics Inc. (NASDAQ:ABEO) does carry debt. The latest balance sheet data shows that Abeona Therapeutics had liabilities of US$42.0m due within a year, and liabilities of US$6.69m falling due after that. Succinctly put, Abeona Therapeutics boasts net cash, so it's fair to say it does not have a heavy debt load! | NasdaqCM:ABEO Debt to Equity History April 22nd 2021 How Healthy Is Abeona Therapeutics' Balance Sheet? The latest balance sheet data shows that Abeona Therapeutics had liabilities of US$42.0m due within a year, and liabilities of US$6.69m falling due after that. Importantly, Abeona Therapeutics Inc. (NASDAQ:ABEO) does carry debt. | But ultimately the future profitability of the business will decide if Abeona Therapeutics can strengthen its balance sheet over time. So How Risky Is Abeona Therapeutics? Importantly, Abeona Therapeutics Inc. (NASDAQ:ABEO) does carry debt. |
28050.0 | 2021-03-22 00:00:00 UTC | Abeona Therapeutics Names Michael Amoroso President & CEO - Quick Facts | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-names-michael-amoroso-president-ceo-quick-facts-2021-03-22 | nan | nan | (RTTNews) - Abeona Therapeutics Inc. (ABEO) announced the promotion of Michael Amoroso, Executive Vice President, Chief Operating Officer, to President, Chief Executive Officer and a member of the Board, effective immediately. Most recently, Amoroso has been responsible for overseeing the operational management of Abeona and business development as COO and principal executive officer.
"Michael's promotion to CEO reflects his unwavering commitment and outstanding operational leadership during a period of important transition for the company, and the Board fully supports him and the Abeona senior management team," said Steven Rouhandeh, Chairman of Abeona's Board.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abeona Therapeutics Inc. (ABEO) announced the promotion of Michael Amoroso, Executive Vice President, Chief Operating Officer, to President, Chief Executive Officer and a member of the Board, effective immediately. Most recently, Amoroso has been responsible for overseeing the operational management of Abeona and business development as COO and principal executive officer. "Michael's promotion to CEO reflects his unwavering commitment and outstanding operational leadership during a period of important transition for the company, and the Board fully supports him and the Abeona senior management team," said Steven Rouhandeh, Chairman of Abeona's Board. | (RTTNews) - Abeona Therapeutics Inc. (ABEO) announced the promotion of Michael Amoroso, Executive Vice President, Chief Operating Officer, to President, Chief Executive Officer and a member of the Board, effective immediately. Most recently, Amoroso has been responsible for overseeing the operational management of Abeona and business development as COO and principal executive officer. "Michael's promotion to CEO reflects his unwavering commitment and outstanding operational leadership during a period of important transition for the company, and the Board fully supports him and the Abeona senior management team," said Steven Rouhandeh, Chairman of Abeona's Board. | (RTTNews) - Abeona Therapeutics Inc. (ABEO) announced the promotion of Michael Amoroso, Executive Vice President, Chief Operating Officer, to President, Chief Executive Officer and a member of the Board, effective immediately. "Michael's promotion to CEO reflects his unwavering commitment and outstanding operational leadership during a period of important transition for the company, and the Board fully supports him and the Abeona senior management team," said Steven Rouhandeh, Chairman of Abeona's Board. Most recently, Amoroso has been responsible for overseeing the operational management of Abeona and business development as COO and principal executive officer. | (RTTNews) - Abeona Therapeutics Inc. (ABEO) announced the promotion of Michael Amoroso, Executive Vice President, Chief Operating Officer, to President, Chief Executive Officer and a member of the Board, effective immediately. Most recently, Amoroso has been responsible for overseeing the operational management of Abeona and business development as COO and principal executive officer. "Michael's promotion to CEO reflects his unwavering commitment and outstanding operational leadership during a period of important transition for the company, and the Board fully supports him and the Abeona senior management team," said Steven Rouhandeh, Chairman of Abeona's Board. |
28051.0 | 2021-02-25 00:00:00 UTC | Billionaire Ken Griffin Pulls the Trigger on These 2 Penny Stocks | ABEO | https://www.nasdaq.com/articles/billionaire-ken-griffin-pulls-the-trigger-on-these-2-penny-stocks-2021-02-25 | nan | nan | Risk and reward are the yin and yang of stock trading, the two opposite but essential ingredients in every market success. And there are no stocks that better embody both sides – the risk factors and the reward potentials – than penny stocks.
These equities, priced below $5 per share, typically offer high upside potentials. Even a small gain in share price – just a few cents – quickly translates into a high yield return. Of course, the risk is real, too; not every penny stock is going to show these sort of gains, some of them are cheap for a reason, and not every reason is a good one.
So, how are investors supposed to distinguish between the long-term winners and those set to come up short? Following the activity of the investing titans is one strategy.
Hedge fund manager Ken Griffin, chief of the investment firm Citadel, is one of those titans, having turned his college trading – from a PC in his dorm room – into a multi-billion dollar market giant.
A look at Griffin’s performance during the coronavirus crisis shows just how successful he can be. In March of last year, when corona knocked the bottom out of the markets, Griffin’s Citadel still brought in a net positive return of 1.7%. And for the year as a whole, Citadel’s revenues totaled $6.7 billion, almost double the previous high in 2018.
Turning to Griffin for inspiration, we took a closer look at two penny stocks Griffin’s Citadel made moves on recently. Using TipRanks’ database to find out what the analyst community has to say, we learned that each ticker boasts Buy ratings and massive upside potential.
Abeona Therapeutics (ABEO)
We will start with Abeona Therapeutics, a clinical-stage biopharma company focused on gene and cell therapy. This is a cutting edge field, using the latest genome technology to treat genetic diseases by inserting corrected copies of the DNA directly into affected cells. Abeona has seven drug candidates in the pipeline, with EB-101 and ABO-102 being the furthest along, and of most interest to investors.
EB-101 is set to begin a Phase III trial as a treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB). This is a disorder of the connective tissue, leaving sufferers prone to serious skin lesions and wounds. The cause is a genetic defect that leaves patients unable to produce the collagen needed to secure the skin layers. If approved, EB-101 would become the first – and only available – treatment for RDEB. Treatment involves using the drug to transplant the affected gene into the patient’s skin cells, which are then themselves transplanted into affected skin areas. In early phase trials, the drug was well tolerated by patients, who showed distinct improvement up to 2 years after treatment. The Phase III trial is now enrolling patients.
ABO-102, the next farthest-along drug candidate, is in a Phase I/II study as a treatment for Sanfilippo Syndrome, a fatal disease of early childhood. The syndrome is currently untreatable, except by supportive care, and affected children typically survive to age 15. ABO-102 is a gene therapy drug given through a one-time IV infusion. It delivers working copies of the affected gene to the child’s central nervous system, allowing the body to naturally correct the enzyme deficiency behind the disease.
Both of these drug candidates have received Orphan Drug Designation in the US and Europe, making governmental assistance available for their development. In addition, they have also received the FDA’s Rare Pediatric Disease Designation.
Abeona’s drug pipeline and $2.22 share price have scored it substantial praise from the pros on Wall Street.
This is the stance taken by Griffin. Increasing its stake in the company by a whopping 181%, Citadel snapped up 1.846 million shares in Q4, which are now worth $4.06 million.
5-star analyst Ram Selvaraju, of H.C. Wainwright, also counts himself as a fan. Selvaraju has recently published two notes on ABEO, focusing on the potential of both EB-101 and ABO-102.
Regarding the first, the analyst notes that the “Following the successful completion of the FDA meeting, Abeona is continuing with all necessary steps to enroll the next patient in the VIITAL study and expects to complete enrollment in 2021… In our view, FDA meeting and resultant feedback bode well for Abeona, since the agency appears to be on board with the company's study design and statistical analysis plan for the VIITAL [Phase III] trial…”
Turning to ABO-102, Selvaraju said, “In our view, this data is highly intriguing and bears watching to see if it can be confirmed in a larger patient cohort. From our vantage point, preservation of neurocognitive development in young children with MPS IIIA is likely to be the principal efficacy measure that resonates with regulators.”
In line with his optimistic view, Selvaraju rates ABEO a Buy along with a $8 price target. Should his thesis play out, a potential twelve-month jump of ~264% could be in the cards. (To watch Selvaraju’s track record, click here)
Overall, 2 Buys and no Holds or Sells have been assigned in the last three months. Therefore, the analyst consensus is a Moderate Buy. At $6.50, the average price target puts the upside potential at ~188%. (See ABEO stock analysis on TipRanks)
Mereo Biopharma (MREO)
The second stock we’re looking at, Mereo, is another biopharma company with a focus on rare diseases. Mereo has a large and diverse pipeline, with six drug candidates in various stages of development. The company’s research programs are looking at treatments for solid tumor cancers, ovarian cancer, and chronic obstructive pulmonary disease, among other severe conditions.
Griffin is among those that have high hopes for this healthcare name. Griffin’s Citadel picked up 4.097 million shares in Q4, which are now worth $16.3 million.
The biggest news for Mereo was the December 17 announcement of a collaboration and license agreement with the California company Ultragenyx for further development of Setrusumab, a candidate undergoing testing as a treatment for osteogenesis imperfecta, or brittle bone disease. This incurable condition is usually treated with lifestyle changes and exercise. Setrusumab, however, has shown in Phase 2b studies that it can cause dose-dependent increase in bone formation in affected adults.
Leerink analyst Joseph Schwartz writes of the Mereo/Ultragenyx partnership: “Although the RARE/MREO deal was unexpected, we are not surprised by the news considering MREO has been looking for a partner and RARE has ample experience developing and launching successful bone agents… We view [the] announcement as a win-win for both RARE and MREO since the two could complement each other’s strengths to bring setrusumab to market.”
In light of these comments, Schwartz rates MREO shares as a Buy, and his $8 price target suggests it has a one-year upside of 103%. (To watch Schwartz’s track record, click here)
Some stocks fly under the radar, and MREO is one of those. MREO’s is the only recent analyst review of this company, and it is decidedly positive. (See MREO stock analysis on TipRanks)
To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Regarding the first, the analyst notes that the “Following the successful completion of the FDA meeting, Abeona is continuing with all necessary steps to enroll the next patient in the VIITAL study and expects to complete enrollment in 2021… In our view, FDA meeting and resultant feedback bode well for Abeona, since the agency appears to be on board with the company's study design and statistical analysis plan for the VIITAL [Phase III] trial…” Turning to ABO-102, Selvaraju said, “In our view, this data is highly intriguing and bears watching to see if it can be confirmed in a larger patient cohort. From our vantage point, preservation of neurocognitive development in young children with MPS IIIA is likely to be the principal efficacy measure that resonates with regulators.” In line with his optimistic view, Selvaraju rates ABEO a Buy along with a $8 price target. Abeona Therapeutics (ABEO) We will start with Abeona Therapeutics, a clinical-stage biopharma company focused on gene and cell therapy. | Abeona Therapeutics (ABEO) We will start with Abeona Therapeutics, a clinical-stage biopharma company focused on gene and cell therapy. (See ABEO stock analysis on TipRanks) Mereo Biopharma (MREO) The second stock we’re looking at, Mereo, is another biopharma company with a focus on rare diseases. Abeona has seven drug candidates in the pipeline, with EB-101 and ABO-102 being the furthest along, and of most interest to investors. | Regarding the first, the analyst notes that the “Following the successful completion of the FDA meeting, Abeona is continuing with all necessary steps to enroll the next patient in the VIITAL study and expects to complete enrollment in 2021… In our view, FDA meeting and resultant feedback bode well for Abeona, since the agency appears to be on board with the company's study design and statistical analysis plan for the VIITAL [Phase III] trial…” Turning to ABO-102, Selvaraju said, “In our view, this data is highly intriguing and bears watching to see if it can be confirmed in a larger patient cohort. Abeona Therapeutics (ABEO) We will start with Abeona Therapeutics, a clinical-stage biopharma company focused on gene and cell therapy. Abeona has seven drug candidates in the pipeline, with EB-101 and ABO-102 being the furthest along, and of most interest to investors. | Abeona Therapeutics (ABEO) We will start with Abeona Therapeutics, a clinical-stage biopharma company focused on gene and cell therapy. Abeona has seven drug candidates in the pipeline, with EB-101 and ABO-102 being the furthest along, and of most interest to investors. Abeona’s drug pipeline and $2.22 share price have scored it substantial praise from the pros on Wall Street. |
28052.0 | 2021-02-21 00:00:00 UTC | Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO) | ABEO | https://www.nasdaq.com/articles/independent-director-paul-mann-just-sold-a-bunch-of-shares-in-abeona-therapeutics-inc. | nan | nan | Anyone interested in Abeona Therapeutics Inc. (NASDAQ:ABEO) should probably be aware that the Independent Director, Paul Mann, recently divested US$310k worth of shares in the company, at an average price of US$2.34 each. Equally important, that sale actually reduced their holding by a full 100% which hardly makes us feel bullish about the stock.
Abeona Therapeutics Insider Transactions Over The Last Year
Notably, that recent sale by Paul Mann is the biggest insider sale of Abeona Therapeutics shares that we've seen in the last year. That means that an insider was selling shares at slightly below the current price (US$2.41). We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. It is worth noting that this sale was 100% of Paul Mann's holding.
Insiders in Abeona Therapeutics didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
NasdaqCM:ABEO Insider Trading Volume February 21st 2021
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).
Insider Ownership
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From our data, it seems that Abeona Therapeutics insiders own 2.2% of the company, worth about US$5.2m. We do generally prefer see higher levels of insider ownership.
So What Do The Abeona Therapeutics Insider Transactions Indicate?
An insider sold stock recently, but they haven't been buying. Looking to the last twelve months, our data doesn't show any insider buying. When you combine this with the relatively low insider ownership, we are very cautious about the stock. So we're not rushing to buy, to say the least. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Case in point: We've spotted 4 warning signs for Abeona Therapeutics you should be aware of.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Anyone interested in Abeona Therapeutics Inc. (NASDAQ:ABEO) should probably be aware that the Independent Director, Paul Mann, recently divested US$310k worth of shares in the company, at an average price of US$2.34 each. Abeona Therapeutics Insider Transactions Over The Last Year Notably, that recent sale by Paul Mann is the biggest insider sale of Abeona Therapeutics shares that we've seen in the last year. Insiders in Abeona Therapeutics didn't buy any shares in the last year. | Abeona Therapeutics Insider Transactions Over The Last Year Notably, that recent sale by Paul Mann is the biggest insider sale of Abeona Therapeutics shares that we've seen in the last year. Insiders in Abeona Therapeutics didn't buy any shares in the last year. So What Do The Abeona Therapeutics Insider Transactions Indicate? | Abeona Therapeutics Insider Transactions Over The Last Year Notably, that recent sale by Paul Mann is the biggest insider sale of Abeona Therapeutics shares that we've seen in the last year. NasdaqCM:ABEO Insider Trading Volume February 21st 2021 If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. Anyone interested in Abeona Therapeutics Inc. (NASDAQ:ABEO) should probably be aware that the Independent Director, Paul Mann, recently divested US$310k worth of shares in the company, at an average price of US$2.34 each. | Insiders in Abeona Therapeutics didn't buy any shares in the last year. NasdaqCM:ABEO Insider Trading Volume February 21st 2021 If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. Anyone interested in Abeona Therapeutics Inc. (NASDAQ:ABEO) should probably be aware that the Independent Director, Paul Mann, recently divested US$310k worth of shares in the company, at an average price of US$2.34 each. |
28053.0 | 2020-09-29 00:00:00 UTC | GNFT Soars On LabCorp Deal, INO's COVID-19 Vaccine Trial On Partial Hold, FDA Expands Xeljanz Label | ABEO | https://www.nasdaq.com/articles/gnft-soars-on-labcorp-deal-inos-covid-19-vaccine-trial-on-partial-hold-fda-expands-xeljanz | nan | nan | (RTTNews) - Today's Daily Dose brings you news about Abeaona's leadership and Board transitions, GENFIT's deal with LabCorp., FDA hold on Inovio's planned Phase 2/3 Covid-19 vaccine trial, the new CEO of Merck KGaA, and label expansion of Pfizer's blockbuster drug Xeljanz.
Read on…
1. Abeona Plunges as CEO, Directors Resign
Abeona Therapeutics Inc. (ABEO) announced that João Siffert resigned from his positions as CEO, Head of Research and Development, and Chief Medical Officer, as well as member of the Board of Directors, on September 23, 2020.
The company added that on September 27, 2020, Brian Pereira, Stefano Buono, Stephen Howell, George Migausky and Shawn Tomasello had all stepped down from the Board, effective immediately.
Abeona is reviewing and exploring all strategic options and alternatives to maximize stakeholder value, including its sale.
ABEO touched a new 52-week low of $1.07 in intraday trading Monday, before closing at $1.09, down 41.40%.
2. GENFIT in Deal with LabCorp for NASH Diagnostic Test
Shares of GENFIT (GNFT) soared over 30% on Monday on news of the company entering into a five-year exclusive licensing agreement with LabCorp (LH).
As part of the agreement, LabCorp will develop and commercialize a blood-based molecular diagnostic test powered by GENFIT's NIS4 technology throughout the U.S. and Canada to help identify patients with at-risk non-alcoholic steatohepatitis (NASH).
NASH remains a highly underdiagnosed disease due to its asymptomatic nature and the limitations of existing diagnostic approaches. Liver biopsy, a highly invasive procedure, is the current clinical standard to formally diagnose NASH and to determine the stage of fibrosis, the company noted.
The diagnostic test is expected to be available from LabCorp by early 2021.
GENFIT's lead candidate is Elafibranor, currently under a global pivotal phase III study in Primary Biliary Cholangitis, a severe cholestatic liver disease that impacts and gradually destroys the bile ducts, leading to inflammation and scarring in the liver.
GNFT closed Monday's trading at $5.50, up 31.26%.
3. Inovio's Planned Phase 2/3 Covid-19 Vaccine Trial Placed On Partial Hold
Shares of Inovio Pharmaceuticals, Inc. (INO) plunged over 28% on Monday, following the FDA's decision to place the company's planned phase II/III trial of COVID-19 vaccine candidate INO-4800 on partial hold.
INO-4800 is a nucleic-acid based vaccine that is stable at room temperature for more than a year and does not require to be frozen in transport or storage. In the clinical trial, INO-4800 is injected directly into the participant's skin via the device CELLECTRA 2000, where the vaccine prompts the body's immune system to drive a robust immune response.
The FDA has asked for additional questions about the company's planned phase II/III trial of INO-4800, including its CELLECTRA 2000 delivery device to be used in the trial. Inovio plans to respond to the questions posed by the FDA in October, after which the regulatory agency has up to 30 days to notify the company of its decision as to whether the trial may proceed.
INO-4800 is under an expanded phase I study in the U.S., and the partial hold will not affect the ongoing phase I trial. The company noted that the partial clinical hold is not due to the occurrence of any adverse events related to the ongoing expanded phase I study of INO-4800.
A phase I/II clinical trial of INO-4800 in South Korea that is being conducted by Inovio and the International Vaccine Institute in partnership with Seoul National University Hospital is also underway.
INO closed Monday's trading at $12.14, down 28.34%. In after-hours, the stock fell another 3.62% to $11.70.
4. Merck KGaA Names New CEO
Merck KGaA (MKGAY.PK) has appointed Belén Garijo as new Chair of the Executive Board and CEO of the company, effective May 1, 2021, replacing Stefan Oschmann.
Garijo is currently Vice-Chair of the Executive Board and Deputy CEO of Merck as well as CEO of the company's healthcare unit. Oschmann who has served the company ten years on the Executive Board, five of them as Chairman and CEO, is stepping down "to turn to other tasks".
Peter Guenter, the CEO of Spain-based pharma company Almirall, has been roped in as a replacement for Garijo in the company's healthcare business sector.
5. FDA expands Label of Pfizer's Blockbuster Drug Xeljanz
Pfizer Inc.'s (PFE) rheumatoid arthritis drug Xeljanz has been approved by the FDA for yet another indication, i.e., for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis.
Xeljanz is the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of polyarticular course juvenile idiopathic arthritis.
Juvenile idiopathic arthritis, or JIA, defined as arthritis that begins before 16 years of age and persists for at least six weeks and is of unknown cause, affects about 300,000 children in the U.S. There are 6 categories of JIA - systemic, oligoarticular, polyarticular, enthesitis-related, psoriatic, and undifferentiated. Polyarticular JIA is characterized by arthritis in five or more joints and affects both the small joints of the hands and feet, and large joints like the knees, hips, and ankles.
Xeljanz is already approved for three other indications - rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
The drug brought in global annual sales of $2.24 billion in 2019, up 29% over 2018.
PFE closed Monday's trading at $36.39, up 0.94%.
6. Stocks That Moved On No News
Galectin Therapeutics Inc. (GALT) closed Monday's trading at $3.64, up 32.36%.
Trxade Group Inc. (MEDS) closed Monday's trading at $5.96, up 22.38%.
Anavex Life Sciences Corp. (AVXL) closed Monday's trading at $4.66, up 20.41%.
COMPASS Pathways plc (CMPS) closed Monday's trading at $37.00, down 14.29%.
PolyPid Ltd. (PYPD) closed Monday's trading at $11.00, down 13.45%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Plunges as CEO, Directors Resign Abeona Therapeutics Inc. (ABEO) announced that João Siffert resigned from his positions as CEO, Head of Research and Development, and Chief Medical Officer, as well as member of the Board of Directors, on September 23, 2020. Abeona is reviewing and exploring all strategic options and alternatives to maximize stakeholder value, including its sale. ABEO touched a new 52-week low of $1.07 in intraday trading Monday, before closing at $1.09, down 41.40%. | Abeona Plunges as CEO, Directors Resign Abeona Therapeutics Inc. (ABEO) announced that João Siffert resigned from his positions as CEO, Head of Research and Development, and Chief Medical Officer, as well as member of the Board of Directors, on September 23, 2020. Abeona is reviewing and exploring all strategic options and alternatives to maximize stakeholder value, including its sale. ABEO touched a new 52-week low of $1.07 in intraday trading Monday, before closing at $1.09, down 41.40%. | Abeona Plunges as CEO, Directors Resign Abeona Therapeutics Inc. (ABEO) announced that João Siffert resigned from his positions as CEO, Head of Research and Development, and Chief Medical Officer, as well as member of the Board of Directors, on September 23, 2020. Abeona is reviewing and exploring all strategic options and alternatives to maximize stakeholder value, including its sale. ABEO touched a new 52-week low of $1.07 in intraday trading Monday, before closing at $1.09, down 41.40%. | Abeona Plunges as CEO, Directors Resign Abeona Therapeutics Inc. (ABEO) announced that João Siffert resigned from his positions as CEO, Head of Research and Development, and Chief Medical Officer, as well as member of the Board of Directors, on September 23, 2020. Abeona is reviewing and exploring all strategic options and alternatives to maximize stakeholder value, including its sale. ABEO touched a new 52-week low of $1.07 in intraday trading Monday, before closing at $1.09, down 41.40%. |
28054.0 | 2020-09-18 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Compass Pathways Plc, Unity Software Inc, SpringWorks Therapeutics | ABEO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-compass-pathways-plc-unity-software-inc-springworks | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stocks turned lower in volatile trading on Friday as worries about rising coronavirus cases and a patchy economic recovery dampened risk sentiment, with technology-related stocks reversing early gains to extend their declines to a third day. .N
At 14:00 p.m. ET, the Dow Jones Industrial Average .DJI was down 1.08% at 27,601.36, the S&P 500 .SPX was down 1.37% at 3,311.03 and the Nasdaq Composite .IXIC was down 1.67% at 10,727.702. The top three S&P 500 .PG.INX percentage gainers: ** Aptiv PLC , up 5.4% ** Fleetcor Technologies Inc , up 2.6% ** AES Corp , up 2.6% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line Holdings Ltd , down 6.7% ** Carnival Corp , down 6.3% ** Royal Caribbean Cruises Ltd , down 5.2% The top three NYSE .PG.N percentage gainers: ** Unity Software Inc U.N, up 31% ** ReneSola Ltd SOL.N, up 27.7% ** Renren Inc , up 20.7% The top three NYSE .PL.N percentage losers: ** Vince Holding Corp , down 11.6% ** Cantel Medical Corp , down 9.2% ** 500.Com Ltd , down 9% The top three Nasdaq .PG.O percentage gainers: ** Compass Pathways PLC , up 42.1% ** Westport Fuel Systems Inc , up 35.5% ** Cassava Sciences Inc , up 34.3% The top three Nasdaq .PL.O percentage losers: ** Biovie Inc , down 20% ** Oasis Midstream Partners LP , down 14.8% ** Priority Technology Holdings Inc , down 13.7% ** Adamis Pharmaceuticals Corp ADMP.O: down 8.4%
BUZZ-Slides on proposed stock offering ** Tesla Inc TSLA.O: up 3.1%
BUZZ-Wedbush, Piper Sandler raise PTs ahead of Battery Day ** Checkpoint Therapeutics Inc CKPT.O: down 8.8%
BUZZ-Drops on discounted stock deal ** Eastman Kodak Co KODK.N: up 8.3%
BUZZ-Set for best week since loan news after review clears CEO of insider trading ** Kinross Gold Corp KGC.N: up 8.9%
BUZZ-Rises on dividend, higher production outlook ** Pivotal Investment Corporation II PIC.N: up 13.0%
BUZZ-To take XL Fleet public through merger, hits record high ** Kezar Life Sciences KZR.O: up 0.8%
BUZZ-Jumps on positive data from lupus drug trial ** OneWater Marine Inc ONEW.O: down 9.5%
BUZZ-Drops as Goldman offloads in share offering ** Oasis Petroleum Inc OAS.O: down 18.1%
BUZZ-Slips on reports of missing debt payments ** Mirati Therapeutics Inc MRTX.O: down 3.2%
BUZZ-Citi downgrades on 'appropriate' market credit for co's cancer therapy ** PG&E Corp PCG.N: down 1.7%
BUZZ-Falls as CFO resigns to join CenterPoint Energy ** Oracle Corp ORCL.N: down 0.6%
BUZZ-Slips as U.S. may ban downloading TikTok app ** Essential Properties Realty Trust EPRT.N: down 1.8%
BUZZ-Falls on equity offering ** Steel Dynamics Inc STLD.O: up 2.5%
BUZZ-Rises on upbeat Q3 profit forecast ** IsoRay Inc ISR.N: down 19.1%
BUZZ-Slumps on bigger Q4 loss ** Beyond Meat Inc BYND.O: down 6.1%
BUZZ-JPM downgrades on 'sluggish' fundamentals, shares fall ** Dave & Buster's Entertainment Inc PLAY.O: up 13.5%
BUZZ-Jumps as brokerages upgrade to 'buy' following bankruptcy report ** Fastly Inc FSLY.N: down 1.6%
BUZZ-Falls after Trump says to block TikTok, WeChat apps ** Home Depot Inc HD.N: down 2.8% ** Lowe's Companies Inc LOW.N: down 2.6%
BUZZ-Oppenheimer downgrades Home Depot, Lowe's on near-term risks ** Carnival Corp CCL.N: down 6.3% ** Royal Caribbean Cruises Ltd RCL.N: down 5.3%
BUZZ-U.S. travel, leisure stocks fall on speculation over UK lockdown ** Aptiv PLC APTV.N: up 5.5%
BUZZ-Jumps as MS hikes price target to top of Street ** Blink Charging Co BLNK.O: up 4.1%
BUZZ-Gains on deal to buy BlueLA Carsharing ** SunPower Corp SPWR.O: up 2.7%
BUZZ-Rises as MS upgrades on stronger business model after recent spin-off ** Abeona Therapeutics Inc ABEO.O: up 6.1%
BUZZ-Surges as B. Riley FBR starts coverage with 'buy' ** Roku Inc ROKU.O: down 3.2% ** Comcast Corp CMCSA.O: down 1.8%
BUZZ-Roku, Comcast down amid Peacock streaming scuffle ** Brinker International Inc EAT.N: up 2.9%
BUZZ-Rises as Evercore raises PT, sees margin boost ** SpringWorks Therapeutics Inc SWTX.O: up 4.4%
BUZZ-Hits three-month high on tumor therapy research agreement ** Unity Software Inc U.N: up 31.1%
BUZZ-Jumps 44% in NYSE debut ** United States Steel Corp X.N: up 5.9%
BUZZ-Says recovery trend extends to Q3; shares jump ** Limelight Networks Inc LLNW.O: up 7.9%
BUZZ-Brokerage initiates with 'buy' on market share opportunity ** Compass Pathways Plc CMPS.O: up 42.1%
BUZZ-Jumps 37.64% in Nasdaq debut
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 1.56%
Consumer Discretionary
.SPLRCD
down 1.86%
Consumer Staples
.SPLRCS
down 1.18%
Energy
.SPNY
down 1.70%
Financial
.SPSY
down 0.08%
Health
.SPXHC
down 0.67%
Industrial
.SPLRCI
down 0.85%
Information Technology
.SPLRCT
down 2.01%
Materials
.SPLRCM
down 1.49%
Real Estate
.SPLRCR
down 1.78%
Utilities
.SPLRCU
down 1.48%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Aptiv PLC , up 5.4% ** Fleetcor Technologies Inc , up 2.6% ** AES Corp , up 2.6% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line Holdings Ltd , down 6.7% ** Carnival Corp , down 6.3% ** Royal Caribbean Cruises Ltd , down 5.2% The top three NYSE .PG.N percentage gainers: ** Unity Software Inc U.N, up 31% ** ReneSola Ltd SOL.N, up 27.7% ** Renren Inc , up 20.7% The top three NYSE .PL.N percentage losers: ** Vince Holding Corp , down 11.6% ** Cantel Medical Corp , down 9.2% ** 500.Com Ltd , down 9% The top three Nasdaq .PG.O percentage gainers: ** Compass Pathways PLC , up 42.1% ** Westport Fuel Systems Inc , up 35.5% ** Cassava Sciences Inc , up 34.3% The top three Nasdaq .PL.O percentage losers: ** Biovie Inc , down 20% ** Oasis Midstream Partners LP , down 14.8% ** Priority Technology Holdings Inc , down 13.7% ** Adamis Pharmaceuticals Corp ADMP.O: down 8.4% BUZZ-Slides on proposed stock offering ** Tesla Inc TSLA.O: up 3.1% BUZZ-Wedbush, Piper Sandler raise PTs ahead of Battery Day ** Checkpoint Therapeutics Inc CKPT.O: down 8.8% BUZZ-Drops on discounted stock deal ** Eastman Kodak Co KODK.N: up 8.3% BUZZ-Set for best week since loan news after review clears CEO of insider trading ** Kinross Gold Corp KGC.N: up 8.9% BUZZ-Rises on dividend, higher production outlook ** Pivotal Investment Corporation II PIC.N: up 13.0% BUZZ-To take XL Fleet public through merger, hits record high ** Kezar Life Sciences KZR.O: up 0.8% BUZZ-Jumps on positive data from lupus drug trial ** OneWater Marine Inc ONEW.O: down 9.5% BUZZ-Drops as Goldman offloads in share offering ** Oasis Petroleum Inc OAS.O: down 18.1% BUZZ-Slips on reports of missing debt payments ** Mirati Therapeutics Inc MRTX.O: down 3.2% BUZZ-Citi downgrades on 'appropriate' market credit for co's cancer therapy ** PG&E Corp PCG.N: down 1.7% BUZZ-Falls as CFO resigns to join CenterPoint Energy ** Oracle Corp ORCL.N: down 0.6% BUZZ-Slips as U.S. may ban downloading TikTok app ** Essential Properties Realty Trust EPRT.N: down 1.8% BUZZ-Falls on equity offering ** Steel Dynamics Inc STLD.O: up 2.5% BUZZ-Rises on upbeat Q3 profit forecast ** IsoRay Inc ISR.N: down 19.1% BUZZ-Slumps on bigger Q4 loss ** Beyond Meat Inc BYND.O: down 6.1% BUZZ-JPM downgrades on 'sluggish' fundamentals, shares fall ** Dave & Buster's Entertainment Inc PLAY.O: up 13.5% BUZZ-Jumps as brokerages upgrade to 'buy' following bankruptcy report ** Fastly Inc FSLY.N: down 1.6% BUZZ-Falls after Trump says to block TikTok, WeChat apps ** Home Depot Inc HD.N: down 2.8% ** Lowe's Companies Inc LOW.N: down 2.6% BUZZ-Oppenheimer downgrades Home Depot, Lowe's on near-term risks ** Carnival Corp CCL.N: down 6.3% ** Royal Caribbean Cruises Ltd RCL.N: down 5.3% BUZZ-U.S. travel, leisure stocks fall on speculation over UK lockdown ** Aptiv PLC APTV.N: up 5.5% BUZZ-Jumps as MS hikes price target to top of Street ** Blink Charging Co BLNK.O: up 4.1% BUZZ-Gains on deal to buy BlueLA Carsharing ** SunPower Corp SPWR.O: up 2.7% BUZZ-Rises as MS upgrades on stronger business model after recent spin-off ** Abeona Therapeutics Inc ABEO.O: up 6.1% BUZZ-Surges as B. Riley FBR starts coverage with 'buy' ** Roku Inc ROKU.O: down 3.2% ** Comcast Corp CMCSA.O: down 1.8% BUZZ-Roku, Comcast down amid Peacock streaming scuffle ** Brinker International Inc EAT.N: up 2.9% BUZZ-Rises as Evercore raises PT, sees margin boost ** SpringWorks Therapeutics Inc SWTX.O: up 4.4% BUZZ-Hits three-month high on tumor therapy research agreement ** Unity Software Inc U.N: up 31.1% BUZZ-Jumps 44% in NYSE debut ** United States Steel Corp X.N: up 5.9% BUZZ-Says recovery trend extends to Q3; shares jump ** Limelight Networks Inc LLNW.O: up 7.9% BUZZ-Brokerage initiates with 'buy' on market share opportunity ** Compass Pathways Plc CMPS.O: up 42.1% BUZZ-Jumps 37.64% in Nasdaq debut The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks turned lower in volatile trading on Friday as worries about rising coronavirus cases and a patchy economic recovery dampened risk sentiment, with technology-related stocks reversing early gains to extend their declines to a third day. ET, the Dow Jones Industrial Average .DJI was down 1.08% at 27,601.36, the S&P 500 .SPX was down 1.37% at 3,311.03 and the Nasdaq Composite .IXIC was down 1.67% at 10,727.702. | The top three S&P 500 .PG.INX percentage gainers: ** Aptiv PLC , up 5.4% ** Fleetcor Technologies Inc , up 2.6% ** AES Corp , up 2.6% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line Holdings Ltd , down 6.7% ** Carnival Corp , down 6.3% ** Royal Caribbean Cruises Ltd , down 5.2% The top three NYSE .PG.N percentage gainers: ** Unity Software Inc U.N, up 31% ** ReneSola Ltd SOL.N, up 27.7% ** Renren Inc , up 20.7% The top three NYSE .PL.N percentage losers: ** Vince Holding Corp , down 11.6% ** Cantel Medical Corp , down 9.2% ** 500.Com Ltd , down 9% The top three Nasdaq .PG.O percentage gainers: ** Compass Pathways PLC , up 42.1% ** Westport Fuel Systems Inc , up 35.5% ** Cassava Sciences Inc , up 34.3% The top three Nasdaq .PL.O percentage losers: ** Biovie Inc , down 20% ** Oasis Midstream Partners LP , down 14.8% ** Priority Technology Holdings Inc , down 13.7% ** Adamis Pharmaceuticals Corp ADMP.O: down 8.4% BUZZ-Slides on proposed stock offering ** Tesla Inc TSLA.O: up 3.1% BUZZ-Wedbush, Piper Sandler raise PTs ahead of Battery Day ** Checkpoint Therapeutics Inc CKPT.O: down 8.8% BUZZ-Drops on discounted stock deal ** Eastman Kodak Co KODK.N: up 8.3% BUZZ-Set for best week since loan news after review clears CEO of insider trading ** Kinross Gold Corp KGC.N: up 8.9% BUZZ-Rises on dividend, higher production outlook ** Pivotal Investment Corporation II PIC.N: up 13.0% BUZZ-To take XL Fleet public through merger, hits record high ** Kezar Life Sciences KZR.O: up 0.8% BUZZ-Jumps on positive data from lupus drug trial ** OneWater Marine Inc ONEW.O: down 9.5% BUZZ-Drops as Goldman offloads in share offering ** Oasis Petroleum Inc OAS.O: down 18.1% BUZZ-Slips on reports of missing debt payments ** Mirati Therapeutics Inc MRTX.O: down 3.2% BUZZ-Citi downgrades on 'appropriate' market credit for co's cancer therapy ** PG&E Corp PCG.N: down 1.7% BUZZ-Falls as CFO resigns to join CenterPoint Energy ** Oracle Corp ORCL.N: down 0.6% BUZZ-Slips as U.S. may ban downloading TikTok app ** Essential Properties Realty Trust EPRT.N: down 1.8% BUZZ-Falls on equity offering ** Steel Dynamics Inc STLD.O: up 2.5% BUZZ-Rises on upbeat Q3 profit forecast ** IsoRay Inc ISR.N: down 19.1% BUZZ-Slumps on bigger Q4 loss ** Beyond Meat Inc BYND.O: down 6.1% BUZZ-JPM downgrades on 'sluggish' fundamentals, shares fall ** Dave & Buster's Entertainment Inc PLAY.O: up 13.5% BUZZ-Jumps as brokerages upgrade to 'buy' following bankruptcy report ** Fastly Inc FSLY.N: down 1.6% BUZZ-Falls after Trump says to block TikTok, WeChat apps ** Home Depot Inc HD.N: down 2.8% ** Lowe's Companies Inc LOW.N: down 2.6% BUZZ-Oppenheimer downgrades Home Depot, Lowe's on near-term risks ** Carnival Corp CCL.N: down 6.3% ** Royal Caribbean Cruises Ltd RCL.N: down 5.3% BUZZ-U.S. travel, leisure stocks fall on speculation over UK lockdown ** Aptiv PLC APTV.N: up 5.5% BUZZ-Jumps as MS hikes price target to top of Street ** Blink Charging Co BLNK.O: up 4.1% BUZZ-Gains on deal to buy BlueLA Carsharing ** SunPower Corp SPWR.O: up 2.7% BUZZ-Rises as MS upgrades on stronger business model after recent spin-off ** Abeona Therapeutics Inc ABEO.O: up 6.1% BUZZ-Surges as B. Riley FBR starts coverage with 'buy' ** Roku Inc ROKU.O: down 3.2% ** Comcast Corp CMCSA.O: down 1.8% BUZZ-Roku, Comcast down amid Peacock streaming scuffle ** Brinker International Inc EAT.N: up 2.9% BUZZ-Rises as Evercore raises PT, sees margin boost ** SpringWorks Therapeutics Inc SWTX.O: up 4.4% BUZZ-Hits three-month high on tumor therapy research agreement ** Unity Software Inc U.N: up 31.1% BUZZ-Jumps 44% in NYSE debut ** United States Steel Corp X.N: up 5.9% BUZZ-Says recovery trend extends to Q3; shares jump ** Limelight Networks Inc LLNW.O: up 7.9% BUZZ-Brokerage initiates with 'buy' on market share opportunity ** Compass Pathways Plc CMPS.O: up 42.1% BUZZ-Jumps 37.64% in Nasdaq debut The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks turned lower in volatile trading on Friday as worries about rising coronavirus cases and a patchy economic recovery dampened risk sentiment, with technology-related stocks reversing early gains to extend their declines to a third day. down 1.48% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Aptiv PLC , up 5.4% ** Fleetcor Technologies Inc , up 2.6% ** AES Corp , up 2.6% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line Holdings Ltd , down 6.7% ** Carnival Corp , down 6.3% ** Royal Caribbean Cruises Ltd , down 5.2% The top three NYSE .PG.N percentage gainers: ** Unity Software Inc U.N, up 31% ** ReneSola Ltd SOL.N, up 27.7% ** Renren Inc , up 20.7% The top three NYSE .PL.N percentage losers: ** Vince Holding Corp , down 11.6% ** Cantel Medical Corp , down 9.2% ** 500.Com Ltd , down 9% The top three Nasdaq .PG.O percentage gainers: ** Compass Pathways PLC , up 42.1% ** Westport Fuel Systems Inc , up 35.5% ** Cassava Sciences Inc , up 34.3% The top three Nasdaq .PL.O percentage losers: ** Biovie Inc , down 20% ** Oasis Midstream Partners LP , down 14.8% ** Priority Technology Holdings Inc , down 13.7% ** Adamis Pharmaceuticals Corp ADMP.O: down 8.4% BUZZ-Slides on proposed stock offering ** Tesla Inc TSLA.O: up 3.1% BUZZ-Wedbush, Piper Sandler raise PTs ahead of Battery Day ** Checkpoint Therapeutics Inc CKPT.O: down 8.8% BUZZ-Drops on discounted stock deal ** Eastman Kodak Co KODK.N: up 8.3% BUZZ-Set for best week since loan news after review clears CEO of insider trading ** Kinross Gold Corp KGC.N: up 8.9% BUZZ-Rises on dividend, higher production outlook ** Pivotal Investment Corporation II PIC.N: up 13.0% BUZZ-To take XL Fleet public through merger, hits record high ** Kezar Life Sciences KZR.O: up 0.8% BUZZ-Jumps on positive data from lupus drug trial ** OneWater Marine Inc ONEW.O: down 9.5% BUZZ-Drops as Goldman offloads in share offering ** Oasis Petroleum Inc OAS.O: down 18.1% BUZZ-Slips on reports of missing debt payments ** Mirati Therapeutics Inc MRTX.O: down 3.2% BUZZ-Citi downgrades on 'appropriate' market credit for co's cancer therapy ** PG&E Corp PCG.N: down 1.7% BUZZ-Falls as CFO resigns to join CenterPoint Energy ** Oracle Corp ORCL.N: down 0.6% BUZZ-Slips as U.S. may ban downloading TikTok app ** Essential Properties Realty Trust EPRT.N: down 1.8% BUZZ-Falls on equity offering ** Steel Dynamics Inc STLD.O: up 2.5% BUZZ-Rises on upbeat Q3 profit forecast ** IsoRay Inc ISR.N: down 19.1% BUZZ-Slumps on bigger Q4 loss ** Beyond Meat Inc BYND.O: down 6.1% BUZZ-JPM downgrades on 'sluggish' fundamentals, shares fall ** Dave & Buster's Entertainment Inc PLAY.O: up 13.5% BUZZ-Jumps as brokerages upgrade to 'buy' following bankruptcy report ** Fastly Inc FSLY.N: down 1.6% BUZZ-Falls after Trump says to block TikTok, WeChat apps ** Home Depot Inc HD.N: down 2.8% ** Lowe's Companies Inc LOW.N: down 2.6% BUZZ-Oppenheimer downgrades Home Depot, Lowe's on near-term risks ** Carnival Corp CCL.N: down 6.3% ** Royal Caribbean Cruises Ltd RCL.N: down 5.3% BUZZ-U.S. travel, leisure stocks fall on speculation over UK lockdown ** Aptiv PLC APTV.N: up 5.5% BUZZ-Jumps as MS hikes price target to top of Street ** Blink Charging Co BLNK.O: up 4.1% BUZZ-Gains on deal to buy BlueLA Carsharing ** SunPower Corp SPWR.O: up 2.7% BUZZ-Rises as MS upgrades on stronger business model after recent spin-off ** Abeona Therapeutics Inc ABEO.O: up 6.1% BUZZ-Surges as B. Riley FBR starts coverage with 'buy' ** Roku Inc ROKU.O: down 3.2% ** Comcast Corp CMCSA.O: down 1.8% BUZZ-Roku, Comcast down amid Peacock streaming scuffle ** Brinker International Inc EAT.N: up 2.9% BUZZ-Rises as Evercore raises PT, sees margin boost ** SpringWorks Therapeutics Inc SWTX.O: up 4.4% BUZZ-Hits three-month high on tumor therapy research agreement ** Unity Software Inc U.N: up 31.1% BUZZ-Jumps 44% in NYSE debut ** United States Steel Corp X.N: up 5.9% BUZZ-Says recovery trend extends to Q3; shares jump ** Limelight Networks Inc LLNW.O: up 7.9% BUZZ-Brokerage initiates with 'buy' on market share opportunity ** Compass Pathways Plc CMPS.O: up 42.1% BUZZ-Jumps 37.64% in Nasdaq debut The 11 major S&P 500 sectors: Communication Services down 1.56% Consumer Discretionary down 1.86% Consumer Staples | The top three S&P 500 .PG.INX percentage gainers: ** Aptiv PLC , up 5.4% ** Fleetcor Technologies Inc , up 2.6% ** AES Corp , up 2.6% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line Holdings Ltd , down 6.7% ** Carnival Corp , down 6.3% ** Royal Caribbean Cruises Ltd , down 5.2% The top three NYSE .PG.N percentage gainers: ** Unity Software Inc U.N, up 31% ** ReneSola Ltd SOL.N, up 27.7% ** Renren Inc , up 20.7% The top three NYSE .PL.N percentage losers: ** Vince Holding Corp , down 11.6% ** Cantel Medical Corp , down 9.2% ** 500.Com Ltd , down 9% The top three Nasdaq .PG.O percentage gainers: ** Compass Pathways PLC , up 42.1% ** Westport Fuel Systems Inc , up 35.5% ** Cassava Sciences Inc , up 34.3% The top three Nasdaq .PL.O percentage losers: ** Biovie Inc , down 20% ** Oasis Midstream Partners LP , down 14.8% ** Priority Technology Holdings Inc , down 13.7% ** Adamis Pharmaceuticals Corp ADMP.O: down 8.4% BUZZ-Slides on proposed stock offering ** Tesla Inc TSLA.O: up 3.1% BUZZ-Wedbush, Piper Sandler raise PTs ahead of Battery Day ** Checkpoint Therapeutics Inc CKPT.O: down 8.8% BUZZ-Drops on discounted stock deal ** Eastman Kodak Co KODK.N: up 8.3% BUZZ-Set for best week since loan news after review clears CEO of insider trading ** Kinross Gold Corp KGC.N: up 8.9% BUZZ-Rises on dividend, higher production outlook ** Pivotal Investment Corporation II PIC.N: up 13.0% BUZZ-To take XL Fleet public through merger, hits record high ** Kezar Life Sciences KZR.O: up 0.8% BUZZ-Jumps on positive data from lupus drug trial ** OneWater Marine Inc ONEW.O: down 9.5% BUZZ-Drops as Goldman offloads in share offering ** Oasis Petroleum Inc OAS.O: down 18.1% BUZZ-Slips on reports of missing debt payments ** Mirati Therapeutics Inc MRTX.O: down 3.2% BUZZ-Citi downgrades on 'appropriate' market credit for co's cancer therapy ** PG&E Corp PCG.N: down 1.7% BUZZ-Falls as CFO resigns to join CenterPoint Energy ** Oracle Corp ORCL.N: down 0.6% BUZZ-Slips as U.S. may ban downloading TikTok app ** Essential Properties Realty Trust EPRT.N: down 1.8% BUZZ-Falls on equity offering ** Steel Dynamics Inc STLD.O: up 2.5% BUZZ-Rises on upbeat Q3 profit forecast ** IsoRay Inc ISR.N: down 19.1% BUZZ-Slumps on bigger Q4 loss ** Beyond Meat Inc BYND.O: down 6.1% BUZZ-JPM downgrades on 'sluggish' fundamentals, shares fall ** Dave & Buster's Entertainment Inc PLAY.O: up 13.5% BUZZ-Jumps as brokerages upgrade to 'buy' following bankruptcy report ** Fastly Inc FSLY.N: down 1.6% BUZZ-Falls after Trump says to block TikTok, WeChat apps ** Home Depot Inc HD.N: down 2.8% ** Lowe's Companies Inc LOW.N: down 2.6% BUZZ-Oppenheimer downgrades Home Depot, Lowe's on near-term risks ** Carnival Corp CCL.N: down 6.3% ** Royal Caribbean Cruises Ltd RCL.N: down 5.3% BUZZ-U.S. travel, leisure stocks fall on speculation over UK lockdown ** Aptiv PLC APTV.N: up 5.5% BUZZ-Jumps as MS hikes price target to top of Street ** Blink Charging Co BLNK.O: up 4.1% BUZZ-Gains on deal to buy BlueLA Carsharing ** SunPower Corp SPWR.O: up 2.7% BUZZ-Rises as MS upgrades on stronger business model after recent spin-off ** Abeona Therapeutics Inc ABEO.O: up 6.1% BUZZ-Surges as B. Riley FBR starts coverage with 'buy' ** Roku Inc ROKU.O: down 3.2% ** Comcast Corp CMCSA.O: down 1.8% BUZZ-Roku, Comcast down amid Peacock streaming scuffle ** Brinker International Inc EAT.N: up 2.9% BUZZ-Rises as Evercore raises PT, sees margin boost ** SpringWorks Therapeutics Inc SWTX.O: up 4.4% BUZZ-Hits three-month high on tumor therapy research agreement ** Unity Software Inc U.N: up 31.1% BUZZ-Jumps 44% in NYSE debut ** United States Steel Corp X.N: up 5.9% BUZZ-Says recovery trend extends to Q3; shares jump ** Limelight Networks Inc LLNW.O: up 7.9% BUZZ-Brokerage initiates with 'buy' on market share opportunity ** Compass Pathways Plc CMPS.O: up 42.1% BUZZ-Jumps 37.64% in Nasdaq debut The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks turned lower in volatile trading on Friday as worries about rising coronavirus cases and a patchy economic recovery dampened risk sentiment, with technology-related stocks reversing early gains to extend their declines to a third day. ET, the Dow Jones Industrial Average .DJI was down 1.08% at 27,601.36, the S&P 500 .SPX was down 1.37% at 3,311.03 and the Nasdaq Composite .IXIC was down 1.67% at 10,727.702. |
28055.0 | 2020-09-18 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Aptiv PLC, Great Elm Capital Group, Blink Charging Co, Abeona Therapeutics | ABEO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-aptiv-plc-great-elm-capital-group-blink-charging-co-abeona | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stocks turned lower in volatile trading on Friday as worries about rising coronavirus cases and a patchy economic recovery dampened risk sentiment, with technology-related stocks reversing early gains to extend their declines to a third day. .N
At 11:35 a.m. ET, the Dow Jones Industrial Average .DJI was down 0.37% at 27,799.34. The S&P 500 .SPX was down 0.72% at 3,332.8 and the Nasdaq Composite .IXIC was down 1.06% at 10,794.769. The top three S&P 500 .PG.INX percentage gainers: ** Aptiv PLC , up 5.6% ** Marathon Oil Corp , up 3% ** AES Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line Hldings Ltd , down 5.7% ** Carnival Corp , down 5.5% ** H & R Block Inc , down 4.8% The top three NYSE .PG.N percentage gainers: ** Renren Inc , up 26.9% ** ReneSola Ltd SOL.N, up 23.8% ** Bloom Energy Corp , up 23.8% The top three NYSE .PL.N percentage losers: ** Garret Motion Inc , down 12.2% ** 500.Com Ltd , down 8.7% ** Carnival PLC , down 7.5% The top three Nasdaq .PG.O percentage gainers: ** Westport Fuel Systems Inc , up 38.9% ** Cassava Sciences Inc , up 34.7% ** Ituran Location & Control Ltd , up 20.8% The top three Nasdaq .PL.O percentage losers: ** Biovie Inc , down 19% ** Priority Technology Holdings Inc , down 11.6% ** Oasis Midstream Partners LP , down 10.5% ** Adamis Pharmaceuticals Corp ADMP.O: down 9.4%
BUZZ-Slides on proposed stock offering ** Tesla Inc TSLA.O: up 4.3%
BUZZ-Wedbush, Piper Sandler raise PTs ahead of Battery Day ** Checkpoint Therapeutics Inc CKPT.O: down 5.9%
BUZZ-Drops on discounted stock deal ** Eastman Kodak Co KODK.N: up 4.4%
BUZZ-Set for best week since loan news after review clears CEO of insider trading ** Kinross Gold Corp KGC.N: up 7.0%
BUZZ-Rises on dividend, higher production outlook ** Pivotal Investment Corporation II PIC.N: up 13.6%
BUZZ-To take XL Fleet public through merger, hits record high ** Kezar Life Sciences KZR.O: up 0.4%
BUZZ-Jumps on positive data from lupus drug trial ** OneWater Marine Inc ONEW.O: down 9.7%
BUZZ-Drops as Goldman offloads in share offering ** Oasis Petroleum Inc OAS.O: down 14.1%
BUZZ-Slips on reports of missing debt payments ** PG&E Corp PCG.N: down 2.1%
BUZZ-Falls as CFO resigns to join CenterPoint Energy ** Agenus Inc AGEN.O: up 0.7%
BUZZ-Rises after cervical cancer treatment studies show promise ** Oracle Corp ORCL.N: down 0.3%
BUZZ-Slips as U.S. may ban downloading TikTok app ** Essential Properties Realty Trust EPRT.N: down 1.6%
BUZZ-Falls on equity offering ** NIO Inc NIO.N: up 0.2%
BUZZ-Rises on $75 mln Chinese equity stake redemption ** Steel Dynamics Inc STLD.O: up 3.4%
BUZZ-Rises on upbeat Q3 profit forecast ** IsoRay Inc ISR.N: down 18.9%
BUZZ-Slumps on bigger Q4 loss ** Intuit Inc INTU.O: down 2.8%
BUZZ-Piper Sandler starts with 'overweight' rating ** Beyond Meat Inc BYND.O: down 6.3%
BUZZ-JPM downgrades on 'sluggish' fundamentals, shares fall ** Dave & Buster's Entertainment Inc PLAY.O: up 13.2%
BUZZ-Jumps as brokerages upgrade to 'buy' following bankruptcy report ** Fastly Inc FSLY.N: down 2.1%
BUZZ-Falls after Trump says to block TikTok, WeChat apps ** Home Depot Inc HD.N: down 1.3% ** Lowe's Companies Inc LOW.N: down 1.2%
BUZZ-Oppenheimer downgrades Home Depot, Lowe's on near-term risks ** Carnival Corp CCL.N: down 5.5% ** Royal Caribbean Cruises Ltd RCL.N: down 4.5%
BUZZ-U.S. travel, leisure stocks fall on speculation over UK lockdown ** Aptiv PLC APTV.N: up 5.6%
BUZZ-Jumps as MS hikes price target to top of Street ** Blink Charging Co BLNK.O: up 4.5%
BUZZ-Gains on deal to buy BlueLA Carsharing ** Pacira Biosciences Inc PCRX.O: up 0.7%
BUZZ-Rises as European panel recommends approval for pain therapy ** Great Elm Capital Group Inc GEC.O: up 3.8%
BUZZ-Jumps on Q4 profit vs year-ago loss ** SunPower Corp SPWR.O: up 3.5%
BUZZ-Rises as MS upgrades on stronger business model after recent spin-off ** Nike Inc NKE.N: up 0.1%
BUZZ-Gains as brokerages raise PT ahead of results ** Abeona Therapeutics Inc ABEO.O: up 13.3%
BUZZ-Surges as B. Riley FBR starts coverage with 'buy' ** Roku Inc ROKU.O: down 2.2% ** Comcast Corp CMCSA.O: down 1.0%
BUZZ-Roku, Comcast down amid Peacock streaming scuffle
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 0.87%
Consumer Discretionary
.SPLRCD
down 1.06%
Consumer Staples
.SPLRCS
down 0.45%
Energy
.SPNY
down 0.59%
Financial
.SPSY
up 0.31%
Health
.SPXHC
up 0.10%
Industrial
.SPLRCI
up 0.11%
Information Technology
.SPLRCT
down 1.55%
Materials
.SPLRCM
down 0.69%
Real Estate
.SPLRCR
down 1.43%
Utilities
.SPLRCU
down 1.16%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Aptiv PLC , up 5.6% ** Marathon Oil Corp , up 3% ** AES Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line Hldings Ltd , down 5.7% ** Carnival Corp , down 5.5% ** H & R Block Inc , down 4.8% The top three NYSE .PG.N percentage gainers: ** Renren Inc , up 26.9% ** ReneSola Ltd SOL.N, up 23.8% ** Bloom Energy Corp , up 23.8% The top three NYSE .PL.N percentage losers: ** Garret Motion Inc , down 12.2% ** 500.Com Ltd , down 8.7% ** Carnival PLC , down 7.5% The top three Nasdaq .PG.O percentage gainers: ** Westport Fuel Systems Inc , up 38.9% ** Cassava Sciences Inc , up 34.7% ** Ituran Location & Control Ltd , up 20.8% The top three Nasdaq .PL.O percentage losers: ** Biovie Inc , down 19% ** Priority Technology Holdings Inc , down 11.6% ** Oasis Midstream Partners LP , down 10.5% ** Adamis Pharmaceuticals Corp ADMP.O: down 9.4% BUZZ-Slides on proposed stock offering ** Tesla Inc TSLA.O: up 4.3% BUZZ-Wedbush, Piper Sandler raise PTs ahead of Battery Day ** Checkpoint Therapeutics Inc CKPT.O: down 5.9% BUZZ-Drops on discounted stock deal ** Eastman Kodak Co KODK.N: up 4.4% BUZZ-Set for best week since loan news after review clears CEO of insider trading ** Kinross Gold Corp KGC.N: up 7.0% BUZZ-Rises on dividend, higher production outlook ** Pivotal Investment Corporation II PIC.N: up 13.6% BUZZ-To take XL Fleet public through merger, hits record high ** Kezar Life Sciences KZR.O: up 0.4% BUZZ-Jumps on positive data from lupus drug trial ** OneWater Marine Inc ONEW.O: down 9.7% BUZZ-Drops as Goldman offloads in share offering ** Oasis Petroleum Inc OAS.O: down 14.1% BUZZ-Slips on reports of missing debt payments ** PG&E Corp PCG.N: down 2.1% BUZZ-Falls as CFO resigns to join CenterPoint Energy ** Agenus Inc AGEN.O: up 0.7% BUZZ-Rises after cervical cancer treatment studies show promise ** Oracle Corp ORCL.N: down 0.3% BUZZ-Slips as U.S. may ban downloading TikTok app ** Essential Properties Realty Trust EPRT.N: down 1.6% BUZZ-Falls on equity offering ** NIO Inc NIO.N: up 0.2% BUZZ-Rises on $75 mln Chinese equity stake redemption ** Steel Dynamics Inc STLD.O: up 3.4% BUZZ-Rises on upbeat Q3 profit forecast ** IsoRay Inc ISR.N: down 18.9% BUZZ-Slumps on bigger Q4 loss ** Intuit Inc INTU.O: down 2.8% BUZZ-Piper Sandler starts with 'overweight' rating ** Beyond Meat Inc BYND.O: down 6.3% BUZZ-JPM downgrades on 'sluggish' fundamentals, shares fall ** Dave & Buster's Entertainment Inc PLAY.O: up 13.2% BUZZ-Jumps as brokerages upgrade to 'buy' following bankruptcy report ** Fastly Inc FSLY.N: down 2.1% BUZZ-Falls after Trump says to block TikTok, WeChat apps ** Home Depot Inc HD.N: down 1.3% ** Lowe's Companies Inc LOW.N: down 1.2% BUZZ-Oppenheimer downgrades Home Depot, Lowe's on near-term risks ** Carnival Corp CCL.N: down 5.5% ** Royal Caribbean Cruises Ltd RCL.N: down 4.5% BUZZ-U.S. travel, leisure stocks fall on speculation over UK lockdown ** Aptiv PLC APTV.N: up 5.6% BUZZ-Jumps as MS hikes price target to top of Street ** Blink Charging Co BLNK.O: up 4.5% BUZZ-Gains on deal to buy BlueLA Carsharing ** Pacira Biosciences Inc PCRX.O: up 0.7% BUZZ-Rises as European panel recommends approval for pain therapy ** Great Elm Capital Group Inc GEC.O: up 3.8% BUZZ-Jumps on Q4 profit vs year-ago loss ** SunPower Corp SPWR.O: up 3.5% BUZZ-Rises as MS upgrades on stronger business model after recent spin-off ** Nike Inc NKE.N: up 0.1% BUZZ-Gains as brokerages raise PT ahead of results ** Abeona Therapeutics Inc ABEO.O: up 13.3% BUZZ-Surges as B. Riley FBR starts coverage with 'buy' ** Roku Inc ROKU.O: down 2.2% ** Comcast Corp CMCSA.O: down 1.0% BUZZ-Roku, Comcast down amid Peacock streaming scuffle The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks turned lower in volatile trading on Friday as worries about rising coronavirus cases and a patchy economic recovery dampened risk sentiment, with technology-related stocks reversing early gains to extend their declines to a third day. down 1.16% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Aptiv PLC , up 5.6% ** Marathon Oil Corp , up 3% ** AES Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line Hldings Ltd , down 5.7% ** Carnival Corp , down 5.5% ** H & R Block Inc , down 4.8% The top three NYSE .PG.N percentage gainers: ** Renren Inc , up 26.9% ** ReneSola Ltd SOL.N, up 23.8% ** Bloom Energy Corp , up 23.8% The top three NYSE .PL.N percentage losers: ** Garret Motion Inc , down 12.2% ** 500.Com Ltd , down 8.7% ** Carnival PLC , down 7.5% The top three Nasdaq .PG.O percentage gainers: ** Westport Fuel Systems Inc , up 38.9% ** Cassava Sciences Inc , up 34.7% ** Ituran Location & Control Ltd , up 20.8% The top three Nasdaq .PL.O percentage losers: ** Biovie Inc , down 19% ** Priority Technology Holdings Inc , down 11.6% ** Oasis Midstream Partners LP , down 10.5% ** Adamis Pharmaceuticals Corp ADMP.O: down 9.4% BUZZ-Slides on proposed stock offering ** Tesla Inc TSLA.O: up 4.3% BUZZ-Wedbush, Piper Sandler raise PTs ahead of Battery Day ** Checkpoint Therapeutics Inc CKPT.O: down 5.9% BUZZ-Drops on discounted stock deal ** Eastman Kodak Co KODK.N: up 4.4% BUZZ-Set for best week since loan news after review clears CEO of insider trading ** Kinross Gold Corp KGC.N: up 7.0% BUZZ-Rises on dividend, higher production outlook ** Pivotal Investment Corporation II PIC.N: up 13.6% BUZZ-To take XL Fleet public through merger, hits record high ** Kezar Life Sciences KZR.O: up 0.4% BUZZ-Jumps on positive data from lupus drug trial ** OneWater Marine Inc ONEW.O: down 9.7% BUZZ-Drops as Goldman offloads in share offering ** Oasis Petroleum Inc OAS.O: down 14.1% BUZZ-Slips on reports of missing debt payments ** PG&E Corp PCG.N: down 2.1% BUZZ-Falls as CFO resigns to join CenterPoint Energy ** Agenus Inc AGEN.O: up 0.7% BUZZ-Rises after cervical cancer treatment studies show promise ** Oracle Corp ORCL.N: down 0.3% BUZZ-Slips as U.S. may ban downloading TikTok app ** Essential Properties Realty Trust EPRT.N: down 1.6% BUZZ-Falls on equity offering ** NIO Inc NIO.N: up 0.2% BUZZ-Rises on $75 mln Chinese equity stake redemption ** Steel Dynamics Inc STLD.O: up 3.4% BUZZ-Rises on upbeat Q3 profit forecast ** IsoRay Inc ISR.N: down 18.9% BUZZ-Slumps on bigger Q4 loss ** Intuit Inc INTU.O: down 2.8% BUZZ-Piper Sandler starts with 'overweight' rating ** Beyond Meat Inc BYND.O: down 6.3% BUZZ-JPM downgrades on 'sluggish' fundamentals, shares fall ** Dave & Buster's Entertainment Inc PLAY.O: up 13.2% BUZZ-Jumps as brokerages upgrade to 'buy' following bankruptcy report ** Fastly Inc FSLY.N: down 2.1% BUZZ-Falls after Trump says to block TikTok, WeChat apps ** Home Depot Inc HD.N: down 1.3% ** Lowe's Companies Inc LOW.N: down 1.2% BUZZ-Oppenheimer downgrades Home Depot, Lowe's on near-term risks ** Carnival Corp CCL.N: down 5.5% ** Royal Caribbean Cruises Ltd RCL.N: down 4.5% BUZZ-U.S. travel, leisure stocks fall on speculation over UK lockdown ** Aptiv PLC APTV.N: up 5.6% BUZZ-Jumps as MS hikes price target to top of Street ** Blink Charging Co BLNK.O: up 4.5% BUZZ-Gains on deal to buy BlueLA Carsharing ** Pacira Biosciences Inc PCRX.O: up 0.7% BUZZ-Rises as European panel recommends approval for pain therapy ** Great Elm Capital Group Inc GEC.O: up 3.8% BUZZ-Jumps on Q4 profit vs year-ago loss ** SunPower Corp SPWR.O: up 3.5% BUZZ-Rises as MS upgrades on stronger business model after recent spin-off ** Nike Inc NKE.N: up 0.1% BUZZ-Gains as brokerages raise PT ahead of results ** Abeona Therapeutics Inc ABEO.O: up 13.3% BUZZ-Surges as B. Riley FBR starts coverage with 'buy' ** Roku Inc ROKU.O: down 2.2% ** Comcast Corp CMCSA.O: down 1.0% BUZZ-Roku, Comcast down amid Peacock streaming scuffle The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks turned lower in volatile trading on Friday as worries about rising coronavirus cases and a patchy economic recovery dampened risk sentiment, with technology-related stocks reversing early gains to extend their declines to a third day. down 1.16% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Aptiv PLC , up 5.6% ** Marathon Oil Corp , up 3% ** AES Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line Hldings Ltd , down 5.7% ** Carnival Corp , down 5.5% ** H & R Block Inc , down 4.8% The top three NYSE .PG.N percentage gainers: ** Renren Inc , up 26.9% ** ReneSola Ltd SOL.N, up 23.8% ** Bloom Energy Corp , up 23.8% The top three NYSE .PL.N percentage losers: ** Garret Motion Inc , down 12.2% ** 500.Com Ltd , down 8.7% ** Carnival PLC , down 7.5% The top three Nasdaq .PG.O percentage gainers: ** Westport Fuel Systems Inc , up 38.9% ** Cassava Sciences Inc , up 34.7% ** Ituran Location & Control Ltd , up 20.8% The top three Nasdaq .PL.O percentage losers: ** Biovie Inc , down 19% ** Priority Technology Holdings Inc , down 11.6% ** Oasis Midstream Partners LP , down 10.5% ** Adamis Pharmaceuticals Corp ADMP.O: down 9.4% BUZZ-Slides on proposed stock offering ** Tesla Inc TSLA.O: up 4.3% BUZZ-Wedbush, Piper Sandler raise PTs ahead of Battery Day ** Checkpoint Therapeutics Inc CKPT.O: down 5.9% BUZZ-Drops on discounted stock deal ** Eastman Kodak Co KODK.N: up 4.4% BUZZ-Set for best week since loan news after review clears CEO of insider trading ** Kinross Gold Corp KGC.N: up 7.0% BUZZ-Rises on dividend, higher production outlook ** Pivotal Investment Corporation II PIC.N: up 13.6% BUZZ-To take XL Fleet public through merger, hits record high ** Kezar Life Sciences KZR.O: up 0.4% BUZZ-Jumps on positive data from lupus drug trial ** OneWater Marine Inc ONEW.O: down 9.7% BUZZ-Drops as Goldman offloads in share offering ** Oasis Petroleum Inc OAS.O: down 14.1% BUZZ-Slips on reports of missing debt payments ** PG&E Corp PCG.N: down 2.1% BUZZ-Falls as CFO resigns to join CenterPoint Energy ** Agenus Inc AGEN.O: up 0.7% BUZZ-Rises after cervical cancer treatment studies show promise ** Oracle Corp ORCL.N: down 0.3% BUZZ-Slips as U.S. may ban downloading TikTok app ** Essential Properties Realty Trust EPRT.N: down 1.6% BUZZ-Falls on equity offering ** NIO Inc NIO.N: up 0.2% BUZZ-Rises on $75 mln Chinese equity stake redemption ** Steel Dynamics Inc STLD.O: up 3.4% BUZZ-Rises on upbeat Q3 profit forecast ** IsoRay Inc ISR.N: down 18.9% BUZZ-Slumps on bigger Q4 loss ** Intuit Inc INTU.O: down 2.8% BUZZ-Piper Sandler starts with 'overweight' rating ** Beyond Meat Inc BYND.O: down 6.3% BUZZ-JPM downgrades on 'sluggish' fundamentals, shares fall ** Dave & Buster's Entertainment Inc PLAY.O: up 13.2% BUZZ-Jumps as brokerages upgrade to 'buy' following bankruptcy report ** Fastly Inc FSLY.N: down 2.1% BUZZ-Falls after Trump says to block TikTok, WeChat apps ** Home Depot Inc HD.N: down 1.3% ** Lowe's Companies Inc LOW.N: down 1.2% BUZZ-Oppenheimer downgrades Home Depot, Lowe's on near-term risks ** Carnival Corp CCL.N: down 5.5% ** Royal Caribbean Cruises Ltd RCL.N: down 4.5% BUZZ-U.S. travel, leisure stocks fall on speculation over UK lockdown ** Aptiv PLC APTV.N: up 5.6% BUZZ-Jumps as MS hikes price target to top of Street ** Blink Charging Co BLNK.O: up 4.5% BUZZ-Gains on deal to buy BlueLA Carsharing ** Pacira Biosciences Inc PCRX.O: up 0.7% BUZZ-Rises as European panel recommends approval for pain therapy ** Great Elm Capital Group Inc GEC.O: up 3.8% BUZZ-Jumps on Q4 profit vs year-ago loss ** SunPower Corp SPWR.O: up 3.5% BUZZ-Rises as MS upgrades on stronger business model after recent spin-off ** Nike Inc NKE.N: up 0.1% BUZZ-Gains as brokerages raise PT ahead of results ** Abeona Therapeutics Inc ABEO.O: up 13.3% BUZZ-Surges as B. Riley FBR starts coverage with 'buy' ** Roku Inc ROKU.O: down 2.2% ** Comcast Corp CMCSA.O: down 1.0% BUZZ-Roku, Comcast down amid Peacock streaming scuffle The 11 major S&P 500 sectors: Communication Services ET, the Dow Jones Industrial Average .DJI was down 0.37% at 27,799.34. down 0.87% Consumer Discretionary | The top three S&P 500 .PG.INX percentage gainers: ** Aptiv PLC , up 5.6% ** Marathon Oil Corp , up 3% ** AES Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line Hldings Ltd , down 5.7% ** Carnival Corp , down 5.5% ** H & R Block Inc , down 4.8% The top three NYSE .PG.N percentage gainers: ** Renren Inc , up 26.9% ** ReneSola Ltd SOL.N, up 23.8% ** Bloom Energy Corp , up 23.8% The top three NYSE .PL.N percentage losers: ** Garret Motion Inc , down 12.2% ** 500.Com Ltd , down 8.7% ** Carnival PLC , down 7.5% The top three Nasdaq .PG.O percentage gainers: ** Westport Fuel Systems Inc , up 38.9% ** Cassava Sciences Inc , up 34.7% ** Ituran Location & Control Ltd , up 20.8% The top three Nasdaq .PL.O percentage losers: ** Biovie Inc , down 19% ** Priority Technology Holdings Inc , down 11.6% ** Oasis Midstream Partners LP , down 10.5% ** Adamis Pharmaceuticals Corp ADMP.O: down 9.4% BUZZ-Slides on proposed stock offering ** Tesla Inc TSLA.O: up 4.3% BUZZ-Wedbush, Piper Sandler raise PTs ahead of Battery Day ** Checkpoint Therapeutics Inc CKPT.O: down 5.9% BUZZ-Drops on discounted stock deal ** Eastman Kodak Co KODK.N: up 4.4% BUZZ-Set for best week since loan news after review clears CEO of insider trading ** Kinross Gold Corp KGC.N: up 7.0% BUZZ-Rises on dividend, higher production outlook ** Pivotal Investment Corporation II PIC.N: up 13.6% BUZZ-To take XL Fleet public through merger, hits record high ** Kezar Life Sciences KZR.O: up 0.4% BUZZ-Jumps on positive data from lupus drug trial ** OneWater Marine Inc ONEW.O: down 9.7% BUZZ-Drops as Goldman offloads in share offering ** Oasis Petroleum Inc OAS.O: down 14.1% BUZZ-Slips on reports of missing debt payments ** PG&E Corp PCG.N: down 2.1% BUZZ-Falls as CFO resigns to join CenterPoint Energy ** Agenus Inc AGEN.O: up 0.7% BUZZ-Rises after cervical cancer treatment studies show promise ** Oracle Corp ORCL.N: down 0.3% BUZZ-Slips as U.S. may ban downloading TikTok app ** Essential Properties Realty Trust EPRT.N: down 1.6% BUZZ-Falls on equity offering ** NIO Inc NIO.N: up 0.2% BUZZ-Rises on $75 mln Chinese equity stake redemption ** Steel Dynamics Inc STLD.O: up 3.4% BUZZ-Rises on upbeat Q3 profit forecast ** IsoRay Inc ISR.N: down 18.9% BUZZ-Slumps on bigger Q4 loss ** Intuit Inc INTU.O: down 2.8% BUZZ-Piper Sandler starts with 'overweight' rating ** Beyond Meat Inc BYND.O: down 6.3% BUZZ-JPM downgrades on 'sluggish' fundamentals, shares fall ** Dave & Buster's Entertainment Inc PLAY.O: up 13.2% BUZZ-Jumps as brokerages upgrade to 'buy' following bankruptcy report ** Fastly Inc FSLY.N: down 2.1% BUZZ-Falls after Trump says to block TikTok, WeChat apps ** Home Depot Inc HD.N: down 1.3% ** Lowe's Companies Inc LOW.N: down 1.2% BUZZ-Oppenheimer downgrades Home Depot, Lowe's on near-term risks ** Carnival Corp CCL.N: down 5.5% ** Royal Caribbean Cruises Ltd RCL.N: down 4.5% BUZZ-U.S. travel, leisure stocks fall on speculation over UK lockdown ** Aptiv PLC APTV.N: up 5.6% BUZZ-Jumps as MS hikes price target to top of Street ** Blink Charging Co BLNK.O: up 4.5% BUZZ-Gains on deal to buy BlueLA Carsharing ** Pacira Biosciences Inc PCRX.O: up 0.7% BUZZ-Rises as European panel recommends approval for pain therapy ** Great Elm Capital Group Inc GEC.O: up 3.8% BUZZ-Jumps on Q4 profit vs year-ago loss ** SunPower Corp SPWR.O: up 3.5% BUZZ-Rises as MS upgrades on stronger business model after recent spin-off ** Nike Inc NKE.N: up 0.1% BUZZ-Gains as brokerages raise PT ahead of results ** Abeona Therapeutics Inc ABEO.O: up 13.3% BUZZ-Surges as B. Riley FBR starts coverage with 'buy' ** Roku Inc ROKU.O: down 2.2% ** Comcast Corp CMCSA.O: down 1.0% BUZZ-Roku, Comcast down amid Peacock streaming scuffle The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks turned lower in volatile trading on Friday as worries about rising coronavirus cases and a patchy economic recovery dampened risk sentiment, with technology-related stocks reversing early gains to extend their declines to a third day. ET, the Dow Jones Industrial Average .DJI was down 0.37% at 27,799.34. |
28056.0 | 2020-08-17 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Interpace Biosciences, Overstock, Unity Biotechnology | ABEO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-interpace-biosciences-overstock-unity-biotechnology-2020-08 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Technology-related shares lifted the S&P 500 and Nasdaq on Monday as investors turned to sectors that have been resilient to the shocks of the coronavirus pandemic, while awaiting the earnings of big retailers later this week. .N
At 11:56 ET, the Dow Jones Industrial Average .DJI was down 0.21% at 27,872.28. The S&P 500 .SPX was up 0.32% at 3,383.55 and the Nasdaq Composite .IXIC was up 0.74% at 11,100.511. The top three S&P 500 .PG.INX percentage gainers: ** L Brands Inc , up 7.3% ** Newmont Corp , up 5.8% ** Nvidia Corp , up 5.6% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corporation , down 5.5% ** Coty Inc , down 4.1% ** Carnival Corp , down 4% The top three NYSE .PG.N percentage gainers: ** China Green Agriculture, Inc , up 22.7% ** Hovnanian Enterprises, Inc , up 15.9% ** Caledonia Mining Corporation Plc , up 12.8% The top three NYSE .PL.N percentage losers: ** Callon Petroleum Company , down 11.7% ** Direxion Daily Gold Miners Index Bear 2x Shares , down 11.5% ** NTN Buzztime Inc , down 10.7% The top three Nasdaq .PG.O percentage gainers: ** Imara Inc , up 62.5% ** LMP Automotive Holdings Inc , up 32.7% ** CureVac NV , up 31.7% The top three Nasdaq .PL.O percentage losers: ** Unity Biotechnology Inc , down 59.9% ** Interpace Biosciences Inc , down 30.9% ** Thermogenesis Holdings Inc , down 19.7% ** OncoSec Medical Inc ONCS.O: down 1.9%
BUZZ-Down on discounted stock offering ** TRACON Pharmaceuticals Inc TCON.O: up 7.6%
BUZZ-Up on FDA nod for human trials of potential cancer treatment ** Teladoc Health Inc TDOC.N: up 5.1%
BUZZ-CS says Livongo merger creates digital health giant; upgrades ** Revolve Group Inc RVLV.N: down 4.1%
BUZZ-Drops after big block prices ** Lazydays Holdings Inc LAZY.O: up 3.9%
BUZZ-Rises on strong demand ** Medley Management Inc MDLY.N: down 6.3%
BUZZ-Drops on bigger quarterly loss ** GenMark Diagnostics Inc GNMK.O: up 4.5%
BUZZ-Up as co seeks FDA's emergency use allowance for COVID-19 test ** Ross Stores Inc ROST.O: up 3.1%
BUZZ-Retail bankruptcies provide potential share gains for Ross Stores - Telsey ** Trinity Biotech Plc TRIB.O: down 7.0%
BUZZ-Down as co's unit receives FDA warning for Hemoglobin product ** ThermoGenesis Holdings Inc THMO.O: down 19.7%
BUZZ-Falls after Q2 revenue nearly halves ** Domino's Pizza Inc DPZ.N: up 1.6%
BUZZ-Up on plans to hire 20,000 U.S. workers ** Parsons Corp PSN.N: down 8.4%
BUZZ-Falls on planned $300 mln convertible debt deal ** Noodles & Co NDLS.O: down 1.6%
BUZZ-Falls as CFO resigns ** Yintech Investment Holdings Ltd YIN.O: up 8.4%
BUZZ-Rises after signing go-private deal ** Rackspace Technology Inc RXT.O: up 11.9%
BUZZ-Jumps as Amazon could invest in company ** Applied Therapeutics Inc APLT.O: down 17.5%
BUZZ-Drops after partial clinical hold on galactosemia study ** Enphase Energy Inc ENPH.O: up 1.8%
BUZZ-Up on partnership to launch AC modules in Europe ** Occidental Petroleum Corp OXY.N: down 5.6%
BUZZ-Falls as Berkshire Hathaway dissolves stake ** Union Pacific Corp UNP.N: up 1%
BUZZ-Hits record high after Baird upgrade ** Jamf Holding Corp JAMF.O: up 6.7%
BUZZ-Analysts bullish on rising adoption of Apple in the enterprise ** Sasol Ltd SSL.N: down 5.3%
BUZZ-Drops on $2 bln rights issue plan as pandemic hits earnings ** Microbot Medical Inc MBOT.O: up 24.3%
BUZZ-Jumps as surgical robot succeeds animal study ** Unity Biotechnology Inc UBX.O: down 59.9%
BUZZ-Drops over 50% as arthritis treatment fails ** Novavax Inc NVAX.O: up 3.7% BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink
** Bristol Myers Squibb Co BMY.N: up 1.0% BUZZ-Up on license agreement for potential cancer treatment ** Principia Biopharma Inc PRNB.O: up 9.3% BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 3.6% BUZZ-Rises on licensing agreement for gene therapy
** Pluristem Therapeutics Inc PSTI.O: up 8.4% BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 4.3% BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Tesla Inc TSLA.O: up 7.3% BUZZ-Hits record high as Wedbush raises PT on likely battery developments ** Lyft Inc LYFT.O: down 5.9% ** Uber Technologies Inc UBER.N: down 1.8% BUZZ-Zephirin Group expects long legal clash for Uber, Lyft; downgrades ** Barrick Gold GOLD.N: up 11.6% BUZZ-Gains as Buffett takes stake ** Overstock.com Inc OSTK.O: up 18.4% BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Medtronic PLC MDT.N: up 1.9% BUZZ-Poised for stronger-than-expected Q1 of 2021 results- JPM ** Interpace Biosciences IDXG.O: down 30.9% BUZZ-Slumps on internal probe, delay in quarterly filing
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 0.06%
Consumer Discretionary
.SPLRCD
up 0.82%
Consumer Staples
.SPLRCS
up 0.76%
Energy
.SPNY
down 0.92%
Financial
.SPSY
down 1.15%
Health
.SPXHC
up 0.85%
Industrial
.SPLRCI
down 0.16%
Information Technology
.SPLRCT
up 0.59%
Materials
.SPLRCM
up 0.58%
Real Estate
.SPLRCR
up 0.42%
Utilities
.SPLRCU
up 0.36%
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** L Brands Inc , up 7.3% ** Newmont Corp , up 5.8% ** Nvidia Corp , up 5.6% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corporation , down 5.5% ** Coty Inc , down 4.1% ** Carnival Corp , down 4% The top three NYSE .PG.N percentage gainers: ** China Green Agriculture, Inc , up 22.7% ** Hovnanian Enterprises, Inc , up 15.9% ** Caledonia Mining Corporation Plc , up 12.8% The top three NYSE .PL.N percentage losers: ** Callon Petroleum Company , down 11.7% ** Direxion Daily Gold Miners Index Bear 2x Shares , down 11.5% ** NTN Buzztime Inc , down 10.7% The top three Nasdaq .PG.O percentage gainers: ** Imara Inc , up 62.5% ** LMP Automotive Holdings Inc , up 32.7% ** CureVac NV , up 31.7% The top three Nasdaq .PL.O percentage losers: ** Unity Biotechnology Inc , down 59.9% ** Interpace Biosciences Inc , down 30.9% ** Thermogenesis Holdings Inc , down 19.7% ** OncoSec Medical Inc ONCS.O: down 1.9% BUZZ-Down on discounted stock offering ** TRACON Pharmaceuticals Inc TCON.O: up 7.6% BUZZ-Up on FDA nod for human trials of potential cancer treatment ** Teladoc Health Inc TDOC.N: up 5.1% BUZZ-CS says Livongo merger creates digital health giant; upgrades ** Revolve Group Inc RVLV.N: down 4.1% BUZZ-Drops after big block prices ** Lazydays Holdings Inc LAZY.O: up 3.9% BUZZ-Rises on strong demand ** Medley Management Inc MDLY.N: down 6.3% BUZZ-Drops on bigger quarterly loss ** GenMark Diagnostics Inc GNMK.O: up 4.5% BUZZ-Up as co seeks FDA's emergency use allowance for COVID-19 test ** Ross Stores Inc ROST.O: up 3.1% BUZZ-Retail bankruptcies provide potential share gains for Ross Stores - Telsey ** Trinity Biotech Plc TRIB.O: down 7.0% BUZZ-Down as co's unit receives FDA warning for Hemoglobin product ** ThermoGenesis Holdings Inc THMO.O: down 19.7% BUZZ-Falls after Q2 revenue nearly halves ** Domino's Pizza Inc DPZ.N: up 1.6% BUZZ-Up on plans to hire 20,000 U.S. workers ** Parsons Corp PSN.N: down 8.4% BUZZ-Falls on planned $300 mln convertible debt deal ** Noodles & Co NDLS.O: down 1.6% BUZZ-Falls as CFO resigns ** Yintech Investment Holdings Ltd YIN.O: up 8.4% BUZZ-Rises after signing go-private deal ** Rackspace Technology Inc RXT.O: up 11.9% BUZZ-Jumps as Amazon could invest in company ** Applied Therapeutics Inc APLT.O: down 17.5% BUZZ-Drops after partial clinical hold on galactosemia study ** Enphase Energy Inc ENPH.O: up 1.8% BUZZ-Up on partnership to launch AC modules in Europe ** Occidental Petroleum Corp OXY.N: down 5.6% BUZZ-Falls as Berkshire Hathaway dissolves stake ** Union Pacific Corp UNP.N: up 1% BUZZ-Hits record high after Baird upgrade ** Jamf Holding Corp JAMF.O: up 6.7% BUZZ-Analysts bullish on rising adoption of Apple in the enterprise ** Sasol Ltd SSL.N: down 5.3% BUZZ-Drops on $2 bln rights issue plan as pandemic hits earnings ** Microbot Medical Inc MBOT.O: up 24.3% BUZZ-Jumps as surgical robot succeeds animal study ** Unity Biotechnology Inc UBX.O: down 59.9% BUZZ-Drops over 50% as arthritis treatment fails ** Novavax Inc NVAX.O: up 3.7% BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Bristol Myers Squibb Co BMY.N: up 1.0% BUZZ-Up on license agreement for potential cancer treatment ** Principia Biopharma Inc PRNB.O: up 9.3% BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 3.6% BUZZ-Rises on licensing agreement for gene therapy ** Pluristem Therapeutics Inc PSTI.O: up 8.4% BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 4.3% BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Tesla Inc TSLA.O: up 7.3% BUZZ-Hits record high as Wedbush raises PT on likely battery developments ** Lyft Inc LYFT.O: down 5.9% ** Uber Technologies Inc UBER.N: down 1.8% BUZZ-Zephirin Group expects long legal clash for Uber, Lyft; downgrades ** Barrick Gold GOLD.N: up 11.6% BUZZ-Gains as Buffett takes stake ** Overstock.com Inc OSTK.O: up 18.4% BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Medtronic PLC MDT.N: up 1.9% BUZZ-Poised for stronger-than-expected Q1 of 2021 results- JPM ** Interpace Biosciences IDXG.O: down 30.9% BUZZ-Slumps on internal probe, delay in quarterly filing The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Technology-related shares lifted the S&P 500 and Nasdaq on Monday as investors turned to sectors that have been resilient to the shocks of the coronavirus pandemic, while awaiting the earnings of big retailers later this week. up 0.36% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** L Brands Inc , up 7.3% ** Newmont Corp , up 5.8% ** Nvidia Corp , up 5.6% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corporation , down 5.5% ** Coty Inc , down 4.1% ** Carnival Corp , down 4% The top three NYSE .PG.N percentage gainers: ** China Green Agriculture, Inc , up 22.7% ** Hovnanian Enterprises, Inc , up 15.9% ** Caledonia Mining Corporation Plc , up 12.8% The top three NYSE .PL.N percentage losers: ** Callon Petroleum Company , down 11.7% ** Direxion Daily Gold Miners Index Bear 2x Shares , down 11.5% ** NTN Buzztime Inc , down 10.7% The top three Nasdaq .PG.O percentage gainers: ** Imara Inc , up 62.5% ** LMP Automotive Holdings Inc , up 32.7% ** CureVac NV , up 31.7% The top three Nasdaq .PL.O percentage losers: ** Unity Biotechnology Inc , down 59.9% ** Interpace Biosciences Inc , down 30.9% ** Thermogenesis Holdings Inc , down 19.7% ** OncoSec Medical Inc ONCS.O: down 1.9% BUZZ-Down on discounted stock offering ** TRACON Pharmaceuticals Inc TCON.O: up 7.6% BUZZ-Up on FDA nod for human trials of potential cancer treatment ** Teladoc Health Inc TDOC.N: up 5.1% BUZZ-CS says Livongo merger creates digital health giant; upgrades ** Revolve Group Inc RVLV.N: down 4.1% BUZZ-Drops after big block prices ** Lazydays Holdings Inc LAZY.O: up 3.9% BUZZ-Rises on strong demand ** Medley Management Inc MDLY.N: down 6.3% BUZZ-Drops on bigger quarterly loss ** GenMark Diagnostics Inc GNMK.O: up 4.5% BUZZ-Up as co seeks FDA's emergency use allowance for COVID-19 test ** Ross Stores Inc ROST.O: up 3.1% BUZZ-Retail bankruptcies provide potential share gains for Ross Stores - Telsey ** Trinity Biotech Plc TRIB.O: down 7.0% BUZZ-Down as co's unit receives FDA warning for Hemoglobin product ** ThermoGenesis Holdings Inc THMO.O: down 19.7% BUZZ-Falls after Q2 revenue nearly halves ** Domino's Pizza Inc DPZ.N: up 1.6% BUZZ-Up on plans to hire 20,000 U.S. workers ** Parsons Corp PSN.N: down 8.4% BUZZ-Falls on planned $300 mln convertible debt deal ** Noodles & Co NDLS.O: down 1.6% BUZZ-Falls as CFO resigns ** Yintech Investment Holdings Ltd YIN.O: up 8.4% BUZZ-Rises after signing go-private deal ** Rackspace Technology Inc RXT.O: up 11.9% BUZZ-Jumps as Amazon could invest in company ** Applied Therapeutics Inc APLT.O: down 17.5% BUZZ-Drops after partial clinical hold on galactosemia study ** Enphase Energy Inc ENPH.O: up 1.8% BUZZ-Up on partnership to launch AC modules in Europe ** Occidental Petroleum Corp OXY.N: down 5.6% BUZZ-Falls as Berkshire Hathaway dissolves stake ** Union Pacific Corp UNP.N: up 1% BUZZ-Hits record high after Baird upgrade ** Jamf Holding Corp JAMF.O: up 6.7% BUZZ-Analysts bullish on rising adoption of Apple in the enterprise ** Sasol Ltd SSL.N: down 5.3% BUZZ-Drops on $2 bln rights issue plan as pandemic hits earnings ** Microbot Medical Inc MBOT.O: up 24.3% BUZZ-Jumps as surgical robot succeeds animal study ** Unity Biotechnology Inc UBX.O: down 59.9% BUZZ-Drops over 50% as arthritis treatment fails ** Novavax Inc NVAX.O: up 3.7% BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Bristol Myers Squibb Co BMY.N: up 1.0% BUZZ-Up on license agreement for potential cancer treatment ** Principia Biopharma Inc PRNB.O: up 9.3% BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 3.6% BUZZ-Rises on licensing agreement for gene therapy ** Pluristem Therapeutics Inc PSTI.O: up 8.4% BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 4.3% BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Tesla Inc TSLA.O: up 7.3% BUZZ-Hits record high as Wedbush raises PT on likely battery developments ** Lyft Inc LYFT.O: down 5.9% ** Uber Technologies Inc UBER.N: down 1.8% BUZZ-Zephirin Group expects long legal clash for Uber, Lyft; downgrades ** Barrick Gold GOLD.N: up 11.6% BUZZ-Gains as Buffett takes stake ** Overstock.com Inc OSTK.O: up 18.4% BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Medtronic PLC MDT.N: up 1.9% BUZZ-Poised for stronger-than-expected Q1 of 2021 results- JPM ** Interpace Biosciences IDXG.O: down 30.9% BUZZ-Slumps on internal probe, delay in quarterly filing The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Technology-related shares lifted the S&P 500 and Nasdaq on Monday as investors turned to sectors that have been resilient to the shocks of the coronavirus pandemic, while awaiting the earnings of big retailers later this week. up 0.36% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** L Brands Inc , up 7.3% ** Newmont Corp , up 5.8% ** Nvidia Corp , up 5.6% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corporation , down 5.5% ** Coty Inc , down 4.1% ** Carnival Corp , down 4% The top three NYSE .PG.N percentage gainers: ** China Green Agriculture, Inc , up 22.7% ** Hovnanian Enterprises, Inc , up 15.9% ** Caledonia Mining Corporation Plc , up 12.8% The top three NYSE .PL.N percentage losers: ** Callon Petroleum Company , down 11.7% ** Direxion Daily Gold Miners Index Bear 2x Shares , down 11.5% ** NTN Buzztime Inc , down 10.7% The top three Nasdaq .PG.O percentage gainers: ** Imara Inc , up 62.5% ** LMP Automotive Holdings Inc , up 32.7% ** CureVac NV , up 31.7% The top three Nasdaq .PL.O percentage losers: ** Unity Biotechnology Inc , down 59.9% ** Interpace Biosciences Inc , down 30.9% ** Thermogenesis Holdings Inc , down 19.7% ** OncoSec Medical Inc ONCS.O: down 1.9% BUZZ-Down on discounted stock offering ** TRACON Pharmaceuticals Inc TCON.O: up 7.6% BUZZ-Up on FDA nod for human trials of potential cancer treatment ** Teladoc Health Inc TDOC.N: up 5.1% BUZZ-CS says Livongo merger creates digital health giant; upgrades ** Revolve Group Inc RVLV.N: down 4.1% BUZZ-Drops after big block prices ** Lazydays Holdings Inc LAZY.O: up 3.9% BUZZ-Rises on strong demand ** Medley Management Inc MDLY.N: down 6.3% BUZZ-Drops on bigger quarterly loss ** GenMark Diagnostics Inc GNMK.O: up 4.5% BUZZ-Up as co seeks FDA's emergency use allowance for COVID-19 test ** Ross Stores Inc ROST.O: up 3.1% BUZZ-Retail bankruptcies provide potential share gains for Ross Stores - Telsey ** Trinity Biotech Plc TRIB.O: down 7.0% BUZZ-Down as co's unit receives FDA warning for Hemoglobin product ** ThermoGenesis Holdings Inc THMO.O: down 19.7% BUZZ-Falls after Q2 revenue nearly halves ** Domino's Pizza Inc DPZ.N: up 1.6% BUZZ-Up on plans to hire 20,000 U.S. workers ** Parsons Corp PSN.N: down 8.4% BUZZ-Falls on planned $300 mln convertible debt deal ** Noodles & Co NDLS.O: down 1.6% BUZZ-Falls as CFO resigns ** Yintech Investment Holdings Ltd YIN.O: up 8.4% BUZZ-Rises after signing go-private deal ** Rackspace Technology Inc RXT.O: up 11.9% BUZZ-Jumps as Amazon could invest in company ** Applied Therapeutics Inc APLT.O: down 17.5% BUZZ-Drops after partial clinical hold on galactosemia study ** Enphase Energy Inc ENPH.O: up 1.8% BUZZ-Up on partnership to launch AC modules in Europe ** Occidental Petroleum Corp OXY.N: down 5.6% BUZZ-Falls as Berkshire Hathaway dissolves stake ** Union Pacific Corp UNP.N: up 1% BUZZ-Hits record high after Baird upgrade ** Jamf Holding Corp JAMF.O: up 6.7% BUZZ-Analysts bullish on rising adoption of Apple in the enterprise ** Sasol Ltd SSL.N: down 5.3% BUZZ-Drops on $2 bln rights issue plan as pandemic hits earnings ** Microbot Medical Inc MBOT.O: up 24.3% BUZZ-Jumps as surgical robot succeeds animal study ** Unity Biotechnology Inc UBX.O: down 59.9% BUZZ-Drops over 50% as arthritis treatment fails ** Novavax Inc NVAX.O: up 3.7% BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Bristol Myers Squibb Co BMY.N: up 1.0% BUZZ-Up on license agreement for potential cancer treatment ** Principia Biopharma Inc PRNB.O: up 9.3% BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 3.6% BUZZ-Rises on licensing agreement for gene therapy ** Pluristem Therapeutics Inc PSTI.O: up 8.4% BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 4.3% BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Tesla Inc TSLA.O: up 7.3% BUZZ-Hits record high as Wedbush raises PT on likely battery developments ** Lyft Inc LYFT.O: down 5.9% ** Uber Technologies Inc UBER.N: down 1.8% BUZZ-Zephirin Group expects long legal clash for Uber, Lyft; downgrades ** Barrick Gold GOLD.N: up 11.6% BUZZ-Gains as Buffett takes stake ** Overstock.com Inc OSTK.O: up 18.4% BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Medtronic PLC MDT.N: up 1.9% BUZZ-Poised for stronger-than-expected Q1 of 2021 results- JPM ** Interpace Biosciences IDXG.O: down 30.9% BUZZ-Slumps on internal probe, delay in quarterly filing The 11 major S&P 500 sectors: Communication Services .N At 11:56 ET, the Dow Jones Industrial Average .DJI was down 0.21% at 27,872.28. up 0.06% Consumer Discretionary | The top three S&P 500 .PG.INX percentage gainers: ** L Brands Inc , up 7.3% ** Newmont Corp , up 5.8% ** Nvidia Corp , up 5.6% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corporation , down 5.5% ** Coty Inc , down 4.1% ** Carnival Corp , down 4% The top three NYSE .PG.N percentage gainers: ** China Green Agriculture, Inc , up 22.7% ** Hovnanian Enterprises, Inc , up 15.9% ** Caledonia Mining Corporation Plc , up 12.8% The top three NYSE .PL.N percentage losers: ** Callon Petroleum Company , down 11.7% ** Direxion Daily Gold Miners Index Bear 2x Shares , down 11.5% ** NTN Buzztime Inc , down 10.7% The top three Nasdaq .PG.O percentage gainers: ** Imara Inc , up 62.5% ** LMP Automotive Holdings Inc , up 32.7% ** CureVac NV , up 31.7% The top three Nasdaq .PL.O percentage losers: ** Unity Biotechnology Inc , down 59.9% ** Interpace Biosciences Inc , down 30.9% ** Thermogenesis Holdings Inc , down 19.7% ** OncoSec Medical Inc ONCS.O: down 1.9% BUZZ-Down on discounted stock offering ** TRACON Pharmaceuticals Inc TCON.O: up 7.6% BUZZ-Up on FDA nod for human trials of potential cancer treatment ** Teladoc Health Inc TDOC.N: up 5.1% BUZZ-CS says Livongo merger creates digital health giant; upgrades ** Revolve Group Inc RVLV.N: down 4.1% BUZZ-Drops after big block prices ** Lazydays Holdings Inc LAZY.O: up 3.9% BUZZ-Rises on strong demand ** Medley Management Inc MDLY.N: down 6.3% BUZZ-Drops on bigger quarterly loss ** GenMark Diagnostics Inc GNMK.O: up 4.5% BUZZ-Up as co seeks FDA's emergency use allowance for COVID-19 test ** Ross Stores Inc ROST.O: up 3.1% BUZZ-Retail bankruptcies provide potential share gains for Ross Stores - Telsey ** Trinity Biotech Plc TRIB.O: down 7.0% BUZZ-Down as co's unit receives FDA warning for Hemoglobin product ** ThermoGenesis Holdings Inc THMO.O: down 19.7% BUZZ-Falls after Q2 revenue nearly halves ** Domino's Pizza Inc DPZ.N: up 1.6% BUZZ-Up on plans to hire 20,000 U.S. workers ** Parsons Corp PSN.N: down 8.4% BUZZ-Falls on planned $300 mln convertible debt deal ** Noodles & Co NDLS.O: down 1.6% BUZZ-Falls as CFO resigns ** Yintech Investment Holdings Ltd YIN.O: up 8.4% BUZZ-Rises after signing go-private deal ** Rackspace Technology Inc RXT.O: up 11.9% BUZZ-Jumps as Amazon could invest in company ** Applied Therapeutics Inc APLT.O: down 17.5% BUZZ-Drops after partial clinical hold on galactosemia study ** Enphase Energy Inc ENPH.O: up 1.8% BUZZ-Up on partnership to launch AC modules in Europe ** Occidental Petroleum Corp OXY.N: down 5.6% BUZZ-Falls as Berkshire Hathaway dissolves stake ** Union Pacific Corp UNP.N: up 1% BUZZ-Hits record high after Baird upgrade ** Jamf Holding Corp JAMF.O: up 6.7% BUZZ-Analysts bullish on rising adoption of Apple in the enterprise ** Sasol Ltd SSL.N: down 5.3% BUZZ-Drops on $2 bln rights issue plan as pandemic hits earnings ** Microbot Medical Inc MBOT.O: up 24.3% BUZZ-Jumps as surgical robot succeeds animal study ** Unity Biotechnology Inc UBX.O: down 59.9% BUZZ-Drops over 50% as arthritis treatment fails ** Novavax Inc NVAX.O: up 3.7% BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Bristol Myers Squibb Co BMY.N: up 1.0% BUZZ-Up on license agreement for potential cancer treatment ** Principia Biopharma Inc PRNB.O: up 9.3% BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 3.6% BUZZ-Rises on licensing agreement for gene therapy ** Pluristem Therapeutics Inc PSTI.O: up 8.4% BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 4.3% BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Tesla Inc TSLA.O: up 7.3% BUZZ-Hits record high as Wedbush raises PT on likely battery developments ** Lyft Inc LYFT.O: down 5.9% ** Uber Technologies Inc UBER.N: down 1.8% BUZZ-Zephirin Group expects long legal clash for Uber, Lyft; downgrades ** Barrick Gold GOLD.N: up 11.6% BUZZ-Gains as Buffett takes stake ** Overstock.com Inc OSTK.O: up 18.4% BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Medtronic PLC MDT.N: up 1.9% BUZZ-Poised for stronger-than-expected Q1 of 2021 results- JPM ** Interpace Biosciences IDXG.O: down 30.9% BUZZ-Slumps on internal probe, delay in quarterly filing The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Technology-related shares lifted the S&P 500 and Nasdaq on Monday as investors turned to sectors that have been resilient to the shocks of the coronavirus pandemic, while awaiting the earnings of big retailers later this week. .N At 11:56 ET, the Dow Jones Industrial Average .DJI was down 0.21% at 27,872.28. |
28057.0 | 2020-08-17 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-TRACON Pharma, Interpace Biosciences, Microbot Medical | ABEO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tracon-pharma-interpace-biosciences-microbot-medical-2020-08 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes opened higher on Monday as retailers prepared to wind down a better-than-feared quarterly earnings season, while the S&P 500 continued to hover just below record-high levels. .N
At 10:07 ET, the Dow Jones Industrial Average .DJI was down 0.29% at 27,849.99. The S&P 500 .SPX was up 0.25% at 3,381.37 and the Nasdaq Composite .IXIC was up 0.80% at 11,107.596. The top three S&P 500 .PG.INX percentage gainers: ** Davita Inc , up 5.5% ** Nvidia Corp , up 5.5% ** Newmont Corp , up 3.4% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corporation , down 5.5% ** Carnival Corp , down 4.2% ** United Airlines Holdings Inc , down 4.1% The top three NYSE .PG.N percentage gainers: ** Colony Capital Inc , up 10.8% ** Caledonia Mining Corporation Plc , up 10.7% ** Haverty Furniture Companies, Inc. , up 9.9% The top three NYSE .PL.N percentage losers: ** Callon Petroleum Company , down 11.7% ** NTN Buzztime Inc , down 10.1% ** Jumia Technologies AG , down 8.9% The top three Nasdaq .PG.O percentage gainers: ** BOQI International Medical Inc , up 28.1% ** CureVac NV , up 28.1% ** Microbot Medical Inc , up 25.4% The top three Nasdaq .PL.O percentage losers: ** Unity Biotechnology Inc , down 62.7% ** Interpace Biosciences Inc , down 26% ** Thermogenesis Holdings Inc , down 19% ** OncoSec Medical Inc ONCS.O: down 5.1%
BUZZ-Down on discounted stock offering ** TRACON Pharmaceuticals Inc TCON.O: up 20.5%
BUZZ-Up on FDA nod for human trials of potential cancer treatment ** Teladoc Health Inc TDOC.N: up 3.6%
BUZZ-CS says Livongo merger creates digital health giant; upgrades ** Revolve Group Inc RVLV.N: down 2.4%
BUZZ-Drops after big block prices ** Lazydays Holdings Inc LAZY.O: up 4.9%
BUZZ-Rises on strong demand ** Medley Management Inc MDLY.N: down 9.7%
BUZZ-Drops on bigger quarterly loss ** GenMark Diagnostics Inc GNMK.O: up 2.2%
BUZZ-Up as co seeks FDA's emergency use allowance for COVID-19 test ** Ross Stores Inc ROST.O: up 1.4%
BUZZ-Retail bankruptcies provide potential share gains for Ross Stores - Telsey ** Trinity Biotech Plc TRIB.O: down 6.4%
BUZZ-Down as co's unit receives FDA warning for Hemoglobin product ** ThermoGenesis Holdings Inc THMO.O: down 19.0%
BUZZ-Falls after Q2 revenue nearly halves ** Jamf Holding Corp JAMF.O: up 1.3%
BUZZ-Analysts bullish on rising adoption of Apple in the enterprise ** Sasol Ltd SSL.N: down 4.2%
BUZZ-Drops on $2 bln rights issue plan as pandemic hits earnings ** Microbot Medical Inc MBOT.O: up 25.4%
BUZZ-Jumps as surgical robot succeeds animal study ** Unity Biotechnology Inc UBX.O: down 62.7%
BUZZ-Drops over 50% as arthritis treatment fails ** Novavax Inc NVAX.O: up 3.1% BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Principia Biopharma Inc PRNB.O: up 9.3% BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 5.5% BUZZ-Rises on licensing agreement for gene therapy
** Pluristem Therapeutics Inc PSTI.O: up 9.7% BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 5.3% BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Tesla Inc TSLA.O: up 5.8% BUZZ-Wedbush raises PT on likely 'game changing' battery developments ** Lyft Inc LYFT.O: down 4.2% ** Uber Technologies Inc UBER.N: down 1.0% BUZZ-Zephirin Group expects long legal clash for Uber, Lyft; downgrades ** Barrick Gold GOLD.N: up 9.6% BUZZ-Gains as Buffett takes stake, gold prices rise ** Overstock.com Inc OSTK.O: up 13.8% BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Medtronic PLC MDT.N: up 1.3% BUZZ-Poised for stronger-than-expected Q1 of 2021 results- JPM ** Interpace Biosciences IDXG.O: down 26.0% BUZZ-Slumps on internal probe, delay in quarterly filing
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 0.04%
Consumer Discretionary
.SPLRCD
up 0.67%
Consumer Staples
.SPLRCS
up 0.25%
Energy
.SPNY
down 1.04%
Financial
.SPSY
down 1.00%
Health
.SPXHC
up 0.59%
Industrial
.SPLRCI
down 0.43%
Information Technology
.SPLRCT
up 0.82%
Materials
.SPLRCM
up 0.52%
Real Estate
.SPLRCR
up 0.20%
Utilities
.SPLRCU
down 0.07%
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Davita Inc , up 5.5% ** Nvidia Corp , up 5.5% ** Newmont Corp , up 3.4% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corporation , down 5.5% ** Carnival Corp , down 4.2% ** United Airlines Holdings Inc , down 4.1% The top three NYSE .PG.N percentage gainers: ** Colony Capital Inc , up 10.8% ** Caledonia Mining Corporation Plc , up 10.7% ** Haverty Furniture Companies, Inc. , up 9.9% The top three NYSE .PL.N percentage losers: ** Callon Petroleum Company , down 11.7% ** NTN Buzztime Inc , down 10.1% ** Jumia Technologies AG , down 8.9% The top three Nasdaq .PG.O percentage gainers: ** BOQI International Medical Inc , up 28.1% ** CureVac NV , up 28.1% ** Microbot Medical Inc , up 25.4% The top three Nasdaq .PL.O percentage losers: ** Unity Biotechnology Inc , down 62.7% ** Interpace Biosciences Inc , down 26% ** Thermogenesis Holdings Inc , down 19% ** OncoSec Medical Inc ONCS.O: down 5.1% BUZZ-Down on discounted stock offering ** TRACON Pharmaceuticals Inc TCON.O: up 20.5% BUZZ-Up on FDA nod for human trials of potential cancer treatment ** Teladoc Health Inc TDOC.N: up 3.6% BUZZ-CS says Livongo merger creates digital health giant; upgrades ** Revolve Group Inc RVLV.N: down 2.4% BUZZ-Drops after big block prices ** Lazydays Holdings Inc LAZY.O: up 4.9% BUZZ-Rises on strong demand ** Medley Management Inc MDLY.N: down 9.7% BUZZ-Drops on bigger quarterly loss ** GenMark Diagnostics Inc GNMK.O: up 2.2% BUZZ-Up as co seeks FDA's emergency use allowance for COVID-19 test ** Ross Stores Inc ROST.O: up 1.4% BUZZ-Retail bankruptcies provide potential share gains for Ross Stores - Telsey ** Trinity Biotech Plc TRIB.O: down 6.4% BUZZ-Down as co's unit receives FDA warning for Hemoglobin product ** ThermoGenesis Holdings Inc THMO.O: down 19.0% BUZZ-Falls after Q2 revenue nearly halves ** Jamf Holding Corp JAMF.O: up 1.3% BUZZ-Analysts bullish on rising adoption of Apple in the enterprise ** Sasol Ltd SSL.N: down 4.2% BUZZ-Drops on $2 bln rights issue plan as pandemic hits earnings ** Microbot Medical Inc MBOT.O: up 25.4% BUZZ-Jumps as surgical robot succeeds animal study ** Unity Biotechnology Inc UBX.O: down 62.7% BUZZ-Drops over 50% as arthritis treatment fails ** Novavax Inc NVAX.O: up 3.1% BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Principia Biopharma Inc PRNB.O: up 9.3% BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 5.5% BUZZ-Rises on licensing agreement for gene therapy ** Pluristem Therapeutics Inc PSTI.O: up 9.7% BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 5.3% BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Tesla Inc TSLA.O: up 5.8% BUZZ-Wedbush raises PT on likely 'game changing' battery developments ** Lyft Inc LYFT.O: down 4.2% ** Uber Technologies Inc UBER.N: down 1.0% BUZZ-Zephirin Group expects long legal clash for Uber, Lyft; downgrades ** Barrick Gold GOLD.N: up 9.6% BUZZ-Gains as Buffett takes stake, gold prices rise ** Overstock.com Inc OSTK.O: up 13.8% BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Medtronic PLC MDT.N: up 1.3% BUZZ-Poised for stronger-than-expected Q1 of 2021 results- JPM ** Interpace Biosciences IDXG.O: down 26.0% BUZZ-Slumps on internal probe, delay in quarterly filing The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes opened higher on Monday as retailers prepared to wind down a better-than-feared quarterly earnings season, while the S&P 500 continued to hover just below record-high levels. down 0.07% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Davita Inc , up 5.5% ** Nvidia Corp , up 5.5% ** Newmont Corp , up 3.4% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corporation , down 5.5% ** Carnival Corp , down 4.2% ** United Airlines Holdings Inc , down 4.1% The top three NYSE .PG.N percentage gainers: ** Colony Capital Inc , up 10.8% ** Caledonia Mining Corporation Plc , up 10.7% ** Haverty Furniture Companies, Inc. , up 9.9% The top three NYSE .PL.N percentage losers: ** Callon Petroleum Company , down 11.7% ** NTN Buzztime Inc , down 10.1% ** Jumia Technologies AG , down 8.9% The top three Nasdaq .PG.O percentage gainers: ** BOQI International Medical Inc , up 28.1% ** CureVac NV , up 28.1% ** Microbot Medical Inc , up 25.4% The top three Nasdaq .PL.O percentage losers: ** Unity Biotechnology Inc , down 62.7% ** Interpace Biosciences Inc , down 26% ** Thermogenesis Holdings Inc , down 19% ** OncoSec Medical Inc ONCS.O: down 5.1% BUZZ-Down on discounted stock offering ** TRACON Pharmaceuticals Inc TCON.O: up 20.5% BUZZ-Up on FDA nod for human trials of potential cancer treatment ** Teladoc Health Inc TDOC.N: up 3.6% BUZZ-CS says Livongo merger creates digital health giant; upgrades ** Revolve Group Inc RVLV.N: down 2.4% BUZZ-Drops after big block prices ** Lazydays Holdings Inc LAZY.O: up 4.9% BUZZ-Rises on strong demand ** Medley Management Inc MDLY.N: down 9.7% BUZZ-Drops on bigger quarterly loss ** GenMark Diagnostics Inc GNMK.O: up 2.2% BUZZ-Up as co seeks FDA's emergency use allowance for COVID-19 test ** Ross Stores Inc ROST.O: up 1.4% BUZZ-Retail bankruptcies provide potential share gains for Ross Stores - Telsey ** Trinity Biotech Plc TRIB.O: down 6.4% BUZZ-Down as co's unit receives FDA warning for Hemoglobin product ** ThermoGenesis Holdings Inc THMO.O: down 19.0% BUZZ-Falls after Q2 revenue nearly halves ** Jamf Holding Corp JAMF.O: up 1.3% BUZZ-Analysts bullish on rising adoption of Apple in the enterprise ** Sasol Ltd SSL.N: down 4.2% BUZZ-Drops on $2 bln rights issue plan as pandemic hits earnings ** Microbot Medical Inc MBOT.O: up 25.4% BUZZ-Jumps as surgical robot succeeds animal study ** Unity Biotechnology Inc UBX.O: down 62.7% BUZZ-Drops over 50% as arthritis treatment fails ** Novavax Inc NVAX.O: up 3.1% BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Principia Biopharma Inc PRNB.O: up 9.3% BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 5.5% BUZZ-Rises on licensing agreement for gene therapy ** Pluristem Therapeutics Inc PSTI.O: up 9.7% BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 5.3% BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Tesla Inc TSLA.O: up 5.8% BUZZ-Wedbush raises PT on likely 'game changing' battery developments ** Lyft Inc LYFT.O: down 4.2% ** Uber Technologies Inc UBER.N: down 1.0% BUZZ-Zephirin Group expects long legal clash for Uber, Lyft; downgrades ** Barrick Gold GOLD.N: up 9.6% BUZZ-Gains as Buffett takes stake, gold prices rise ** Overstock.com Inc OSTK.O: up 13.8% BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Medtronic PLC MDT.N: up 1.3% BUZZ-Poised for stronger-than-expected Q1 of 2021 results- JPM ** Interpace Biosciences IDXG.O: down 26.0% BUZZ-Slumps on internal probe, delay in quarterly filing The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes opened higher on Monday as retailers prepared to wind down a better-than-feared quarterly earnings season, while the S&P 500 continued to hover just below record-high levels. down 0.07% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Davita Inc , up 5.5% ** Nvidia Corp , up 5.5% ** Newmont Corp , up 3.4% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corporation , down 5.5% ** Carnival Corp , down 4.2% ** United Airlines Holdings Inc , down 4.1% The top three NYSE .PG.N percentage gainers: ** Colony Capital Inc , up 10.8% ** Caledonia Mining Corporation Plc , up 10.7% ** Haverty Furniture Companies, Inc. , up 9.9% The top three NYSE .PL.N percentage losers: ** Callon Petroleum Company , down 11.7% ** NTN Buzztime Inc , down 10.1% ** Jumia Technologies AG , down 8.9% The top three Nasdaq .PG.O percentage gainers: ** BOQI International Medical Inc , up 28.1% ** CureVac NV , up 28.1% ** Microbot Medical Inc , up 25.4% The top three Nasdaq .PL.O percentage losers: ** Unity Biotechnology Inc , down 62.7% ** Interpace Biosciences Inc , down 26% ** Thermogenesis Holdings Inc , down 19% ** OncoSec Medical Inc ONCS.O: down 5.1% BUZZ-Down on discounted stock offering ** TRACON Pharmaceuticals Inc TCON.O: up 20.5% BUZZ-Up on FDA nod for human trials of potential cancer treatment ** Teladoc Health Inc TDOC.N: up 3.6% BUZZ-CS says Livongo merger creates digital health giant; upgrades ** Revolve Group Inc RVLV.N: down 2.4% BUZZ-Drops after big block prices ** Lazydays Holdings Inc LAZY.O: up 4.9% BUZZ-Rises on strong demand ** Medley Management Inc MDLY.N: down 9.7% BUZZ-Drops on bigger quarterly loss ** GenMark Diagnostics Inc GNMK.O: up 2.2% BUZZ-Up as co seeks FDA's emergency use allowance for COVID-19 test ** Ross Stores Inc ROST.O: up 1.4% BUZZ-Retail bankruptcies provide potential share gains for Ross Stores - Telsey ** Trinity Biotech Plc TRIB.O: down 6.4% BUZZ-Down as co's unit receives FDA warning for Hemoglobin product ** ThermoGenesis Holdings Inc THMO.O: down 19.0% BUZZ-Falls after Q2 revenue nearly halves ** Jamf Holding Corp JAMF.O: up 1.3% BUZZ-Analysts bullish on rising adoption of Apple in the enterprise ** Sasol Ltd SSL.N: down 4.2% BUZZ-Drops on $2 bln rights issue plan as pandemic hits earnings ** Microbot Medical Inc MBOT.O: up 25.4% BUZZ-Jumps as surgical robot succeeds animal study ** Unity Biotechnology Inc UBX.O: down 62.7% BUZZ-Drops over 50% as arthritis treatment fails ** Novavax Inc NVAX.O: up 3.1% BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Principia Biopharma Inc PRNB.O: up 9.3% BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 5.5% BUZZ-Rises on licensing agreement for gene therapy ** Pluristem Therapeutics Inc PSTI.O: up 9.7% BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 5.3% BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Tesla Inc TSLA.O: up 5.8% BUZZ-Wedbush raises PT on likely 'game changing' battery developments ** Lyft Inc LYFT.O: down 4.2% ** Uber Technologies Inc UBER.N: down 1.0% BUZZ-Zephirin Group expects long legal clash for Uber, Lyft; downgrades ** Barrick Gold GOLD.N: up 9.6% BUZZ-Gains as Buffett takes stake, gold prices rise ** Overstock.com Inc OSTK.O: up 13.8% BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Medtronic PLC MDT.N: up 1.3% BUZZ-Poised for stronger-than-expected Q1 of 2021 results- JPM ** Interpace Biosciences IDXG.O: down 26.0% BUZZ-Slumps on internal probe, delay in quarterly filing The 11 major S&P 500 sectors: Communication Services .N At 10:07 ET, the Dow Jones Industrial Average .DJI was down 0.29% at 27,849.99. down 0.04% Consumer Discretionary | The top three S&P 500 .PG.INX percentage gainers: ** Davita Inc , up 5.5% ** Nvidia Corp , up 5.5% ** Newmont Corp , up 3.4% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corporation , down 5.5% ** Carnival Corp , down 4.2% ** United Airlines Holdings Inc , down 4.1% The top three NYSE .PG.N percentage gainers: ** Colony Capital Inc , up 10.8% ** Caledonia Mining Corporation Plc , up 10.7% ** Haverty Furniture Companies, Inc. , up 9.9% The top three NYSE .PL.N percentage losers: ** Callon Petroleum Company , down 11.7% ** NTN Buzztime Inc , down 10.1% ** Jumia Technologies AG , down 8.9% The top three Nasdaq .PG.O percentage gainers: ** BOQI International Medical Inc , up 28.1% ** CureVac NV , up 28.1% ** Microbot Medical Inc , up 25.4% The top three Nasdaq .PL.O percentage losers: ** Unity Biotechnology Inc , down 62.7% ** Interpace Biosciences Inc , down 26% ** Thermogenesis Holdings Inc , down 19% ** OncoSec Medical Inc ONCS.O: down 5.1% BUZZ-Down on discounted stock offering ** TRACON Pharmaceuticals Inc TCON.O: up 20.5% BUZZ-Up on FDA nod for human trials of potential cancer treatment ** Teladoc Health Inc TDOC.N: up 3.6% BUZZ-CS says Livongo merger creates digital health giant; upgrades ** Revolve Group Inc RVLV.N: down 2.4% BUZZ-Drops after big block prices ** Lazydays Holdings Inc LAZY.O: up 4.9% BUZZ-Rises on strong demand ** Medley Management Inc MDLY.N: down 9.7% BUZZ-Drops on bigger quarterly loss ** GenMark Diagnostics Inc GNMK.O: up 2.2% BUZZ-Up as co seeks FDA's emergency use allowance for COVID-19 test ** Ross Stores Inc ROST.O: up 1.4% BUZZ-Retail bankruptcies provide potential share gains for Ross Stores - Telsey ** Trinity Biotech Plc TRIB.O: down 6.4% BUZZ-Down as co's unit receives FDA warning for Hemoglobin product ** ThermoGenesis Holdings Inc THMO.O: down 19.0% BUZZ-Falls after Q2 revenue nearly halves ** Jamf Holding Corp JAMF.O: up 1.3% BUZZ-Analysts bullish on rising adoption of Apple in the enterprise ** Sasol Ltd SSL.N: down 4.2% BUZZ-Drops on $2 bln rights issue plan as pandemic hits earnings ** Microbot Medical Inc MBOT.O: up 25.4% BUZZ-Jumps as surgical robot succeeds animal study ** Unity Biotechnology Inc UBX.O: down 62.7% BUZZ-Drops over 50% as arthritis treatment fails ** Novavax Inc NVAX.O: up 3.1% BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Principia Biopharma Inc PRNB.O: up 9.3% BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 5.5% BUZZ-Rises on licensing agreement for gene therapy ** Pluristem Therapeutics Inc PSTI.O: up 9.7% BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 5.3% BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Tesla Inc TSLA.O: up 5.8% BUZZ-Wedbush raises PT on likely 'game changing' battery developments ** Lyft Inc LYFT.O: down 4.2% ** Uber Technologies Inc UBER.N: down 1.0% BUZZ-Zephirin Group expects long legal clash for Uber, Lyft; downgrades ** Barrick Gold GOLD.N: up 9.6% BUZZ-Gains as Buffett takes stake, gold prices rise ** Overstock.com Inc OSTK.O: up 13.8% BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Medtronic PLC MDT.N: up 1.3% BUZZ-Poised for stronger-than-expected Q1 of 2021 results- JPM ** Interpace Biosciences IDXG.O: down 26.0% BUZZ-Slumps on internal probe, delay in quarterly filing The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes opened higher on Monday as retailers prepared to wind down a better-than-feared quarterly earnings season, while the S&P 500 continued to hover just below record-high levels. .N At 10:07 ET, the Dow Jones Industrial Average .DJI was down 0.29% at 27,849.99. |
28058.0 | 2020-08-17 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Washington Prime, Abeona Therapeutics, Principia Biopharma | ABEO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-washington-prime-abeona-therapeutics-principia-biopharma-2020 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes were set to open higher on Monday as retailers prepared to wind down a better-than-feared quarterly earnings season, while investors continued to watch for the S&P 500 to breach record-high levels..N
At 08:27 ET, Dow e-minis 1YMc1 were up 0.24% at 27,859. S&P 500 e-minis ESc1 were up 0.32% at 3,372.25, while Nasdaq 100 e-minis NQc1 were up 0.67% at 11,208.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** CooTek (Cayman) Inc , up 17.6% ** Washington Prime Group Inc , up 17.5% ** American Renal Associates Holdings Inc , up 10.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** Regis Corporation , down 12% ** Medley Management Inc , down 9.1% ** Barnes & Noble Education Inc , down 8.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Stein Mart Inc , up 155.9% ** Oxbridge Re Holdings Equity Warrants , up 77.5% ** CureVac AG , up 43.1% The top three Nasdaq percentage losers premarket .PRPL.O: ** Unity Biotechnology Inc , down 54.5% ** Spar Group Inc , down 16.4% ** Taiwan Liposome , down 15.7% ** Novavax Inc NVAX.O: up 2.8% premarket BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Washington Prime Group Inc WPG.N: up 14.5% premarket BUZZ-Rises on modifying credit facilities ** Principia Biopharma Inc PRNB.O: up 9.3% premarket BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 10.9% premarket BUZZ-Rises on licensing agreement for gene therapy
** Pluristem Therapeutics Inc PSTI.O: up 7.7% premarket BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 4.5% premarket BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Barrick Gold GOLD.N: up 9.3% premarket BUZZ-Gains as Buffett takes stake, gold prices rise ** Overstock.com Inc OSTK.O: up 8.5% premarket BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Interpace Biosciences IDXG.O: down 14.4% premarket BUZZ-Slumps on internal probe, delay in quarterly filing
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** CooTek (Cayman) Inc , up 17.6% ** Washington Prime Group Inc , up 17.5% ** American Renal Associates Holdings Inc , up 10.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** Regis Corporation , down 12% ** Medley Management Inc , down 9.1% ** Barnes & Noble Education Inc , down 8.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Stein Mart Inc , up 155.9% ** Oxbridge Re Holdings Equity Warrants , up 77.5% ** CureVac AG , up 43.1% The top three Nasdaq percentage losers premarket .PRPL.O: ** Unity Biotechnology Inc , down 54.5% ** Spar Group Inc , down 16.4% ** Taiwan Liposome , down 15.7% ** Novavax Inc NVAX.O: up 2.8% premarket BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Washington Prime Group Inc WPG.N: up 14.5% premarket BUZZ-Rises on modifying credit facilities ** Principia Biopharma Inc PRNB.O: up 9.3% premarket BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 10.9% premarket BUZZ-Rises on licensing agreement for gene therapy ** Pluristem Therapeutics Inc PSTI.O: up 7.7% premarket BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 4.5% premarket BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Barrick Gold GOLD.N: up 9.3% premarket BUZZ-Gains as Buffett takes stake, gold prices rise ** Overstock.com Inc OSTK.O: up 8.5% premarket BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Interpace Biosciences IDXG.O: down 14.4% premarket BUZZ-Slumps on internal probe, delay in quarterly filing (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were set to open higher on Monday as retailers prepared to wind down a better-than-feared quarterly earnings season, while investors continued to watch for the S&P 500 to breach record-high levels..N At 08:27 ET, Dow e-minis 1YMc1 were up 0.24% at 27,859. S&P 500 e-minis ESc1 were up 0.32% at 3,372.25, while Nasdaq 100 e-minis NQc1 were up 0.67% at 11,208.5. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** CooTek (Cayman) Inc , up 17.6% ** Washington Prime Group Inc , up 17.5% ** American Renal Associates Holdings Inc , up 10.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** Regis Corporation , down 12% ** Medley Management Inc , down 9.1% ** Barnes & Noble Education Inc , down 8.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Stein Mart Inc , up 155.9% ** Oxbridge Re Holdings Equity Warrants , up 77.5% ** CureVac AG , up 43.1% The top three Nasdaq percentage losers premarket .PRPL.O: ** Unity Biotechnology Inc , down 54.5% ** Spar Group Inc , down 16.4% ** Taiwan Liposome , down 15.7% ** Novavax Inc NVAX.O: up 2.8% premarket BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Washington Prime Group Inc WPG.N: up 14.5% premarket BUZZ-Rises on modifying credit facilities ** Principia Biopharma Inc PRNB.O: up 9.3% premarket BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 10.9% premarket BUZZ-Rises on licensing agreement for gene therapy ** Pluristem Therapeutics Inc PSTI.O: up 7.7% premarket BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 4.5% premarket BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Barrick Gold GOLD.N: up 9.3% premarket BUZZ-Gains as Buffett takes stake, gold prices rise ** Overstock.com Inc OSTK.O: up 8.5% premarket BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Interpace Biosciences IDXG.O: down 14.4% premarket BUZZ-Slumps on internal probe, delay in quarterly filing (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were set to open higher on Monday as retailers prepared to wind down a better-than-feared quarterly earnings season, while investors continued to watch for the S&P 500 to breach record-high levels..N At 08:27 ET, Dow e-minis 1YMc1 were up 0.24% at 27,859. S&P 500 e-minis ESc1 were up 0.32% at 3,372.25, while Nasdaq 100 e-minis NQc1 were up 0.67% at 11,208.5. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** CooTek (Cayman) Inc , up 17.6% ** Washington Prime Group Inc , up 17.5% ** American Renal Associates Holdings Inc , up 10.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** Regis Corporation , down 12% ** Medley Management Inc , down 9.1% ** Barnes & Noble Education Inc , down 8.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Stein Mart Inc , up 155.9% ** Oxbridge Re Holdings Equity Warrants , up 77.5% ** CureVac AG , up 43.1% The top three Nasdaq percentage losers premarket .PRPL.O: ** Unity Biotechnology Inc , down 54.5% ** Spar Group Inc , down 16.4% ** Taiwan Liposome , down 15.7% ** Novavax Inc NVAX.O: up 2.8% premarket BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Washington Prime Group Inc WPG.N: up 14.5% premarket BUZZ-Rises on modifying credit facilities ** Principia Biopharma Inc PRNB.O: up 9.3% premarket BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 10.9% premarket BUZZ-Rises on licensing agreement for gene therapy ** Pluristem Therapeutics Inc PSTI.O: up 7.7% premarket BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 4.5% premarket BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Barrick Gold GOLD.N: up 9.3% premarket BUZZ-Gains as Buffett takes stake, gold prices rise ** Overstock.com Inc OSTK.O: up 8.5% premarket BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Interpace Biosciences IDXG.O: down 14.4% premarket BUZZ-Slumps on internal probe, delay in quarterly filing (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were set to open higher on Monday as retailers prepared to wind down a better-than-feared quarterly earnings season, while investors continued to watch for the S&P 500 to breach record-high levels..N At 08:27 ET, Dow e-minis 1YMc1 were up 0.24% at 27,859. S&P 500 e-minis ESc1 were up 0.32% at 3,372.25, while Nasdaq 100 e-minis NQc1 were up 0.67% at 11,208.5. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** CooTek (Cayman) Inc , up 17.6% ** Washington Prime Group Inc , up 17.5% ** American Renal Associates Holdings Inc , up 10.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** Regis Corporation , down 12% ** Medley Management Inc , down 9.1% ** Barnes & Noble Education Inc , down 8.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Stein Mart Inc , up 155.9% ** Oxbridge Re Holdings Equity Warrants , up 77.5% ** CureVac AG , up 43.1% The top three Nasdaq percentage losers premarket .PRPL.O: ** Unity Biotechnology Inc , down 54.5% ** Spar Group Inc , down 16.4% ** Taiwan Liposome , down 15.7% ** Novavax Inc NVAX.O: up 2.8% premarket BUZZ-Rises after starting mid-stage trial for COVID-19 vaccine in South Africa BUZZ-Animal data from Novavax's COVID-19 vaccine most encouraging - SVB Leerink ** Washington Prime Group Inc WPG.N: up 14.5% premarket BUZZ-Rises on modifying credit facilities ** Principia Biopharma Inc PRNB.O: up 9.3% premarket BUZZ-Eyes record high after Sanofi's $3.7 bln buyout deal ** Abeona Therapeutics Inc ABEO.O: up 10.9% premarket BUZZ-Rises on licensing agreement for gene therapy ** Pluristem Therapeutics Inc PSTI.O: up 7.7% premarket BUZZ-Up on deal with UAE stem cell firm to develop therapies ** JD.com Inc JD.O: up 4.5% premarket BUZZ-China's JD.com gains on sales beat as more customers shop during COVID-19 ** Barrick Gold GOLD.N: up 9.3% premarket BUZZ-Gains as Buffett takes stake, gold prices rise ** Overstock.com Inc OSTK.O: up 8.5% premarket BUZZ-Piper Sandler starts coverage with 'overweight' rating ** Interpace Biosciences IDXG.O: down 14.4% premarket BUZZ-Slumps on internal probe, delay in quarterly filing (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were set to open higher on Monday as retailers prepared to wind down a better-than-feared quarterly earnings season, while investors continued to watch for the S&P 500 to breach record-high levels..N At 08:27 ET, Dow e-minis 1YMc1 were up 0.24% at 27,859. S&P 500 e-minis ESc1 were up 0.32% at 3,372.25, while Nasdaq 100 e-minis NQc1 were up 0.67% at 11,208.5. |
28059.0 | 2020-02-22 00:00:00 UTC | 3 Biotech Stocks That Soared This Week: Are They Buys? | ABEO | https://www.nasdaq.com/articles/3-biotech-stocks-that-soared-this-week%3A-are-they-buys-2020-02-22 | nan | nan | The COVID-19 coronavirus. Presidential campaigns. Uncertainty about what the Federal Reserve Board will do with interest rates. All of these factors have weighed on investors' minds as the stock market pulled back this week.
But some stocks zoomed higher instead of pulling back. Three biotech stocks that absolutely soared this week were Arcus Biosciences (NYSE: RCUS), Avadel Pharmaceuticals (NASDAQ: AVDL), and Abeona Therapeutics (NASDAQ: ABEO). Here's what fueled huge gains for these stocks -- and whether or not they're smart picks to buy now.
Image source: Getty Images.
1. Arcus Biosciences
Shares of Arcus Biosciences skyrocketed 51% higher this week. Most of this huge jump came after Mizuho Securities' analyst Mara Goldstein reiterated a buy rating on Arcus with a one-year price target of $22, twice as high as the biotech stock's closing price in the previous week.
Arcus boasts a robust pipeline for a clinical-stage biotech. Its lead candidate is AB928, which is being evaluated in several early- and mid-stage clinical studies for treating multiple types of cancer.
The biotech expects to announce results from some of those clinical studies featuring AB928 beginning in mid-2020. It also plans to start a phase 1b/2 study early this year combining the experimental drug with current standards of care in treating prostate cancer. In addition, Arcus anticipates reporting results from studies evaluating other pipeline candidates, including AB122 and AB154, later in 2020.
2. Avadel Pharmaceuticals
Shares of Avadel Pharmaceuticals soared nearly 32% this week. The drugmaker's big news came on Friday with the announcement that it had entered into a definitive agreement to sell new shares in a private placement with a group of institutional investors.
Stock offerings often cause biotech stocks to fall. In Avadel's case, though, investors appeared to be excited that the company was raising gross proceeds of close to $65 million to fund its development of experimental sleep disorder drug FT128.
Avadel completed enrollment in December for a late-stage study evaluating FT128 in treating excessive daytime sleepiness and cataplexy in patients with narcolepsy. The company expects to announce results from this study in the second quarter of 2020.
3. Abeona Therapeutics
Abeona Therapeutics stock jumped 30% higher this week. The company didn't have any news over the last five days, though. Its big gain this week appears to stem from continued momentum from a clinical trial update on Feb. 12.
That update actually didn't even come from Abeona. Researchers from the Abigail Wexner Research Institute (AWRI) presented interim data from a couple of clinical studies featuring Abeona's drugs at the WORLD Symposium. This data indicated promising potential for ABO-102 in treating mucopolysaccharidosis type IIIA (MPS IIIA) and ABO-101 in treating MPS IIIB.
AWRI initially developed the gene therapies for treating these two rare diseases. Abeona licensed the underlying technology from AWRI. The biotech's lead pipeline candidate, though, is EB-101, which the company recently advanced to a phase 3 clinical study for treating rare genetic disease recessive dystrophic epidermolysis bullosa (RDEB).
Are they buys?
Most investors are better off steering clear of clinical-stage biotech stocks. That rules out Arcus Biosciences and Abeona Therapeutics.
Avadel, on the other hand, already markets four sterile injectable products, with its latest Food and Drug Administration approval coming in December 2019. However, the company's primary focus right now is on FT128. The experimental narcolepsy drug could have a significant opportunity if approved, especially with the appeal of its once-nightly dosing formulation.
I wouldn't go so far as to call Avadel a stock to buy right now. But it's definitely one for investors to keep on their radar.
10 stocks we like better than Avadel Pharmaceuticals plc
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Avadel Pharmaceuticals plc wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Three biotech stocks that absolutely soared this week were Arcus Biosciences (NYSE: RCUS), Avadel Pharmaceuticals (NASDAQ: AVDL), and Abeona Therapeutics (NASDAQ: ABEO). Abeona Therapeutics Abeona Therapeutics stock jumped 30% higher this week. That update actually didn't even come from Abeona. | Three biotech stocks that absolutely soared this week were Arcus Biosciences (NYSE: RCUS), Avadel Pharmaceuticals (NASDAQ: AVDL), and Abeona Therapeutics (NASDAQ: ABEO). Abeona Therapeutics Abeona Therapeutics stock jumped 30% higher this week. Researchers from the Abigail Wexner Research Institute (AWRI) presented interim data from a couple of clinical studies featuring Abeona's drugs at the WORLD Symposium. | Three biotech stocks that absolutely soared this week were Arcus Biosciences (NYSE: RCUS), Avadel Pharmaceuticals (NASDAQ: AVDL), and Abeona Therapeutics (NASDAQ: ABEO). Abeona Therapeutics Abeona Therapeutics stock jumped 30% higher this week. That update actually didn't even come from Abeona. | Three biotech stocks that absolutely soared this week were Arcus Biosciences (NYSE: RCUS), Avadel Pharmaceuticals (NASDAQ: AVDL), and Abeona Therapeutics (NASDAQ: ABEO). Abeona Therapeutics Abeona Therapeutics stock jumped 30% higher this week. That update actually didn't even come from Abeona. |
28060.0 | 2019-12-20 00:00:00 UTC | Here's Why Abeona Therapeutics Fell as Much as 43.8% Today | ABEO | https://www.nasdaq.com/articles/heres-why-abeona-therapeutics-fell-as-much-as-43.8-today-2019-12-20 | nan | nan | What happened
Shares of Abeona Therapeutics (NASDAQ: ABEO) dropped nearly 44% today after the company announced the pricing of a public offering of common stock and pre-funded warrants. The gene therapy developer is offering up to 32.4 million shares at $2.50 apiece and 9 million pre-funded warrants at roughly the same price. Pre-funded warrants provide the right to purchase shares of common stock in the future.
Abeona Therapeutics expects to raise up to $103.5 million in gross proceeds from the offerings, which will be needed to fund late-stage clinical programs aimed at rare diseases. But investors are more concerned over the amount of dilution that will result from the offerings.
As of 11:36 a.m. EST, the pharma stock had settled to a 33.2% loss.
Image source: Getty Images.
So what
The small-cap biopharma ended September with only $47.9 million in cash, so another fundraising round was inevitable. However, there are currently just 51 million shares of common stock outstanding. That means the public offerings will increase the share count by 81% -- a staggering amount of dilution.
Management didn't really have other options. The business needed more cash to fund operations and pulling the trigger now takes advantage of a recent surge in the stock price. Shares of Abeona Therapeutics dipped below $2 apiece at the end of August, but had climbed back toward $5 as of last week.
Now what
After the shock of today's plunge wears off, investors will be able to turn their attention to the company's lead drug candidate, EB-101. The U.S. Food and Drug Administration (FDA) recently removed a clinical hold on the gene therapy (related to transporting the drug candidate to clinical trial sites), which paves the way for Abeona Therapeutics to begin a phase 3 study in recessive dystrophic epidermolysis bullosa (RDEB) in early 2020. The results of that study will ultimately determine the fate of this stock.
10 stocks we like better than Abeona Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abeona Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Abeona Therapeutics (NASDAQ: ABEO) dropped nearly 44% today after the company announced the pricing of a public offering of common stock and pre-funded warrants. Abeona Therapeutics expects to raise up to $103.5 million in gross proceeds from the offerings, which will be needed to fund late-stage clinical programs aimed at rare diseases. Shares of Abeona Therapeutics dipped below $2 apiece at the end of August, but had climbed back toward $5 as of last week. | What happened Shares of Abeona Therapeutics (NASDAQ: ABEO) dropped nearly 44% today after the company announced the pricing of a public offering of common stock and pre-funded warrants. Abeona Therapeutics expects to raise up to $103.5 million in gross proceeds from the offerings, which will be needed to fund late-stage clinical programs aimed at rare diseases. Shares of Abeona Therapeutics dipped below $2 apiece at the end of August, but had climbed back toward $5 as of last week. | What happened Shares of Abeona Therapeutics (NASDAQ: ABEO) dropped nearly 44% today after the company announced the pricing of a public offering of common stock and pre-funded warrants. 10 stocks we like better than Abeona Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abeona Therapeutics expects to raise up to $103.5 million in gross proceeds from the offerings, which will be needed to fund late-stage clinical programs aimed at rare diseases. | What happened Shares of Abeona Therapeutics (NASDAQ: ABEO) dropped nearly 44% today after the company announced the pricing of a public offering of common stock and pre-funded warrants. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abeona Therapeutics wasn't one of them! Abeona Therapeutics expects to raise up to $103.5 million in gross proceeds from the offerings, which will be needed to fund late-stage clinical programs aimed at rare diseases. |
28061.0 | 2019-12-20 00:00:00 UTC | Health Care Sector Update for 12/20/2019: ABEO, CBAY, LXRX, JNJ, PFE, ABT, MRK, AMGN | ABEO | https://www.nasdaq.com/articles/health-care-sector-update-for-12-20-2019%3A-abeo-cbay-lxrx-jnj-pfe-abt-mrk-amgn-2019-12-20 | nan | nan | Top Health Care Stocks:
JNJ: -0.17%
PFE: +0.31%
ABT: Flat
MRK: +0.57%
AMGN: +0.31%
Health care giants were mixed in pre-market trading Friday.
Stocks moving on news include:
(-) Abeona Therapeutics (ABEO), which was slipping more than 29% after unveiling plans to offer and sell shares of its common stock and pre-funded warrants in an underwritten public offering, subject to market conditions.
(-) CymaBay Therapeutics (CBAY) was down more than 6% amid its plans to cut about 60% of its workforce by the end of Q1 2020 as part of measures to decrease operating expenses. The company said it expects to record a $3 million to $4 million charge in Q4 and Q1 2020 as a result of cost cutting measures.
(-) Lexicon Pharmaceuticals (LXRX) was slipping more than 5% after after it released positive topline results from its phase 3 clinical trial of sotagliflozin in patients with type 2 diabetes.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks moving on news include: (-) Abeona Therapeutics (ABEO), which was slipping more than 29% after unveiling plans to offer and sell shares of its common stock and pre-funded warrants in an underwritten public offering, subject to market conditions. (-) CymaBay Therapeutics (CBAY) was down more than 6% amid its plans to cut about 60% of its workforce by the end of Q1 2020 as part of measures to decrease operating expenses. (-) Lexicon Pharmaceuticals (LXRX) was slipping more than 5% after after it released positive topline results from its phase 3 clinical trial of sotagliflozin in patients with type 2 diabetes. | Stocks moving on news include: (-) Abeona Therapeutics (ABEO), which was slipping more than 29% after unveiling plans to offer and sell shares of its common stock and pre-funded warrants in an underwritten public offering, subject to market conditions. Top Health Care Stocks: Health care giants were mixed in pre-market trading Friday. | Stocks moving on news include: (-) Abeona Therapeutics (ABEO), which was slipping more than 29% after unveiling plans to offer and sell shares of its common stock and pre-funded warrants in an underwritten public offering, subject to market conditions. ABT: Flat The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks moving on news include: (-) Abeona Therapeutics (ABEO), which was slipping more than 29% after unveiling plans to offer and sell shares of its common stock and pre-funded warrants in an underwritten public offering, subject to market conditions. Top Health Care Stocks: ABT: Flat |
28062.0 | 2019-10-17 00:00:00 UTC | Top 5 Losers In Healthcare Sector (TMDI, ABEO, ZEAL...) | ABEO | https://www.nasdaq.com/articles/top-5-losers-in-healthcare-sector-tmdi-abeo-zeal...-2019-10-17 | nan | nan | (RTTNews) - The following are some of the healthcare stocks that posted the biggest percentage decline on Wednesday.
1. Titan Medical Inc. (TMDI)
Titan Medical is a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery.
Lost 50.93% to close Wednesday's (Oct.16) trading at $0.52.
News: The Company announced that it has filed an amended and restated preliminary prospectus and withdrawn its previously published milestones.
Previously, the Company was hoping to submit its Investigational Device Exemption application for its SPORT Surgical System and was expecting to receive FDA approval in the third quarter of 2019. But now, it has withdrawn these anticipated milestones.
The SPORT Surgical System is a single-port robotic surgical system, being developed for one or more of gynecologic, urologic, colorectal or general abdominal procedures.
Also, earlier, the Company was expecting to file 510(k) for SPORT Surgical System in the U.S. and file for the CE mark by year-end 2019. These two anticipated milestones have also been withdrawn.
2. Entera Bio Ltd. (ENTX)
Entera Bio is a clinical-stage biopharmaceutical company focused on developing orally-delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs.
Lost 19.39% to close Wednesday's trading at $2.32.
News: No news
Clinical Trials & Near-term Catalysts:
-- A phase II clinical trial of Oral PTH 1-34 for hypoparathyroidism is underway. The Phase 2 trial is designed to evaluate the pharmacokinetics and pharmacodynamics of oral PTH (1-34) and Natpar, an injectable PTH, in patients with hypoparathyroidism. The Company reported positive results from Part I of this study last November, and positive results from Part 2 of the study in September of this year.
-- A phase II study of osteoporosis drug candidate EB613 was initiated as recently as July 2, 2019, and results are expected in 2020.
3. ViewRay Inc. (VRAY)
ViewRay designs, manufactures and markets the MRIdian radiation therapy system.
Lost 11.19% to close Wednesday's trading at $2.54.
News: No News
Recent event:
On October 15, 2019, the Company announced preliminary results for the third quarter of 2019.
Total revenue was $20.9 million in the third quarter of 2019, primarily from three revenue units, compared to total revenue of $17.7 million, primarily from three revenue units, in the third quarter of 2018.
The Company also reaffirmed its full-year 2019 guidance of revenue in the range of $80-95 million, and cash use in the range of $80-90 million.
Near-term Catalyst:
The Company is slated to report third-quarter financial results on November 12, 2019.
4. Abeona Therapeutics Inc. (ABEO)
Abeona is a gene and cell therapy company.
Lost 10.15% to close Wednesday's trading at $2.43.
News: No news
Near-term Catalyst:
The Company's planned phase III clinical trial of EB-101 in Recessive Dystrophic Epidermolysis Bullosa, dubbed VIITAL, is under clinical hold by the FDA. The Company continues to anticipate receiving Chemical, Manufacturing and Controls (CMC) clearance for VIITAL trial in Q4 2019.
Recent event:
On September 3, 2019, the Company initiated a process to explore a broad range of strategic alternatives, including, but not limited to the partnering of its various clinical and pre-clinical programs, or a sale or merger.
Jefferies LLC has been retained as the Company's financial advisor to assist with the review of strategic options.
5. Zealand Pharma A/S (ZEAL)
Zealand is a biotechnology company focused on developing peptide-based medicines for gastrointestinal, metabolic and other specialty diseases.
Lost 9.26% to close Wednesday's trading at $25.
News: No news
Near-term Catalyst:
The Company looks forward to submitting the New Drug Application for Dasiglucagon HypoPal rescue pen in early 2020.
The Dasiglucagon HypoPal rescue pen is being developed as an easy-to-use, fast and effective rescue treatment for diabetes patients having a severe hypoglycemic event.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc. (ABEO) Abeona is a gene and cell therapy company. News: The Company announced that it has filed an amended and restated preliminary prospectus and withdrawn its previously published milestones. Previously, the Company was hoping to submit its Investigational Device Exemption application for its SPORT Surgical System and was expecting to receive FDA approval in the third quarter of 2019. | Abeona Therapeutics Inc. (ABEO) Abeona is a gene and cell therapy company. Titan Medical Inc. (TMDI) Titan Medical is a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery. News: No news Clinical Trials & Near-term Catalysts: -- A phase II clinical trial of Oral PTH 1-34 for hypoparathyroidism is underway. | Abeona Therapeutics Inc. (ABEO) Abeona is a gene and cell therapy company. Titan Medical Inc. (TMDI) Titan Medical is a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery. News: No news Near-term Catalyst: The Company's planned phase III clinical trial of EB-101 in Recessive Dystrophic Epidermolysis Bullosa, dubbed VIITAL, is under clinical hold by the FDA. | Abeona Therapeutics Inc. (ABEO) Abeona is a gene and cell therapy company. News: No news Clinical Trials & Near-term Catalysts: -- A phase II clinical trial of Oral PTH 1-34 for hypoparathyroidism is underway. News: No News Recent event: On October 15, 2019, the Company announced preliminary results for the third quarter of 2019. |
28063.0 | 2019-10-15 00:00:00 UTC | 5 Top Gainers In Healthcare Sector (RETA, ABEO, CNST...) | ABEO | https://www.nasdaq.com/articles/5-top-gainers-in-healthcare-sector-reta-abeo-cnst...-2019-10-15 | nan | nan | (RTTNews) - The following are some of today's top gainers in the healthcare sector.
1. Relmada Therapeutics Inc. (RLMD)
Relmada is a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases.
Gained 134.03% to close Tuesday's (Oct.15) trading at $26.20.
News: The Company reported promising results from a phase II clinical study evaluating two doses of REL-1017, 25 mg once a day and 50 mg once a day, as an adjunctive treatment in patients with treatment-resistant depression.
According to the Company, subjects in both the REL-1017 25 mg and 50 mg treatment groups experienced statistically significant improvement of their depression compared to subjects in the placebo group on all efficacy measures.
2. Reata Pharmaceuticals Inc. (RETA)
Reata Pharma is a clinical-stage biopharmaceutical company.
Gained 56.99% to close Tuesday's trading at $157.92.
News: The Company announced positive data from the registrational Part 2 portion of a phase II trial of Omaveloxolone in patients with Friedreich's ataxia, dubbed MOXIe.
The patients treated with Omaveloxolone demonstrated a statistically significant, placebo-corrected 2.40 point improvement in modified Friedreich's Ataxia Rating Scale (mFARS) after 48 weeks of treatment. Omaveloxolone treatment was generally reported to be well-tolerated.
The Company plans to proceed with the submission of regulatory filings for marketing approval in the United States and internationally based on the positive results and subject to discussions with regulatory authorities.
3. Abeona Therapeutics Inc. (ABEO)
Abeona is a gene and cell therapy company.
Gained 24.88% to close Tuesday's trading at $2.71.
News: The Company announced the publication of long-term data from its Phase 1/2a clinical trial evaluating EB-101, a gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB) in the peer-reviewed journal JCI insight.
Three years after treatment with EB-101, a majority of RDEB patients had sustained wound healing, with 80% of wounds achieving 50% healing, and 70% achieving "equal to or greater than" 75%, noted the Company.
4. Ra Medical Systems Inc. (RMED)
Ra Medical is a commercial-stage medical device company, with a focus on vascular and dermatological diseases.
Gained 23.48% to close Tuesday's trading at $1.42.
News: No news
Recent event:
On August 23, 2019, the Company received a notice from the NYSE indicating that it is not in compliance with the NYSE's continued listing requirements due to delay in Form 10-Q filing.
Ra Medical has six months from August 19, 2019, to file the Form 10-Q with the SEC.
5. Constellation Pharmaceuticals Inc. (CNST)
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer.
Gained 22.96% to close Tuesday's trading at $11.78.
News: No news
Clinical Trials & Near-term Catalysts:
-- A phase II trial of CPI-0610 in myelofibrosis, dubbed MANIFEST, is ongoing. An interim data update of this trial was presented in Q2, 2019. Updated data from this trial will be presented at the American Society of Hematology (ASH) annual meeting on December 9, 2019. -- A phase Ib/II trial of CPI-1205 in metastatic castration-resistant prostate cancer (mCRPC) in combination with either abiraterone or enzalutamide, dubbed ProSTAR, is underway. An update for ProSTAR is expected to be provided in the fourth quarter and additional data in early 2020. -- A phase I study of CPI-0209 in solid tumors is underway.
We alerted our premium subscribers to CNST on October 3, 2019, when it was trading around $7.50 (Report titled "Will this stock brighten up investors' portfolio?").
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc. (ABEO) Abeona is a gene and cell therapy company. News: The Company announced positive data from the registrational Part 2 portion of a phase II trial of Omaveloxolone in patients with Friedreich's ataxia, dubbed MOXIe. The patients treated with Omaveloxolone demonstrated a statistically significant, placebo-corrected 2.40 point improvement in modified Friedreich's Ataxia Rating Scale (mFARS) after 48 weeks of treatment. | Abeona Therapeutics Inc. (ABEO) Abeona is a gene and cell therapy company. News: The Company reported promising results from a phase II clinical study evaluating two doses of REL-1017, 25 mg once a day and 50 mg once a day, as an adjunctive treatment in patients with treatment-resistant depression. According to the Company, subjects in both the REL-1017 25 mg and 50 mg treatment groups experienced statistically significant improvement of their depression compared to subjects in the placebo group on all efficacy measures. | Abeona Therapeutics Inc. (ABEO) Abeona is a gene and cell therapy company. News: The Company reported promising results from a phase II clinical study evaluating two doses of REL-1017, 25 mg once a day and 50 mg once a day, as an adjunctive treatment in patients with treatment-resistant depression. News: The Company announced positive data from the registrational Part 2 portion of a phase II trial of Omaveloxolone in patients with Friedreich's ataxia, dubbed MOXIe. | Abeona Therapeutics Inc. (ABEO) Abeona is a gene and cell therapy company. News: The Company reported promising results from a phase II clinical study evaluating two doses of REL-1017, 25 mg once a day and 50 mg once a day, as an adjunctive treatment in patients with treatment-resistant depression. Constellation Pharmaceuticals Inc. (CNST) Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. |
28064.0 | 2019-10-15 00:00:00 UTC | Tuesday Sector Leaders: Biotechnology, Drugs | ABEO | https://www.nasdaq.com/articles/tuesday-sector-leaders%3A-biotechnology-drugs-2019-10-15 | nan | nan | In trading on Tuesday, biotechnology shares were relative leaders, up on the day by about 3.7%. Leading the group were shares of Relmada Therapeutics, up about 136.7% and shares of Abeona Therapeutics up about 24.4% on the day.
Also showing relative strength are drugs shares, up on the day by about 2.8% as a group, led by Reata Pharmaceuticals, trading up by about 56.4% and Axsome Therapeutics, trading higher by about 13.9% on Tuesday.
VIDEO: Tuesday Sector Leaders: Biotechnology, Drugs
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Leading the group were shares of Relmada Therapeutics, up about 136.7% and shares of Abeona Therapeutics up about 24.4% on the day. In trading on Tuesday, biotechnology shares were relative leaders, up on the day by about 3.7%. Also showing relative strength are drugs shares, up on the day by about 2.8% as a group, led by Reata Pharmaceuticals, trading up by about 56.4% and Axsome Therapeutics, trading higher by about 13.9% on Tuesday. | Leading the group were shares of Relmada Therapeutics, up about 136.7% and shares of Abeona Therapeutics up about 24.4% on the day. In trading on Tuesday, biotechnology shares were relative leaders, up on the day by about 3.7%. Also showing relative strength are drugs shares, up on the day by about 2.8% as a group, led by Reata Pharmaceuticals, trading up by about 56.4% and Axsome Therapeutics, trading higher by about 13.9% on Tuesday. | Leading the group were shares of Relmada Therapeutics, up about 136.7% and shares of Abeona Therapeutics up about 24.4% on the day. Also showing relative strength are drugs shares, up on the day by about 2.8% as a group, led by Reata Pharmaceuticals, trading up by about 56.4% and Axsome Therapeutics, trading higher by about 13.9% on Tuesday. VIDEO: Tuesday Sector Leaders: Biotechnology, Drugs The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Leading the group were shares of Relmada Therapeutics, up about 136.7% and shares of Abeona Therapeutics up about 24.4% on the day. In trading on Tuesday, biotechnology shares were relative leaders, up on the day by about 3.7%. Also showing relative strength are drugs shares, up on the day by about 2.8% as a group, led by Reata Pharmaceuticals, trading up by about 56.4% and Axsome Therapeutics, trading higher by about 13.9% on Tuesday. |
28065.0 | 2019-10-11 00:00:00 UTC | Big Pharma Has Mad Love For These 2 Biotechs | ABEO | https://www.nasdaq.com/articles/big-pharma-has-mad-love-for-these-2-biotechs-2019-10-11 | nan | nan | It can be hard for a non-scientist to judge the validity of a biotech's claims. Are this company's drugs going to be approved by the FDA? How valid is its research? These questions are almost impossible to answer. Even the scientists themselves can't be sure they're right until the clinical trials are complete. So how can a layperson invest with any sort of assurance?
The quick and dirty truth is that you can't. There's a huge amount of risk in biotech investing, and some of it can't even be quantified. But it is possible to reduce it.
One thing I love to see in a biotech is a collaboration with a big-pharma company. I love it when very smart and knowledgable people in the drug industry invest millions in my little biotech. This investment validates the science. It brings in cash, and promises of future cash. It reduces expenses (if the partner is paying for drug development).
So when I am researching a possible biotech investment, I am happy when I see collaboration. In fact, it's one of the first things I look for on a biotech's website: Right after I check out the company's pipeline, I look to see whether they have any collaborators. RegenXbio (NASDAQ: RGNX) and Denali Therapeutics (NASDAQ: DNLI) are two biotechs that pass my test with flying colors.
Image Source: Getty Images.
A leader in AAV vectors for drug discovery
One promising sector in biotech investing is gene therapy for rare diseases. This is a very exciting area because these drugs promise an actual, "one-and-done" cure for the disease they treat. Patients take the drug a single time, and they're cured.
One way of delivering gene therapy is via AAV vectors, which are viruses that are manipulated to introduce the therapy into the patient's body. Many scientists believe this is the best mechanism for delivering these drugs -- and if they're right, then RegenXbio should be a fantastic investment. This company specializes in AAV vectors and licenses out its technology to other companies that are pursuing gene therapies as well.
And it doesn't lack for partners: RegenXbio is currently collaborating with Pfizer (NYSE: PFE), Novartis (NYSE: NVS), Takeda Pharma (NYSE: TAK), Ultragenyx Pharma (NASDAQ: RARE), Audentes Therapeutics (NASDAQ: BOLD), Rocket Pharma (NASDAQ: RCKT), Abeona Therapeutics (NASDAQ: ABEO), Prevail Therapeutics, Lysogene, and Esteve.
This licensing arrangement gives RegenXbio a very large pipeline of future drug payments. The above companies are funding 27 clinical trials using RegenXbio's AAV vectors. RegenXbio gets paid up front for the use of its technology; the company also receives milestone payments as the drugs make their way through clinical trials, and royalties on the sales if and when the drugs are approved.
We can see how this process works in the case of Novartis's drug Zolgensma, which uses RegenXbio's AAV vector and was approved by the FDA last year. So far, RegenXbio has received almost $190 million in payments on this one molecule. The company will also receive royalties on sales of the drug, plus an $80 million payout when the drug passes $1 billion in cumulative sales. All in all, this one drug should pay out more than $300 million to RegenXbio.
While some of those 27 trials will no doubt fail, several of the drugs will be approved. Given the sheer number of opportunities for success, RegenXbio's market cap of $1.4 billion seems positively cheap.
Image Source: Denali Therapeutics.
Sneaking past the blood-brain barrier
Meanwhile, Denali Therapeutics is setting its sights on something incredibly difficult. The blood-brain barrier prevents almost all drugs from reaching the brain -- of large-molecule drugs, 100% are stopped, and for small-molecule drugs, that number is 98%. Nature does this in order to protect the brain. But what can we do when a patient has a neurodegenerative disease? How do we cure Alzheimer's, Parkinson's, and ALS when our drugs can't reach the brain?
Denali believes it has solved that problem. It has a mechanism that allows drugs to sneak past the blood-brain barrier, which in theory will allow cures for the above conditions to start working. It's a hugely ambitious goal, and if the company pulls it off, investors will make a lot of money. The $1.4-billion-market-cap company is currently running early clinical trials on five different molecules.
Denali was founded by Ryan Watts, who was the head of the neuroscience department at Genentech. He's staffed his company with several veterans of the famous biotech -- the chief operating officer, chief medical officer, chief financial officer, chief manufacturing officer, and head of discovery all come from Genentech, which was acquired by Roche (OTC: RHHBY) for $46 billion in 2009.
Drug powerhouse Sanofi (NASDAQ: SNY) is on board, having signed what is potentially a $1 billion deal with the young biotech in 2018. The much larger pharmaceutical company paid $125 million upfront for partial rights to two of Denali's drugs. One of those drugs, DNL747, is being tested for multiple indications, including MS, Alzheimer's, and ALS. It's in early phase-one trials now.
Denali is flush with cash -- the company is sitting on $478 million -- and the people running the business are incredibly smart. But what they are attempting is difficult enough to keep me on the sidelines until we see some results in the real world. Partnerships with big pharma companies are encouraging, but they're not everything; for investors in pharmaceuticals who are looking to contain their risk somewhat, RegenXbio seems like a smarter and safer investment at this point.
10 stocks we like better than Regenxbio
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Regenxbio wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 1, 2019
Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And it doesn't lack for partners: RegenXbio is currently collaborating with Pfizer (NYSE: PFE), Novartis (NYSE: NVS), Takeda Pharma (NYSE: TAK), Ultragenyx Pharma (NASDAQ: RARE), Audentes Therapeutics (NASDAQ: BOLD), Rocket Pharma (NASDAQ: RCKT), Abeona Therapeutics (NASDAQ: ABEO), Prevail Therapeutics, Lysogene, and Esteve. A leader in AAV vectors for drug discovery One promising sector in biotech investing is gene therapy for rare diseases. We can see how this process works in the case of Novartis's drug Zolgensma, which uses RegenXbio's AAV vector and was approved by the FDA last year. | And it doesn't lack for partners: RegenXbio is currently collaborating with Pfizer (NYSE: PFE), Novartis (NYSE: NVS), Takeda Pharma (NYSE: TAK), Ultragenyx Pharma (NASDAQ: RARE), Audentes Therapeutics (NASDAQ: BOLD), Rocket Pharma (NASDAQ: RCKT), Abeona Therapeutics (NASDAQ: ABEO), Prevail Therapeutics, Lysogene, and Esteve. A leader in AAV vectors for drug discovery One promising sector in biotech investing is gene therapy for rare diseases. He's staffed his company with several veterans of the famous biotech -- the chief operating officer, chief medical officer, chief financial officer, chief manufacturing officer, and head of discovery all come from Genentech, which was acquired by Roche (OTC: RHHBY) for $46 billion in 2009. | And it doesn't lack for partners: RegenXbio is currently collaborating with Pfizer (NYSE: PFE), Novartis (NYSE: NVS), Takeda Pharma (NYSE: TAK), Ultragenyx Pharma (NASDAQ: RARE), Audentes Therapeutics (NASDAQ: BOLD), Rocket Pharma (NASDAQ: RCKT), Abeona Therapeutics (NASDAQ: ABEO), Prevail Therapeutics, Lysogene, and Esteve. RegenXbio gets paid up front for the use of its technology; the company also receives milestone payments as the drugs make their way through clinical trials, and royalties on the sales if and when the drugs are approved. The blood-brain barrier prevents almost all drugs from reaching the brain -- of large-molecule drugs, 100% are stopped, and for small-molecule drugs, that number is 98%. | And it doesn't lack for partners: RegenXbio is currently collaborating with Pfizer (NYSE: PFE), Novartis (NYSE: NVS), Takeda Pharma (NYSE: TAK), Ultragenyx Pharma (NASDAQ: RARE), Audentes Therapeutics (NASDAQ: BOLD), Rocket Pharma (NASDAQ: RCKT), Abeona Therapeutics (NASDAQ: ABEO), Prevail Therapeutics, Lysogene, and Esteve. RegenXbio (NASDAQ: RGNX) and Denali Therapeutics (NASDAQ: DNLI) are two biotechs that pass my test with flying colors. RegenXbio gets paid up front for the use of its technology; the company also receives milestone payments as the drugs make their way through clinical trials, and royalties on the sales if and when the drugs are approved. |
28066.0 | 2019-09-23 00:00:00 UTC | Monday Sector Laggards: Biotechnology, Diagnostics | ABEO | https://www.nasdaq.com/articles/monday-sector-laggards%3A-biotechnology-diagnostics-2019-09-23 | nan | nan | In trading on Monday, biotechnology shares were relative laggards, down on the day by about 1%. Helping drag down the group were shares of Akcea Therapeutics (AKCA), off about 23.6% and shares of Abeona Therapeutics (ABEO) down about 11.8% on the day.
Also lagging the market Monday are diagnostics shares, down on the day by about 0.9% as a group, led down by Diplomat Pharmacy (DPLO), trading lower by about 5.6% and Catasys (CATS), trading lower by about 4.2%.
VIDEO: Monday Sector Laggards: Biotechnology, Diagnostics
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Helping drag down the group were shares of Akcea Therapeutics (AKCA), off about 23.6% and shares of Abeona Therapeutics (ABEO) down about 11.8% on the day. In trading on Monday, biotechnology shares were relative laggards, down on the day by about 1%. Also lagging the market Monday are diagnostics shares, down on the day by about 0.9% as a group, led down by Diplomat Pharmacy (DPLO), trading lower by about 5.6% and Catasys (CATS), trading lower by about 4.2%. | Helping drag down the group were shares of Akcea Therapeutics (AKCA), off about 23.6% and shares of Abeona Therapeutics (ABEO) down about 11.8% on the day. In trading on Monday, biotechnology shares were relative laggards, down on the day by about 1%. Also lagging the market Monday are diagnostics shares, down on the day by about 0.9% as a group, led down by Diplomat Pharmacy (DPLO), trading lower by about 5.6% and Catasys (CATS), trading lower by about 4.2%. | Helping drag down the group were shares of Akcea Therapeutics (AKCA), off about 23.6% and shares of Abeona Therapeutics (ABEO) down about 11.8% on the day. Also lagging the market Monday are diagnostics shares, down on the day by about 0.9% as a group, led down by Diplomat Pharmacy (DPLO), trading lower by about 5.6% and Catasys (CATS), trading lower by about 4.2%. VIDEO: Monday Sector Laggards: Biotechnology, Diagnostics The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Helping drag down the group were shares of Akcea Therapeutics (AKCA), off about 23.6% and shares of Abeona Therapeutics (ABEO) down about 11.8% on the day. In trading on Monday, biotechnology shares were relative laggards, down on the day by about 1%. Also lagging the market Monday are diagnostics shares, down on the day by about 0.9% as a group, led down by Diplomat Pharmacy (DPLO), trading lower by about 5.6% and Catasys (CATS), trading lower by about 4.2%. |
28067.0 | 2019-09-03 00:00:00 UTC | Health Care Sector Update for 09/03/2019: ABEO,EBS,TMD.TO,TMDI,APLS | ABEO | https://www.nasdaq.com/articles/health-care-sector-update-for-09-03-2019%3A-abeoebstmd.totmdiapls-2019-09-03 | nan | nan | Top Health Care Stocks
JNJ +0.32%
PFE +1.45%
ABT -1.71%
MRK +0.19%
AMGN -1.36%
Health care stocks were moderately lower compared with most other sectors this afternoon, with the NYSE Health Care Index slipping about 0.3% while the shares of health care companies in the S&P 500 also were down almost 0.8% as a group. The Nasdaq Biotechnology index was falling just under 2.0%.
Among health care stocks moving on news:
(+) Abeona Therapeutics (ABEO) roared 90% higher on Tuesday after the biopharmaceutical company said it has hired Jefferies to assist with a review of its strategic alternatives, which could include a potential sale or merger or partnering its clinical and pre-clinical programs with an outside party.
In other sector news:
(+) Emergent BioSolutions (EBS) climbed 14% on Tuesday after saying it received a 10-year contract from the US Department of Health and Human Services to continue supplying the federal agency with the company's AM2000 smallpox vaccine. The new contract is valued up to $2 billion, with an initial one-year period paying around $170 million plus nine option years. The company is expecting to deliver most of the doses before Dec. 31, with those sales already included in its FY19 financial forecast.
(+) Titan Medical (TMDI) declined 2%, giving back a previous rise. The medical device company said it has received a US patent for the camera positioning and image-capture tools on its dual-view camera system for use during robotic surgery. The dual-view system consists of an endoscope module and one flexible 3-D and 2-D high-definition camera each along with independent light sources and a camera insertion tube.
(-) Apellis Pharmaceuticals (APLS) fell over 5% this afternoon. The biopharmaceutical company began dosing patients in a phase III study of its APL-2 drug candidate in patients with paroxysmal nocturnal hemoglobinuria who have not undergone prior treatment for the disease that impairs bone marrow function and destroys red blood cells.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among health care stocks moving on news: (+) Abeona Therapeutics (ABEO) roared 90% higher on Tuesday after the biopharmaceutical company said it has hired Jefferies to assist with a review of its strategic alternatives, which could include a potential sale or merger or partnering its clinical and pre-clinical programs with an outside party. In other sector news: (+) Emergent BioSolutions (EBS) climbed 14% on Tuesday after saying it received a 10-year contract from the US Department of Health and Human Services to continue supplying the federal agency with the company's AM2000 smallpox vaccine. The biopharmaceutical company began dosing patients in a phase III study of its APL-2 drug candidate in patients with paroxysmal nocturnal hemoglobinuria who have not undergone prior treatment for the disease that impairs bone marrow function and destroys red blood cells. | Among health care stocks moving on news: (+) Abeona Therapeutics (ABEO) roared 90% higher on Tuesday after the biopharmaceutical company said it has hired Jefferies to assist with a review of its strategic alternatives, which could include a potential sale or merger or partnering its clinical and pre-clinical programs with an outside party. Top Health Care Stocks Health care stocks were moderately lower compared with most other sectors this afternoon, with the NYSE Health Care Index slipping about 0.3% while the shares of health care companies in the S&P 500 also were down almost 0.8% as a group. | Among health care stocks moving on news: (+) Abeona Therapeutics (ABEO) roared 90% higher on Tuesday after the biopharmaceutical company said it has hired Jefferies to assist with a review of its strategic alternatives, which could include a potential sale or merger or partnering its clinical and pre-clinical programs with an outside party. Health care stocks were moderately lower compared with most other sectors this afternoon, with the NYSE Health Care Index slipping about 0.3% while the shares of health care companies in the S&P 500 also were down almost 0.8% as a group. The medical device company said it has received a US patent for the camera positioning and image-capture tools on its dual-view camera system for use during robotic surgery. | Among health care stocks moving on news: (+) Abeona Therapeutics (ABEO) roared 90% higher on Tuesday after the biopharmaceutical company said it has hired Jefferies to assist with a review of its strategic alternatives, which could include a potential sale or merger or partnering its clinical and pre-clinical programs with an outside party. The Nasdaq Biotechnology index was falling just under 2.0%. In other sector news: (+) Emergent BioSolutions (EBS) climbed 14% on Tuesday after saying it received a 10-year contract from the US Department of Health and Human Services to continue supplying the federal agency with the company's AM2000 smallpox vaccine. |
28068.0 | 2019-08-12 00:00:00 UTC | Abeona Therapeutics Inc (ABEO) Q2 2019 Earnings Call Transcript | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-inc-abeo-q2-2019-earnings-call-transcript-2019-08-12 | nan | nan | Image source: The Motley Fool.
Abeona Therapeutics Inc (NASDAQ: ABEO)
Q2 2019 Earnings Call
Aug 12, 2019, 10:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning, ladies and gentlemen, and welcome to the Abeona Therapeutics Inc. Second Quarter 2019 Earnings and Business Update Conference Call. Today's call is being recorded. And at this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. For opening remarks and introductions, I'll turn the call over to Sofia Warner, Senior Director, Investor Relations. Thank you. You may begin.
Sofia Warner -- Senior Director, Investor Relations
Thank you. Good morning, and welcome, everyone. Today's call will be led by Joao Siffert, our Chief Executive Officer. Following Joao, Tim Miller, our President and Chief Scientific Officer, will present preclinical highlights; and Christine Silverstein, our Chief Financial Officer, will review our financials. Before I turn the call over to them, I need to remind our listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in these statements is based on current expectations and is subject to change, and actual results may differ materially from forward-looking statements. Some of the factors that could cause actual results to differ may be found in the company's annual report on Form 10-K and quarterly report on Form 10-Q to filed by the company with the Securities and Exchange Commission. These documents are available on our website www.abeonatherapeutics.com.
With that said, it is now my pleasure to introduce to you, Dr. Joao Siffert. Joao, you have the floor.
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Thank you, Sofia, and thank you all for joining us today for our second quarter results and business highlights, which we believe reflects substantial progress in the continued development of our clinical and preclinical programs, as well as our manufacturing and quality operations. Today, I'll review the key quarter accomplishments and recent events and then turn the call over to Tim, who will discuss the developments within our preclinical programs and updates from our next-generation AIM capsid platform.
I'd like to start off with an update on our recessive dystrophic epidermolysis bullosa program. As a reminder, RDEB is a rare and severely debilitating genetic skin disorder caused by mutations, which result in lack of functional Collagen VII, the main component of the anchoring fibrils that attach the dermis to the epidermis. Without functional Collagen VII, RDEB patients have extremely fragile skin, the blisters and tears, ultimately leading to multiple wounds, some of which remain open for years and cover a significant amount of the body. RDEB wounds are very painful lead to multiple dermatological and sustained complications and currently have no effective treatment options.
Patients rely on palliative treatments that include time-consuming and expensive wound care to protect open wounds, reduce pain, prevent infection and often require comprehensive pain management. We're currently developing EB-101, autologous, gene-corrected cell therapy that restores normal functional Collagen VII to keratinocytes and their progenitors. Each EB-101 gene-corrected keratinocyte sheet, which can cover an area of approximately 35 to 40 centimeter squared, is transplanted into open wounds provided -- providing prompt wound healing. Two skin biopsies allow manufacture of six EB-101 sheets, which combined can cover wound areas measuring up to 240 centimeters squared.
To our knowledge, EB-101 is the only product in development for RDEB with clinical data, so we could heal large chronic wounds that had been open for years. The Phase 1/2a trial, conducted by Stanford University, show that EB-101 healed an average of approximately 130 centimeters square per patient and up to 160 centimeter square in some patients with durability of two to five-plus years post treatment. The majority of our RDEB wounds are chronic, often remain open for years and tend to be larger than 120 centimeter square. Wound healing of such large wounds is in itself clinically significant and the long term follow-up from the Phase 1/2a trial show that 50% or more wound healing was associated with meaningful reduction in pain.
Our goal is to bring this transformative therapy to patients with RDEB as soon as possible. We recently met with the FDA to discuss the final stages of a preparation for upcoming Phase 3 clinical trial called VITAL, aimed at confirming the safety and efficacy of EB-101 observed in the Phase 1/2a study. At this meeting, the FDA addressed information that we previously submitted regarding quality testing of the product in certain aspects of our Phase 3 clinical trial protocol. We believe we have successfully completed the manufacturing process of the EB-101 and the request for clarification on chemistry, manufacturing and controls are focused on product transport and on the protocol to assess comparability of the to-be-commercial retrovirus used in EB-101 manufacturing.
In addition, FDA provided feedback on selection, measurement and timing of certain patient-reported outcome measures. We are currently addressing the valuable feedback received and will provide clarification and supplemental documentation for items previously submitted to the FDA as soon as possible. We have requested meetings with the respective FDA reviewers to address their questions, so we can proceed with the Phase 3 trial in fourth quarter 2019. The VITAL Phase 3 study will be a multi-center randomized clinical trial assessing EB-101 for treatment of approximately 35 wound sites across 10 to 15 RDEB patients.
The primary outcome measure of the study will be wound healing at three months, comparing the proportion of treated wound sites with at least 50% healing to untreated ones on the same patients. By protocol, participants eligible to enroll in VITAL will have chronic wounds larger than 40 centimeters squared. In most cases, their chronic wounds exceed 120 centimeters squared, require frequent wound care and are associated with disabling pain and are a great risk for infection. Additional study endpoints will include the patient global impression of change for pain at each wound site compared with baseline as well as measurements of pain intensity during dressing changes in a clinic visit. Patients will be followed for up to six months for assessment of wound healing durability and overall safety. We estimate there are about 2,500 RDEB patients in the US who could benefit from multiple EB-101 treatments, given the large number and size of wounds observed among the population.
The RDEB patient community and their treating physicians are anxious to have EB-101 available as soon as possible. Learnings from the Phase 1/2a trial have equipped our clinical team to best prepare for Phase 3. The Stanford University team is also ready to start involving patients as soon as we receive that key endorsement to proceed. Additional study sites will begin in the ensuing months.
I'd next like to provide an update for a program assessing ABO-102 for MPS IIIA, also known as Sanfilippo syndrome type A, a rare, lysosomal storage disease with no approved treatment that primarily affects the central nervous system or CNS. ABO-102 is our novel gene therapy dosed one time intravenously using a self-complementary, AAV9 vector to deliver two functional copies of the SGSH gene to sell them on the CNS as well as to peripheral organs. The therapy is designed to correct the underlying SGSH enzyme deficiency and prevents cellular accumulation of heparan sulfate that leads to cell dysfunction, cell death and rapid neurodevelopmental decline and physical impairment. We're currently assessing the safety and efficacy of ABO-102 in the Transpher A Study, also known as ABT-001.
This study is a two-year open label dose escalation Phase 1/2 global clinical trial for patients with MPS IIIA who have a developmental quotient of at least 60% of normal levels for age and meet other eligibility criteria. The study primary outcome measure focused on neurodevelopmental progress and safety with secondary measures of behavior, quality of life, heparan sulfate levels and CSF, plasma and urine and brain and liver volume.
Last month, we were excited to share positive interim data for a Transpher A study showing that the three youngest patients involved in the study at ages 26, 19 and 12.5 months at dosing all enrolled in cohort 3 continue to track within normal range of the age equivalent development at ages 44, 31 and 24.5 months, respectively, that is 12 to 18 months post treatment. To our knowledge, our data are the only reported evidence suggesting that a gene therapy treatment could alter the typical nerve developmental course in children with MPS IIIA. We believe our data also corroborates the basic principle that treating neurodegenerative disorders before they become more advanced can provide the best chance for a benefit, especially in a disease that causes rapid neurological impairment within the first few years of life.
The study data show that intravenous ABO-102 administration resulted in a durable reduction in CSF heparan sulfate, a key biomarker of MPS IIIA. Improvement in CSF heparan sulfate was dose-dependent and reached their lower limit of metal detection from eight patients enrolled in cohort 3. Reductions in liver volume were also sustained during the observation period of up to two years. In addition, safety profile of ABO-102 remained favorable and no product-related serious adverse events were reported to-date. We'll continue to screen patients for enrollment in the Transpher A at sites in the US, Spain and Australia. We're pursuing on our meeting with the FDA in the second half of this year to discuss study data and gain clarity on the development path forward.
Moving on, I'd like to discuss our ABO-101 program, an investigational one-time gene therapy for the treatment of MPS IIIB, also known as Sanfilippo syndrome type B. MPS IIIB is a rare, devastating and fatal lysosomal storage disease with no approved treatment that is characterized primarily by rapid neurodevelopmental decline leading to early death. We recently announced that FDA granted Fast Track designation to ABO-101, recognizing the severity and importance of addressing this rare orphan disease.
To briefly review the Transpher B, also known as the ABT-002, is a two-year open label Phase 1/2 study, primarily evaluating safety and neurodevelopment of the MPS IIIB children treated with ABO-101. Eligible patients need to have a developmental quotient of at least 60% of normal levels for age and meet other standard criteria. Secondary outcome measures include CSF in urine heparan sulfat levels, CSF and serum NAGLU enzyme activity in liver and brain volume by MRI. We're pleased to share that to-date we have treated a total of five patients with MPS IIIB, two in cohort 1 and three in cohort 2. Study recruitment efforts continue and we have a queue of patients awaiting screening across sites in the US, Spain and France.
With a post-treatment follow-up ranging from less than one month to more than 20 months post dosing, the overall safety profile remains favorable and there have been no serious adverse events being related to ABO-101. Improvements in disease-specific biomarkers were similar to that observed for MPS III program.
We expect to report interim data for the trial in the second half of this year. We also have made progress advancing our CLN1 program to the clinic. CLN1 disease, also known as, Infantile Batten disease is a rare, fatal, inherited disorder of the nervous system that generally presents in childhood and leads to visual neurological impairment and early death. In May, we announced the FDA clearance of our R&D for ABO-202 and AAV9 gene therapy for CLN1 disease. And in June, we received FDA Fast Track designation for this program. These regulatory milestones in combination with a previously reported preclinical data, which showed a favorable safety profile and low significant toxicities leave us excited about the potential for ABO-202 in CLN1. We will provide guidance on the timing of the study later this year.
Finally, from a company standpoint, this quarter, we'll strengthen our management team with two important appointments. We're fortunate to announce the recruitment of Dr. Victor Paulus as Senior Vice President of Regulatory Affairs and Jodie Gillon as Vice President of Patient Advocacy and Clinical Affairs. Victor brings to Abeona over 30 years of experience in the pharmaceutical industry, including over 20 years specializing in regulatory affairs. His experience will be instrumental as he will bring our gene and cell therapies to patients. Jodie brings over 20 years of valuable industry experience and makes for an ideal person to lead our patient advocacy and clinical affairs functions in close collaboration with patients, families, medical and scientific stakeholders. Both Victor and Jodie have already had an immediate positive impact for Abeona.
Before I turn the call over to Tim, I'd like to close by taking a moment to heartfully thank all the patients, families, clinicians and patient organizations who have participated in and partnered in our efforts to advance our mission of working together to deliver gene and cell therapies for people impacted by serious diseases.
With that, I'll now turn the call over to Tim. Tim?
Timothy J. Miller -- President & Chief Scientific Officer
Thank you, Joao. During the second quarter, we reported new preclinical data developed from our AIM capsids platform, a next-generation of adeno-associated virus capsids for use in gene therapies. The AIM capsid library can utilize AB biology to selectively target delivery of genetic payloads to the central nervous system, lungs, eye, muscle, liver and other tissues. In April, we presented new data from the ABO-401 program, our novel gene therapy for cystic fibrosis at the American Society of Gene and Cell Therapy 22nd annual meeting in Washington, DC.
ABO-401 has a regulatable human mini-CFTR gene that is efficiently packaged into AAV204, one of our next-generation library capsids. The data presented at ASGCT demonstrate that ABO-401 efficiently delivered a highly expressed functional copy of human mini-CFTR to the lung of CF mice and restored CFTR lung function in human CF patient nasal and bronchial epithelial cells. This adds to the growing body of evidence suggesting ABO-401 may address the challenges in lung delivery and transgene expression that have limited the advancement of gene therapy for CF patients.
In this and other preclinical studies, ABO-401 restored CFTR expression and chloride conductance in airway epithelial, the main cells of the lung that contribute to CF pathology in humans. Robust expression of AAV204 in the lungs of CF mice was observed and demonstrated that the AAV204 capsid was equally or more efficient at delivering gene expression cassettes to the lung compared to other naturally occurring AAV capsids. Further, the data demonstrated that the ABO-401 restored CFTR-specific nasal potential difference in the CF mice and that the ABO-401 gene expression cassette that makes a fully functional and processed CFTR. We believe that the recent data are encouraging and ABO-401 is a promising candidate that may ultimately change the landscape of CF treatment by introducing a one-time gene therapy.
Also during the quarter, Abeona presented new preclinical data of our -- on our novel AIM AAV204 capsid, demonstrating the broad therapeutic potential of AIM gene therapy in retinal diseases. The data were presented in May at the Association for Research in Vision and Ophthalmology Annual Meeting in Vancouver. The data showed that intravitreal administration of our novel AIM AAV204 capsid to non-human primates led to a robust transgene expression in the inner and outer retina. Expression was observed in the peripheral retina and fovea 25 days post administration.
AAV204 also transduced the photoreceptor cells in retinal explants and transduced the outer retina with positive green fluorescent protein expression. These data support the potential use of AAV204 for intravitreal administration to deliver gene therapy in an outpatient setting for a wide range of inherited and acquired retinal diseases. The non-human primate data were complemented by findings from mouse models, which identified AAV204 as one of the three lead candidate AIM capsids that demonstrates robust transduction of retinal cells. The data demonstrated in mice that intravitreal administration resulted in broad retinal expression of AAV204 that penetrated to the photoreceptor and retinal pigmented epithelial layers.
The broader retinal tropism of AAV204 capsid in non-human primates underscores the potential of our platform to deliver gene therapy beyond inherited diseases, including the treatment of acquired retinal disorders that may be currently underserved. Intravitreal administration of AAV gene therapy, which does not require surgery, could potentially be performed in an outpatient setting and may be a safer and less-invasive approach than suffering administration. AIM vectors are non-replicating and have shown the potential to evade the immune responses generated by exposure to naturally occurring AAV vectors. Our library contains more than 100 capsids with tissue tropism selected for the potential to target a wide range of organs and multiple routes of delivery.
An important consideration is the route of administration and we have shown data in rodents and non-human primates that we can utilize different AIM capsids to target the photoreceptors and the retinal pigmented epithelium using either subretinal or intravitreal injections. The AIM capsid increased our potential for targeting multiple eye disorders through delivery of therapeutic means are employing the machinery to enable gene editing.
Lastly, we have now demonstrated in vitro that selected AIM capsid can evade neutralizing antibody against naturally occurring AAV capsids that may be present in some patients. We believe this finding is significant as it may allow AIM-based AAV gene therapy for patients who have been previously treated or excluded from study participation owing to existing anti-AAV antibodies. Evading anti-AAV immunity could potentially also enable retreatment of patients who previously received AAV gene therapy with other serotypes. We look forward to discussing these and additional AIM programs in the future.
I will now turn the call over to Christine, who will review our financials. Christine?
Christine Silverstein -- Chief Financial Officer
Thank you, Tim. We have recently filed a 10-Q where you can find all specific information on our financial results. But in summary, our cash, cash equivalents and marketable securities as of June 30th, 2019 were $62.5 million compared to $68.3 million as of March 31st, 2019. Net cash used in operating activities for the quarter was $15.2 million as compared to $9 million in the same period of 2018, an increase in cash outflows of $6.2 million. R&D expenses for the three months ended June 30th, 2019 was $16.3 million compared to $7.9 million in the same period of 2018. The increase in research and development expenses primarily attributed to increased in-house manufacturing activities and related headcount costs. General and administrative expenses for the quarter were $5.6 million compared to $4.6 million in the same period of 2018. The increase in G&A expenses is primarily due to the increased headcount and related facility costs. Net loss was $0.49 per share for the second quarter of 2019, compared to $0.26 per share in the same period 2018. That's the summary financials.
With respect to upcoming investor and scientific conferences, I'd like to highlight that on September 4th, we'll be in Boston, attending the Citi's 14th Annual Biotech Conference and on September 5th, we will also be attending the Wells Fargo Securities Healthcare Conference also in Boston. We will update you on those planned presentations as we get closer to the events.
And with that, I'd like to turn it back over to Joao.
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Thank you, Christine. In summary, in the second quarter, we have made important progress that we believe positions Abeona well to drive forward our mission of turning hope into reality for our patients.
Thank you. I'll now turn over to the operator to open up for questions. Operator?
Questions and Answers:
Operator
Thank you. The floor is now open for your questions. [Operator Instructions] We will take our first question from Maury Raycroft of Jefferies. Please state your question.
Maury Raycroft -- Jefferies -- Analyst
Hi. Good morning, everyone, and thanks for taking my question. First question is on ABO-101. It seems like you expanded the 5E13 cohort from three to six to four to seven in July, added an efficacy-based primary endpoint to look at neuro target and then added some secondary endpoints as shown on clinicaltrials.gov. And so I'm just wondering if there are any specific reasons why some of these changes were made and if FDA or KOLs encouraged the changes? And then just bigger picture, what else is -- what is needed in IIIB to eventually seek approval for this indication?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
So just to be -- hi, Maury, Joao here. I'll take this question. So you were referring to the MPS IIIB programs. is that correct as I understood?
Maury Raycroft -- Jefferies -- Analyst
That's correct.
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
[Speech Overlap] beginning of it? Yes. So these are essentially changes to harmonize the IIIB program with the IIIA program. So what we're trying to do is again focus the enrollment of patients who we believe are not -- that have not undergone much advancement in their disease and therefore could stand to benefit the most from the therapy. Not to say that children who have more advanced disease couldn't benefit, it's just that the effect size likely would be larger in children who were still functioning at a higher level and that's codified by setting up the inclusion criteria with a developmental quotient of 60% or greater. So is that your question and then we will continue to take the same approach on the IIIB program as we have on the IIIA program and that we continue to collect both biomarkers and the developmental data from this program and once we have sufficient data to identify clinical benefit beyond just the biological benefit of markers, which we expect to see and have seen in the first patient, expect to see in the ensuing patients will again engage the agency in discussions for the further development of the program.
Maury Raycroft -- Jefferies -- Analyst
Got it. That's helpful. And then, for the IIIB patients, can you talk about some of their baseline characteristics at this point? Maybe anything on age and baseline neurocog function? And then it seems like some -- yes, I'll let you answer that and then do a follow-up.
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Yes. So, these patients meet the eligibility criteria. So, we'll not disclose specific age at this point. We'll provide an update on the study overall, including some early data readouts later this year. As you know and since this is an update from the past quarter, these patients were enrolled relatively recently, all but one in 2019. So relatively early follow-up. But they meet criteria for the developmental quotient. That is in general looking at the -- just as a framework and then not necessarily providing specific ages, which I don't know by heart for all the patients, but a child with the developmental quotient of 60% or greater who has either MPS IIIA or IIIB with the rapid progressive phenotype tend to be usually younger than 40 months or so, give or take. They tend to be younger.
Maury Raycroft -- Jefferies -- Analyst
Got it. Okay. And for IIIB also, it seems like some other companies enrolling IIIB studies have had a difficult time enrolling those studies. It seems like your enrollment has picked up recently. Is there anything that you can say about enrollment and potential investor -- investigator enthusiasm for your particular approach in IIIB?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Yes. I think there is a good momentum on both programs, actually, although IIIA, we have not enrolled anyone this year yet, we have continued to screen patients who unfortunately were not eligible for the trial and then we continue to screen patients as we speak. So, we hope to enroll patients later this year. IIIB and I think IIIA both are benefiting from an effort that was started sometime last year to really expand our footprint in terms of clinical trial sites. The sites continue to be very engaged. We have also a pretty concerted international outreach and that's -- the question of whether IIIB, which tends to be viewed as less common than IIIA at least in the United States, it may not be as uncommon as we thought to be in some European countries and other places such as South America. So we're having success identifying these patients.
I also believe that with the continued positive data in IIIA from the standpoint of the maintenance of improvements in biomarkers now up to two years in CSF heparan sulfate as well as the recent data we announced on the youngest patients showing some neurocognitive preservation, I think that also creates the momentum in terms of interest that we're showing that this is not only a biologically active intervention, but also seems at this point that we can also demonstrate some preservation of actual clinical data, which is important.
Maury Raycroft -- Jefferies -- Analyst
Got it. Yes. And for IIIA, for those young and higher functioning patients that you're treated and you're showing their preservation of neurocog function, can you just comment on their underlying IIIA mutation and also the strength of natural history data over a similar 12 to 18 month time frame for those particular patients?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Yes. So the patients by protocol eligibility, all patients need to have mutations that are associated with a rapid progressive phenotype. So in general, if you look at the various natural history studies, including the one we've worked most closely with from National Children's Hospital, but if you look at the Pittsburgh data, also data from University of Minnesota, albeit it was a different scale but certainly something that we should look at because it's a pretty comprehensive dataset as well.
Most children with the rapid progressive form of MPS IIIA or IIIB for that matter tend to plateau in their new development before they reach age of three almost by a rule. Obviously, this is biology, not sort of mathematics, but by and large. And if you look at all these studies, most of these children decelerate in their development during their second year of life and before they reach age three, they tend to plateau in their neurodevelopment and start declining.
So anything that sort of deviates from that in terms of the neurocognitive development in this case, following the intervention with ABO-102, we believe it could be already an indication that this treatment is having a biological effect and also diverging in terms of the neurocognitive course. Does that your answer question?
Maury Raycroft -- Jefferies -- Analyst
Yes, that does. And Just last question on EB-101. So, for the CMC protocol item, particularly the one related to their retrovirus batch, just to be clear, you don't need to accumulate any new data for this until after the trial has started, right? And then I'm wondering -- yes, and then I'm wondering how much our Brammer is involved with helping with the protocol design and finalizing the protocol for this?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
So, two separate questions. So, what we are submitting to the agency, the request is the actual protocol. We're not submitting any data going ahead of the Phase 3. So the transfer from the original retrovirus to the Brammer retrovirus, which has been planned all along in agreement with the agency, will take place during Phase 3. So, we will be conducting the comparability studies, which are no different than the release -- generally speaking, no different than the release of studies that we do, quality assurance that we do for any kind of GMP product. So in this case, for ABO-101.
So, we'll be testing those for the Indiana University retrovirus material and testing those for the Brammer retrovirus material as we would do anyway to -- the only thing we'll do in this to set up a protocol prospectively to show what the acceptance criteria are, which are generally already agreed upon with the agency. So, it's literally having the protocol written. Data will be generated as we release these batches for clinical use as we would normally.
Now, we have used the Brammer material to manufacture a sheet all throughout the past say six months. These are obviously not for clinical use, but certainly using the same retrovirus that we are intending to use them to Phase 3. So we have experience using the retrovirus and it has performed well as expected. So, we don't anticipate any surprises here.
Maury Raycroft -- Jefferies -- Analyst
Okay. And then how involved is Brammer in the process for you with helping finalize these protocols?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
They have been very good partner of Abeona for a while now and very closely -- we'll work closely with them. Yes. And we have already, so it's not forward-looking, this has taken place, this part of the whole manufacturing readiness for the program has included manufacturing ABO-101 using the Brammer retrovirus. So we've done this before. This is not the first time we're going to do this. This is just going to be officially for -- during the Phase 3.
Maury Raycroft -- Jefferies -- Analyst
Got it. OK. Thank you very much for taking my questions. And I'll hop back in the queue.
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Sure. Thank you.
Operator
Our next question comes from Kennen MacKay of RBC Capital. Please state your question.
Bikramjot Singh -- RBC Capital -- Analyst
Hi, guys. Thanks for taking our questions. This is Bikram on for Kevin. So, we had one on the patient-related outcomes that actually had -- has to be included in the Phase 3 study for EB-101. Could you please elaborate what those outcomes are and how would this further validate maybe the wound healing it will show in these patients?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Yes. Thank you for the question. The patient-reported outcomes, there are several. The main one being pain. Especially for the larger wounds that we're addressing in our Phase 3 trial, pain is among the most disabling patient experiences. Obviously, having an open wound has all sorts of other medical implications, including risk of infection and the need for repeat wound dressing and then extensive wound care and whatnot but the pain is really the main cause of sort of discomfort and suffering for these patients.
So the FDA is obviously interested in understanding how wound healing and pain intersect. If you ask patients, they'll tell you that their intact skin, there is a healed wound doesn't hurt and if you ask them which wounds hurt the most, they uniformly will tell you the larger wounds. Smaller wounds are not -- they can still be uncomfortable, but the larger wounds tend to be the ones mostly associated with higher intensity of pain. This has been shown not only anecdotally by asking the patients, but also in natural history studies that's been presented.
So, FDA wanted to just agree with us in exactly timing and how to collect those using scales that are pretty well known and it's been validated in pain trials before. So, it was not much about the scales themselves, it's just about the collection timing in relation to some of the wound care, basically wound care as they remove the bandages that can cause pain, because sometimes the bandages, especially in the larger ones, get stuck. Also, as you tender to the wounds and cleanse the wounds can cause also acute pain. So the patients have both the chronic pain from just having these open wounds chronically but then acute exacerbations of pain during procedures. So it was just a matter of getting coordinated and making sure we get as much information as possible in those while the patient is at home, but also recalling the experience when they come to the clinic visits.
Bikramjot Singh -- RBC Capital -- Analyst
Got it. Just to follow-up on that. Is there are any specific percentage of pain improvement you're looking in these patients? Or will it just depend from wound to wound, depending on the size of the wound? How are you thinking about that?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
I'm sorry. I missed the -- can you repeat the first part of your question? I just couldn't hear well.
Bikramjot Singh -- RBC Capital -- Analyst
Absolutely. So just to follow up on that, I was thinking what percentage of improvement on the pain scales that you said are pretty standardized? Will you be looking to -- will it be something similar to, as you said 50% wound healing? How shall we be thinking about that?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Yes. So, this is -- this is sort of the difficult question about EB because there aren't [Phonetic] much data for EB specifically. There's obviously a ton of data in pain, both chronic and acute pain files in variety of conditions from cancer to neuropathic pain [Indecipherable] migraines, but as you can imagine, there's not a lot of this for EB. The sense that we get from talking to patients is the wound healing essentially large relief for pain also can be quite variable. And it's served under wraps, meaning that the wound is well dressed and they're not touching it or cleaning it. There's some base pain, but it's not that severe. Of course, as you remove the wound dressings that the pain spikes up. So there isn't a set threshold to success. Ultimately in the end, the intent here is to heal the wounds and of course, having an open large wound in of itself is clinically very meaningful.
So if you could heal a large area of wound, this in of itself will cause much benefit to the patients and all the ramifications of EB wounds. But we would expect that it will also provide us with a pain relief. So we'll measure as a continuous variable as well as categorical variable.
Bikramjot Singh -- RBC Capital -- Analyst
Got it. Got it. That is super helpful. Thanks for the color.
Operator
Any further questions, sir?
Bikramjot Singh -- RBC Capital -- Analyst
That would be all.
Operator
Thank you. Our next question comes from Joon Lee of SunTrust. Please state your question.
Fang-Ke Huang -- SunTrust -- Analyst
Hi. Thank you for taking our question. This is Fang-Ke Huang for Joon. I'm just wondering if you can tell us a bit more about the timing of initiating the EB online trial. It's going to be an early 4Q [Phonetic] event or you're going to anticipate going to be late 4Q event or it's too difficult to tell at this moment?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
So we can't provide any more guidance than we already have provided publicly in the case filing. Much of what remains there are questions about quality and this particular question about PROs that we've been discussing. The timing now for initiations is entirely predicated on resolving these questions. So, this is largely driven by the timing of how efficiently we can communicate with the agency. On our end, we're working diligently to get all the answers submitted soon. So just a matter of ensuring that FDA is satisfied with the answers and that if there are any remaining questions that we can address those ASAP. From the actual trial readiness in terms of the clinical operations and the ability to manufacture the product, we feel that we're ready as soon as the FDA is ready. Sanford has obviously been very close partner that we're dealing for years now and they are ready and willing and eager to start as long as we get the final go ahead.
Fang-Ke Huang -- SunTrust -- Analyst
Got it. That's helpful. And then secondly, you mentioned that beyond Stanford you're -- potentially can open other treatment sites for the EB patients. And just wondering, what are the potential logistics of opening a site and how long you need to train their employee just starting treating patients?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Sure. These are sites we've been working with already for several months now. So this is a long lead time in terms of just getting all the travel logistics set up. But there are also sites that are very familiar with care of patients with EB and also have very good standard, well qualified plastic surgery staff. So they would be equipped in terms of all the moving parts. They'll be fully equipped to participate in the trial and of course, the team at Sanford has offered -- has had conversation with some of these sites and would offer to help train them on these more [Indecipherable] protocol itself. But in terms of the capabilities of caring for the EB population and in terms of the actual procedure of applying these products to be 101, these would be fully qualified sites.
Fang-Ke Huang -- SunTrust -- Analyst
Okay. And then thirdly, I think just in terms of the timing of data you're going to report for -- in ABO-101, ABO-102 your second half, are you going to present them at medical conference or scientific conference where you're going to press release or going to host the R&D day to present the data?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
All these are possibilities. We haven't disclosed that. As soon as some of the presentations that were submitted and get approved and we'll confirm the presentation day and then we may -- if there are updates that emerge outside of a conference scheduled, then we may either call a call or a press release it.
Fang-Ke Huang -- SunTrust -- Analyst
Perfect. And last question, if I may. So you mentioned about AIM platform and then there's a number of capsids potentially can be used and you also mentioned that in the lastearnings call are -- you may discuss the potential to leverage the value of the AIM platforms through external collaborations. Maybe you can give us some updates there what you see. Is there any discussions going on currently in terms of -- for external collaborations and how are you thinking about AIM platform and how you're going to capture that value?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Yes. So, that's a good question and one that we didn't, in fact, announce that we would seek partnerships. As you know we have a very broad pipeline, both clinical pipeline and pre-clinical pipeline. And so it's a good problem to have, but we have obviously been careful that prioritizing our efforts under the products. So while also trying to continue to develop the AIM platform, we've been in discussions actually for months now with several interested parties and these have been fruitful. We will announce in due course when we have anything that is concrete in terms of something to disclose. But there's obviously interest in this platform, the interest in the data that Tim and his team have generated and presented as you heard earlier. And we're looking forward to continue this process. Obviously, it takes time, but we're -- we've been active at it for quite a while now. So, of course, some of these relationships are now maturing and we hope to have something to report in coming months.
Fang-Ke Huang -- SunTrust -- Analyst
Got it. Thanks so much and thanks again for taking our questions.
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Sure. Thank you.
Operator
Our next question comes from Liav Abraham of Citi. Please state your question.
Liav Abraham -- Citi -- Analyst
Good morning. Many of my questions have been asked, maybe just one on EB-101. Joao, could you just remind us how quickly you'll be able to enroll the trial and when we could see data on the primary endpoint?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Thanks, Liav. So, we have and Stanford through a protocol they've had under way for a while now have been identified and screened -- formally screened I think 10 patients now or 11 patients. We expect to have enrolled somewhere between 10 patients and 15 patients to have the number of wounds that give the power for the study. As soon as we are ready to go, obviously, we'll start carefully in the first patient or two to make sure everything goes well in terms of the logistics of it. After that, we could accelerate enrollment. So it's just a matter of scheduling patients for treatment. They're all waiting for the study. So, could envision enrollment, of course, we'll provide updates on that, but could envision enrollment, say, six months, up to six months. We'll try to do faster, but it could be a little longer, depends on ability to schedule. And then the trial itself has a six month follow up built in. So, we've primary endpoint of three months and we call for an additional three months to look both at ongoing safety and healing durability so that could bring us to the end of next year, depending how quickly we can get this up and running.
Liav Abraham -- Citi -- Analyst
Great. Thank you. And then on your -- on that meeting with FDA in the second half of the year, can you just remind us what are the objectives of this meeting and do you anticipate communicating the outcome of the meeting to investors?
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Yes. So you're referring now to MPS IIIA, right, ABO-102?
Liav Abraham -- Citi -- Analyst
Yes.
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Okay. Yes. So we have now made a two-plus years on safety for half of the patients, at least. Others are getting close to it. Obviously cohort 3 is a bit more recent. The biomarkers have been very consistently showing that this product can improve the disease -- the underlying disease pathology, that is the activity of the enzyme and clear the accumulation of heparan sulfate. And now we're having more data now, 12 to 18 months data in cognition for the younger children.
So the question now is what next, right? So that's exactly what we're going to ask the agency. So what's the path between now and sort of moving this toward a path that can lead to BLA and approval. So this is broadly speaking that the overarching question here. And this, of course, will cover multiple aspects of the development program, including CMC, of course, clinical safety and whatnot.
So that's what we're looking to, to engage the agency with. We'll provide updates as they materialize. Obviously, regulatory feedback is not something that we would provide in details because obviously there's a full context and one so it's not often not sort of ready for progress. But we do -- we will provide guidance to the extent that the guidance is material and something that is actionable and whatnot.
Liav Abraham -- Citi -- Analyst
Thank you.
Operator
Any further questions, Ms. Liav Abraham?
Liav Abraham -- Citi -- Analyst
No, I'm good. Thank you.
Operator
Thank you.
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Thanks, Liav.
Operator
[Operator Closing Remarks]
Duration: 49 minutes
Call participants:
Sofia Warner -- Senior Director, Investor Relations
Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer
Timothy J. Miller -- President & Chief Scientific Officer
Christine Silverstein -- Chief Financial Officer
Maury Raycroft -- Jefferies -- Analyst
Bikramjot Singh -- RBC Capital -- Analyst
Fang-Ke Huang -- SunTrust -- Analyst
Liav Abraham -- Citi -- Analyst
More ABEO analysis
All earnings call transcripts
10 stocks we like better than Abeona Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abeona Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 1, 2019
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc (NASDAQ: ABEO) Q2 2019 Earnings Call Aug 12, 2019, 10:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, ladies and gentlemen, and welcome to the Abeona Therapeutics Inc. Second Quarter 2019 Earnings and Business Update Conference Call. These documents are available on our website www.abeonatherapeutics.com. | Operator [Operator Closing Remarks] Duration: 49 minutes Call participants: Sofia Warner -- Senior Director, Investor Relations Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer Timothy J. Miller -- President & Chief Scientific Officer Christine Silverstein -- Chief Financial Officer Maury Raycroft -- Jefferies -- Analyst Bikramjot Singh -- RBC Capital -- Analyst Fang-Ke Huang -- SunTrust -- Analyst Liav Abraham -- Citi -- Analyst More ABEO analysis All earnings call transcripts 10 stocks we like better than Abeona Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abeona Therapeutics Inc (NASDAQ: ABEO) Q2 2019 Earnings Call Aug 12, 2019, 10:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, ladies and gentlemen, and welcome to the Abeona Therapeutics Inc. Second Quarter 2019 Earnings and Business Update Conference Call. | Operator [Operator Closing Remarks] Duration: 49 minutes Call participants: Sofia Warner -- Senior Director, Investor Relations Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer Timothy J. Miller -- President & Chief Scientific Officer Christine Silverstein -- Chief Financial Officer Maury Raycroft -- Jefferies -- Analyst Bikramjot Singh -- RBC Capital -- Analyst Fang-Ke Huang -- SunTrust -- Analyst Liav Abraham -- Citi -- Analyst More ABEO analysis All earnings call transcripts 10 stocks we like better than Abeona Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abeona Therapeutics Inc (NASDAQ: ABEO) Q2 2019 Earnings Call Aug 12, 2019, 10:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, ladies and gentlemen, and welcome to the Abeona Therapeutics Inc. Second Quarter 2019 Earnings and Business Update Conference Call. | Operator [Operator Closing Remarks] Duration: 49 minutes Call participants: Sofia Warner -- Senior Director, Investor Relations Joao Siffert -- Chief Exeuctive Officer, Head of Research & Development and Chief Medical Officer Timothy J. Miller -- President & Chief Scientific Officer Christine Silverstein -- Chief Financial Officer Maury Raycroft -- Jefferies -- Analyst Bikramjot Singh -- RBC Capital -- Analyst Fang-Ke Huang -- SunTrust -- Analyst Liav Abraham -- Citi -- Analyst More ABEO analysis All earnings call transcripts 10 stocks we like better than Abeona Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abeona Therapeutics Inc (NASDAQ: ABEO) Q2 2019 Earnings Call Aug 12, 2019, 10:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, ladies and gentlemen, and welcome to the Abeona Therapeutics Inc. Second Quarter 2019 Earnings and Business Update Conference Call. |
28069.0 | 2019-05-14 00:00:00 UTC | Abeona Therapeutics Inc (ABEO) Q1 2019 Earnings Call Transcript | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-inc-abeo-q1-2019-earnings-call-transcript-2019-05-15 | nan | nan | Image source: The Motley Fool.
Abeona Therapeutics Inc (NASDAQ: ABEO)
Q1 2019 Earnings Call
May 14, 2019, 10:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning, ladies and gentlemen, and welcome to the Abeona Therapeutics Inc. First Quarter 2019 Earnings and Business Update Conference Call. Today's call is being recorded. And at this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation.
For opening remarks and introductions, I'll turn the call over to Sofia Warner, Senior Director, Investor Relations. Thank you. You may begin.
Sofia Warner -- Senior Director, Investor Relations
Thank you. Good morning, and welcome, everyone. Today's call will be led by Joao Siffert, our CEO. Following Joao, Tim Miller, our President and CSO, will present preclinical highlights; and Christine Silverstein, our CFO will review our financials.
Before I turn the call over to them, I need to remind our listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the Safe Harbor provisions of the federal securities laws. Information contained in these statements is based on current expectations and is subject to change, and actual results may differ materially from forward-looking statements. Some of the factors that could cause actual results to differ may be found in the company's annual reports on Form 10-K and quarterly reports on Form 10-Q filed by the company with the Securities and Exchange Commission. These documents are available on our website, www.abeonatherapeutics.com.
With that said, it is now my pleasure to introduce you to Dr. Joao Siffert. Joao, you have the floor.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Thank you, Sofia, and thank you all for joining us today for our first quarter business highlights, which reflect the continued development of our clinical and preclinical programs, as well as manufacturing quality operations.
I'd like to start with some key quarter events and then we'll turn the call over to Tim who will take you through the exciting advancements within our next-generation AIM vector platform. Earlier this year, we presented AIM data at several conferences highlighting the potential of this technology to treat patients with a variety of disorders and to evade pre-existing or neutralizing antibodies to naturally occurring AAV. We have grown this library now to over 100 novel capsids, some of which have specific tissue tropisms outside of our current pipeline targets and thus open the possibility of collaborating with external partners that might help accelerate and expand our ability to develop them into new treatments. Since our lastearnings call we also completed our CMC work for upcoming Phase 3 clinical trial in recessive dystrophic epidermolysis bullosa or RDEB. The FDA is completing the review of our work before we can proceed with the Phase 3 trial, which remains on track for mid 2019 start. Our dedicated cGMP suites at our Cleveland facility are currently in operation by an experienced trained staff, positioning us well to produce clinical product on time for a Phase 3 start.
We also remain focused on our efforts to identify screen and enroll patients for our clinical trials in MPS. As stated last quarter, we have stepped up our efforts to engage the broad network of healthcare professionals and communities involved in the care and support of children affected by lysosomal storage diseases and remain on track to activate additional study sites globally by the end of this year. This concerted effort has begun to bear fruit as announced via press release this morning. We have now completed dosing cohort 1 and treated the first patient in cohort 2 in the ongoing Phase 1 global clinical trial evaluating ABO-101. Our gene therapy for patients with MPS IIIB also known as Sanfilippo syndrome type B. MPS IIIB is a rare fatal lysosomal storage disease with no approved treatment that is characterized primarily by rapid neurodevelopmental decline.
The two-year open label study is currently designed to evaluate two doses of ABO-101. The dose for the first cohort is 2E13 and the second cohort does is 5E13. The main objectives of the study are to assess safety and neurodevelopmental milestones with multiple secondary endpoints including changes in CSF and urine heparan sulphate. Additional measurements include CSF and serum NAGLU enzyme activity in liver and brain volume by MRI. We expect to report interim data for the trial in the second half of this year. Last month, the FDA granted fast-track designation to ABO-101, recognizing the severity and importance of addressing this rare orphan disease.
Now, I'd like to provide an update on our progress within our other two clinical programs and share with you the important milestones we're working toward in the balance of this year. As last presented at WORLDSymposium in February, the ongoing Phase 1, 2 clinical trial in MPS IIIA also known as Sanfilippo syndrome type A has enrolled 14 patients to date. The data from this trial demonstrate that ABO-102 has been well tolerated with no serious drug-related adverse events to date. I have also observed substantial and durable improvements in biomarkers, including dose-related reductions in cerebral spinal fluid heparan sulfate levels as well as reduction in liver volume in all treated patients. These biochemical and biophysical improvements were observed within four weeks post dosing and have persisted to date with two plus years of follow-up.
In addition, investigators observed encouraging neurocognitive signals in younger, higher-functioning patients enrolled in the higher dose cohort 3. We believe we're on track to assess the benefits of ABO-102 and plan to provide data updates from this trial in the second half of 2019, a recruitment initiative that also provide a continuous screening activity for this study.
Finally, as mentioned earlier, our lead clinical program in RDEB with EB-101 is planned to enter Phase 3 midyear. RDEB is a rare genetic skin disorder caused by mutations, which result in lack of functional collagen VII, the main component of the anchoring fibrils that attach the dermis to the epidermis. RDEB patients have extremely fragile skin that blisters and tears, resulting in large open wounds, some of which remain open for years. RDEB wounds are painfully debilitating and patients currently have no available effective treatment options, relying only on palliative treatments such as wound care to prevent infection and pain management for relief.
EB-101 is the next vivo gene-corrected autologous cell therapy designed to enable normal type VII collagen expression in wound healing in patients with RDEB. The gene-corrected keratinocytes are transplanted onto open wounds and have been shown to produce durable healing. The VITAL Phase 3 study will be a multi-center, randomized clinical trial assessing 10 RDEB patients to 15 RDEB patients treated with EB-101. The primary outcome measure of the study will be the proportion of patients' wounds with greater than 50% healing at three months compared with untreated wounds sites on the same patients. Additional endpoints will include the patient's global assessment of the wound changed from baseline, as well as patient reported changes in pain in itch from baseline.
The design of the Phase 3 study is similar to the completed Phase 1/2 trial. Data from the Phase 1/2 trial recently presented at the Society for Investigative Dermatology Conference shows sustainable wound healing for three years in addition to positive patient reported outcomes, such as reduction in pain and itch. Efficacy of EB-101 including collagen VII expression and reconstitution of anchoring fibrils was observed as early as one month post engraftment of treated wounds and remained functional up to the observation period of three years. To date, EB-101 exhibited a favorable safety profile with no product-related SAEs.
In addition to the start of the Phase 3 development, the upcoming EB-101 clinical trial stands to validate a successful completion of an 18-month long effort that brought to life our in-house GMP-compliant facility in Cleveland. Our investment in CMC preparations in diligence also positions us well toward an eventual BLA filing, commercialization and will ultimately help us provide treatment to patients suffering from RDEB.
R&D manufacturing, regulatory and quality teams have also worked diligently toward expanding our clinical stage pipeline. R&D has been submitted for ABO-202 in CLN1 disease, also known as infantile Batten disease. IND-enabling data shared at WORLDsymposium and ASGCT showed a favorable safety profile for ABO-202 with no significant toxicities seen in preclinical dose escalation studies.
Other IND-enabling studies also demonstrated normalized survival and improvement of motor and cognitive function in affected mice treated with ABO-202. Data collected to date suggest that combined dosing with intravenous and intrathecal administrations may enhance the therapeutic potential of ABO-202. As with other neurodegenerative diseases, our preclinical studies also showed a dose-related increase in efficacy and importantly a substantially higher survival of animals treated during earlier stages of disease.
Preclinical development of ABO-201 are AAV based program that targets CLN3 or Juvenile Batten disease continues to advance. We will provide an update on the program later this year.
I want to take a moment to thank all of our hard work of Abeona employees as well as of expert collaborators, and most of all thank the patients and their families who placed their trust in us.
With that, I'll pass the call over to Tim, who will take you through the exciting advancements within our next-generation AIM vector platform. Tim?
Timothy J. Miller -- President & Chief Scientific Officer
Thank you, Joao. In the first quarter and the month thereafter, we unveiled exciting progress at three separate events on programs utilizing our novel AIM vector platform. This proprietary technology continues to demonstrate how novel AAV capsids that have been selected to target specific body tissues with high efficiency are being developed by Abeona to potentially address Pompe and Fabry diseases, cystic fibrosis, muscle diseases as well as multiple eye disorders.
At the annual WORLDsymposium in February, we presented data demonstrating how AIM-based capsids delivered novel transgenes and demonstrated proof of concept data in animals for Fabry and Pompe diseases. While current enzyme replacement therapy significantly reduces the mortality of infantile Pompe patients, it fails to completely ameliorate all symptoms, primarily due to its inability to inefficiently enter the CNS and due to the immune responses to the GAA protein.
Notably, additional data have now demonstrated that AAV204 (ph) in GAA delivered intravenously identified multiple viable transgene cassettes that produced significant levels of active GAA protein in cells and animals. In multiple disease models and animal species, our novel AIM AAV capsids have demonstrated broad tissue tropism when compared to existing natural AAV capsids. The AIM capsid also performed better than existing natural serotypes that are transducing the brain, spinal cord and eye in rodents and primates.
Taken together, these data leave us strongly encouraged about the therapeutic potential of the AIM AAV vector platform in multiple disease targets. More recently, in April, we presented data at the American Society of Gene & Cell Therapy Annual Meeting in Washington DC for ABO-401, our novel gene therapy for Cystic Fibrosis. Some key highlights from the data showed that our novel AIM AAV vector with the CFTR mini gene can address all CF mutations and that it efficiently targets lung cells. There, we demonstrated that ABO-401 can correct the underlying CF chloride channel deficit regardless of underlying mutations of the CF transmembrane conductance regulators in CF mice and in human CF patient cells. Importantly, ABO-401 can correct the defect of the most common CF mutation, delta-F508, which accounts for greater than 60% of the CF population. This is an important differentiator as this could enable treatment for CF patients that may be non responsive to current CF modulating drugs or those that have mutations or refractory to currently available CF drugs.
ABO-401 has a regulatable human mini-CFTR gene that is efficiently packaged into AAV204, one of our next-generation AIM library capsids. In this and other preclinical studies, ABO-401 restored CFTR expression and chloride conductance in airway epithelia, the main cells of the lung that contribute to CF pathology in humans.
Immunostaining has demonstrated that ABO-401 is able to transduction express CFTR in basal cells from the human airway epithelia, increasing our confidence in using AIM vector as a delivery tool for gene editing as well as gene replacement strategies. ABO-401 was also shown to transduce human CF nasal and bronchial epithelial cells, with CFTR-specific change in short-circuit current that was comparable or superior to existing modulator therapy in these same cells. Robust expression of AAV204 in the lungs of CF mice was observed and demonstrated that the AAV204 capsid was equally or more efficient at delivering gene expression cassettes to the lung compared to other naturally occurring AAV capsids.
Further, the data demonstrated that ABO-401 restored CFTR-specific nasal potential difference in CF mice, and that the ABO-401 gene expression cassette makes a fully processed CFTR. In May, we presented data at the Association for Research in Vision and Ophthalmology Annual Meeting in Vancouver, demonstrating the AIM platforms broad therapeutic potential in potentially treating retinal diseases. The presented data showed that intravitreal administration of the AAV204 capsid to non-human primate eyes led to robust transgene expression in the inner and outer retina as well as intense expression in the fovea 25 days post-administration. AAV204 also transduced photoreceptor cells in retinal explants and transduced the outer retina. These data support the potential use of intravitreal administration to deliver gene therapy and gene editing strategy in in-patient and out-patient setting for a wide range of inherited and acquired retinal diseases. 80% of eye diseases affect the photoreceptors in the retina, highlighting the importance of cellular targeting and how AAV can be an efficient tool in gene delivery. An important consideration is route of administration. And we have shown data in rodents and non-human primates that we can utilize different AIM capsids to target the photoreceptors and retinal pigmented epithelium using either subretinal or intravitreal injections. The AIM capsids increased our potential for targeting multiple eye disorders through delivery of therapeutic genes or employing the machinery to enable gene editing.
Lastly, we have now demonstrated in vitro that select AIM capsids can evade neutralizing antibodies against naturally occurring AAV capsids that may be present in some patients. This finding is significant as it may allow AIM-based AAV gene therapy for patients that may have previously been excluded owing to existing anti-AAV antibodies and also may enable retreatment of patients who previously received AAV gene therapy with other serotypes. We look forward to discussing these and additional AIM programs in the future.
I will now turn the call over to Christine who will review our financials. Christine?
Christine Silverstein -- Chief Financial Officer
Thank you Tim. I would like to remind everyone that we have recently filed a 10-Q, where you can kind all the specific information on our financial results. But in summary, our cash, cash equivalents and marketable securities as of March 31, 2019, were $68.3 million compared to $85 million as of December 31, 2018. Net cash used in operating activities for the three months ended March 31, 2019, was $15.1 million as compared to $4.1 million in the same period of 2018, an increase in cash outflows of $11 million.
R&D expenses for the three months ended March 31, 2019, were $11.7 million compared to $8.2 million in the same period of 2018. The increase in research and development expense was primarily attributable to increased R&D headcount related to facility costs and internal manufacturing costs. General and administrative expenses for the three months ended March 31, 2019, were $5.7 million compared to $2.9 million in the same period of 2018. The increase in G&A expenses was primarily due to increased headcount and related facility costs. Net loss was $0.39 per share for the first quarter of 2019 compared to $0.22 per share in the same period of 2018. That's the summary financials.
With respect to upcoming Investor Relations and scientific conferences, I'd like to highlight that we'll be participating in the following events. On May 22, we'll be participating in the RBC Healthcare Conference; and on June 5, we will be at the Jefferies Healthcare Conference, both taking place in New York City. Later this summer, on July 30, we will be participating in the Wells Fargo Biotech Corporate Access Day in Boston. We will update you on all those planned presentations as we get closer to the events.
And with that, I would like to turn it back over to Joao.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Thank you, Christine. In summary, we achieved important interim milestones in the first quarter that positioned Abeona well to deliver long-term growth and value for our shareholders and turn hope into reality for our patients. Thank you. I will now turn over to the operator to open up for questions. Operator?
Questions and Answers:
Operator
Thank you, Doctor. (Operator Instructions) And we'll take our first question today from Maurice Raycroft with Jefferies. Please go ahead, sir. Your line is open.
David Steinberg -- Jefferies & Company, Inc. -- Analyst
Hi. This is David for Maury. Thank you for taking my questions. My first question is regarding ABO-101 program for MPS IIIB. Can you talk about the individual age of the patients they have treated so far, and are you aimed to recruit quota patients below age of two?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Sorry. Could you ask the second -- this is Joao. Hi, thanks for your questions. So, could you just repeat the last part of your question regarding the --?
David Steinberg -- Jefferies & Company, Inc. -- Analyst
Yes. So, you mentioned before that you are trying to enroll certain number of patients below the age of two. So, I am just wondering can you talk about the sort of quota you are trying to aim for, for the number of patients below age of two?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Okay. So, just a clarification, so thanks for your question again. Clarification, no, we are not restricting to below age of two. We are allowed to enroll from six months and up, and the enrollment criteria for the trial is based on cognitive functioning. So, participants need to have at least 60% of the normalized cognitive function for the age, which if you back into the age, it will be up to patients approximately 3.5 years. So it's not restricted by age, but rather by cognitive function, and of course, the patients that were enrolled or eligible for this criterion.
David Steinberg -- Jefferies & Company, Inc. -- Analyst
Okay. That's helpful. So, just to clarify, you are saying that -- can you disclose the number of patients who are under, you know, in terms of the age for the update in the second half for the Type 3 patients?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
I don't have the age handy, but Dave, actually all met enrollment criteria.
David Steinberg -- Jefferies & Company, Inc. -- Analyst
Okay, good. So then just kind of a follow-up with the ABO-102, can you comment on the screening and the enrollment rates at this time? And where are you finding these new patients? And are you doing anything different with finding these patients at this time?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
So, we continue to screen actively and we have in fact screened several additional patients, but some of the patients had no mutations which make such that there's a risk for developing antibodies against the transgene protein. So, these are not eligible for the trial.
David Steinberg -- Jefferies & Company, Inc. -- Analyst
Okay, thank you. Thank you for your time.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Thank you.
Operator
Our next question will come from Liav Abraham with Citi. Go ahead sir, your line is open.
Liav Abraham -- Citi -- Analyst
Good morning. Two quick questions for me. Firstly, regarding ABO-102, my understanding is that you are meeting with FDA regarding this clinical program in the second half of this year. Please correct me if I am wrong, and if I am not, what can we -- what do you hope to get from this meeting and what can we expect to hear from you? And then secondly, on your EB-101 program, given that this -- the pivotal trial is about to commence pretty soon, could you comment on progress that you are making on the commercial front, if any, at this stage to prepare for the launch of the product and any early discussions with payers that you have had so far? Thank you.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Thank you, Liav. So, two answers. So, the first one, we have not disclosed plans to meet with the agency. And generally speaking, we don't provide guidance on this. This is obviously a program where we have designations, including RMAT designation that allows to have ongoing discussions with the agency. So as the data for follow-up of the patients become known to us as patients come back for their scheduled follow-up, we will obviously be analyzing these data points, and at some point, reengage the agency when we have some more critical mass in terms of the data set. We have not planned a specific date or time for this. We do expect to update the Street and of course, internally and also our advisors when we have sufficient data in the second half of this year and this much we have announced. On the EB-101, the RDEB program, you asked whether -- so first of all, obviously we have not yet started Phase 3, we continue to be on track for a midyear 2019 start. And as you can imagine, Phase 3 starts especially in a program that we hope we will enroll in a reasonable timeframe and also given all the designations in the unmet need that the progress can actually accelerate as we move from Phase 3 in terms of commercial launch preparations. So, we have been very active in preparatory work, but we have not yet in terms of the commercial landscape assessment of the addressable patient population and on some assumptions of the commercial opportunity. We have not yet engaged formally with payors at this point, but we will as soon as we are in Phase 3.
Liav Abraham -- Citi -- Analyst
Thanks for the feedback.
Operator
Thank you, Ms. Abraham. And we'll take our next question from Raghuram Selvaraju with H.C. Wainwright. Your line is open. Please go ahead.
Edward Marks -- H.C. Wainwright & Co., LLC -- Analyst
Good morning. This is Edward Marks on for Ram. Thanks for taking the questions. You just mentioned enrollment for the EB-101 Phase 3. I am just wondering if you could provide a little more clarity on the timeline that you are expecting for full enrollment? And then looking at little bit into the future, what long-term clinical follow-ups might be necessary to support that regulatory approval for EB-101 following the Phase 3?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Okay. Thank you for your question. So, the plan for enrollment in the Phase 3 trial is anywhere from 10 patients to 15 patients, and this is based on the number of wounds that patients have in general. So, the estimate is that we will need about 35 wounds to be assessed as part of the clinical trial, so divided into 10 patients to 15 patients depending on the area involved in these patients. Many of these patients have already been pre-screened at Stanford. So, we are poised to start enrolling as soon as we are allowed to. And we have not provided a formal guidance as to the rate of enrollment, but we hope that given the fact that these patients are pre-identified or most of them are pre-identified that we should be able to have an expedition enrollment rate, and of course, we will provide updates as we make progress. So -- of course, there's a range here, but we expect to complete enrollment in 2020 and hopefully having results also in 2020.
As for the second question, in long term as we announced, we just recently presented follow-up data for the initial cohort of patients treated under the Phase 1/2 trial at Stanford. This follow-up now is a median of three years, so would that two patients actually out to five years with durable wound healing. So, this is quite remarkable to be at this stage of development and having such long-term follow-up. The commitment in terms of the Phase 3 trial is that we will have the primary endpoint assessed to three months and then there's an additional three months of follow-up to a total of six months. And that's to both examined wound healing durability as well as of course is safety. But as you know for gene therapy, we continue to follow these patients long term, although this is not necessarily gating for the BLA submission.
Edward Marks -- H.C. Wainwright & Co., LLC -- Analyst
Okay. Thank you. And following up on that commercial question previously, just wondered what additional work might need to be done to produce manufacturing readiness for a commercial stage process, and will all of that be done at the Cleveland facility or will you be expanding that manufacturing elsewhere?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
We haven't made a final decision on the site, but we are prepared to move from -- so just to back track a little bit, we have first of all made a tremendous amount of investment and progress in the clinical manufacturing. And that has brought us very close to commercial readiness. Obviously, we are not ready yet until we get a drug approved, but it has really equipped Abeona as a company aside from the geographic localization of the manufacturing. Two, to progress into commercial manufacturing with just few additions. The actual manufacturing process itself will not change substantially from Phase 3 to commercial, as you know, because we need to be the commercial light product, have been tested in Phase 3. We will announce in terms of the plans, we do have -- currently we have facility under lease in Cleveland that would allow us to expand the manufacturing footprint for EB-101. Whether or not this will include commercial in Cleveland or not, we haven't disclosed yet.
Edward Marks -- H.C. Wainwright & Co., LLC -- Analyst
Okay. Thank you. And then just considering the news that just came out this morning on Sanfilippo, just two more quick questions on cognitive function. Just wondering what the best outcome measure would be for the really young Sanfilippo syndrome patients? And how might cognitive function impact be achieved using some of the systemically administered gene therapy similar to some of that using CNS-administered gene therapy such as the intracranial delivery?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Okay, yes. So these are two separate questions. First, the neurodevelopmental scales that are used for these trials include scales that have been widely validated. One is the Mullen scale and the other one is the Bayley developmental scale. Both of these are used in this trial and we have normative data based on the natural history of studies that were previously conducted that use both scales. Ultimately, these also can be converted into, we will call age-equivalent cognition, which essentially is comparing the raw results of these scales with the normative data from the general population of infants and toddlers that get tested as part of the validation process. So, I think we have a good grasp on that and as much as you can do a good devaluation of a toddler and for those of you who are parents know, it's not so easy to do that. But these are obviously experienced under psychologist and study centers that do this routinely. So in that sense, I think we have recovered here and I think that's pretty much the standard for these trials. As for the -- can you repeat your next question?
Edward Marks -- H.C. Wainwright & Co., LLC -- Analyst
Yes. Just wondering how -- I'm sorry?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Yes. I remembered it's just on the biodistribution, yes. So although it may appear intuitive to deliver intracranially or in the cerebral spinal fluid as a means to deliver to the brain parenchyma, it turns out and I think there's accumulating evidence including our own, from our own studies both in MPS as well as in CLN Batten disease, that intravenous delivery actually provides a substantially higher biodistribution to the brain, to the CNS, to actual brain parenchyma. So, if you look at the actual empirical evidence that is available to us to-date, the most compelling one is the data from AveXis where the SMA children receive intravenous AAV9-based vector therapy for what it is a CNS disorder. So, where there's a lot of sort of recent publications on this and the fact of the matter is that to-date the most advanced and validated outcome with actual demonstrable clinical outcome is for CNS disorders through intravenous delivery.
Edward Marks -- H.C. Wainwright & Co., LLC -- Analyst
Okay, excellent. Well, thank you for all those details and I appreciate you taking the questions.
Operator
Our next question today comes from the line of Edward Nash with SunTrust Robinson Humphrey. Please go ahead. Your line is open.
Fang-Ke Huang -- SunTrust Robinson Humphrey -- Analyst
Hi, good morning. This is Fang-Ke on for Edward. Congratulations on the progress. And first question is, so Joao, you mentioned in the earlier remarks saying that you are considering collaborating externally with your AIM platform. I just want to -- can you help us understand in terms of when you are deciding whether it's external or internal, what other focus are going to be your therapeutic area you want decide to develop internally and what other considerations potentially in the future you are going to think about external collaborations?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Thanks. Yes, so it's a compounded question. So I will try to answer as much as I can at this point. So, as you know and we have announced and Tim has nicely recapped, the team at Abeona and Tim's team have been quite prolific in advancing the AIM platform across therapeutic areas because essentially these capsids have shown the potential for targeting different tissues, from brain to the retina, to the lungs and other areas, including the liver as well and kidney potentially. So that opens up to a lot of possibilities. We have announced our core pipeline. As you know, this is public information, but we have many other projects that we have for which we present a scientific data that are not currently formal, not development projects. So, we view partnerships as a tremendous opportunity for Abeona to both add resources to programs that either not prioritize or that could benefit from particular expertise and also accelerate both existing programs and programs that are currently not on the fast track in terms of developmental efforts. So, I think we are looking for partnerships that are win-win for both parties and I think ultimately could add a tremendous amount of value to this very promising platform.
Fang-Ke Huang -- SunTrust Robinson Humphrey -- Analyst
Great. That's very helpful. Just follow-up on the EB-101 program, so you mentioned your primary endpoint is going to be at three months and measuring the 50% wound healing, and I think a competitor proposing that they are going to measure the complete wound closure at three months as well. So, I just want to understand that when you are thinking about your primary endpoint versus one of your competitor's endpoint, what FDA have been saying, what they require, and then why have you decided on the 50%? Clearly, you have shown in your Phase 1/2 trial that a lot of patients actually have more than 70% wound healing like as far as five years. So just want to understand your rationale for choosing 50%. Thanks.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Yeah. Thank you. So I can't necessarily comment on the competitors, but I will talk a little bit about our endpoint and the rationale behind it. So, the data presented on the long-term follow-up and then also a publication and draft that will come out basically shows that greater than 50% wound healing in the large RDEB wounds, right. Keep in mind that we are talking about wounds that are greater than 20-centimeter square, sometimes much larger than that. In fact, 40 centimeters, sometimes 60-centimeter square. The wound healing greater than 50% is very clearly associated with improvement in patient reported outcomes, namely pain, reduction and reduction in itch as well as their global impression of improvement. So, we know that this 50% threshold is clinically meaningful based on our own data. Obviously, we will measure wound healing as a percentage of the original wound. So, it's a continuous measurement even though the endpoint itself, the mechanics of the endpoint is the proportion of wounds that reach at least 50%, obviously would not planning to low ball it, and of course, to the extent that we replicate the data from the Phase 1/2, this percentage would be much higher. But keep in mind that these are large wounds, the skin surrounding -- even the product application, so the skin itself, the remaining skin around the wound is also not normal. So, what the concern here especially for larger wounds is that you may have near full healing, which we did actually report in several of these patients, but we don't want to be penalized if there's a small area that might not heal in the edges where small abrasion areas, because the skin's somewhat sensitive. So, that could throw the baby out with the bath water. So, we want to make sure that any substantial healing, which we believe to be greater than 50% is a clinically demonstrable threshold. And actually by the patients themselves, they have been very clearly articulating that any healing in a large wound is meaningful to them.
Just to remind everyone, the wounds, the selection of patients for the Phase 3 trials are patients such that they have chronic wounds and these are greater than six months in duration. Sometimes they have those open wounds for several years as well as wound sizes that are greater than 20 centimeters in area -- square centimeters in area. So, these wounds based on all the natural history data that's been published, tend not to heal, certainly not in three months and in most cases, not even in years. So in fact, one could argue that any healing of these wounds will be clinically meaningful and we're setting it up 50%. The experience too from the natural history studies is that smaller wounds, especially the very small wounds as some of the competitors are targeting, tend to heal spontaneously even without intervention. So, in very small wounds, it may be plausible to AIM at complete wound healing, which would be an expectation if we were to use EB-101 as well. But that's not what we are targeting in the clinical trial.
Fang-Ke Huang -- SunTrust Robinson Humphrey -- Analyst
Yes, that's really helpful. And then lastly, so in the news you put out this morning regarding the Sanfilippo B and you mentioned you started dosing the first patient in cohort 2. So is that just to confirm whether right now you have four patients enrolled in the trial, and three in cohort 1, and down one in cohort 2, is that right?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
No. We have not announced that, but we do actually have only two patients in cohort 1. We've been -- this is a joint decision between Abeona, of course our data safety monitoring board as well as the regulators based on the excellent safety of the first patient who is now one plus year for post dosing. So this is somewhat unusual that we have such long sort of follow-up for the first patient and also the excellent outcome so far in terms of safety of the second patient enrolled earlier this year. So, with these two patients, we felt that the safety of this program also combined with the safety on the MPS IIIA program which uses the same capsid as well as the increasing data, safety data collectively on use of AAV9-based vectors that we have, we are in good grounds to propose a faster dose escalation, which I think ultimately stands to benefit progress of this trial, but ultimately provide these children with their best chance for a clinical benefit. So, we approached the DSMB who reviewed very carefully all that safety data and also approached the regulators who supported this transition. So, I think this, in the end, is a testament to the safety of the program of both the IIIB program and the IIIA program.
Fang-Ke Huang -- SunTrust Robinson Humphrey -- Analyst
Great. Thank you so much for taking my question.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Thank you.
Operator
Our next question comes from Kennen MacKay with RBC Capital. Your line is open, please go ahead.
Vikram Kaushik -- RBC Capital Markets, LLC -- Analyst
Hi guys, this is Vikram on for Kennen. Thanks for taking our questions. Couple for us, from the morning -- your announcement on ABO-101 in MPS IIIB, could you remind us what type of data shall be expect second half of 2019,And what specific magnitude on the new development cell scale if you are referring to, Mullen scale, shall we expect or anything you can share on that would be really helpful?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
We haven't provided any guidance in terms of the magnitude of cognitive. Obviously, the goal here is both to treat the underlying pathology that is the enzyme that is defective. And for that, we can measure the biomarkers as we have done for MPS IIIA. So, we look at CSF and urine heparan sulfate, which is the substrate of the enzyme. So, the expectation is that we will continue to bore the accumulation of GAGs systemically including the CSF. And that was the case for the first patient treated in this trial. We will continue to measure cognition. Obviously, cognition is somewhat of more a variable outcome and more meaningful results will come at six months in a year. So we will provide data that we have, but obviously patients dose just now won't have a very long-term follow-up for cognition.
Vikram Kaushik -- RBC Capital Markets, LLC -- Analyst
Thanks for the color. That's really helpful. If I can squeeze in one follow-up on your licensing agreement, how should we be modeling that in our model with REGENXBIO? Where would the $10 million payment that is expected to go out this year, shall we think about or shall we be thinking about that?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Yes. So, that's basically the anniversary of the agreement. And so, we will pay one more $10 million in the fourth quarter, I think of this year.
Vikram Kaushik -- RBC Capital Markets, LLC -- Analyst
Thank you so much. Really helpful.
Operator
We will take our next question from the Difei Yang with Mizuho. Please go ahead. Your line is open.
Alexander Lim -- Mizuho Securities -- Analyst
Hey, good morning guys. This is Alex on for Difei. Thank you for taking the questions. Just on EB-101 and the FDA review, could you comment on what are the gating factors for the review to conclude?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
There are not specific gating factors, it is just -- because we completed the work internal manufacturing work, this is still being reviewed by the agency, this is just the totality of all the data, it's mostly quality assays.
Alexander Lim -- Mizuho Securities -- Analyst
Okay. Thank you. And then you mentioned a data update for the MPS IIIA program second half of 2019, maybe you could just comment on what we should be expecting there? Thank you.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
We are expecting -- so these patients who have already been enrolled come back approximately every six months for follow-ups. So, we will provide similar types of data sets including biomarkers and cognitive data from the patients already enrolled.
Alexander Lim -- Mizuho Securities -- Analyst
Okay. Thank you.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Sure.
Operator
Our next question will come from Elemer Piros with Cantor Fitzgerald.
Elemer Piros -- Cantor Fitzgerald -- Analyst
Yes. Good morning, everyone. Joao, just following up on this last question, so if you plan to provide an update on the IIIA program in the second half, based on the enrollment pattern, they might have more than one year or more data for all 14 patients. Would that be a correct assumption?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
I'm trying to think off the top of my mind. If you probably look into the data, I am not sure if all the patients, but certainly for the large proportion of the patients. Clearly, cohort 1 and 2 are well past one year for sure, at your past two years for cohort 1.
Elemer Piros -- Cantor Fitzgerald -- Analyst
Yes. I mean just, based on your disclosure last November, you had 14 patients by then. And now how many more patients in this trial do you expect to enroll?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Will depend on how many more we need to basically corroborate the findings we have now. So, the patients, so first -- sorry missed pause here. The trial is still open for enrollment. It was still actively screening, have screened several more patients and as mentioned earlier, part of the screening process, we are excluding patients. We have historically excluded patients who have no mutations or mutations that will lead to no protein production. So, the enrollment is open. So, we haven't made a final determination and a lot of it will depend on next steps once we have analyzed the full data set that we are disclosing later this year. I don't know if that makes sense, but it's largely data driven, you know, how much many more patients will enroll.
Elemer Piros -- Cantor Fitzgerald -- Analyst
And I'm presuming the same would be the answer to the IIIB program, which you set your plan to roll up to 9. I don't know if that number has changed or will it change based on what you will see in this 8 or 9 -- first 8 or 9 patients to extend that into your program.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Yes. We may adjust if we need to. For now, 9 patients seems a good estimate, but obviously as the program progresses and we get additional data, and as you know, we may adjust this, but for now that's what we're announcing the plans are. Of course, this is a combination of safety data, which is critical obviously for patients as well as efficacy data. In terms of safety, the IIIA and also to some extent to IIIB although much fewer patients, but given the long-term follow-up, we are pretty confident that we have a fairly thus strong safety data set so far. So I think at least that aspect of the program is well served.
Elemer Piros -- Cantor Fitzgerald -- Analyst
And I don't mean to ask you to comment on a competitor as a projection, but in IIIA, company X have enrolled two patients and project to enroll up to 20 patients during the next 12 months. Just, I mean, you have probably the most experience in the field in terms of finding eligible patients. How ambitious in general to enroll 20 IIIA patients in 12 months time? Again specific to the competitive or just in general, your experience?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Yes. It's not easy. These are above -- although it depends there, I think the competitor has similar entry criteria. So especially by limiting the subset of the population with a higher cognitive functioning, it will require a very broad concerted effort globally not just U.S. here.
Elemer Piros -- Cantor Fitzgerald -- Analyst
I see. Turning on to the EB program, so the CMC package is complete. Now, your interactions with the FDA, would it entail a facility inspection as well?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
No, not planned. No. They had a DMPQ assessment a while back for the GMP qualification of the facility. But there was no inspection planned although the agency of course has the right to inspect at any time.
Elemer Piros -- Cantor Fitzgerald -- Analyst
And you feel that the protocol is actually locked down? What do you need to have a final determination?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
We will announce when we have all the final dot the i's and cross the t's.
Elemer Piros -- Cantor Fitzgerald -- Analyst
Okay. Thank you. And one last question, do you plan to engage additional centers, besides Stanford for the Phase 3?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Yes. So we have actually announced this previously that this is a multi-center trial. So, Stanford obviously will continue to be the lead center because they have the most experience and they are fully prepared to enroll the first patient. The question is what are the centers could come on online and how fast? And we have a couple of candidates centers that we have been in discussions with in preparation. So, we expect those will be announced later this year.
Elemer Piros -- Cantor Fitzgerald -- Analyst
Okay. Thank you so much, Joao.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Yes.
Operator
And that was the final question from our audience today. Dr. Siffert, I would like to turn the conference back over to you for any additional or closing remarks, sir.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Yes. Thank you very much. And thank you all for joining in for our call today. We are very excited about the prospects for Abeona later this year. We hope to provide new announcements in the coming months. Also wanted to take this opportunity to thank, especially in light of the announcement on the MPS IIIB trial, but also progress across the board and our clinical programs to specifically acknowledge the two centers that have been working very hard to get this trial moving, both Nationwide Children's Hospital led by Kevin Flanigan as the PI, and also the hospital in Spain, Hospital Clinico Universitario de Santiago de Compostela, for doctors Maria Couce and Maria Lopez Castro, so just want to acknowledge them. They have been key advisors to Abeona and put a lot of efforts in this program. And we look forward to also announcing new sites (inaudible) for this program in the near future. And thank you everyone.
Operator
Ladies and gentlemen, this does conclude today's teleconference. And we do thank you all for your participation. You may now disconnect your lines and we hope that you enjoy the rest of your day.
Duration: 51 minutes
Call participants:
Sofia Warner -- Senior Director, Investor Relations
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Timothy J. Miller -- President & Chief Scientific Officer
Christine Silverstein -- Chief Financial Officer
David Steinberg -- Jefferies & Company, Inc. -- Analyst
Liav Abraham -- Citi -- Analyst
Edward Marks -- H.C. Wainwright & Co., LLC -- Analyst
Fang-Ke Huang -- SunTrust Robinson Humphrey -- Analyst
Vikram Kaushik -- RBC Capital Markets, LLC -- Analyst
Alexander Lim -- Mizuho Securities -- Analyst
Elemer Piros -- Cantor Fitzgerald -- Analyst
More ABEO analysis
All earnings call transcripts
10 stocks we like better than Abeona Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abeona Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 1, 2019
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc (NASDAQ: ABEO) Q1 2019 Earnings Call May 14, 2019, 10:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, ladies and gentlemen, and welcome to the Abeona Therapeutics Inc. First Quarter 2019 Earnings and Business Update Conference Call. These documents are available on our website, www.abeonatherapeutics.com. | This proprietary technology continues to demonstrate how novel AAV capsids that have been selected to target specific body tissues with high efficiency are being developed by Abeona to potentially address Pompe and Fabry diseases, cystic fibrosis, muscle diseases as well as multiple eye disorders. Duration: 51 minutes Call participants: Sofia Warner -- Senior Director, Investor Relations Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer Timothy J. Miller -- President & Chief Scientific Officer Christine Silverstein -- Chief Financial Officer David Steinberg -- Jefferies & Company, Inc. -- Analyst Liav Abraham -- Citi -- Analyst Edward Marks -- H.C. Wainwright & Co., LLC -- Analyst Fang-Ke Huang -- SunTrust Robinson Humphrey -- Analyst Vikram Kaushik -- RBC Capital Markets, LLC -- Analyst Alexander Lim -- Mizuho Securities -- Analyst Elemer Piros -- Cantor Fitzgerald -- Analyst More ABEO analysis All earnings call transcripts 10 stocks we like better than Abeona Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abeona Therapeutics Inc (NASDAQ: ABEO) Q1 2019 Earnings Call May 14, 2019, 10:00 a.m. | Duration: 51 minutes Call participants: Sofia Warner -- Senior Director, Investor Relations Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer Timothy J. Miller -- President & Chief Scientific Officer Christine Silverstein -- Chief Financial Officer David Steinberg -- Jefferies & Company, Inc. -- Analyst Liav Abraham -- Citi -- Analyst Edward Marks -- H.C. Wainwright & Co., LLC -- Analyst Fang-Ke Huang -- SunTrust Robinson Humphrey -- Analyst Vikram Kaushik -- RBC Capital Markets, LLC -- Analyst Alexander Lim -- Mizuho Securities -- Analyst Elemer Piros -- Cantor Fitzgerald -- Analyst More ABEO analysis All earnings call transcripts 10 stocks we like better than Abeona Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abeona Therapeutics Inc (NASDAQ: ABEO) Q1 2019 Earnings Call May 14, 2019, 10:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, ladies and gentlemen, and welcome to the Abeona Therapeutics Inc. First Quarter 2019 Earnings and Business Update Conference Call. | Duration: 51 minutes Call participants: Sofia Warner -- Senior Director, Investor Relations Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer Timothy J. Miller -- President & Chief Scientific Officer Christine Silverstein -- Chief Financial Officer David Steinberg -- Jefferies & Company, Inc. -- Analyst Liav Abraham -- Citi -- Analyst Edward Marks -- H.C. Wainwright & Co., LLC -- Analyst Fang-Ke Huang -- SunTrust Robinson Humphrey -- Analyst Vikram Kaushik -- RBC Capital Markets, LLC -- Analyst Alexander Lim -- Mizuho Securities -- Analyst Elemer Piros -- Cantor Fitzgerald -- Analyst More ABEO analysis All earnings call transcripts 10 stocks we like better than Abeona Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abeona Therapeutics Inc (NASDAQ: ABEO) Q1 2019 Earnings Call May 14, 2019, 10:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, ladies and gentlemen, and welcome to the Abeona Therapeutics Inc. First Quarter 2019 Earnings and Business Update Conference Call. |
28070.0 | 2019-04-11 00:00:00 UTC | Thursday 4/11 Insider Buying Report: TREC, ABEO | ABEO | https://www.nasdaq.com/articles/thursday-411-insider-buying-report-trec-abeo-2019-04-11 | nan | nan | As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys.
On Wednesday, Trecora Resources' CEO, Patrick D. Quarles, made a $63,446 purchase of TREC, buying 6,952 shares at a cost of $9.13 a piece. Trecora Resources is trading up about 0.3% on the day Thursday. This purchase marks the first one filed by Quarles in the past year.
And at Abeona Therapeutics, there was insider buying on Monday, by Director Stephen B. Howell who bought 4,000 shares for a cost of $7.77 each, for a trade totaling $31,080. This buy marks the first one filed by Howell in the past twelve months. Abeona Therapeutics is trading up about 3.6% on the day Thursday.
VIDEO: Thursday 4/11 Insider Buying Report: TREC, ABEO
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And at Abeona Therapeutics, there was insider buying on Monday, by Director Stephen B. Howell who bought 4,000 shares for a cost of $7.77 each, for a trade totaling $31,080. Abeona Therapeutics is trading up about 3.6% on the day Thursday. VIDEO: Thursday 4/11 Insider Buying Report: TREC, ABEO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And at Abeona Therapeutics, there was insider buying on Monday, by Director Stephen B. Howell who bought 4,000 shares for a cost of $7.77 each, for a trade totaling $31,080. VIDEO: Thursday 4/11 Insider Buying Report: TREC, ABEO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abeona Therapeutics is trading up about 3.6% on the day Thursday. | And at Abeona Therapeutics, there was insider buying on Monday, by Director Stephen B. Howell who bought 4,000 shares for a cost of $7.77 each, for a trade totaling $31,080. VIDEO: Thursday 4/11 Insider Buying Report: TREC, ABEO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abeona Therapeutics is trading up about 3.6% on the day Thursday. | And at Abeona Therapeutics, there was insider buying on Monday, by Director Stephen B. Howell who bought 4,000 shares for a cost of $7.77 each, for a trade totaling $31,080. Abeona Therapeutics is trading up about 3.6% on the day Thursday. VIDEO: Thursday 4/11 Insider Buying Report: TREC, ABEO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
28071.0 | 2019-04-11 00:00:00 UTC | Thursday 4/11 Insider Buying Report: TREC, ABEO | ABEO | https://www.nasdaq.com/articles/thursday-411-insider-buying-report-trec-abeo-2019-04-11-0 | nan | nan | As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy - they expect to make money. So let's look at two noteworthy recent insider buys.
On Wednesday, Trecora Resources' CEO, Patrick D. Quarles, made a $63,446 purchase of TREC, buying 6,952 shares at a cost of $9.13 a piece. Trecora Resources is trading up about 0.3% on the day Thursday. This purchase marks the first one filed by Quarles in the past year.
And at Abeona Therapeutics, there was insider buying on Monday, by Director Stephen B. Howell who bought 4,000 shares for a cost of $7.77 each, for a trade totaling $31,080. This buy marks the first one filed by Howell in the past twelve months. Abeona Therapeutics is trading up about 3.6% on the day Thursday.
VIDEO: Thursday 4/11 Insider Buying Report: TREC, ABEO
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And at Abeona Therapeutics, there was insider buying on Monday, by Director Stephen B. Howell who bought 4,000 shares for a cost of $7.77 each, for a trade totaling $31,080. Abeona Therapeutics is trading up about 3.6% on the day Thursday. VIDEO: Thursday 4/11 Insider Buying Report: TREC, ABEO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: Thursday 4/11 Insider Buying Report: TREC, ABEO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And at Abeona Therapeutics, there was insider buying on Monday, by Director Stephen B. Howell who bought 4,000 shares for a cost of $7.77 each, for a trade totaling $31,080. Abeona Therapeutics is trading up about 3.6% on the day Thursday. | And at Abeona Therapeutics, there was insider buying on Monday, by Director Stephen B. Howell who bought 4,000 shares for a cost of $7.77 each, for a trade totaling $31,080. VIDEO: Thursday 4/11 Insider Buying Report: TREC, ABEO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abeona Therapeutics is trading up about 3.6% on the day Thursday. | And at Abeona Therapeutics, there was insider buying on Monday, by Director Stephen B. Howell who bought 4,000 shares for a cost of $7.77 each, for a trade totaling $31,080. Abeona Therapeutics is trading up about 3.6% on the day Thursday. VIDEO: Thursday 4/11 Insider Buying Report: TREC, ABEO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
28072.0 | 2019-03-27 00:00:00 UTC | U.S. STOCKS ON THE MOVE-Homebuilders, Wellcare, Shoe Carnival, Avon, DropCar | ABEO | https://www.nasdaq.com/articles/us-stocks-move-homebuilders-wellcare-shoe-carnival-avon-dropcar-2019-03-27 | nan | nan | The Day Ahead newsletter:
The Morning News Call newsletter:
Wall Street's main indexes were lower on Wednesday, as a prolonged inversion in the U.S. treasury yield curve fanned worries of an economic slowdown.
At 13:21 ET, the Dow Jones Industrial Average was down 0.28 percent at 25,586.65. The S&P 500 was down 0.48 percent at 2,804.92 and the Nasdaq Composite was down 0.71 percent at 7,636.528.
The top three S&P 500 percentage gainers:
** Wellcare Health, up 10.1 pct
** Pultegroup Inc, up 5.1 pct
** Lennar, up 4.4 pct
The top three S&P 500 percentage losers:
** Centene Corp, down 6.9 pct
** Fortinet, down 4.2 pct
** Western Digital Corp, down 4 pct
The top three NYSE percentage gainers:
** CorMedix iNC, up 27.1 pct
** Navios Maritime, up 26.4 pct
** Drexn Reg Ber3x, up 25.7 pct
The top three NYSE percentage losers:
** At Home Group Inc, down 19.2 pct [nL3N21E2WZ
** Ra Medical Systems Inc, down 12.1 pct
** Avon Products Inc, down 10.3 pct
The top three Nasdaq percentage gainers:
** Reebonz Holding Ltd, up 173.3 pct
** Castor Maritime Inc, up 55.1 pct
** Navios Maritime Containers LP, up 50 pct
The top three Nasdaq percentage losers:
** Phunware Inc, down 46.7 pct
** Abeona Therapeutics Inc, down 30.2 pct
** DropCar Inc, down 28.3 pct
** Wellcare Health Plans Inc: up 10.1 pct
** Centene Corp: down 6.9 pct
** CVS Health Corp: down 3.1 pct
WellCare Health Plans: Surges on Centene deal
Street View: Centene shares drop after WellCare deal
CVS Health drops as Centene set to acquire WellCare
** Lennar Corp: up 4.4 pct
** Toll Brothers: up 2.5 pct
** D.R. Horton: up 2.7 pct
** PulteGroup: up 5.1 pct
** Cavco: up 0.8 pct
** LGI Homes: up 7.1 pct
Homebuilders hit near 7-month high as optimism builds
Lennar Corp sees improving housing market, shares now higher
** Cronos Group Inc: down 10.1 pct
Cronos Group: Drops after Canaccord Genuity says sell
** Skechers USA Inc: up 3.6 pct
Skechers gaining momentum, says Susquehanna, raises to "positive"
** CBL Properties: down 21.2 pct
CBL Properties: Hits record low after suspending dividend
** Shoe Carnival Inc: up 20.3 pct
Shoe Carnival: Jumps as strong Q4 sets co for FY19 beat
** At Home Group Inc: down 19.1 pct
At Home Group: Drops after Q4 profit miss, weak forecast
** Avon Products Inc: down 9.1 pct
Avon: Down as optimism around potential sale wears off
** DropCar Inc: down 28.3 pct
Dropcar: Sputters on deep-discounted direct stock offering
** Moleculin Biotech Inc: down 27.0 pct
Moleculin Biotech: Down after proposed public offering
** PagSeguro Digital Ltd: up 1.1 pct
PagSeguro Digital: JP Morgan sees TPV to remain solid; upgrades to 'overweight'
** Tesla Inc: up 2.3 pct
Tesla: Chairman Denholm says Musk uses Twitter "wisely"
** Ralph Lauren Corp: up 2.6 pct
Wells Fargo says Ralph Lauren 'rare standout', upgrades to 'outperform'
** Papa John's International Inc: up 1.0 pct premarket
Papa John's: Stifel says investor optimism outweighs fundamentals, upgrades
** Walgreens Boots Alliance Inc: down 0.2 pct
Cowen cuts PT, Q2 estimate on Walgreens as it faces issues similar to CVS
** Scotts Miracle-Gro Co: down 1.0 pct
Scotts Miracle-Gro Co: Raymond James downgrades; expects U.S. consumer sales to moderate
** Lannett Company Inc: up 4.9 pct
Lannett: Up as FDA approves co's generic version of stroke drug
** OneSpaWorld Holdings Ltd: up 3.5 pct
OneSpaWorld: "Even Orchids of Asia didn't generate this much FCF"
** Axsome Therapeutics Inc: up 4.8 pct
Axsome: FDA grants 'Breakthrough Therapy' label to depression drug
** Oil States International Inc: up 6.6 pct
Oil States International: Raymond James upgrades; says valuation, estimates support entry
** SecureWorks Corp: down 11.9 pct
SecureWorks: Gloomy forecast, revenue miss weigh on shares
** Square Inc: down 1.8 pct
Square: Up as Macquarie says "buy"
** Lumentum Holdings Inc: up 2.7 pct
Optical makers: Top analyst upgrades Lumentum to 'overweight', downgrades Acacia
** Navios Maritime Containers LP: up 50.0 pct
Navios Maritime Containers: Stock soars as JPM starts at "overweight"
** KeyW Holding Corp: up 1.7 pct
Seaport upgrades KeyW Holding to 'buy'
** Jazz Pharmaceuticals Plc: up 1.3 pct
Jazz Pharma: Gains after sleep disorder drug soothes Xyrem woes
** Merus NV: up 3.9 pct
** Seattle Genetics Inc: down 0.1 pct
** Immunomedics Inc: down 0.3 pct
** Xencor Inc: up 1.1 pct
An investor's shortlist for next Regeneron - Berenberg
** DowDuPont Inc: down 1.1 pct
DowDuPont: Drops on losing place in Dow Industrials
** Qualcomm Inc: down 1.8 pct
Qualcomm: JPM starts with 'neutral' on downside risk from Apple litigation
** Pfizer Inc: down 0.8 pct
Pfizer heart medicine tafamidis could snag early U.S. approval - BMO Capital
** Carmax Inc: up 2.9 pct
Carmax jumps to 10-week high, reports Fri
** Carbo Ceramics Inc: down 10.3 pct
Carbo Ceramics: Erases YTD gains as losing place in S&P 600 extends slide
** Syndax Pharmaceuticals Inc: up 17.0 pct
Syndax Pharma: Surges on $26.2 mln stock and warrant offering at premium
** Titan Machinery Inc: down 15.3 pct
Titan Machinery: Bleak outlook, surprise Q4 loss weigh
** ImmuCell Corp: down 13.7 pct
Immucell: Hits 16-month low as $9 mln stock deal prices
** Warrior Met Coal Inc: up 6.3 pct
Warrior Met Coal: Charges to 10-month high on buyback, div plans
** Altria Group Inc: down 0.7 pct
** Philip Morris International Inc: down 1.7 pct
Philip Morris, Altria hit by Imperial Brands' U.S. caution
** ChemoCentryx Inc: up 7.6 pct
ChemoCentryx Inc jumps to 6-mth high, B. Riley FBR raises PT
** Monster Beverage Corp: down 1.4 pct
Monster Beverage: UBS "Reign(s)" in expectations
** Gildan Activewear Inc: down 1.0 pct
Gildan Activewear falls on 2019, Q1 EPS outlook cut
** Nio Inc: up 1.7 pct
Tesla rival Nio stemming 5-day skid after China slashes EV subsidies
** iRhythm Technologies: down 13.9 pct
iRhythm Technologies: Drops on reported reimbursement cut for heart monitor
** Arcos Dorados Holdings: down 7.8 pct
Arcos Dorados Holdings down after earnings
The 11 major S&P 500 sectors:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 percentage gainers: ** Wellcare Health, up 10.1 pct ** Pultegroup Inc, up 5.1 pct ** Lennar, up 4.4 pct The top three S&P 500 percentage losers: ** Centene Corp, down 6.9 pct ** Fortinet, down 4.2 pct ** Western Digital Corp, down 4 pct The top three NYSE percentage gainers: ** CorMedix iNC, up 27.1 pct ** Navios Maritime, up 26.4 pct ** Drexn Reg Ber3x, up 25.7 pct The top three NYSE percentage losers: ** At Home Group Inc, down 19.2 pct [nL3N21E2WZ ** Ra Medical Systems Inc, down 12.1 pct ** Avon Products Inc, down 10.3 pct The top three Nasdaq percentage gainers: ** Reebonz Holding Ltd, up 173.3 pct ** Castor Maritime Inc, up 55.1 pct ** Navios Maritime Containers LP, up 50 pct The top three Nasdaq percentage losers: ** Phunware Inc, down 46.7 pct ** Abeona Therapeutics Inc, down 30.2 pct ** DropCar Inc, down 28.3 pct ** Wellcare Health Plans Inc: up 10.1 pct ** Centene Corp: down 6.9 pct ** CVS Health Corp: down 3.1 pct WellCare Health Plans: Surges on Centene deal Street View: Centene shares drop after WellCare deal CVS Health drops as Centene set to acquire WellCare ** Lennar Corp: up 4.4 pct ** Toll Brothers: up 2.5 pct ** D.R. The Day Ahead newsletter: The Morning News Call newsletter: Wall Street's main indexes were lower on Wednesday, as a prolonged inversion in the U.S. treasury yield curve fanned worries of an economic slowdown. At 13:21 ET, the Dow Jones Industrial Average was down 0.28 percent at 25,586.65. | The top three S&P 500 percentage gainers: ** Wellcare Health, up 10.1 pct ** Pultegroup Inc, up 5.1 pct ** Lennar, up 4.4 pct The top three S&P 500 percentage losers: ** Centene Corp, down 6.9 pct ** Fortinet, down 4.2 pct ** Western Digital Corp, down 4 pct The top three NYSE percentage gainers: ** CorMedix iNC, up 27.1 pct ** Navios Maritime, up 26.4 pct ** Drexn Reg Ber3x, up 25.7 pct The top three NYSE percentage losers: ** At Home Group Inc, down 19.2 pct [nL3N21E2WZ ** Ra Medical Systems Inc, down 12.1 pct ** Avon Products Inc, down 10.3 pct The top three Nasdaq percentage gainers: ** Reebonz Holding Ltd, up 173.3 pct ** Castor Maritime Inc, up 55.1 pct ** Navios Maritime Containers LP, up 50 pct The top three Nasdaq percentage losers: ** Phunware Inc, down 46.7 pct ** Abeona Therapeutics Inc, down 30.2 pct ** DropCar Inc, down 28.3 pct ** Wellcare Health Plans Inc: up 10.1 pct ** Centene Corp: down 6.9 pct ** CVS Health Corp: down 3.1 pct WellCare Health Plans: Surges on Centene deal Street View: Centene shares drop after WellCare deal CVS Health drops as Centene set to acquire WellCare ** Lennar Corp: up 4.4 pct ** Toll Brothers: up 2.5 pct ** D.R. The Day Ahead newsletter: The Morning News Call newsletter: Wall Street's main indexes were lower on Wednesday, as a prolonged inversion in the U.S. treasury yield curve fanned worries of an economic slowdown. Horton: up 2.7 pct ** PulteGroup: up 5.1 pct ** Cavco: up 0.8 pct ** LGI Homes: up 7.1 pct Homebuilders hit near 7-month high as optimism builds Lennar Corp sees improving housing market, shares now higher ** Cronos Group Inc: down 10.1 pct Cronos Group: Drops after Canaccord Genuity says sell ** Skechers USA Inc: up 3.6 pct Skechers gaining momentum, says Susquehanna, raises to "positive" ** CBL Properties: down 21.2 pct CBL Properties: Hits record low after suspending dividend ** Shoe Carnival Inc: up 20.3 pct Shoe Carnival: Jumps as strong Q4 sets co for FY19 beat ** At Home Group Inc: down 19.1 pct At Home Group: Drops after Q4 profit miss, weak forecast ** Avon Products Inc: down 9.1 pct Avon: Down as optimism around potential sale wears off ** DropCar Inc: down 28.3 pct Dropcar: Sputters on deep-discounted direct stock offering ** Moleculin Biotech Inc: down 27.0 pct Moleculin Biotech: Down after proposed public offering ** PagSeguro Digital Ltd: up 1.1 pct PagSeguro Digital: JP Morgan sees TPV to remain solid; upgrades to 'overweight' ** Tesla Inc: up 2.3 pct Tesla: Chairman Denholm says Musk uses Twitter "wisely" ** Ralph Lauren Corp: up 2.6 pct Wells Fargo says Ralph Lauren 'rare standout', upgrades to 'outperform' ** Papa John's International Inc: up 1.0 pct premarket Papa John's: Stifel says investor optimism outweighs fundamentals, upgrades ** Walgreens Boots Alliance Inc: down 0.2 pct Cowen cuts PT, Q2 estimate on Walgreens as it faces issues similar to CVS ** Scotts Miracle-Gro Co: down 1.0 pct Scotts Miracle-Gro Co: Raymond James downgrades; expects U.S. consumer sales to moderate ** Lannett Company Inc: up 4.9 pct Lannett: Up as FDA approves co's generic version of stroke drug ** OneSpaWorld Holdings Ltd: up 3.5 pct OneSpaWorld: "Even Orchids of Asia didn't generate this much FCF" ** Axsome Therapeutics Inc: up 4.8 pct Axsome: FDA grants 'Breakthrough Therapy' label to depression drug ** Oil States International Inc: up 6.6 pct Oil States International: Raymond James upgrades; says valuation, estimates support entry ** SecureWorks Corp: down 11.9 pct SecureWorks: Gloomy forecast, revenue miss weigh on shares ** Square Inc: down 1.8 pct Square: Up as Macquarie says "buy" ** Lumentum Holdings Inc: up 2.7 pct Optical makers: Top analyst upgrades Lumentum to 'overweight', downgrades Acacia ** Navios Maritime Containers LP: up 50.0 pct Navios Maritime Containers: Stock soars as JPM starts at "overweight" ** KeyW Holding Corp: up 1.7 pct Seaport upgrades KeyW Holding to 'buy' ** Jazz Pharmaceuticals Plc: up 1.3 pct Jazz Pharma: Gains after sleep disorder drug soothes Xyrem woes ** Merus NV: up 3.9 pct ** Seattle Genetics Inc: down 0.1 pct ** Immunomedics Inc: down 0.3 pct ** Xencor Inc: up 1.1 pct An investor's shortlist for next Regeneron - Berenberg ** DowDuPont Inc: down 1.1 pct DowDuPont: Drops on losing place in Dow Industrials ** Qualcomm Inc: down 1.8 pct Qualcomm: JPM starts with 'neutral' on downside risk from Apple litigation ** Pfizer Inc: down 0.8 pct Pfizer heart medicine tafamidis could snag early U.S. approval - BMO Capital ** Carmax Inc: up 2.9 pct Carmax jumps to 10-week high, reports Fri ** Carbo Ceramics Inc: down 10.3 pct Carbo Ceramics: Erases YTD gains as losing place in S&P 600 extends slide ** Syndax Pharmaceuticals Inc: up 17.0 pct Syndax Pharma: Surges on $26.2 mln stock and warrant offering at premium ** Titan Machinery Inc: down 15.3 pct Titan Machinery: Bleak outlook, surprise Q4 loss weigh ** ImmuCell Corp: down 13.7 pct Immucell: Hits 16-month low as $9 mln stock deal prices ** Warrior Met Coal Inc: up 6.3 pct Warrior Met Coal: Charges to 10-month high on buyback, div plans ** Altria Group Inc: down 0.7 pct ** Philip Morris International Inc: down 1.7 pct Philip Morris, Altria hit by Imperial Brands' U.S. caution ** ChemoCentryx Inc: up 7.6 pct ChemoCentryx Inc jumps to 6-mth high, B. Riley FBR raises PT ** Monster Beverage Corp: down 1.4 pct Monster Beverage: UBS "Reign(s)" in expectations ** Gildan Activewear Inc: down 1.0 pct Gildan Activewear falls on 2019, Q1 EPS outlook cut ** Nio Inc: up 1.7 pct Tesla rival Nio stemming 5-day skid after China slashes EV subsidies ** iRhythm Technologies: down 13.9 pct iRhythm Technologies: Drops on reported reimbursement cut for heart monitor ** Arcos Dorados Holdings: down 7.8 pct Arcos Dorados Holdings down after earnings The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 percentage gainers: ** Wellcare Health, up 10.1 pct ** Pultegroup Inc, up 5.1 pct ** Lennar, up 4.4 pct The top three S&P 500 percentage losers: ** Centene Corp, down 6.9 pct ** Fortinet, down 4.2 pct ** Western Digital Corp, down 4 pct The top three NYSE percentage gainers: ** CorMedix iNC, up 27.1 pct ** Navios Maritime, up 26.4 pct ** Drexn Reg Ber3x, up 25.7 pct The top three NYSE percentage losers: ** At Home Group Inc, down 19.2 pct [nL3N21E2WZ ** Ra Medical Systems Inc, down 12.1 pct ** Avon Products Inc, down 10.3 pct The top three Nasdaq percentage gainers: ** Reebonz Holding Ltd, up 173.3 pct ** Castor Maritime Inc, up 55.1 pct ** Navios Maritime Containers LP, up 50 pct The top three Nasdaq percentage losers: ** Phunware Inc, down 46.7 pct ** Abeona Therapeutics Inc, down 30.2 pct ** DropCar Inc, down 28.3 pct ** Wellcare Health Plans Inc: up 10.1 pct ** Centene Corp: down 6.9 pct ** CVS Health Corp: down 3.1 pct WellCare Health Plans: Surges on Centene deal Street View: Centene shares drop after WellCare deal CVS Health drops as Centene set to acquire WellCare ** Lennar Corp: up 4.4 pct ** Toll Brothers: up 2.5 pct ** D.R. The Day Ahead newsletter: The Morning News Call newsletter: Wall Street's main indexes were lower on Wednesday, as a prolonged inversion in the U.S. treasury yield curve fanned worries of an economic slowdown. Horton: up 2.7 pct ** PulteGroup: up 5.1 pct ** Cavco: up 0.8 pct ** LGI Homes: up 7.1 pct Homebuilders hit near 7-month high as optimism builds Lennar Corp sees improving housing market, shares now higher ** Cronos Group Inc: down 10.1 pct Cronos Group: Drops after Canaccord Genuity says sell ** Skechers USA Inc: up 3.6 pct Skechers gaining momentum, says Susquehanna, raises to "positive" ** CBL Properties: down 21.2 pct CBL Properties: Hits record low after suspending dividend ** Shoe Carnival Inc: up 20.3 pct Shoe Carnival: Jumps as strong Q4 sets co for FY19 beat ** At Home Group Inc: down 19.1 pct At Home Group: Drops after Q4 profit miss, weak forecast ** Avon Products Inc: down 9.1 pct Avon: Down as optimism around potential sale wears off ** DropCar Inc: down 28.3 pct Dropcar: Sputters on deep-discounted direct stock offering ** Moleculin Biotech Inc: down 27.0 pct Moleculin Biotech: Down after proposed public offering ** PagSeguro Digital Ltd: up 1.1 pct PagSeguro Digital: JP Morgan sees TPV to remain solid; upgrades to 'overweight' ** Tesla Inc: up 2.3 pct Tesla: Chairman Denholm says Musk uses Twitter "wisely" ** Ralph Lauren Corp: up 2.6 pct Wells Fargo says Ralph Lauren 'rare standout', upgrades to 'outperform' ** Papa John's International Inc: up 1.0 pct premarket Papa John's: Stifel says investor optimism outweighs fundamentals, upgrades ** Walgreens Boots Alliance Inc: down 0.2 pct Cowen cuts PT, Q2 estimate on Walgreens as it faces issues similar to CVS ** Scotts Miracle-Gro Co: down 1.0 pct Scotts Miracle-Gro Co: Raymond James downgrades; expects U.S. consumer sales to moderate ** Lannett Company Inc: up 4.9 pct Lannett: Up as FDA approves co's generic version of stroke drug ** OneSpaWorld Holdings Ltd: up 3.5 pct OneSpaWorld: "Even Orchids of Asia didn't generate this much FCF" ** Axsome Therapeutics Inc: up 4.8 pct Axsome: FDA grants 'Breakthrough Therapy' label to depression drug ** Oil States International Inc: up 6.6 pct Oil States International: Raymond James upgrades; says valuation, estimates support entry ** SecureWorks Corp: down 11.9 pct SecureWorks: Gloomy forecast, revenue miss weigh on shares ** Square Inc: down 1.8 pct Square: Up as Macquarie says "buy" ** Lumentum Holdings Inc: up 2.7 pct Optical makers: Top analyst upgrades Lumentum to 'overweight', downgrades Acacia ** Navios Maritime Containers LP: up 50.0 pct Navios Maritime Containers: Stock soars as JPM starts at "overweight" ** KeyW Holding Corp: up 1.7 pct Seaport upgrades KeyW Holding to 'buy' ** Jazz Pharmaceuticals Plc: up 1.3 pct Jazz Pharma: Gains after sleep disorder drug soothes Xyrem woes ** Merus NV: up 3.9 pct ** Seattle Genetics Inc: down 0.1 pct ** Immunomedics Inc: down 0.3 pct ** Xencor Inc: up 1.1 pct An investor's shortlist for next Regeneron - Berenberg ** DowDuPont Inc: down 1.1 pct DowDuPont: Drops on losing place in Dow Industrials ** Qualcomm Inc: down 1.8 pct Qualcomm: JPM starts with 'neutral' on downside risk from Apple litigation ** Pfizer Inc: down 0.8 pct Pfizer heart medicine tafamidis could snag early U.S. approval - BMO Capital ** Carmax Inc: up 2.9 pct Carmax jumps to 10-week high, reports Fri ** Carbo Ceramics Inc: down 10.3 pct Carbo Ceramics: Erases YTD gains as losing place in S&P 600 extends slide ** Syndax Pharmaceuticals Inc: up 17.0 pct Syndax Pharma: Surges on $26.2 mln stock and warrant offering at premium ** Titan Machinery Inc: down 15.3 pct Titan Machinery: Bleak outlook, surprise Q4 loss weigh ** ImmuCell Corp: down 13.7 pct Immucell: Hits 16-month low as $9 mln stock deal prices ** Warrior Met Coal Inc: up 6.3 pct Warrior Met Coal: Charges to 10-month high on buyback, div plans ** Altria Group Inc: down 0.7 pct ** Philip Morris International Inc: down 1.7 pct Philip Morris, Altria hit by Imperial Brands' U.S. caution ** ChemoCentryx Inc: up 7.6 pct ChemoCentryx Inc jumps to 6-mth high, B. Riley FBR raises PT ** Monster Beverage Corp: down 1.4 pct Monster Beverage: UBS "Reign(s)" in expectations ** Gildan Activewear Inc: down 1.0 pct Gildan Activewear falls on 2019, Q1 EPS outlook cut ** Nio Inc: up 1.7 pct Tesla rival Nio stemming 5-day skid after China slashes EV subsidies ** iRhythm Technologies: down 13.9 pct iRhythm Technologies: Drops on reported reimbursement cut for heart monitor ** Arcos Dorados Holdings: down 7.8 pct Arcos Dorados Holdings down after earnings The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 percentage gainers: ** Wellcare Health, up 10.1 pct ** Pultegroup Inc, up 5.1 pct ** Lennar, up 4.4 pct The top three S&P 500 percentage losers: ** Centene Corp, down 6.9 pct ** Fortinet, down 4.2 pct ** Western Digital Corp, down 4 pct The top three NYSE percentage gainers: ** CorMedix iNC, up 27.1 pct ** Navios Maritime, up 26.4 pct ** Drexn Reg Ber3x, up 25.7 pct The top three NYSE percentage losers: ** At Home Group Inc, down 19.2 pct [nL3N21E2WZ ** Ra Medical Systems Inc, down 12.1 pct ** Avon Products Inc, down 10.3 pct The top three Nasdaq percentage gainers: ** Reebonz Holding Ltd, up 173.3 pct ** Castor Maritime Inc, up 55.1 pct ** Navios Maritime Containers LP, up 50 pct The top three Nasdaq percentage losers: ** Phunware Inc, down 46.7 pct ** Abeona Therapeutics Inc, down 30.2 pct ** DropCar Inc, down 28.3 pct ** Wellcare Health Plans Inc: up 10.1 pct ** Centene Corp: down 6.9 pct ** CVS Health Corp: down 3.1 pct WellCare Health Plans: Surges on Centene deal Street View: Centene shares drop after WellCare deal CVS Health drops as Centene set to acquire WellCare ** Lennar Corp: up 4.4 pct ** Toll Brothers: up 2.5 pct ** D.R. The Day Ahead newsletter: The Morning News Call newsletter: Wall Street's main indexes were lower on Wednesday, as a prolonged inversion in the U.S. treasury yield curve fanned worries of an economic slowdown. At 13:21 ET, the Dow Jones Industrial Average was down 0.28 percent at 25,586.65. |
28073.0 | 2019-03-19 00:00:00 UTC | Abeona Therapeutics Inc (ABEO) Q4 2018 Earnings Conference Call Transcript | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-inc-abeo-q4-2018-earnings-conference-call-transcript-2019-03-19 | nan | nan | Abeona Therapeutics Inc (NASDAQ: ABEO)
Q4 2018 Earnings Conference Call
March 19, 2019 , 10:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning, and welcome to the Abeona Therapeutics Incorporated Fourth Quarter and Full-Year 2018 Earnings and Business Update Conference Call. Today's call is being recorded. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation.
For opening remarks and introductions, I'll turn the call over to Sofia Warner, Senior Director, Investor Relations. Thank you. You may begin.
Sofia Warner -- Senior Director, Investor Relations
Thank you. Good morning and welcome everyone. Today's call will be led by Joao Siffert, our CEO. Following Joao, Tim Miller, our President and CSO will present preclinical highlights; and Christine Silverstein, our CFO will review our financials.
Before I turn the call over to them, I need to remind our listeners that remarks made during the call may contain forward-looking statements that involve risks and uncertainties. Forward looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws.
Information contained in these statements is based on current expectations and is subject to change, and actual results may differ materially from forward looking statements. Some of the factors that could cause actual results to differ may be found in the Company's annual reports on Form 10-K and quarterly reports on Form 10-Q filed by the Company with the Securities and Exchange Commission. These documents are available on our website www.abeonatherapeutics.com.
With that said, it is now my pleasure to introduce to you Dr. Joao Siffert, Joao, you have the floor.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Thank you, Sofia, and thank you all for joining us today. Since this is my first quarterly update since joining Abeona, let me start by saying how honored I am to assume the role of CEO and thankful for the Board's confidence in me. I'm also excited to partner with Abeona's highly qualified and experienced leadership team who is committed to our mission to deliver transformative cell and gene therapies for people impacted by serious diseases.
After a year of intense foundational work, we're poised to deliver an important near-term milestones for our lead clinical program; for a world-class cell and gene therapy manufacturing facility in Cleveland; and for a next generation AIM vector platform, which Tim will detail for you shortly.
On the management side, we recently strengthened the financial leadership with the internal appointments of Christine Silverstein to Chief Financial Officer and Ed Carr to Chief Accounting Officer. Christine and Ed are working in concert on expert financial management and controls for Abeona.
We continue to carefully prioritize our growing pipeline to further establish pathways to success and bringing treatments to patients in need. At our R&D Day in December, we highlighted our late and early stage assets with the potential to transform the treatment of devastating genetic diseases.
The update included long-term results from our completed Phase 1 trial evaluating EB-101 or gene corrected cell therapy for the treatment of recessive dystrophic epidermolysis bullosa or RDEB. The Phase 1/2 trial demonstrated continuous type VII collagen expression for over two years post EB-101 treatment as well as significant and durable wound healing lasted for -- lasting for several years.
With up to five years of follow up, EB-101 was shown to have a favorable safety profile with no product-related SAEs FCAs. With the establish of the Elisa Linton Center for Rare Disease Therapies in Cleveland, we now have state-of-the-art internal CMC capabilities through a robust process development, assay developments and manufacturing.
In addition, we now have a comprehensive quality system capable of governing all aspects of product lifecycle from preclinical through commercial stage across multiple manufacturing modalities. With GMP-compliant clinical scale manufacturing capabilities for cell therapy and AAV based gene therapies.
By developing and managing these manufacturing technologies internally, we will significantly increase control of our supply chain, improve timelines and reduce costs. In addition, work done at Abeona will continue to enhance the manufacturing knowhow and potentially generate important intellectual property.
Considering the few contract manufacturing organizations, supply availability can be limited to meet the rapidly increasing demand from a growing number of gene therapy companies. We're also poised to expand our cGMP facility, which will allow us to soon be ready to manufacture and distribute commercial product.
Having our facility in Cleveland is cost effective and readily scalable. Once we complete the current expansion, we will have 26,000 square feet of space, featuring state-of-the-art laboratories that support CMC development for process and analytics.
For cell therapy, we now have three dedicated cGMP suites operated by an experienced, trained staff who are dedicated to the manufacture of EB-101, positioning us well to produce clinical products for upcoming Phase 3 trial. Our facility has scalable capacity in the existing suites to support the commercial launch of EB-101 enabling treatment of up to 120 patients per year from the outset.
We continue working toward receiving FDA GMP validation of our facility to produce commercial supply of this novel therapy. Internal manufacturing and quality knowledge stand to facilitate a more expeditious transition toward BLA filing in readiness for commercial launch in the near future.
The VITAL study will be a multi-center, randomized Phase 3 trial assessing 10 to 15 RDEB patients treated with EB-101. The primary outcome measure of the study will be the proportion of patient's wounds with greater than 50% healing at three months with additional endpoints of investigator global assessment of wounds and change from baseline in pain and itch.
Regarding our AAV AIM gene therapies, we are currently pursuing, in parallel, via SELLAS (ph) adherent technology, HEK293 suspension technology, and baculovirus suspension technology to provide Abeona with the versatility and flexibility to meet a growing pipeline of products and identify the most cost effective technology for each product. With yields capable of supporting clinical programs, our team is working hard to continue to improve our scale and commence cGMP AAV clinical manufacturing by the second half of 2019.
Our clinical trials also continue to make progress. We continue to follow patients treated with ABO102 for MPS IIIA or Sanfilippo A with follow up now beyond two years of -- since the original dose cohort. As presented at WORLDSymposium, the product has been well tolerated to date with no serious drug-related adverse events.
We have observed a substantial and durable improvement in biomarkers, including dose-related reductions in cerebrospinal fluid heparan sulfate levels and a reduction in liver volume in all treated patients. These biochemical and biophysical improvements were observed within four weeks post dosing and have persisted to-date with two years of follow-up.
Looking ahead, and with an amendment study protocol focusing on enrolling younger, higher functioning patients, we believe we were in the right track to assess the benefits of ABO102 with an updated protocol currently in effect in the US, Australia and the EU. We have also made progress on our Phase 1/2 trial with ABO101 for patients suffering from MPS IIIB or Sanfilippo B. New clinical sites are being activated in the UK, France and Germany to expand the geographical reach abroad and complement the ongoing enrollment efforts at our US site.
Lastly, and in an effort to increase efficiency in our clinical operations, we have begun implementing patient recruitment initiatives designed to accelerate enrollment across the lysosomal storage disease programs globally. This multi-prong concerted effort to patient recruitment consist of online and offline efforts, including advertising to engage the broad network of healthcare professionals and communities involved in the care and support of children with lysosomal storage disease. We look forward to providing additional updates on the trial data and enrollment in the second half of 2019 for all programs.
Our CSO, Tim Miller and his team, along with the clinical, manufacturing, regulatory and quality teams, have also worked diligently toward expanding our clinical stage pipeline later this year. We remain within our guidance of a first quarter IND submission for ABO-202 for CLN1 or infantile Batten disease.
IND enabling data shared at R&D Day showed a favorable safety profile for ABO-202 with no significant toxicities seen after a combination of preclinical, dose escalation studies. Other IND-enabling studies also demonstrated normalized survival and improvement of motor and cognitive function in affected mice treated with ABO-202.
Data collected to-date also suggests that combining dosing with intravenous and intrathecal administration may enhance the therapeutic potential of ABO-202. In addition, preclinical development of our CLN3 asset ABO-201 continues to advance and we will provide an update on the program later this year.
With that, let's hear from Tim about the latest update on multiple capsids from the AIM AAV vector platform currently under evaluation. Tim?
Timothy J. Miller -- President & Chief Scientific Officer
Thank you, Joao. In the fourth quarter, we unveiled new data from the novel AIM AAV Vector Platform at our R&D Day, where we demonstrated the capability to target multiple tissues with enhanced tropisms, including the eye, muscle, lung and CNS. As examples, we showed data for two new programs that hold significant therapeutic potential as gene therapies for cystic fibrosis and a host of retinal diseases.
Before I review the highlights from R&D Day, I first wanted to provide context for additional data from the AIM platform that we presented at the Annual WORLDSymposium in February. There, we disclosed new data demonstrating that our novel AIM capsids showed efficacy in animal models of Pompe in Fabry diseases.
While current enzyme replacement therapy significantly reduces the mortality of infantile Pompe patients, it fails to completely ameliorate all symptoms, primarily due to the inability to efficiently enter the CNS and due to the immune responses and the actual GAA protein.
Notably in the Pompe study, we also identified multiple viable transgene cassettes that produced significant levels of active GAA protein in animals. In multiple disease models in animal species, our novel AIM AAV capsids have demonstrated broad tissue tropisms when compared to existing natural AAV capsids. The AIM capsid also performed as well as existing natural serotypes at targeting CNS disorders and transducing the brain in rodents and primates.
Taken together, these data levers strongly encourage about the therapeutic potential of the AIM AAV Vector Platform in Pompe and Fabry diseases, they also set the stage for proof-of-concept studies to determine therapeutic efficacy and preliminary toxicology.
In December 2018, we also demonstrated how our novel AIM capsids can be used to target multiple eye disorders. 80% of eye diseases affect the photoreceptors in the retina, highlighting the importance of cellular targeting and how AVV can be an efficient tool in gene delivery. An important consideration is route of administration and we've shown data in rodents and non-human primates that we can utilize different AIM capsid to target the photoreceptors and retinal pigmented epithelium using either subretinal or intravitreal injection.
The AIM capsids increased Abeona's potential for targeting eye diseases through delivery of therapeutic genes or employing the machinery to enable gene editing. We look forward to announcing more programs in the future. The therapeutic potential of the AIM platform is further highlighted by the ability to selectively reach lung tissue, opening a promising avenue to develop a gene therapy product for patients with cystic fibrosis.
The underlying cause of CF is a mutation in the CFTR transgene, which is responsible for the function of chloride channels in the body and regulating the flow of chloride ions and water across cell membranes. Some key highlights from the data showed that our novel AIM AAV vector with the CFTR minigene can address all CF mutations and that efficiently targets lung cells. We demonstrated that ABO-401 can correct the underlying CF chloride channel deficit, regardless of underlying mutations of the CF trans-membrane conductance regulators in CF mice and inhuman CF patient cells.
Importantly, ABO-401 can correct the defect of the most common CF mutation delta-508, which accounts for greater than 60% of the CF population. This is an important differentiator, as this could enable treatment for CF patients that may be non-responsive to current CF modulating drugs or those that have mutations that are refractory to currently available CF drugs. We believe that the utility of AIM and those vectors could change the landscape for the treatment of CF and alter the course of this progressive genetic disease by enabling a one-time treatment.
Lastly, we have now demonstrated in vitro that select AIM capsids can evade neutralizing antibodies against -- that are present, against naturally occurring AAV capsids. This finding is significant as it may allow AAV-based gene therapy for patients that may have previously been excluded owing to existing anti AAV antibodies. It also may enable retreatment of patients who previously received AAV gene therapy with others serotypes. We look forward to discussing additional AIM programs in the future.
And I'll now turn the call back to Christine who will review our financials. Christine?
Christine Silverstein -- Chief Financial Officer
Thank you, Tim. I'd like to remind everyone that we have recently filed a Form 10-K where you can get all the specific details to our financial results. But in summary, our cash, cash equivalents and marketable securities as of December 31st, 2018 were $85 million compared to $112.2 million as of September 30, 2018. The decrease in cash of $27.2 million was driven primarily by the net cash used for operating activities of $17 million and cash used for the acquisition of the REGENX license of $10 million.
Net cash used in operating activities in the 12 months ended December 31st, 2018 was $39.1 million as compared to $22.7 million in the same period in 2017, an increase in cash outflows of $16.4 million. From a revenue perspective, revenues were $0.5 million for the fourth quarter of 2018 compared to $0.2 million for the fourth quarter of 2017. The increased quarterly revenues resulted from the recognition of foundation grants that were announced during the fourth quarter of 2017.
Net loss was $0.36 per share for the fourth quarter of 2018 compared to $0.19 per share in the comparable period of 2017. For the 12 months ended December 31st, 2018, net loss was $1.19 per share compared to $0.66 per share in the same period of 2017. That's the summary financials.
With respect to the upcoming IR and scientific conferences, I'd like to highlight, we'd be participating in the following events. On April 2nd, we will be at the Guggenheim First Annual Rare Disease and Genomics Medicines Day and later in the month, on April 28th, AVRO; The Association for Research in Vision and Ophthalmology. Concurrently that week, we would be participating at ASGCT, The American Society of Gene and Cell Therapy Annual Meeting. Additionally, we will be at Society of Investigative Dermatology on May 8th through the 11th. We will update you on those planned presentations as we get closer.
And with that, I'd like to turn it over back to Joao.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Thank you, Christine. In summary, we achieved interim milestones in the fourth quarter that have Abeona well-positioned to bring long-term value to our shareholders and turned hope into reality for our patients.
Thank you. I will now turn over to the operator to open up for questions. Operator?
Questions and Answers:
Operator
Thank you. The floor is now open for questions. (Operator Instructions) Thank you. And our first question will go from Kennen MacKay with RBC Capital Markets.
Kennen MacKay -- RBC Capital Markets -- Analyst
Clarity on the manufacturing milestones and the disclosures around this in the 0-K, that's super helpful. Joao you'd mentioned potential for treatment of around a 120 patients per year with the current Cleveland manufacturing for EB-101, just wondering if you could maybe elaborate a little bit on the sustainability of this and capacity from, I guess, the current number of suite, how many suits or hood (ph) that is, and how high you could potentially go there? Thank you.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
So, hi, Ken. Thank you for your questions. Yes, we're pretty excited about the ability to scale up the EB-101 manufacturing. because you know, we have three GMP suites currently operational in Cleveland and we have room to expand this up to what, nine, ten suites in the coming years. In addition to that, what's important in terms of the scale up is the -- there is not a linear one-to-one correlation, because we can -- in the new design suites, we'll be able to put multiple incubators in each suite and that allows us to produce more material with the same existing footprint. So that's what allows us to have an efficient scale up both at launch and ultimately post-launch.
Kennen MacKay -- RBC Capital Markets -- Analyst
Thank you. And maybe just to follow up on MPS III, I was wondering if you could just remind us sort of where we are with kind of discussions with the FDA around a potential path to market that agent and maybe when GMP commercial grade material could be used to dose some of these additional younger, more functional patients. Thank you very much.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Sure, so two separate questions. So the first one in terms of the regulatory discussions, these are of course, we have an open line of communication with the agency given our certifications. We will approach the FDA once we have sufficient data from the existing patients. We have several young high functioning patients currently being followed in the 01 study. And as soon as we have sufficient data to be able to make a case to the agency, we'll engage them again.
So this is an open dialogue and will be data driven ultimately we expect to have obviously more data throughout this year and provide an update later this year. With regard to the manufacturing of AAV material, we have currently ability to scale up in Cleveland for AAV manufacturing for clinical supplies and we're working on the baculovirus material technology transfer. So we should be able to provide an update later in the year and that's what the material that will be used for the MPS III program.
Kennen MacKay -- RBC Capital Markets -- Analyst
That's good. Thanks so much for taking the questions and looking forward to seeing the team at some of these conferences that are coming up. Thank you.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Thanks.
Operator
Thank you. Our next question comes from Elemer Piros with Cantor Fitzgerald.
Elemer Piros -- Cantor Fitzgerald -- Analyst
Yes, good morning, Christine, and gentlemen. What I'd like to understand a little bit better is what would be the downstream clinical impact of liver enlargement in Sanfilippo patients? And conversely, what would the measurable benefit be with the significant reduction of those enlargements by gene therapy?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
So, an interesting question Elemer, thanks. So, liver enlargement usually doesn't cause a lot of liver dysfunction. That is mostly something we can measure and in fact measure this prospectively in the clinical trials using MRI for a measurement of liver volume. So the treatment that we are providing to these patients provide a very clear reduction in liver volume, which ultimately is something that I can imagine will be good for these patients in long term, but acutely they're not -- the liver dysfunction is not a main feature of the pathology of MPS IIIA, at least not in the age group where we're treating. I suppose that on the long run, if they live longer following our treatment, obviously all organs, including the heart for that matter, could benefit from systemic delivery of the vector, ultimately improving their or precluding further accumulation of heparin sulfate and lysosomal dysfunction in these organs.
Elemer Piros -- Cantor Fitzgerald -- Analyst
Thank you very much. Thank you Joao
Operator
Thank you. Our next question comes from Maury Raycroft with Jefferies.
Maurice Raycroft -- Jefferies LLC -- Analyst
Hi, good morning, everyone, and welcome Joao as CEO and welcome Christine as CFO. Thanks for taking my questions. So to start, I was wondering about EB-101 in RDEB; so when considering the different types of RDEB wounds that EB-101 would address in the commercial setting, can you provide any comments on competitive disadvantages or advantages for addressing particular wound types?
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Sure. Hi, Maurice; thanks for your question. So for purposes of the clinical trial and as we've announced, we are targeting chronic wounds. So these are wounds that have been open for at least six months. And in reality, many of these wounds are open for several years, as it turns out. And we're restricting the minimum size to 20 square centimeter per wound site.
This gives us a good ability to one; assess the healing of these wounds, but also the understanding that the control wounds that are this large, at least 20 centimeter squared and are chronic are unlikely to heal within the observation period of the clinical trial of just three months plus three months of safety. So this will be a very clear, if in fact any of these wounds heal, which is the expectation for -- with the treatment of EB-101, this will be a very drastic deviation from the natural history of these wounds in RDEB patients, because they essentially won't heal spontaneously. So this is important in terms of the mechanics of the clinical trial to be able to show a difference between treated versus untreated control wounds.
Now, if you were to fast forward to the commercial utility, there's no reason why the EB-101 couldn't be used in smaller wounds. Certainly, smaller wounds are also disabling, obviously, incurring same risks of infection, and of course, the process of wound healing, which is sort of an endless process because the wound can't heal and even in recurring wounds that tend to heal but reopen within a few weeks. So ultimately, all these wounds could still be amenable to treating with EB-101. So we anticipate that ultimately utility of this, this product would be beyond the circumscribed constraints that we're using for the Phase 3 program specifically.
Maurice Raycroft -- Jefferies LLC -- Analyst
Got it. That's great, very helpful. And the other question was just for ABO-102 and 101, I may have missed this in the prepared remarks, but do you anticipate opening new sites for those trials? And if so, what are those plans? And then, now with CLN1 and CLN3 heading into the clinic, do you anticipate synergies with screening that could expedite enrollment rates for all of these trials?
Timothy J. Miller -- President & Chief Scientific Officer
Yes, so, it's a good question, and yes, perhaps we could have been a bit more clear in the prepared remarks. So we are taking a very broad approach to patient recruitment and ultimately enrollment. And there are commonalities across sites who are very qualified for both running gene therapy programs, and these sites are already under way with the programs, but also on expertise in lysosomal storage diseases. So we will -- we are -- to the extent that it's possible, we are harmonizing the sites where they will open for both MPS programs and also looking ahead for the CLN1 program, try to use these sites as much as possible the same ones.
As you know, we have sites open in Australia, US and Spain, and we're close to having sites in UK, France and potentially another country opened in the near future. So, yes, so we're trying to rationalize both the sort of footprint, taking advantage of the fact that these sites already hit -- first of all, they're very -- they're highly selective sites, these are highly qualified sites, but also have the capabilities to run more than one of the clinical trials at a time.
Maurice Raycroft -- Jefferies LLC -- Analyst
Got it. That's great. And then last question is a quick one just on the AIM capsid. I'm just wondering, if you're talking about potential next steps with strategy with those capsid and if you're trying to identify one that you're going to move into the clinic on your own, or are you primarily aiming to partner?
Timothy J. Miller -- President & Chief Scientific Officer
So we're keeping options open. Of course, and it will depend -- of course, but we consider partnerships that are advantageous for -- ultimately for Abeona and for the programs, both in terms of resources and expediency of the development, and obviously ultimately success bringing this to the clinic. We do have the ability to move forward with some of these AIM capsids in some of the programs internally and we have initiated these programs already as we've announced late last year, both for CF and also for retinal disorders, which we have not yet disclosed publicly, the actual indication within retina disorder.
So, we have the ability to move those into preclinical. It would be helpful for Abeona, of course, to have greater reach and resource to support these indications which can be quite large, including CF. We'd also -- I think in addition to the fact that those data we've already shown in terms of the AIM ability to target different organs and we find it very exciting, both CNS, we've shown data targeting the lung and also the retina. We continue to assess the ability of these novel capsids to evade existing immunity to AAV, which we feel is also an important differentiating aspect to this whole portfolio. So we continue to accumulate data and so far this has been confirmed in preclinical and in vitro assays.
Maurice Raycroft -- Jefferies LLC -- Analyst
Got it. Thank you very much.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Okay. Thank you.
Operator
Our next question comes from Edward Nash with SunTrust.
Frank -- SunTrust -- Analyst
Hey, this is Frank on for Edward. And first question, want to talk about EB-101 programs. Can you talk about the differences of targeting keratinocytes versus fibroblasts? We see some reports saying that fibroblasts, and the turnover of fibroblasts is -- it's longer than keratinocytes and maybe have some impact on the durability of the graft. But we know that Abeona has the longest durability to data so far. So can you just comment mechanistically the differences between (inaudible) different cell type?
Timothy J. Miller -- President & Chief Scientific Officer
Yes. So as you know, we target keratinocytes in our product. I think others who are doing fibroblasts can comment on their programs, but we'll comment on ours. So, two things; so, starting back from the clinic, which ultimately is the goal. So I think from the patient perspective, we have patients now who are five years out from the original treatment in the Phase 1/2 trials who have wounds that are healed. So this is -- for me, we could stop the conversation right here because that's the reality -- well ultimately, that's the goal. But we did, of course, go further and the team at Stanford has continued to investigate what happens to these wounds over time, and we have been able to demonstrate that there is collagen VIII expression past two years after grafting.
So we know that there is a persistence of collagen VII expression, even though as you mentioned, keratinocytes tend to recycle and ultimately shed off. But there are cells that have been corrected, that probably remain in the epidermis that are still producing collagen VII sufficient -- sufficiently to maintain wound healing.
Frank -- SunTrust -- Analyst
Got it, that's very helpful. And second question, I may have missed, you probably have mentioned before, Are you planning to file the IND for -- what's the time you're going to file the IND for ABO-202?
Timothy J. Miller -- President & Chief Scientific Officer
For CLN -- so for CLN1, for infantile Battens, we're on track and we're on track to hopefully start the clinical trials later this year.
Frank -- SunTrust -- Analyst
Got it. Thank you. Thank you very much.
Operator
Thank you. Our next question will come from Liav Abraham with Citi.
Liav Abraham -- Citi -- Analyst
Good morning. Just a follow-up question on ABO-102, can you just update us on patient enrollment in the trial? I'm not sure if I missed this in your remarks, but have any additional patients being enrolled over the past few months since December? And what data can we expect to see at ASGCT that's coming up pretty soon? Thank you.
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
So, as I mentioned, we are actually going -- putting extra emphasis, an enhanced emphasis in clinical trial screening and enrollment. We have no updates on enrollment in the IIIA program. We did enroll an additional patient in the BBB program recently, but we do have a fair amount of interest in going -- actually processing a lot of patients who come in for screening, so both US and abroad. So, I guess we'll have to stay tuned in terms of the enrollment and we'll provide updates as patients actually enroll and get treated. But there are several patients at different stages of screening across the clinical trials. So we're excited that there's more momentum going in.
Operator
Thank you. This concludes our question-and-answer session and conference. Thank you for your participation. You may now disconnect. Thank you and have a great day.
Duration: 33 minutes
Call participants:
Sofia Warner -- Senior Director, Investor Relations
Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Timothy J. Miller -- President & Chief Scientific Officer
Christine Silverstein -- Chief Financial Officer
Kennen MacKay -- RBC Capital Markets -- Analyst
Elemer Piros -- Cantor Fitzgerald -- Analyst
Maurice Raycroft -- Jefferies LLC -- Analyst
Frank -- SunTrust -- Analyst
Liav Abraham -- Citi -- Analyst
More ABEO analysis
Transcript powered by AlphaStreet
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see ourTerms and Conditionsfor additional details, including our Obligatory Capitalized Disclaimers of Liability.
10 stocks we like better than Abeona Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abeona Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 1, 2019
Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc (NASDAQ: ABEO) Q4 2018 Earnings Conference Call March 19, 2019 , 10:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, and welcome to the Abeona Therapeutics Incorporated Fourth Quarter and Full-Year 2018 Earnings and Business Update Conference Call. These documents are available on our website www.abeonatherapeutics.com. | Duration: 33 minutes Call participants: Sofia Warner -- Senior Director, Investor Relations Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer Timothy J. Miller -- President & Chief Scientific Officer Christine Silverstein -- Chief Financial Officer Kennen MacKay -- RBC Capital Markets -- Analyst Elemer Piros -- Cantor Fitzgerald -- Analyst Maurice Raycroft -- Jefferies LLC -- Analyst Frank -- SunTrust -- Analyst Liav Abraham -- Citi -- Analyst More ABEO analysis Transcript powered by AlphaStreet This article is a transcript of this conference call produced for The Motley Fool. Abeona Therapeutics Inc (NASDAQ: ABEO) Q4 2018 Earnings Conference Call March 19, 2019 , 10:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, and welcome to the Abeona Therapeutics Incorporated Fourth Quarter and Full-Year 2018 Earnings and Business Update Conference Call. | Duration: 33 minutes Call participants: Sofia Warner -- Senior Director, Investor Relations Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer Timothy J. Miller -- President & Chief Scientific Officer Christine Silverstein -- Chief Financial Officer Kennen MacKay -- RBC Capital Markets -- Analyst Elemer Piros -- Cantor Fitzgerald -- Analyst Maurice Raycroft -- Jefferies LLC -- Analyst Frank -- SunTrust -- Analyst Liav Abraham -- Citi -- Analyst More ABEO analysis Transcript powered by AlphaStreet This article is a transcript of this conference call produced for The Motley Fool. Abeona Therapeutics Inc (NASDAQ: ABEO) Q4 2018 Earnings Conference Call March 19, 2019 , 10:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, and welcome to the Abeona Therapeutics Incorporated Fourth Quarter and Full-Year 2018 Earnings and Business Update Conference Call. | Abeona Therapeutics Inc (NASDAQ: ABEO) Q4 2018 Earnings Conference Call March 19, 2019 , 10:00 a.m. Duration: 33 minutes Call participants: Sofia Warner -- Senior Director, Investor Relations Joao Siffert -- Chief Executive Officer, Head of Research & Development and Chief Medical Officer Timothy J. Miller -- President & Chief Scientific Officer Christine Silverstein -- Chief Financial Officer Kennen MacKay -- RBC Capital Markets -- Analyst Elemer Piros -- Cantor Fitzgerald -- Analyst Maurice Raycroft -- Jefferies LLC -- Analyst Frank -- SunTrust -- Analyst Liav Abraham -- Citi -- Analyst More ABEO analysis Transcript powered by AlphaStreet This article is a transcript of this conference call produced for The Motley Fool. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, and welcome to the Abeona Therapeutics Incorporated Fourth Quarter and Full-Year 2018 Earnings and Business Update Conference Call. |
28074.0 | 2019-01-09 00:00:00 UTC | Japan Approves Amgen/UCB's Osteoporosis Drug - Will U.S. Follow Suit? | ABEO | https://www.nasdaq.com/articles/japan-approves-amgenucbs-osteoporosis-drug-will-us-follow-suit-2019-01-09 | nan | nan | (RTTNews.com) - Today's Daily Dose brings you news about preliminary financial results of Globus Medical, Conformis, and GenMark Diagnostics; approval of Amgen/UCB's osteoporosis drug Evenity in Japan; Genmab's achievement of a milestone payment related to Darzalex; and executive changes in Abeona.
Read on…
Abeona Therapeutics Inc. ( ABEO ) has appointed Christine Silverstein to the position of Chief Financial Officer and named Edward Carr as Chief Accounting Officer.
Silverstein was previously Senior Vice President, Finance and Investor Relations for Abeon, and Carr most recently served as Vice President and Assistant Controller at Coty Inc (COTY), which manufactures, and sells beauty products worldwide.
Clinical Trials & Near-term Catalysts:
The Company's lead drug candidate is EB-101 for Recessive Dystrophic Epidermolysis Bullosa, or RDEB, a skin disease characterized by chronic epidermal wounds in which patients suffer from pain, itching, and widespread complications impacting quality-of-life and life expectancy.
A pivotal clinical trial evaluating the potential of EB-101 for the treatment of RDEB is expected to be initiated in the middle of 2019.
Another clinical drug candidate is ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA), under phase I/II trial.
ABEO closed Tuesday's trading at $7.31, down 2.66%.
Amgen (AMGN) and UCB's drug Evenity has received approval in Japan for the treatment of osteoporosis in patients at high risk of fracture.
In the U.S., Evenity is all set to be reviewed by an FDA panel on January 16, 2019. The drug is also under review by the European Medicines Agency.
AMGN closed Tuesday's trading at $200.61, up 1.28%.
Conformis Inc. (CFMS), a medical technology company, has announced preliminary, unaudited, revenue results for the fourth quarter and the year ended December 31, 2018.
Total revenue for the fourth quarter of 2018 is expected to be approximately $22.0 million, up 6% year-over-year on a reported basis and 7% on a constant currency basis. Total revenue for the full year of 2018 is anticipated to be about $89.8 million, up 15% year-over-year on a reported basis, and 14% on a constant currency basis.
The consensus revenue estimate of analysts polled by Thomson Reuters is $20.75 million for the fourth quarter and $86.37 million for the full year.
The Company expects to report its full financial results for the fourth quarter and the year ended 2018 on February 6, 2019.
CFMS closed Tuesday's trading at $0.50, up 4.43%.
Globus Medical Inc. (GMED), a musculoskeletal implant manufacturer, has reported preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2018.
The Company anticipates fourth quarter 2018 sales of approximately $195.5 million, an increase of 11.0% over the fourth quarter of 2017. Full-year 2018 sales are expected to be approximately $712.5 million, an increase of 12.0% over the prior year.
The consensus revenue estimate of analysts polled by Thomson Reuters is $188.18 million for the fourth quarter and $705.17 million for the full year of 2018.
The Company expects to announce its fourth quarter and full year 2018 financial and operating results on February 21.
GMED closed Tuesday's trading at $39.84, up 2.84%.
Genmab A/S (GMXAY.OB) is all set to receive $75 million from Janssen Biotech, Inc. as a milestone payment from its Darzalex collaboration.
The milestone was triggered by confirmation by Janssen that sales of Darzalex reached $2 billion in the calendar year of 2018.
Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize Darzalex in August 2012. The drug is indicated for the treatment of patients with multiple myeloma.
GMXAY.OB closed Tuesday's trading at $17.00, down 0.50%.
Shares of GenMark Diagnostics Inc. (GNMK) rallied 10% on Tuesday, following solid preliminary operational and financial results for the year ended December 31, 2018.
The Company expects total revenue for 2018 to be approximately $70.8 million, representing an increase of 35% over 2017. Analysts polled by Thomson Reuters are expecting revenue of $70.05 million for the year.
The Company expects to issue full 2018 financial results and 2019 guidance in late February.
GNMK closed Tuesday's trading at $5.75, up 10.15%.
Karyopharm Therapeutics Inc. (KPTI) has submitted a Marketing Authorization Application to the European Medicines Agency for Selinexor, requesting conditional approval for the treatment of patients with Penta-refractory multiple myeloma.
In the U.S., Selinexor is under priority review by the FDA - with a decision expected on April 6, 2019.
KPTI closed Tuesday's trading at $10.25, up 0.20%.
Read the original article on RTTNews (http://www.rttnews.com/2968123/japan-approves-amgen-ucb-s-osteoporosis-drug-will-u-s-follow-suit.aspx)
For comments and feedback: contact editorial@rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - Today's Daily Dose brings you news about preliminary financial results of Globus Medical, Conformis, and GenMark Diagnostics; approval of Amgen/UCB's osteoporosis drug Evenity in Japan; Genmab's achievement of a milestone payment related to Darzalex; and executive changes in Abeona. Read on… Abeona Therapeutics Inc. ( ABEO ) has appointed Christine Silverstein to the position of Chief Financial Officer and named Edward Carr as Chief Accounting Officer. Silverstein was previously Senior Vice President, Finance and Investor Relations for Abeon, and Carr most recently served as Vice President and Assistant Controller at Coty Inc (COTY), which manufactures, and sells beauty products worldwide. | (RTTNews.com) - Today's Daily Dose brings you news about preliminary financial results of Globus Medical, Conformis, and GenMark Diagnostics; approval of Amgen/UCB's osteoporosis drug Evenity in Japan; Genmab's achievement of a milestone payment related to Darzalex; and executive changes in Abeona. Read on… Abeona Therapeutics Inc. ( ABEO ) has appointed Christine Silverstein to the position of Chief Financial Officer and named Edward Carr as Chief Accounting Officer. Silverstein was previously Senior Vice President, Finance and Investor Relations for Abeon, and Carr most recently served as Vice President and Assistant Controller at Coty Inc (COTY), which manufactures, and sells beauty products worldwide. | (RTTNews.com) - Today's Daily Dose brings you news about preliminary financial results of Globus Medical, Conformis, and GenMark Diagnostics; approval of Amgen/UCB's osteoporosis drug Evenity in Japan; Genmab's achievement of a milestone payment related to Darzalex; and executive changes in Abeona. Read on… Abeona Therapeutics Inc. ( ABEO ) has appointed Christine Silverstein to the position of Chief Financial Officer and named Edward Carr as Chief Accounting Officer. Silverstein was previously Senior Vice President, Finance and Investor Relations for Abeon, and Carr most recently served as Vice President and Assistant Controller at Coty Inc (COTY), which manufactures, and sells beauty products worldwide. | ABEO closed Tuesday's trading at $7.31, down 2.66%. (RTTNews.com) - Today's Daily Dose brings you news about preliminary financial results of Globus Medical, Conformis, and GenMark Diagnostics; approval of Amgen/UCB's osteoporosis drug Evenity in Japan; Genmab's achievement of a milestone payment related to Darzalex; and executive changes in Abeona. Read on… Abeona Therapeutics Inc. ( ABEO ) has appointed Christine Silverstein to the position of Chief Financial Officer and named Edward Carr as Chief Accounting Officer. |
28075.0 | 2018-12-11 00:00:00 UTC | Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-abeo-in-focus%3A-stock-moves-5.5-higher-2018-12-11 | nan | nan | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $7.50 to $8.50 in the past one month time frame.
The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Abeona Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.
Abeona Therapeutics Inc. Price
Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider Alexion Pharmaceuticals, Inc. ALXN , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Is ABEO going up? Or down? Predict to see what others think: Up or Down
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise more than 5% on the day. Abeona Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative. Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote Investors interested in the Medical - Biomedical and Genetics industry may consider Alexion Pharmaceuticals, Inc. ALXN , which has a Zacks Rank #1 (Strong Buy). | Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote Investors interested in the Medical - Biomedical and Genetics industry may consider Alexion Pharmaceuticals, Inc. ALXN , which has a Zacks Rank #1 (Strong Buy). Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise more than 5% on the day. | Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote Investors interested in the Medical - Biomedical and Genetics industry may consider Alexion Pharmaceuticals, Inc. ALXN , which has a Zacks Rank #1 (Strong Buy). Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise more than 5% on the day. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise more than 5% on the day. Abeona Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative. Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote Investors interested in the Medical - Biomedical and Genetics industry may consider Alexion Pharmaceuticals, Inc. ALXN , which has a Zacks Rank #1 (Strong Buy). |
28076.0 | 2018-12-10 00:00:00 UTC | Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump | ABEO | https://www.nasdaq.com/articles/why-abeona-therapeutics-abeo-could-be-positioned-for-a-slump-2018-12-10 | nan | nan | Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Abeona Therapeutics Inc.ABEO , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ABEO.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen three estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of 88 cents a share a month ago to its current level of a loss of 98 cents.
Also, for the current quarter, Abeona Therapeutics has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 29 cents a share from a loss of 22 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 13.6% in the past month.
Abeona Therapeutics Inc. Price and Consensus
Abeona Therapeutics Inc. Price and Consensus | Abeona Therapeutics Inc. Quote
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait.
If you are still interested in the Medical - Biomedical and Genetics industry, you may instead consider a better-ranked stock - Anika Therapeutics Inc. ANIK . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today's Zacks #1 Rank stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One such stock that you may want to consider dropping is Abeona Therapeutics Inc.ABEO , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ABEO. Also, for the current quarter, Abeona Therapeutics has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 29 cents a share from a loss of 22 cents over the past 30 days. | Abeona Therapeutics Inc. Price and Consensus Abeona Therapeutics Inc. Price and Consensus | Abeona Therapeutics Inc. Quote So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait. Click to get this free report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. One such stock that you may want to consider dropping is Abeona Therapeutics Inc.ABEO , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. | Also, for the current quarter, Abeona Therapeutics has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 29 cents a share from a loss of 22 cents over the past 30 days. Abeona Therapeutics Inc. Price and Consensus Abeona Therapeutics Inc. Price and Consensus | Abeona Therapeutics Inc. Quote So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait. Click to get this free report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. | Also, for the current quarter, Abeona Therapeutics has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 29 cents a share from a loss of 22 cents over the past 30 days. Abeona Therapeutics Inc. Price and Consensus Abeona Therapeutics Inc. Price and Consensus | Abeona Therapeutics Inc. Quote So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait. Click to get this free report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. |
28077.0 | 2018-12-03 00:00:00 UTC | Moving Average Crossover Alert: Abeona Therapeutics | ABEO | https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-abeona-therapeutics-2018-12-03 | nan | nan | Abeona Therapeutics Inc.ABEO could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ABEO broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
This has already started to take place, as the stock has moved lower by 11.2% in the past four weeks. And with the recent moving average crossover, investors have to think that more unfavorable trading is ahead for ABEO stock.
If that wasn't enough, ABEO isn't looking too great from an earnings estimate revision perspective either. It appears as though many analysts have been reducing their earnings expectations for the stock lately, which is usually not a good sign of things to come.
Consider that in the last 30 days, 3 estimates have been reduced, while none has moved higher. Add this in to a similar move lower in the consensus estimate, and there is plenty of reason to be bearish here.
That is why we currently have a Zacks Rank #4 (Sell) on this stock and are looking for it to underperform in the weeks ahead. So, either avoid this stock or consider jumping ship until the estimates and technical factors turn around for ABEO. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc.ABEO could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. And with the recent moving average crossover, investors have to think that more unfavorable trading is ahead for ABEO stock. Recently, the 50 Day Moving Average for ABEO broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness. | And with the recent moving average crossover, investors have to think that more unfavorable trading is ahead for ABEO stock. Click to get this free report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. | Recently, the 50 Day Moving Average for ABEO broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness. And with the recent moving average crossover, investors have to think that more unfavorable trading is ahead for ABEO stock. Abeona Therapeutics Inc.ABEO could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. | Abeona Therapeutics Inc.ABEO could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ABEO broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness. And with the recent moving average crossover, investors have to think that more unfavorable trading is ahead for ABEO stock. |
28078.0 | 2018-11-12 00:00:00 UTC | Monday Sector Laggards: Semiconductors, Biotechnology Stocks | ABEO | https://www.nasdaq.com/articles/monday-sector-laggards-semiconductors-biotechnology-stocks-2018-11-12 | nan | nan | In trading on Monday, semiconductors shares were relative laggards, down on the day by about 3.7%. Helping drag down the group were shares of Cirrus Logic, off about 12.3% and shares of Universal Display off about 12.2% on the day.
Also lagging the market Monday are biotechnology shares, down on the day by about 3.2% as a group, led down by Infinity Pharmaceuticals, trading lower by about 34% and Abeona Therapeutics, trading lower by about 13%.
VIDEO: Monday Sector Laggards: Semiconductors, Biotechnology Stocks
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also lagging the market Monday are biotechnology shares, down on the day by about 3.2% as a group, led down by Infinity Pharmaceuticals, trading lower by about 34% and Abeona Therapeutics, trading lower by about 13%. In trading on Monday, semiconductors shares were relative laggards, down on the day by about 3.7%. VIDEO: Monday Sector Laggards: Semiconductors, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also lagging the market Monday are biotechnology shares, down on the day by about 3.2% as a group, led down by Infinity Pharmaceuticals, trading lower by about 34% and Abeona Therapeutics, trading lower by about 13%. In trading on Monday, semiconductors shares were relative laggards, down on the day by about 3.7%. VIDEO: Monday Sector Laggards: Semiconductors, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also lagging the market Monday are biotechnology shares, down on the day by about 3.2% as a group, led down by Infinity Pharmaceuticals, trading lower by about 34% and Abeona Therapeutics, trading lower by about 13%. VIDEO: Monday Sector Laggards: Semiconductors, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also lagging the market Monday are biotechnology shares, down on the day by about 3.2% as a group, led down by Infinity Pharmaceuticals, trading lower by about 34% and Abeona Therapeutics, trading lower by about 13%. In trading on Monday, semiconductors shares were relative laggards, down on the day by about 3.7%. Helping drag down the group were shares of Cirrus Logic, off about 12.3% and shares of Universal Display off about 12.2% on the day. |
28079.0 | 2018-11-09 00:00:00 UTC | Abeona Therapeutics (ABEO) Reports Q3 Loss, Tops Revenue Estimates | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-abeo-reports-q3-loss-tops-revenue-estimates-2018-11-09 | nan | nan | Abeona Therapeutics (ABEO) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -47.83%. A quarter ago, it was expected that this drug developer would post a loss of $0.16 per share when it actually produced a loss of $0.25, delivering a surprise of -56.25%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Abeona Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.71 million for the quarter ended September 2018, surpassing the Zacks Consensus Estimate by 68.04%. This compares to year-ago revenues of $0.22 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Abeona Therapeutics shares have lost about 37.7% since the beginning of the year versus the S&P 500's gain of 5%.
What's Next for Abeona Therapeutics?
While Abeona Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Abeona Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.22 on $1.68 million in revenues for the coming quarter and -$0.88 on $6.08 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics (ABEO) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. Abeona Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.71 million for the quarter ended September 2018, surpassing the Zacks Consensus Estimate by 68.04%. Abeona Therapeutics shares have lost about 37.7% since the beginning of the year versus the S&P 500's gain of 5%. | Abeona Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.71 million for the quarter ended September 2018, surpassing the Zacks Consensus Estimate by 68.04%. Click to get this free report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics (ABEO) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. | Abeona Therapeutics (ABEO) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. Abeona Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.71 million for the quarter ended September 2018, surpassing the Zacks Consensus Estimate by 68.04%. Abeona Therapeutics shares have lost about 37.7% since the beginning of the year versus the S&P 500's gain of 5%. | Abeona Therapeutics (ABEO) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. Abeona Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.71 million for the quarter ended September 2018, surpassing the Zacks Consensus Estimate by 68.04%. Abeona Therapeutics shares have lost about 37.7% since the beginning of the year versus the S&P 500's gain of 5%. |
28080.0 | 2018-10-05 00:00:00 UTC | 10 Growth Stocks to Buy With Monster Potential | ABEO | https://www.nasdaq.com/articles/10-growth-stocks-buy-monster-potential-2018-10-05 | nan | nan | The stock market - especially growth stocks - is at an interesting inflection point as we enter the final quarter of 2018.
On the one hand, the Standard & Poor's 500-stock index recovered from a tumultuous midyear with a 7% third-quarter gain that marked its best quarterly performance since 2013. On the other, interest-rate worries have sent a quick scare into the markets, and riskier, growth-oriented equities have suffered a bit of a pullback.
Still, corporate earnings have impressed, unemployment remains at multi-decade lows and the economy is growing. So as we head into the seasonally strong fourth quarter, the question for anyone who still believes the broader trend is up becomes, "Which stocks are Wall Street analysts singling out as compelling investing opportunities?"
We can use TipRanks to pinpoint top growth stocks - as identified by Wall Street's brightest minds - that have significant growth potential. Let's take a closer look at these 10 top picks now:
SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)
Market value: $540.8 million
TipRanks consensus price target: $33.67 (194% upside potential)
TipRanks consensus rating: Strong Buy ( See Details )
Abeona Therapeutics ( ABEO , $11.43), which develops novel gene and cell therapies for the potential treatment of rare diseases, is among the highest-potential growth stocks Wall Street is looking at. Abeona's targets include little-known but devastating diseases such as epidermolysis bullosa, Sanfilippo syndrome and Batten disease.
For H.C. Wainwright analyst Ram Selvaraju ( Track Record & Ratings ), a recent transaction in the gene therapy sector provides an encouraging benchmark for Abeona's value. Amicus Therapeutics ( FOLD ) is acquiring Celenex - which focuses on gene therapy targeting the same rare diseases as ABEO - for $100 million, with up to $262 million in additional milestones.
The Celenex transaction is a "bullish signal for Abeona and may provide additional incentive for investors to consider the company as an intriguing investment opportunity in the gene therapy field, with multiple shots on goal and diversified technology platforms" he states. Most crucially, any potential competition to Abeona from the Amicus acquisition is likely to be muted and, at best, several years away.
As a result, Sevaraju reiterated his "Buy" rating with a $30 price target. This suggests more than 160% upside from current levels.
SEE ALSO: Emerging-Markets Stocks: 10 Ways to Play the Next Bull Market
Market value: $8.2 billion
TipRanks consensus price target: $97.50 (46% upside potential)
TipRanks consensus rating: Moderate Buy ( See Details )
Large regional airline Alaska Air ( ALK , $66.82) is looking increasingly attractive right now. Top Imperial Capital analyst Michael Derchin ( Track Record & Ratings ) sent shares rallying after he upgraded the stock from "In-Line" (equivalent of hold) to "Outperform" (equivalent of buy). HJe also ramped up his price target from $62 to a confident $95 (43% upside potential), arguing that the stock is now trading far too cheaply.
So why the shift in sentiment?
Derchin cited industry-leading unit sales growth of 4% in 2019, as well as Alaska's capacity discipline, merger synergies and a successful loyalty program generating higher sales. He also raises the possibility that Alaska, like its peers, will decide to hike luggage fees.
Alongside Hawaiian Holdings ( HA ) and Spirit Airlines ( SAVE ), ALK is now one of Derchin's three favorite airline stocks.
SEE ALSO: 7 "Strong Buy" Stock Picks for Breakneck Growth
Market value: $393.1 billion
TipRanks consensus price target: $234.63 (47% upside potential)
TipRanks consensus rating: Strong Buy ( See Details )
With 18 back-to-back buy ratings in the last three months, Alibaba ( BABA , $156.13) is undoubtedly one of the Street's favorite growth stocks.
RBC Capital's Mark Mahaney ( Track Record & Rating ) recently attended Alibaba's investor day in Hangzhou, China. He left the event with his bullish thesis on the stock reaffirmed, writing, "We believe management did an impressive job of explaining their long-term vision of empowering businesses to succeed in a digital era." This includes helping businesses use a data-driven approach to boost sales.
Ultimately, Alibaba's fundamentals remain very strong. Alibaba represents a stellar play on Chinese middle-class growth and the rapid boom of e-commerce. Combine this with management's long-term focus and excellent execution and you have a very compelling stock, Mahaney writes.
As a result, this top analyst reiterated his "Outperform" rating on BABA with a bullish $215 price target (38% upside potential).
SEE ALSO: Emerging-Markets Stocks: 10 Ways to Play the Next Bull Market
Market value: $8.7 billion
TipRanks consensus price target: $57.71 (34% upside potential)
TipRanks consensus rating: Strong Buy ( See Details )
Auto-parts maker BorgWarner ( BWA , $42.96) is buzzing right now. Following an upbeat investor day, the company revealed several new production contract wins. These contracts "underscore (BWA's) opportunity set and strong positioning around vehicle electrification," Oppenheimer's Noah Kaye ( Track Record & Ratings ) writes.
Kaye has a "Buy" rating on the stock with a $58 price target (35% upside potential). Kaye is confident that the company's electric vehicle operations "will support cross-cycle topline outperformance and the robust growth targets management outlined." Indeed, BWA is modelling for 6% compound annual growth through 2023 with a total addressable market of $47 billion in combustion, $39 billion in hybrids and $11 billion in electric vehicles.
Kaye explains, "As the global auto industry evolves to meet increasingly stringent emissions regulations, we expect BorgWarner to benefit." This is due to accelerating vehicle electrification, continued runway on turbochargers and the company's "overall strong position" for internal combustion engines.
Bottom line: BorgWarner is perfectly poised for auto industry changes - and this sets the stock up for stellar long-term growth.
SEE ALSO: 5 Blue-Chip "Marijuana Stocks"
Market value: $452.6 billion
TipRanks consensus price target: $206.31 (30% upside potential)
TipRanks consensus rating: Strong Buy ( See Details )
The world's most dominant social platform still has plenty of room to run, say top analysts. This makes sense given that Facebook ( FB , $158.85) shares are currently down 8% over the past month. The stock has pulled back for several reasons, including a security breach that affected 50 million users, and the departure of Instagram's co-founders.
"We reiterate our Strong Buy on FB and view the recent selloff as a buying opportunity as the company's long-term growth story remains intact," cheers Tigress Financial's Ivan Feinseth ( Track Record & Ratings ). He sees "substantial upside" from current levels but doesn't offer a specific price target. No worries: We can see that the average analyst price target indicates 30% upside ahead.
Most notably, Feinseth cites Facebook's gigantic user base as a key competitive advantage. Right now, the company boasts over 2.2 billion MAUs (monthly active users), and 1.5 billion DAUs (daily active users). This enables advertisers to use Facebook's tools to effectively target their best potential customers, he explains.
Plus keep an eye out for Facebook's next big growth drivers: Marketplace, Stories and Watch, an on-demand video service. Meanwhile, SunTrust's Youssef Squali reassures investors that Instagram's founders have left the popular photo-sharing app "in a good place" with "stable footing," and "impressive" user growth.
SEE ALSO: RBC Capital's 10 Best Tech Stocks to Buy for 2025
Market value: $281.1 million
TipRanks consensus price target: $26.33 (72% upside potential)
TipRanks consensus rating: Strong Buy ( See Details )
Gaia Inc. ( GAIA , $15.27) is a global digital video company that streams curated videos to subscribers in more than 120 countries. Currently the platform boasts over 8,000 titles aimed at a very specific audience. The videos, 90% of which belong exclusively to Gaia, focus on Seeking Truth, Transformation and Yoga.
Five-star Roth Capital analyst Darren Aftahi ( Track Record & Ratings ) has just left meetings with Gaia's CFO and CMO with his bullish thesis reaffirmed. He subsequently reiterated his "Buy" rating with a $25 price target (64% upside potential).
According to Aftahi, Gaia is planning to increase subscription prices in mid to late 2019, alongside a new premium service. He sees this as a savvy move. "Given that Netflix has raised prices on multiple occasions in recent years, it is not out of the cards for Gaia to also implement a price increase," the analyst points out.
He also sees any subscriber loss from the price-hike as immaterial longer-term due to the impressive brand loyalty and stickiness of most of Gaia's subscriber base.
SEE ALSO: 7 Top Tech Stocks That Could Catch Fire Soon
Market value: $120.4 billion
TipRanks consensus price target: $174.89 (13% upside potential)
TipRanks consensus rating: Strong Buy ( See Details )
In just the last week, cloud-computing stock Salesforce.com ( CRM , $154.90) has scored multiple buy-equivalent ratings from the Street. The reason: Salesforce's Dreamforce conference and upbeat analyst day.
Alex Zukin ( Track Record & Ratings ) from Piper Jaffray gives the stock his seal of approval. Salesforce "is making all the right moves, at the right time, with the right people" Zukin argues. He tells investors to buy and hold as this is a "set it and forget it" stock. Citing higher demand, rapid product innovation and an impressive ecosystem of products, Zukin boosted his price target from $180 to $190 (23% upside).
Similarly, Oppenheimer's Brian Schwartz ( Track Record & Ratings ) advises investors to "stay the course." "We consider CRM one of the healthiest long-term growth stories in our SaaS/applications software universe," he wrote in a Sept. 27 report. The bullish outlook came with a new price target: $180, up from $160 previously. Note that Schwartz is one of the Top 10 analysts ranked by TipRanks for his precise stock-picking skills.
SEE ALSO: 5 Triple-A Semicondcutor Stocks to Buy Now
Market value: $451.8 million
TipRanks consensus price target: $21.67 (436% upside potential)
TipRanks consensus rating: Strong Buy ( See Details )
Cutting-edge biotech stock Sorrento Therapeutics ( SRNE , $4.04) may only have three recent ratings. But these ratings indicate an extremely compelling story. All three analysts are top-performing analysts, and their consensus opinion is that Sorrento has more than 400% of upside potential.
The best-rated analyst covering the stock is B. Riley FBR's Andrew D'Silva ( Track Record & Ratings ). His price target may be a more cautionary $15, but this still indicates upside potential of more than 270%.
Sorrento is developing new therapies to turn malignant cancers into manageable and possibly curable diseases. This includes a first-in-class non-opioid pain management ("RTX") and a next generation lidocaine patch ("ZTlido").
"SRNE is pioneering cutting-edge immuno-oncology (IO) treatments and is leveraging its proprietary technological expertise, which includes one of the world's most robust fully human monoclonal antibody (mAbs) libraries, to develop novel CAR T-cell treatment" D'Silva writes.
He sees the risk/reward dynamic for Sorrento's pipeline as favorable and notes multiple additional opportunities in animal health and pain management.
SEE ALSO: 7 Health Care Stocks to Buy for Robust Returns
Market value: $240.1 million
TipRanks consensus price target: $38.75 (118% upside potential)
TipRanks consensus rating: Strong Buy ( See Details )
Turtle Beach ( HEAR , $17.80) is one of the leading makers of award-winning gaming headsets. Its motto: "Hear Everything. Defeat Everyone."
According to top D.A. Davidson analyst Tom Forte ( Track Record & Ratings ), it's full steam ahead on Turtle Beach.
The company currently is enjoying the benefits of Epic Games' massively successful Fortnite Battle Royale. "Our headset sales were up over 80%. Gamers want that better headset in order to play Fortnite," Turtle Beach CFO and COO Robert Lloyd told analysts on the recent Q2 earnings call.
However, even aside from Fortnite, the stock still looks compelling. "We see headset usage rates increasing as additional games move towards this more social gaming format, regardless of 'Fortnite's' ability to sustain its meteoric growth" Forte writes.
Forte reiterated his "Buy" rating with a bullish $38 price target. From current levels, this means he expects HEAR to more than double.
SEE ALSO: 10 Cool Things Your Google Home Smart Speaker Can Do
Market value: $4.5 billion
TipRanks consensus price target: $106.80 (52% upside potential)
TipRanks consensus rating: Moderate Buy* ( See Details )
Five-star Oppenheimer analyst Brian Nagel ( Track Record & Rating ) recently initiated coverage on Weight Watchers ( WTW , $70.04). With a "Buy" rating and $98 price target (40% upside potential), it's clear he likes what he sees.
Weight Watchers, one of the world's largest weight loss companies, currently is undergoing a significant transformation. Under the leadership of new CEO Mindy Grossman, WTW is now introducing improved programming and better digital infrastructure. The purpose: to better connect with a larger and more diverse community of subscribers.
"For investors, the new WTW strategy suggests the potential for a sustained, stronger and higher margin growth trajectory," Nagel writes. He calls a recent pullback in shares "largely mechanical in nature and at odds with strengthening fundamentals at the company."
* Note: If we look only at the best-performing Wall Street analysts, the consensus shifts from "Moderate Buy" to "Strong Buy." This is with six buy-equivalent ratings in the past three months vs just one hold rating.
Harriet Lefton is head of content at TipRanks, a comprehensive investing tool that tracks more than 4,700 Wall Street analysts as well as hedge funds and insiders. You can find more of TipRanks' stock insights here .
SEE ALSO: Best Online Brokers, 2018
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Celenex transaction is a "bullish signal for Abeona and may provide additional incentive for investors to consider the company as an intriguing investment opportunity in the gene therapy field, with multiple shots on goal and diversified technology platforms" he states. Let's take a closer look at these 10 top picks now: SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds) Market value: $540.8 million TipRanks consensus price target: $33.67 (194% upside potential) TipRanks consensus rating: Strong Buy ( See Details ) Abeona Therapeutics ( ABEO , $11.43), which develops novel gene and cell therapies for the potential treatment of rare diseases, is among the highest-potential growth stocks Wall Street is looking at. Abeona's targets include little-known but devastating diseases such as epidermolysis bullosa, Sanfilippo syndrome and Batten disease. | Let's take a closer look at these 10 top picks now: SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds) Market value: $540.8 million TipRanks consensus price target: $33.67 (194% upside potential) TipRanks consensus rating: Strong Buy ( See Details ) Abeona Therapeutics ( ABEO , $11.43), which develops novel gene and cell therapies for the potential treatment of rare diseases, is among the highest-potential growth stocks Wall Street is looking at. Abeona's targets include little-known but devastating diseases such as epidermolysis bullosa, Sanfilippo syndrome and Batten disease. For H.C. Wainwright analyst Ram Selvaraju ( Track Record & Ratings ), a recent transaction in the gene therapy sector provides an encouraging benchmark for Abeona's value. | Let's take a closer look at these 10 top picks now: SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds) Market value: $540.8 million TipRanks consensus price target: $33.67 (194% upside potential) TipRanks consensus rating: Strong Buy ( See Details ) Abeona Therapeutics ( ABEO , $11.43), which develops novel gene and cell therapies for the potential treatment of rare diseases, is among the highest-potential growth stocks Wall Street is looking at. Abeona's targets include little-known but devastating diseases such as epidermolysis bullosa, Sanfilippo syndrome and Batten disease. For H.C. Wainwright analyst Ram Selvaraju ( Track Record & Ratings ), a recent transaction in the gene therapy sector provides an encouraging benchmark for Abeona's value. | Let's take a closer look at these 10 top picks now: SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds) Market value: $540.8 million TipRanks consensus price target: $33.67 (194% upside potential) TipRanks consensus rating: Strong Buy ( See Details ) Abeona Therapeutics ( ABEO , $11.43), which develops novel gene and cell therapies for the potential treatment of rare diseases, is among the highest-potential growth stocks Wall Street is looking at. Abeona's targets include little-known but devastating diseases such as epidermolysis bullosa, Sanfilippo syndrome and Batten disease. For H.C. Wainwright analyst Ram Selvaraju ( Track Record & Ratings ), a recent transaction in the gene therapy sector provides an encouraging benchmark for Abeona's value. |
28081.0 | 2018-08-09 00:00:00 UTC | Abeona Therapeutics (ABEO) Reports Q2 Loss, Lags Revenue Estimates | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-abeo-reports-q2-loss-lags-revenue-estimates-2018-08-09 | nan | nan | Abeona Therapeutics (ABEO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -56.25%. A quarter ago, it was expected that this drug developer would post a loss of $0.19 per share when it actually produced a loss of $0.18, delivering a surprise of 5.26%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Abeona Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.82 million for the quarter ended June 2018, missing the Zacks Consensus Estimate by 54.83%. This compares to year-ago revenues of $0.22 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Abeona Therapeutics shares have lost about 7.3% since the beginning of the year versus the S&P 500's gain of 6.9%.
What's Next for Abeona Therapeutics?
While Abeona Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Abeona Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.17 on $1.97 million in revenues for the coming quarter and -$0.71 on $8.73 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics (ABEO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. Abeona Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.82 million for the quarter ended June 2018, missing the Zacks Consensus Estimate by 54.83%. Abeona Therapeutics shares have lost about 7.3% since the beginning of the year versus the S&P 500's gain of 6.9%. | Abeona Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.82 million for the quarter ended June 2018, missing the Zacks Consensus Estimate by 54.83%. Click to get this free report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics (ABEO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. | Abeona Therapeutics (ABEO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. Abeona Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.82 million for the quarter ended June 2018, missing the Zacks Consensus Estimate by 54.83%. Abeona Therapeutics shares have lost about 7.3% since the beginning of the year versus the S&P 500's gain of 6.9%. | Abeona Therapeutics (ABEO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. Abeona Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.82 million for the quarter ended June 2018, missing the Zacks Consensus Estimate by 54.83%. Abeona Therapeutics shares have lost about 7.3% since the beginning of the year versus the S&P 500's gain of 6.9%. |
28082.0 | 2018-07-11 00:00:00 UTC | Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options | ABEO | https://www.nasdaq.com/articles/implied-volatility-surging-for-abeona-therapeutics-abeo-stock-options-2018-07-11 | nan | nan | Investors in Abeona Therapeutics Inc.ABEO need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $17.50 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Abeona Therapeutics shares, but what is the fundamental picture for the company? Currently, Abeona Therapeutics is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Bottom 37% of our Zacks Industry Rank. Over the last 60 days, two analysts have increased their earnings estimates for the current quarter, while none have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 20 cents per share to a loss of 16 cents in that period.
Given the way analysts feel about Abeona Therapeutics right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Looking to Trade Options?
Each week, our very own Dave Bartosiak gives his top options trades. Check out his recent live analysis and options trade for the NFLX earnings report completely free. See it here: Trading Netflix's (NFLX) Earnings with Options or check out the embedded video below for more details:
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors in Abeona Therapeutics Inc.ABEO need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for Abeona Therapeutics shares, but what is the fundamental picture for the company? Currently, Abeona Therapeutics is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Bottom 37% of our Zacks Industry Rank. | Click to get this free report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Investors in Abeona Therapeutics Inc.ABEO need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for Abeona Therapeutics shares, but what is the fundamental picture for the company? | Given the way analysts feel about Abeona Therapeutics right now, this huge implied volatility could mean there's a trade developing. Investors in Abeona Therapeutics Inc.ABEO need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for Abeona Therapeutics shares, but what is the fundamental picture for the company? | Given the way analysts feel about Abeona Therapeutics right now, this huge implied volatility could mean there's a trade developing. Investors in Abeona Therapeutics Inc.ABEO need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for Abeona Therapeutics shares, but what is the fundamental picture for the company? |
28083.0 | 2018-06-20 00:00:00 UTC | 3 Small-Cap Biotech Stocks to Keep on Your Radar | ABEO | https://www.nasdaq.com/articles/3-small-cap-biotech-stocks-keep-your-radar-2018-06-20 | nan | nan | Investing in small-cap biotech stocks can be scary and exciting at the same time. A pipeline failure can devastate the stock, while great clinical results can cause share prices to skyrocket.
There are more small-cap biotech stocks than any investor can realistically keep up with. But three stocks I think you'll want to keep on your radar are Abeona Therapeutics (NASDAQ: ABEO) , Atara Biotherapeutics (NASDAQ: ATRA) , and Viking Therapeutics (NASDAQ: VKTX) . Here's why these small-cap biotech stocks are worth monitoring closely.
1. Abeona Therapeutics
Abeona's candidate that's furthest along in development is EB-101. The biotech plans to begin a pivotal phase 3 study later this year evaluating the gene therapy in treating recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic disease that causes the skin to blister easily. EB-101 showed considerable promise in earlier clinical studies. If it ultimately wins approval, the therapy could achieve peak annual sales of more than $100 million.
The crown jewel for Abeona, though, is another gene therapy: ABO-102. This gene therapy targets treatment of Sanfilippo syndrome type A, which is also known as mucopolysaccharidosis (MPS) IIIA. The rare genetic disease affects the brain and spinal cord, with symptoms typically appearing during early childhood.
Abeona presented data from a phase 1/2 clinical study for ABO-102 in May at the annual meeting of the American Society for Gene and Cell Therapy (ASGCT). Investors were somewhat disappointed by the data despite encouraging efficacy and safety results. However, this disappointment likely stemmed more from what Abeona didn't report -- demonstrable improvement in patients' cognitive scores -- than concerns about the positive results measured by key biomarkers.
ABO-102 could generate peak annual sales in the ballpark of $200 million if approved. Abeona's market cap is currently around $760 million. Success for the two lead products could make this biotech stock much more valuable in the next few years.
2. Atara Biotherapeutics
Atara Biotherapeutics' share price has soared close to 150% so far in 2018, nearly making Atara's market cap too large to allow it in the small-cap category. The big catalyst for the biotech is heightened anticipation for Atara's lead candidate, tab-cel, which is being evaluated in two phase 3 clinical studies.
Tab-cel is an off-the-shelf immunotherapy where T cells (white blood cells that are key to the body's immune system) from a healthy donor are engineered to treat specific conditions, including cancer and viral infections, and are then delivered to a patient. In the ongoing phase 3 studies, the therapy is targeting a type of lymphoma (lymph node cancer) that develops following stem cell transplants or solid organ transplants.
The key thing to really know about tab-cel is that phrase "off the shelf." Currently approved T cell therapies require complex off-site manufacturing that drives up costs and increases the amount of time required for treatment. If Atara is successful, treatment will be able to be delivered quickly to patients at a lower cost.
My colleague George Budwell views Atara as one of the top growth stocks to buy right now . His enthusiasm stems from Atara's timeline of potentially being able to file for European approval for tab-cel next year and the prospects that the biotech could be acquired in the not-too-distant future. I suspect that George could be right.
3. Viking Therapeutics
Viking Therapeutics is the biggest year-to-date winner of these three small-cap biotechs, with its stock price tripling so far this year. While Viking has several pipeline candidates, the one attracting the most attention is thyroid hormone receptor beta-selective agonist VK2809.
The biotech expects to report results later in 2018 from a phase 2 study of VK2809 targeting high cholesterol and non-alcoholic fatty liver disease (NAFLD). It's the latter target indication that has investors especially eager, because NAFLD includes non-alcoholic steatohepatitis (NASH) -- a disease some predict could become "the next hepatitis C."
Viking stock received a huge boost recently thanks to great results reported by Madrigal Pharmaceuticals (NASDAQ: MDGL) from its phase 2 study of NASH candidate MGL-3196. Because Madrigal's drug uses the same mechanism of action as VK2809, expectations are high for similar success for Viking's phase 2 study.
Madrigal has reportedly begun looking seriously at selling to a larger drugmaker. With quite a few big pharma companies wanting to score in the potentially lucrative NASH market, I think Viking could also find itself an acquisition target .
High risk, high reward
Small clinical-stage biotech stocks like Abeona, Atara, and Viking aren't great picks for many investors. The risks are very high. On the other hand, the potential rewards from these stocks are also great.
More cautious investors might prefer to closely watch these biotechs and wait for more clinical results for their lead products. That approach would decrease the risk somewhat, although it also means the potential profits would be lower as well.
Like I said earlier, these kinds of stocks can be both scary and exciting. Your decision on whether or not to buy any of them comes down to whether you prioritize the fear above the excitement, or vice versa.
10 stocks we like better than Atara Biotherapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Atara Biotherapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, this disappointment likely stemmed more from what Abeona didn't report -- demonstrable improvement in patients' cognitive scores -- than concerns about the positive results measured by key biomarkers. But three stocks I think you'll want to keep on your radar are Abeona Therapeutics (NASDAQ: ABEO) , Atara Biotherapeutics (NASDAQ: ATRA) , and Viking Therapeutics (NASDAQ: VKTX) . Abeona Therapeutics Abeona's candidate that's furthest along in development is EB-101. | But three stocks I think you'll want to keep on your radar are Abeona Therapeutics (NASDAQ: ABEO) , Atara Biotherapeutics (NASDAQ: ATRA) , and Viking Therapeutics (NASDAQ: VKTX) . High risk, high reward Small clinical-stage biotech stocks like Abeona, Atara, and Viking aren't great picks for many investors. Abeona Therapeutics Abeona's candidate that's furthest along in development is EB-101. | But three stocks I think you'll want to keep on your radar are Abeona Therapeutics (NASDAQ: ABEO) , Atara Biotherapeutics (NASDAQ: ATRA) , and Viking Therapeutics (NASDAQ: VKTX) . High risk, high reward Small clinical-stage biotech stocks like Abeona, Atara, and Viking aren't great picks for many investors. Abeona Therapeutics Abeona's candidate that's furthest along in development is EB-101. | Abeona presented data from a phase 1/2 clinical study for ABO-102 in May at the annual meeting of the American Society for Gene and Cell Therapy (ASGCT). Abeona's market cap is currently around $760 million. High risk, high reward Small clinical-stage biotech stocks like Abeona, Atara, and Viking aren't great picks for many investors. |
28084.0 | 2018-05-21 00:00:00 UTC | Monday's ETF Movers: XOP, XBI | ABEO | https://www.nasdaq.com/articles/mondays-etf-movers-xop-xbi-2018-05-21 | nan | nan | In trading on Monday, the SPDR S&P Oil & Gas Exploration & Production ETF ( XOP ) is outperforming other ETFs, up about 1.8% on the day. Components of that ETF showing particular strength include shares of Chesapeake Energy ( CHK ), up about 8% and shares of Denbury Resources ( DNR ), up about 7.6% on the day.
And underperforming other ETFs today is the SPDR S&P Biotech ETF ( XBI ), off about 1.1% in Monday afternoon trading. Among components of that ETF with the weakest showing on Monday were shares of Abeona Therapeutics ( ABEO ), lower by about 15.4%, and shares of Insmed (INSM), lower by about 6.8% on the day.
VIDEO: Monday's ETF Movers: XOP, XBI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among components of that ETF with the weakest showing on Monday were shares of Abeona Therapeutics ( ABEO ), lower by about 15.4%, and shares of Insmed (INSM), lower by about 6.8% on the day. Components of that ETF showing particular strength include shares of Chesapeake Energy ( CHK ), up about 8% and shares of Denbury Resources ( DNR ), up about 7.6% on the day. VIDEO: Monday's ETF Movers: XOP, XBI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among components of that ETF with the weakest showing on Monday were shares of Abeona Therapeutics ( ABEO ), lower by about 15.4%, and shares of Insmed (INSM), lower by about 6.8% on the day. VIDEO: Monday's ETF Movers: XOP, XBI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among components of that ETF with the weakest showing on Monday were shares of Abeona Therapeutics ( ABEO ), lower by about 15.4%, and shares of Insmed (INSM), lower by about 6.8% on the day. In trading on Monday, the SPDR S&P Oil & Gas Exploration & Production ETF ( XOP ) is outperforming other ETFs, up about 1.8% on the day. VIDEO: Monday's ETF Movers: XOP, XBI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among components of that ETF with the weakest showing on Monday were shares of Abeona Therapeutics ( ABEO ), lower by about 15.4%, and shares of Insmed (INSM), lower by about 6.8% on the day. In trading on Monday, the SPDR S&P Oil & Gas Exploration & Production ETF ( XOP ) is outperforming other ETFs, up about 1.8% on the day. Components of that ETF showing particular strength include shares of Chesapeake Energy ( CHK ), up about 8% and shares of Denbury Resources ( DNR ), up about 7.6% on the day. |
28085.0 | 2018-05-21 00:00:00 UTC | Monday Sector Laggards: Biotechnology, Drugs | ABEO | https://www.nasdaq.com/articles/monday-sector-laggards-biotechnology-drugs-2018-05-21 | nan | nan | In trading on Monday, biotechnology shares were relative laggards, down on the day by about 1.3%. Helping drag down the group were shares of Abeona Therapeutics ( ABEO ), down about 15.4% and shares of Curis ( CRIS ) down about 8.5% on the day.
Also lagging the market Monday are drugs shares, down on the day by about 0.7% as a group, led down by Nabriva Therapeutics ( NBRV ), trading lower by about 12.3% and Apellis Pharmaceuticals ( APLS ), trading lower by about 8.6%.
VIDEO: Monday Sector Laggards: Biotechnology, Drugs
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Helping drag down the group were shares of Abeona Therapeutics ( ABEO ), down about 15.4% and shares of Curis ( CRIS ) down about 8.5% on the day. In trading on Monday, biotechnology shares were relative laggards, down on the day by about 1.3%. Also lagging the market Monday are drugs shares, down on the day by about 0.7% as a group, led down by Nabriva Therapeutics ( NBRV ), trading lower by about 12.3% and Apellis Pharmaceuticals ( APLS ), trading lower by about 8.6%. | Helping drag down the group were shares of Abeona Therapeutics ( ABEO ), down about 15.4% and shares of Curis ( CRIS ) down about 8.5% on the day. In trading on Monday, biotechnology shares were relative laggards, down on the day by about 1.3%. VIDEO: Monday Sector Laggards: Biotechnology, Drugs The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Helping drag down the group were shares of Abeona Therapeutics ( ABEO ), down about 15.4% and shares of Curis ( CRIS ) down about 8.5% on the day. Also lagging the market Monday are drugs shares, down on the day by about 0.7% as a group, led down by Nabriva Therapeutics ( NBRV ), trading lower by about 12.3% and Apellis Pharmaceuticals ( APLS ), trading lower by about 8.6%. VIDEO: Monday Sector Laggards: Biotechnology, Drugs The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Helping drag down the group were shares of Abeona Therapeutics ( ABEO ), down about 15.4% and shares of Curis ( CRIS ) down about 8.5% on the day. In trading on Monday, biotechnology shares were relative laggards, down on the day by about 1.3%. VIDEO: Monday Sector Laggards: Biotechnology, Drugs The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
28086.0 | 2018-05-18 00:00:00 UTC | Here's Why Abeona Therapeutics Stock Dropped 12% Today | ABEO | https://www.nasdaq.com/articles/heres-why-abeona-therapeutics-stock-dropped-12-today-2018-05-18 | nan | nan | What happened
Shares of gene therapy expert Abeona Therapeutics (NASDAQ: ABEO) closed down 12% on Friday after the company reported updated data from a phase 1/2 trial testing ABO-102, a treatment for a rare genetic disease called Sanfilippo syndrome type A, at the 21st annual meeting of the American Society for Gene and Cell Therapy.
So what
With shares having more than tripled over the past year, it may be more what Abeona didn't say in its update than what it did say that caused the stock to slip today.
But first let's start with the data it did present, which seemed promising enough. Abeona has been following some of the patients for 18 months and the treatment doesn't seem to have waned much -- as measured by biomarkers -- past the initial decline seen around 180 days. In the later cohorts of patients that were treated with higher doses of ABO-102, the 180-day data look better, although those patients haven't been followed as long, so we don't have data out to 18 months.
Investors likely hit the sell button today because of a lack of any data beyond biomarkers and some data on liver size, which was also trending in the right direction. While biomarkers and liver size are likely to be a good indicator that the drug is working, patients' function, measured though neurocognitive scores, is ultimately what doctors and the parents of the kids who have Sanfilippo syndrome really care about.
Now what
Investors will just have to wait until the next update to (hopefully) get more information on the neurocognitive scores of the patients. Presumably investors will also get an update shortly about the plan for the next clinical trial for ABO-102, which should be designed to get the treatment approved.
In the meantime, Abeona has other programs. EB-101, a gene-corrected skin graft cell therapy for patients with recessive dystrophic epidermolysis bullosa, is ready to enter phase 3 development later this year. AB-101, a gene therapy that treats another type of Sanfilippo syndrome, produced positive, albeit early, data in February.
10 stocks we like better than Abeona Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abeona Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 8, 2018
Brian Orelli has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of gene therapy expert Abeona Therapeutics (NASDAQ: ABEO) closed down 12% on Friday after the company reported updated data from a phase 1/2 trial testing ABO-102, a treatment for a rare genetic disease called Sanfilippo syndrome type A, at the 21st annual meeting of the American Society for Gene and Cell Therapy. So what With shares having more than tripled over the past year, it may be more what Abeona didn't say in its update than what it did say that caused the stock to slip today. Abeona has been following some of the patients for 18 months and the treatment doesn't seem to have waned much -- as measured by biomarkers -- past the initial decline seen around 180 days. | What happened Shares of gene therapy expert Abeona Therapeutics (NASDAQ: ABEO) closed down 12% on Friday after the company reported updated data from a phase 1/2 trial testing ABO-102, a treatment for a rare genetic disease called Sanfilippo syndrome type A, at the 21st annual meeting of the American Society for Gene and Cell Therapy. So what With shares having more than tripled over the past year, it may be more what Abeona didn't say in its update than what it did say that caused the stock to slip today. Abeona has been following some of the patients for 18 months and the treatment doesn't seem to have waned much -- as measured by biomarkers -- past the initial decline seen around 180 days. | What happened Shares of gene therapy expert Abeona Therapeutics (NASDAQ: ABEO) closed down 12% on Friday after the company reported updated data from a phase 1/2 trial testing ABO-102, a treatment for a rare genetic disease called Sanfilippo syndrome type A, at the 21st annual meeting of the American Society for Gene and Cell Therapy. 10 stocks we like better than Abeona Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. So what With shares having more than tripled over the past year, it may be more what Abeona didn't say in its update than what it did say that caused the stock to slip today. | What happened Shares of gene therapy expert Abeona Therapeutics (NASDAQ: ABEO) closed down 12% on Friday after the company reported updated data from a phase 1/2 trial testing ABO-102, a treatment for a rare genetic disease called Sanfilippo syndrome type A, at the 21st annual meeting of the American Society for Gene and Cell Therapy. So what With shares having more than tripled over the past year, it may be more what Abeona didn't say in its update than what it did say that caused the stock to slip today. Abeona has been following some of the patients for 18 months and the treatment doesn't seem to have waned much -- as measured by biomarkers -- past the initial decline seen around 180 days. |
28087.0 | 2018-05-18 00:00:00 UTC | Noteworthy Friday Option Activity: ABEO, TGH, CIT | ABEO | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-abeo-tgh-cit-2018-05-18 | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Abeona Therapeutics Inc (Symbol: ABEO), where a total of 6,008 contracts have traded so far, representing approximately 600,800 underlying shares. That amounts to about 73.7% of ABEO's average daily trading volume over the past month of 814,830 shares. Particularly high volume was seen for the $20 strike call option expiring June 15, 2018 , with 1,369 contracts trading so far today, representing approximately 136,900 underlying shares of ABEO. Below is a chart showing ABEO's trailing twelve month trading history, with the $20 strike highlighted in orange:
Textainer Group Holdings Ltd (Symbol: TGH) options are showing a volume of 1,360 contracts thus far today. That number of contracts represents approximately 136,000 underlying shares, working out to a sizeable 73.6% of TGH's average daily trading volume over the past month, of 184,720 shares. Particularly high volume was seen for the $22.50 strike put option expiring August 17, 2018 , with 500 contracts trading so far today, representing approximately 50,000 underlying shares of TGH. Below is a chart showing TGH's trailing twelve month trading history, with the $22.50 strike highlighted in orange:
And CIT Group Inc (Symbol: CIT) saw options trading volume of 9,337 contracts, representing approximately 933,700 underlying shares or approximately 71.7% of CIT's average daily trading volume over the past month, of 1.3 million shares. Particularly high volume was seen for the $70 strike call option expiring June 15, 2018 , with 2,530 contracts trading so far today, representing approximately 253,000 underlying shares of CIT. Below is a chart showing CIT's trailing twelve month trading history, with the $70 strike highlighted in orange:
For the various different available expirations for ABEO options , TGH options , or CIT options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $20 strike call option expiring June 15, 2018 , with 1,369 contracts trading so far today, representing approximately 136,900 underlying shares of ABEO. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Abeona Therapeutics Inc (Symbol: ABEO), where a total of 6,008 contracts have traded so far, representing approximately 600,800 underlying shares. That amounts to about 73.7% of ABEO's average daily trading volume over the past month of 814,830 shares. | Particularly high volume was seen for the $20 strike call option expiring June 15, 2018 , with 1,369 contracts trading so far today, representing approximately 136,900 underlying shares of ABEO. Below is a chart showing ABEO's trailing twelve month trading history, with the $20 strike highlighted in orange: Textainer Group Holdings Ltd (Symbol: TGH) options are showing a volume of 1,360 contracts thus far today. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Abeona Therapeutics Inc (Symbol: ABEO), where a total of 6,008 contracts have traded so far, representing approximately 600,800 underlying shares. | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Abeona Therapeutics Inc (Symbol: ABEO), where a total of 6,008 contracts have traded so far, representing approximately 600,800 underlying shares. That amounts to about 73.7% of ABEO's average daily trading volume over the past month of 814,830 shares. Particularly high volume was seen for the $20 strike call option expiring June 15, 2018 , with 1,369 contracts trading so far today, representing approximately 136,900 underlying shares of ABEO. | Particularly high volume was seen for the $20 strike call option expiring June 15, 2018 , with 1,369 contracts trading so far today, representing approximately 136,900 underlying shares of ABEO. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Abeona Therapeutics Inc (Symbol: ABEO), where a total of 6,008 contracts have traded so far, representing approximately 600,800 underlying shares. That amounts to about 73.7% of ABEO's average daily trading volume over the past month of 814,830 shares. |
28088.0 | 2018-04-10 00:00:00 UTC | Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump | ABEO | https://www.nasdaq.com/articles/why-abeona-therapeutics-abeo-could-be-positioned-for-a-slump-2018-04-10 | nan | nan | Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Abeona Therapeutics Inc.ABEO , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ABEO.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen three estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of 68 cents a share a month ago to its current level of a loss of 79 cents.
Also, for the current quarter, Abeona Therapeutics has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 19 cents a share from a loss of 16 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 7.3% in the past month.
Abeona Therapeutics Inc. Price and Consensus
Abeona Therapeutics Inc. Price and Consensus | Abeona Therapeutics Inc. Quote
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait.
If you are still interested in the Medical - Biomedical and Genetics industry, you may instead consider a better-ranked stock - Biohaven Pharmaceutical Holding Company Ltd. BHVN . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today's Zacks #1 Rank stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
BIOHAVEN PHARM (BHVN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One such stock that you may want to consider dropping is Abeona Therapeutics Inc.ABEO , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ABEO. Also, for the current quarter, Abeona Therapeutics has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 19 cents a share from a loss of 16 cents over the past 30 days. | Abeona Therapeutics Inc. Price and Consensus Abeona Therapeutics Inc. Price and Consensus | Abeona Therapeutics Inc. Quote So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait. Click to get this free report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report BIOHAVEN PHARM (BHVN): Free Stock Analysis Report To read this article on Zacks.com click here. One such stock that you may want to consider dropping is Abeona Therapeutics Inc.ABEO , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. | Also, for the current quarter, Abeona Therapeutics has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 19 cents a share from a loss of 16 cents over the past 30 days. Abeona Therapeutics Inc. Price and Consensus Abeona Therapeutics Inc. Price and Consensus | Abeona Therapeutics Inc. Quote So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait. Click to get this free report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report BIOHAVEN PHARM (BHVN): Free Stock Analysis Report To read this article on Zacks.com click here. | Also, for the current quarter, Abeona Therapeutics has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 19 cents a share from a loss of 16 cents over the past 30 days. Abeona Therapeutics Inc. Price and Consensus Abeona Therapeutics Inc. Price and Consensus | Abeona Therapeutics Inc. Quote So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait. One such stock that you may want to consider dropping is Abeona Therapeutics Inc.ABEO , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. |
28089.0 | 2018-02-08 00:00:00 UTC | Thursday's ETF Movers: GDXJ, XBI | ABEO | https://www.nasdaq.com/articles/thursdays-etf-movers-gdxj-xbi-2018-02-08 | nan | nan | In trading on Thursday, the Junior Gold Miners ETF ( GDXJ ) is outperforming other ETFs, up about 0.7% on the day. Components of that ETF showing particular strength include shares of Oceanagold (OGC.CA), up about 5.9% and shares of Argonaut Gold (AR.CA), up about 5% on the day.
And underperforming other ETFs today is the SPDR S&P Biotech ETF ( XBI ), down about 3.5% in Thursday afternoon trading. Among components of that ETF with the weakest showing on Thursday were shares of Enanta Pharmaceuticals ( ENTA ), lower by about 13.8%, and shares of Abeona Therapeutics ( ABEO ), lower by about 13.1% on the day.
VIDEO: Thursday's ETF Movers: GDXJ, XBI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among components of that ETF with the weakest showing on Thursday were shares of Enanta Pharmaceuticals ( ENTA ), lower by about 13.8%, and shares of Abeona Therapeutics ( ABEO ), lower by about 13.1% on the day. Components of that ETF showing particular strength include shares of Oceanagold (OGC.CA), up about 5.9% and shares of Argonaut Gold (AR.CA), up about 5% on the day. VIDEO: Thursday's ETF Movers: GDXJ, XBI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among components of that ETF with the weakest showing on Thursday were shares of Enanta Pharmaceuticals ( ENTA ), lower by about 13.8%, and shares of Abeona Therapeutics ( ABEO ), lower by about 13.1% on the day. In trading on Thursday, the Junior Gold Miners ETF ( GDXJ ) is outperforming other ETFs, up about 0.7% on the day. VIDEO: Thursday's ETF Movers: GDXJ, XBI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among components of that ETF with the weakest showing on Thursday were shares of Enanta Pharmaceuticals ( ENTA ), lower by about 13.8%, and shares of Abeona Therapeutics ( ABEO ), lower by about 13.1% on the day. In trading on Thursday, the Junior Gold Miners ETF ( GDXJ ) is outperforming other ETFs, up about 0.7% on the day. VIDEO: Thursday's ETF Movers: GDXJ, XBI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among components of that ETF with the weakest showing on Thursday were shares of Enanta Pharmaceuticals ( ENTA ), lower by about 13.8%, and shares of Abeona Therapeutics ( ABEO ), lower by about 13.1% on the day. In trading on Thursday, the Junior Gold Miners ETF ( GDXJ ) is outperforming other ETFs, up about 0.7% on the day. Components of that ETF showing particular strength include shares of Oceanagold (OGC.CA), up about 5.9% and shares of Argonaut Gold (AR.CA), up about 5% on the day. |
28090.0 | 2018-02-07 00:00:00 UTC | Why Abeona Therapeutics Jumped 14% on Wednesday | ABEO | https://www.nasdaq.com/articles/why-abeona-therapeutics-jumped-14-wednesday-2018-02-07 | nan | nan | What happened
Abeona Therapeutics (NASDAQ: ABEO) jumped 14% on Wednesday after the company released data from its phase 1/2 trial testing ABO-101, a gene therapy treatment for patients with MPS IIIB, commonly referred to as Sanfilippo syndrome Type B.
So what
The data was only from the first patient enrolled in the trial, but it looks promising nonetheless. In addition to being well tolerated, without side effects through the 30 days of follow-up, there were also early signs that the treatment is working.
ABO-101, which is designed to express N-acetyl-(alpha)-D-glucosaminidase (NAGLU) that degrades heparan sulfate and is mutated in patients with Sanfilippo Type B, increased the NAGLU enzyme activity by more than 300-fold over baseline at 30 days after the treatment. The increased activity resulted in reduced heparan sulfate levels of 50% to 69% in the patient's cerebral spinal fluid, urine, plasma and urinary total glycosaminoglycan. The reduction in cerebral spinal fluid is especially significant since issues with Sanfilippo patients are mainly neurological.
Now what
Today's data is certainly good news for Abeona, but investors will need to see more before calling the treatment a success. The company plans to test two more patients at this dose level before testing a higher dose on three more patients.
Despite its nomenclature, ABO-101 isn't Abeona's most advanced gene therapy; ABO-102 for Sanfilippo syndrome Type A is further along , as is EB-101. Abeona is testing the latter for recessive dystrophic epidermolysis bullosa, which is set to enter phase 3 development this year.
Simply due to their ability to generate revenue sooner, investors should be more focused on EB-101 and ABO-102, with ABO-101 as icing on the cake -- or a potential backup plan if things don't work out with the lead therapies.
10 stocks we like better than Abeona Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abeona Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 5, 2018
Brian Orelli has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Abeona Therapeutics (NASDAQ: ABEO) jumped 14% on Wednesday after the company released data from its phase 1/2 trial testing ABO-101, a gene therapy treatment for patients with MPS IIIB, commonly referred to as Sanfilippo syndrome Type B. Now what Today's data is certainly good news for Abeona, but investors will need to see more before calling the treatment a success. Despite its nomenclature, ABO-101 isn't Abeona's most advanced gene therapy; ABO-102 for Sanfilippo syndrome Type A is further along , as is EB-101. | What happened Abeona Therapeutics (NASDAQ: ABEO) jumped 14% on Wednesday after the company released data from its phase 1/2 trial testing ABO-101, a gene therapy treatment for patients with MPS IIIB, commonly referred to as Sanfilippo syndrome Type B. Despite its nomenclature, ABO-101 isn't Abeona's most advanced gene therapy; ABO-102 for Sanfilippo syndrome Type A is further along , as is EB-101. Now what Today's data is certainly good news for Abeona, but investors will need to see more before calling the treatment a success. | What happened Abeona Therapeutics (NASDAQ: ABEO) jumped 14% on Wednesday after the company released data from its phase 1/2 trial testing ABO-101, a gene therapy treatment for patients with MPS IIIB, commonly referred to as Sanfilippo syndrome Type B. 10 stocks we like better than Abeona Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Now what Today's data is certainly good news for Abeona, but investors will need to see more before calling the treatment a success. | What happened Abeona Therapeutics (NASDAQ: ABEO) jumped 14% on Wednesday after the company released data from its phase 1/2 trial testing ABO-101, a gene therapy treatment for patients with MPS IIIB, commonly referred to as Sanfilippo syndrome Type B. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abeona Therapeutics wasn't one of them! Now what Today's data is certainly good news for Abeona, but investors will need to see more before calling the treatment a success. |
28091.0 | 2018-01-23 00:00:00 UTC | Commit To Purchase Abeona Therapeutics At $12.50, Earn 16.4% Annualized Using Options | ABEO | https://www.nasdaq.com/articles/commit-purchase-abeona-therapeutics-1250-earn-164-annualized-using-options-2018-01-23 | nan | nan | Investors considering a purchase of Abeona Therapeutics Inc (Symbol: ABEO) stock, but cautious about paying the going market price of $15.45/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $12.50 strike, which has a bid at the time of this writing of $1.35. Collecting that bid as the premium represents a 10.8% return against the $12.50 commitment, or a 16.4% annualized rate of return (at Stock Options Channel we call this the YieldBoost ).
Selling a put does not give an investor access to ABEO's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $12.50 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless Abeona Therapeutics Inc sees its shares decline 18.6% and the contract is exercised (resulting in a cost basis of $11.15 per share before broker commissions, subtracting the $1.35 from $12.50), the only upside to the put seller is from collecting that premium for the 16.4% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for Abeona Therapeutics Inc, and highlighting in green where the $12.50 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the September put at the $12.50 strike for the 16.4% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Abeona Therapeutics Inc (considering the last 253 trading day closing values as well as today's price of $15.45) to be 76%. For other put options contract ideas at the various different available expirations, visit the ABEO Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Tuesday, the put volume among S&P 500 components was 1.72M contracts, with call volume at 1.72M, for a put:call ratio of 0.70 so far for the day, which is above normal compared to the long-term median put:call ratio of .65. In other words, if we look at the number of call buyers and then use the long-term median to project the number of put buyers we'd expect to see, we're actually seeing more put buyers than expected out there in options trading so far today. Find out which 15 call and put options traders are talking about today .
Top YieldBoost Puts of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors considering a purchase of Abeona Therapeutics Inc (Symbol: ABEO) stock, but cautious about paying the going market price of $15.45/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for Abeona Therapeutics Inc, and highlighting in green where the $12.50 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the September put at the $12.50 strike for the 16.4% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Abeona Therapeutics Inc (considering the last 253 trading day closing values as well as today's price of $15.45) to be 76%. | Below is a chart showing the trailing twelve month trading history for Abeona Therapeutics Inc, and highlighting in green where the $12.50 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the September put at the $12.50 strike for the 16.4% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Abeona Therapeutics Inc (considering the last 253 trading day closing values as well as today's price of $15.45) to be 76%. Investors considering a purchase of Abeona Therapeutics Inc (Symbol: ABEO) stock, but cautious about paying the going market price of $15.45/share, might benefit from considering selling puts among the alternative strategies at their disposal. | Below is a chart showing the trailing twelve month trading history for Abeona Therapeutics Inc, and highlighting in green where the $12.50 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the September put at the $12.50 strike for the 16.4% annualized rate of return represents good reward for the risks. Investors considering a purchase of Abeona Therapeutics Inc (Symbol: ABEO) stock, but cautious about paying the going market price of $15.45/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ABEO's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. | Investors considering a purchase of Abeona Therapeutics Inc (Symbol: ABEO) stock, but cautious about paying the going market price of $15.45/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for Abeona Therapeutics Inc, and highlighting in green where the $12.50 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the September put at the $12.50 strike for the 16.4% annualized rate of return represents good reward for the risks. Selling a put does not give an investor access to ABEO's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. |
28092.0 | 2017-12-19 00:00:00 UTC | 7 Stocks Ready to Jump Another 30% in 2018 | ABEO | https://www.nasdaq.com/articles/7-stocks-ready-to-jump-another-30-in-2018-2017-12-19 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
For the 86th time since the 2016 presidential election, the Dow Jones industrial average closed at a record high on Monday, December 18th. This means that 34% of all trading sessions in 2017 closed at new highs and there are still eight trading days left in the year (251 total trading days in 2017).
Source: Shutterstock
The S&P 500 also increased on Monday by roughly 0.5%, to finish at its own record high of 2,690. The market continues to gain momentum heading into 2018 as the long-awaited tax bill inches closer to passing. Many expect a deal to be achieved before the end of the year.
As a result, the S&P 500 has climbed 20.1% in 2017 while the Dow Jones has moved 25.4% higher. Many academics are calling this bull market a "momentum effect" which is simply the tendency of winning stocks to keep winning and losing stocks to keep losing due to investor behavioral biases. It is based on the idea that once a stock establishes a trend, it is more likely to continue in that direction instead of moving against the drift even if the stock's valuation becomes unreasonable.
Amazon (AMZN) Gears Up for 2nd Digital Day Sale on Dec 29
With no signs of this "momentum market" cooling down anytime soon, I decided to search for momentum stocks that have (1) increased by at least 30% in 2017 and (2) still have another 30% upside potential going into 2018.
I determined which stocks still have upside potential by using the finbox.io Fair Value estimate . This estimate is derived by applying a combination of valuation and risk models like discounted cash flow analysis, dividend discount model, comparable companies multiples, earnings power value and more.
To find these momentum stocks, I applied the following filters in finbox.io's stock screener :
YTD Stock Price Change > 30.0%
finbox.io Upside > 30.0%
Fair Value Uncertainty is not very high
Market Capitalization > $500 million
The latest results can be found here: Momentum Stock Screen .
Following are the seven momentum stocks I found that could rise another 30% in 2018.
Stocks Ready to Jump Another 30% in 2018: Abeona Therapeutics Inc (ABEO)
Abeona Therapeutics Inc (NASDAQ: ABEO ), a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015.
4 Retail Stocks to Buy on Strong Industry Sales for November
Maxim Group raised its fair value target to $17.00 per share on July 18th citing positive prospects for its lead gene therapy candidate for the treatment of an inherited disorder characterized by large painful blisters on the skin. The stock sky-rocketed when the FDA confirmed Abeona as the lead cell therapy candidate on August 29th.
source: finbox.io
Shares of the biopharma company are up an enormous 250% since the beginning of the year. The stock last traded at $15.20 as of Monday afternoon and five separate valuation analyses imply there is still another +60% upside potential going into 2018.
Stocks Ready to Jump Another 30% in 2018: Lantheus Holdings Inc (LNTH)
Lantheus Holdings Inc (NASDAQ: LNTH ) develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide. The company sells its products to hospitals, clinics, group practices, and radiopharmacies.
5 Secret Santa ETFs and Stocks to Buy Ahead of Christmas
Lantheus inked a deal with GE Healthcare on February 21st for the continued development of an investigational agent that could improve the diagnosis of coronary artery disease. The partnership news led to a number of upgrades from analysts covering the company and the stock has continued to reach new heights.
source: finbox.io
Shares of Lantheus are up 125% year-to-date and finbox.io's fair value estimate of $25.27 per share calculated from eight cash flow models imply another 23.6% upside. The average price target from four Wall Street analysts of $24.50 also implies similar upside.
Stocks Ready to Jump Another 30% in 2018: Ultra Clean Holdings Inc (UCTT)
Ultra Clean Holdings Inc (NASDAQ: UCTT ) designs, manufactures, and tests production tools, modules, and subsystems for the semiconductor capital equipment and equipment industry segments primarily in North America, Asia, and Europe. Ultra Clean was founded in 1991 and is headquartered in Hayward, California.
3 Casino Stocks to Buy Now
The Semiconductor & Semiconductor Equipment industry has significantly outperformed this year reporting 42% YoY earnings growth in the latest quarter. As a result, Ultra Clean has seen increasing demand for its tools and its stock has appreciated 115% in 2017.
source: finbox.io
However, Ultra Clean's shares have pulled back recently leading to Stifel upgrading the company to a "Buy" rating on December 4th. Stifel noted that Ultra Clean is well positioned to benefit from another strong year in wafer fan equipment and display spending. Finbox.io's nine separate cash flow analyses support the recent buy rating.
Stocks Ready to Jump Another 30% in 2018: Adamas Pharmaceuticals Inc (ADMS)
Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company's product portfolio comprises therapies for the treatment of patients with Parkinson's disease, Alzheimer's disease and patients with epilepsy.
21st Century Fox (FOXA) Stock Shares Surge After Disney (DIS) Deal Made Official
The FDA approved Adamas' new Parkinson's therapy in August. However, shares were relatively flat until Steve Cohen's Point72 Asset Management reported a 5.1% stake in the company on October 30th. In addition, Evercore upgraded its rating on the stock to Outperform along with an $85.00 per share price target. Shares of the company eventually reached as high as $37.15 per share.
source: finbox.io
Adamas' stock is currently trading at $31.70 per share as of Monday, more than 100% higher since the beginning of the year. What's more, finbox.io's six valuation analyses suggest that shares could increase another 50% in 2018.
Stocks Ready to Jump Another 30% in 2018: Plug Power Inc (PLUG)
Plug Power Inc (NASDAQ: PLUG ) engages in the design, development, and manufacture of hydrogen fuel cell systems primarily for the material handling and stationary power markets in the United States. The company offers its products to businesses and government agencies through direct product sales force, original equipment manufacturers, and dealer networks.
Fed Hikes Rate: 4 Stocks to Add Value to Your Portfolio
Plug Power stock jumped nearly 75% on April 5th following news that it signed an agreement with Amazon.com, Inc. (NASDAQ: AMZN ) for multi-site GenKey deployments. The deal involved the company supplying batteries to power forklifts used by Amazon in the online retailer's warehouses in exchange for the right to buy up to 23% of Plug Power.
source: finbox.io
Shares of the company are trading nearly 80% higher on a year-to-date basis. But the stock price could end up trading another 47.1% higher in 2018 based on Plug Power's future cash flows.
Stocks Ready to Jump Another 30% in 2018: Arcos Dorados Holding Inc (ARCO)
Arcos Dorados Holdings Inc (NYSE: ARCO ) operates as a franchisee of McDonald's restaurants. It has the exclusive right to own, operate, and grant franchises of McDonald's restaurants in 20 countries and territories in Latin America and the Caribbean. As of December 31, 2016, the company operated and franchised 2,156 McDonald's branded restaurants.
5 Funds to Buy on Second-Best Small Business Sentiment
Shares of Arcos Dorados have steadily increased throughout the year as favorable consumer recovery trends have played out across Brazil and Argentina in 2017. The franchisee has also benefited from lower beef prices.
source: finbox.io
Arcos Dorados' stock last traded at $9.85 as of Monday, near its 52-week high and nearly 40% higher year-to-date. On a fundamental basis, the company's stock is still trading at a 39.8% discount to finbox.io's intrinsic value.
Looking to next year, the company has signed international soccer superstar Neymar to an exclusive contract in front of the 2018 World Cup. Neymar will serve as an ambassador in Arcos Dorados' media and marketing campaigns related to next year's World Cup.
Stocks Ready to Jump Another 30% in 2018: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc (NASDAQ: SRPT ), a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
3 Value Stocks to Buy Ahead of 2018
On September 6th, the company's stock jumped by more than 15% in response to its announcement of positive results from a study assessing golodirsen in 53 boys with Duchenne muscular dystrophy. The company then reported Q3 sales of $46 million compared to $0 the previous year and lifted its full-year revenue guidance.
source: finbox.io
Shares of the biotech company are up 33.3% year-to-date and have momentum going into 2018. Five of finbox.io's valuation models calculate an average fair value estimate of $67.13 per share implying almost 25% upside potential.
7 Stocks Ready to Jump Another 30% in 2018
In conclusion, the table below ranks all seven stocks by their year-to-date returns.
Stocks Ready To Jump Another 30% in 2018 Ticker Name YTD Stock Return Upside (finbox.io) ABEO Abeona Therapeutics Inc. 266.7% 58.2% LNTH Lantheus Holdings, Inc. 124.5% 30.1% UCTT Ultra Clean Holdings, Inc. 114.9% 36.9% ADMS Adamas Pharmaceuticals, Inc. 103.9% 41.2% PLUG Plug Power, Inc. 78.8% 51.3% ARCO Arcos Dorados Holdings Inc. 77.7% 38.9% SRPT Sarepta Therapeutics, Inc. 69.0% 33.3%
This momentum investing strategy is not for the faint-hearted as it typically calls for investors to "buy high". Many value investors dislike the strategy because it can often result in purchasing shares at a premium valuation.
6 High Tax Paying Stocks to Buy Now
However, this is why I added finbox.io's fair estimates to the stock screen to make sure each stock is still trading at a reasonable level. Therefore, investors looking to ride the current bull market into 2018 may want to consider the companies listed above.
This is not a buy or sell recommendation on any security mentioned.
Compare Brokers
The post 7 Stocks Ready to Jump Another 30% in 2018 appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks Ready to Jump Another 30% in 2018: Abeona Therapeutics Inc (ABEO) Abeona Therapeutics Inc (NASDAQ: ABEO ), a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. The stock sky-rocketed when the FDA confirmed Abeona as the lead cell therapy candidate on August 29th. | Stocks Ready to Jump Another 30% in 2018: Abeona Therapeutics Inc (ABEO) Abeona Therapeutics Inc (NASDAQ: ABEO ), a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Stocks Ready To Jump Another 30% in 2018 Ticker Name YTD Stock Return Upside (finbox.io) ABEO Abeona Therapeutics Inc. 266.7% 58.2% LNTH Lantheus Holdings, Inc. 124.5% 30.1% UCTT Ultra Clean Holdings, Inc. 114.9% 36.9% ADMS Adamas Pharmaceuticals, Inc. 103.9% 41.2% PLUG Plug Power, Inc. 78.8% 51.3% ARCO Arcos Dorados Holdings Inc. 77.7% 38.9% SRPT Sarepta Therapeutics, Inc. 69.0% 33.3% This momentum investing strategy is not for the faint-hearted as it typically calls for investors to "buy high". The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. | Stocks Ready To Jump Another 30% in 2018 Ticker Name YTD Stock Return Upside (finbox.io) ABEO Abeona Therapeutics Inc. 266.7% 58.2% LNTH Lantheus Holdings, Inc. 124.5% 30.1% UCTT Ultra Clean Holdings, Inc. 114.9% 36.9% ADMS Adamas Pharmaceuticals, Inc. 103.9% 41.2% PLUG Plug Power, Inc. 78.8% 51.3% ARCO Arcos Dorados Holdings Inc. 77.7% 38.9% SRPT Sarepta Therapeutics, Inc. 69.0% 33.3% This momentum investing strategy is not for the faint-hearted as it typically calls for investors to "buy high". Stocks Ready to Jump Another 30% in 2018: Abeona Therapeutics Inc (ABEO) Abeona Therapeutics Inc (NASDAQ: ABEO ), a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. | Stocks Ready To Jump Another 30% in 2018 Ticker Name YTD Stock Return Upside (finbox.io) ABEO Abeona Therapeutics Inc. 266.7% 58.2% LNTH Lantheus Holdings, Inc. 124.5% 30.1% UCTT Ultra Clean Holdings, Inc. 114.9% 36.9% ADMS Adamas Pharmaceuticals, Inc. 103.9% 41.2% PLUG Plug Power, Inc. 78.8% 51.3% ARCO Arcos Dorados Holdings Inc. 77.7% 38.9% SRPT Sarepta Therapeutics, Inc. 69.0% 33.3% This momentum investing strategy is not for the faint-hearted as it typically calls for investors to "buy high". Stocks Ready to Jump Another 30% in 2018: Abeona Therapeutics Inc (ABEO) Abeona Therapeutics Inc (NASDAQ: ABEO ), a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. |
28093.0 | 2017-11-15 00:00:00 UTC | Health Care Sector Update for 11/15/2017: ABEO | ABEO | https://www.nasdaq.com/articles/health-care-sector-update-11152017-abeo-2017-11-15 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: +0.4%
ABT: -0.1%
MRK: -0.4%
AMGN: -0.4%
Health-care shares were mainly lower in pre-market trade Wednesday.
In health-care stocks news, Abeona Therapeutics ( ABEO ), a clinical-stage biopharmaceutical company, reported Wednesday Q3 net loss of $0.13 per share, compared to a loss of $0.08 per share in the prior year period.
Analysts polled by Capital IQ expected a net loss of $0.18 per share.
Shares were 0.4% lower at $169.68 pre-bell.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health-care stocks news, Abeona Therapeutics ( ABEO ), a clinical-stage biopharmaceutical company, reported Wednesday Q3 net loss of $0.13 per share, compared to a loss of $0.08 per share in the prior year period. Health-care shares were mainly lower in pre-market trade Wednesday. Analysts polled by Capital IQ expected a net loss of $0.18 per share. | In health-care stocks news, Abeona Therapeutics ( ABEO ), a clinical-stage biopharmaceutical company, reported Wednesday Q3 net loss of $0.13 per share, compared to a loss of $0.08 per share in the prior year period. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health-care stocks news, Abeona Therapeutics ( ABEO ), a clinical-stage biopharmaceutical company, reported Wednesday Q3 net loss of $0.13 per share, compared to a loss of $0.08 per share in the prior year period. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health-care stocks news, Abeona Therapeutics ( ABEO ), a clinical-stage biopharmaceutical company, reported Wednesday Q3 net loss of $0.13 per share, compared to a loss of $0.08 per share in the prior year period. Health-care shares were mainly lower in pre-market trade Wednesday. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
28094.0 | 2017-10-18 00:00:00 UTC | Abeona Therapeutics (ABEO) Surges: Stock Moves 7.2% Higher | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-abeo-surges%3A-stock-moves-7.2-higher-2017-10-18 | nan | nan | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company-as the stock is now up 4.1% in the past one-month time frame.
The move came after the company announced that it has priced an underwritten public offering of five million shares of common stock at a public offering at $16 per share, which is expected to generate gross proceeds of roughly $80 million.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Abeona Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Abeona Therapeutics Inc. Price
Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider Axovant Sciences Ltd. AXON , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is ABEO going up? Or down? Predict to see what others think: Up or Down
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Axovant Sciences Ltd. (AXON): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise more than 7% on the day. Abeona Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%. Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote Investors interested in the Medical - Biomedical and Genetics industry may consider Axovant Sciences Ltd. AXON , which has a Zacks Rank #1 (Strong Buy). | Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote Investors interested in the Medical - Biomedical and Genetics industry may consider Axovant Sciences Ltd. AXON , which has a Zacks Rank #1 (Strong Buy). Click to get this free report Axovant Sciences Ltd. (AXON): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise more than 7% on the day. | Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote Investors interested in the Medical - Biomedical and Genetics industry may consider Axovant Sciences Ltd. AXON , which has a Zacks Rank #1 (Strong Buy). Click to get this free report Axovant Sciences Ltd. (AXON): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise more than 7% on the day. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise more than 7% on the day. Click to get this free report Axovant Sciences Ltd. (AXON): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%. |
28095.0 | 2017-10-11 00:00:00 UTC | Health Care Sector Update for 10/11/2017: ABEO | ABEO | https://www.nasdaq.com/articles/health-care-sector-update-10112017-abeo-2017-10-11 | nan | nan | Top Health-care stocks:
JNJ: +0.4%
PFE: -0.3%
ABT: flat
MRK: flat
AMGN: flat
Health-care shares were mainly unchanged in pre-market trade on Wednesday.
In health-care stocks news, Abeona Therapeutics ( ABEO ) said Wednesday that it has enrolled two patients in its expansion of the ABO-102 phase 1/2 clinical trial in Mucopolysaccharidosis type IIIA disease, a severe, progressive disorder that affects the central nervous system.
Shares in the company were 2.8% higher in early trade. The stock has traded between $4.05 and $20.35 over the past 52 weeks.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health-care stocks news, Abeona Therapeutics ( ABEO ) said Wednesday that it has enrolled two patients in its expansion of the ABO-102 phase 1/2 clinical trial in Mucopolysaccharidosis type IIIA disease, a severe, progressive disorder that affects the central nervous system. Shares in the company were 2.8% higher in early trade. The stock has traded between $4.05 and $20.35 over the past 52 weeks. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In health-care stocks news, Abeona Therapeutics ( ABEO ) said Wednesday that it has enrolled two patients in its expansion of the ABO-102 phase 1/2 clinical trial in Mucopolysaccharidosis type IIIA disease, a severe, progressive disorder that affects the central nervous system. ABT: flat MRK: flat AMGN: flat Health-care shares were mainly unchanged in pre-market trade on Wednesday. | In health-care stocks news, Abeona Therapeutics ( ABEO ) said Wednesday that it has enrolled two patients in its expansion of the ABO-102 phase 1/2 clinical trial in Mucopolysaccharidosis type IIIA disease, a severe, progressive disorder that affects the central nervous system. ABT: flat MRK: flat AMGN: flat Health-care shares were mainly unchanged in pre-market trade on Wednesday. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health-care stocks news, Abeona Therapeutics ( ABEO ) said Wednesday that it has enrolled two patients in its expansion of the ABO-102 phase 1/2 clinical trial in Mucopolysaccharidosis type IIIA disease, a severe, progressive disorder that affects the central nervous system. Top Health-care stocks: Shares in the company were 2.8% higher in early trade. |
28096.0 | 2017-10-11 00:00:00 UTC | Here's Why Abeona Therapeutics Inc. Stock Spiked Today | ABEO | https://www.nasdaq.com/articles/heres-why-abeona-therapeutics-inc-stock-spiked-today-2017-10-11 | nan | nan | What happened
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) , a clinical-stage biotech developing novel gene therapies to treat rare genetic disorders, popped as much as 14% higher on Wednesday morning after an important announcement concerning a candidate that succeeded in an early-stage trial earlier this month. Although the initiation of a pivotal expansion to the study is indeed good news, that pop had fizzled to a gain of 3.3% as of 12:03 p.m. EDT.
So what
Abeona Therapeutics is developing ABO-102 as a potential gene therapy for the treatment of MPS IIIA, a rare metabolic disease caused by a faulty SGSH gene. There are no available treatments for the life-threatening disorder, but results of a small, early stage clinical trial announced earlier this month suggest Abeona could have the first.
MPS IIIA patients seldom survive past their second decade because their bodies can't break down heparin sulfate, which builds up in the body, leading to liver and brain damage. One year after receiving a single injection of ABO-102, though, two patients demonstrated a 69% heparin sulfate reduction in the fluid that bathes the brain, and dramatically reduced liver volumes as well.
Investors were thrilled with Wednesday's announcement because the company has expanded the ongoing trial in a way that could be enough to support its first new drug application. Because the highest dose appeared well-tolerated, the highest-dose cohort will be used to support the new drug application. And since even the lower dose appears highly effective, ABO-102 has a solid shot at an eventual approval.
Now what
ABO-102 is just one of several irons Abeona has in the fire at the moment. In August, its shares jumped higher when the FDA granted EB-101 a breakthrough therapy designation for the treatment of recessive dystrophic epidermolysis bullosa, a debilitating skin disease. The company will begin a phase 3 study for it early next year.
Although the stock has already soared by about 337% this year, its recent market cap of about $856 million suggests it could provide market-beating long-term gains if either of these candidates succeeds
10 stocks we like better than Abeona Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abeona Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) , a clinical-stage biotech developing novel gene therapies to treat rare genetic disorders, popped as much as 14% higher on Wednesday morning after an important announcement concerning a candidate that succeeded in an early-stage trial earlier this month. So what Abeona Therapeutics is developing ABO-102 as a potential gene therapy for the treatment of MPS IIIA, a rare metabolic disease caused by a faulty SGSH gene. There are no available treatments for the life-threatening disorder, but results of a small, early stage clinical trial announced earlier this month suggest Abeona could have the first. | What happened Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) , a clinical-stage biotech developing novel gene therapies to treat rare genetic disorders, popped as much as 14% higher on Wednesday morning after an important announcement concerning a candidate that succeeded in an early-stage trial earlier this month. So what Abeona Therapeutics is developing ABO-102 as a potential gene therapy for the treatment of MPS IIIA, a rare metabolic disease caused by a faulty SGSH gene. There are no available treatments for the life-threatening disorder, but results of a small, early stage clinical trial announced earlier this month suggest Abeona could have the first. | What happened Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) , a clinical-stage biotech developing novel gene therapies to treat rare genetic disorders, popped as much as 14% higher on Wednesday morning after an important announcement concerning a candidate that succeeded in an early-stage trial earlier this month. So what Abeona Therapeutics is developing ABO-102 as a potential gene therapy for the treatment of MPS IIIA, a rare metabolic disease caused by a faulty SGSH gene. Although the stock has already soared by about 337% this year, its recent market cap of about $856 million suggests it could provide market-beating long-term gains if either of these candidates succeeds 10 stocks we like better than Abeona Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | What happened Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) , a clinical-stage biotech developing novel gene therapies to treat rare genetic disorders, popped as much as 14% higher on Wednesday morning after an important announcement concerning a candidate that succeeded in an early-stage trial earlier this month. So what Abeona Therapeutics is developing ABO-102 as a potential gene therapy for the treatment of MPS IIIA, a rare metabolic disease caused by a faulty SGSH gene. There are no available treatments for the life-threatening disorder, but results of a small, early stage clinical trial announced earlier this month suggest Abeona could have the first. |
28097.0 | 2017-10-11 00:00:00 UTC | 2 Bullish and 2 Bearish Charts to Watch | ABEO | https://www.nasdaq.com/articles/2-bullish-and-2-bearish-charts-watch-2017-10-11 | nan | nan | By Harry Boxer, TheTechTrader.com
Here are two stocks breaking out, and two others in bearish consolidations that are looking lower.
On the long side, Abeona Therapeutics Inc. (ABEO) broke through prior resistance at $18.90 on Tuesday and sailed up 14%, or $2.45, closing at $19.95 on heavy volume of 2.4 million shares traded. Worth noting: The technical angle of price as it has ascended shows that its trajectory up the chart has accelerated. That action, coupled with large volume on a breakout day, provides good reason to watch this stock closely. The gene therapy company has had an amazing run recently, enjoying positive market reactions to its August 22 earnings announcement, FDA news and clinical trials data. Next targets: $23 and $28.
Nutanix, Inc. (NTNX) soared on analyst enthusiasm, jumping $2.30, or nearly 10%, to close at $25.61 on huge volume of 15.5 million shares traded. The cloud OS stock broke out of a nearly 3-month consolidation formed in the $20-$25 zone. Having now closed above resistance formed at the September 22 high of $24.97, price may now be filling the significant gap created at earnings on March 3. Next targets are at $28 and $32.
On the short side, Hasbro, Inc. (HAS) lost 43 cents, closing at $96.19 on 644,100 shares traded Tuesday. After reaching an all-time high of $116.20 on July 21, price began falling with the entertainment company's 2Q earnings announcement and formed a bear wedge consolidation pattern in the $91.50-$100 zone that has not yet broken down. Next targets: mid-$80s and then high-$70s.
Dave & Buster's Entertainment, Inc. (PLAY) declined 72 cents and closed at $48.16 on 1.2 million shares traded. The stock reached an all-time high of $73.48 on June 8. Price broke below its last bear wedge on October 2 and has been consolidating over the last week around the $48 level to form another bear wedge. Price has not been this low since December of last year. The stock has lost 33% of its value since June and may probe the $40-42 zone in the near future.
See Harry's video chart analysis on these stocks.
No holdings.
Harry Boxer is founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis, and live chart presentations.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On the long side, Abeona Therapeutics Inc. (ABEO) broke through prior resistance at $18.90 on Tuesday and sailed up 14%, or $2.45, closing at $19.95 on heavy volume of 2.4 million shares traded. The gene therapy company has had an amazing run recently, enjoying positive market reactions to its August 22 earnings announcement, FDA news and clinical trials data. After reaching an all-time high of $116.20 on July 21, price began falling with the entertainment company's 2Q earnings announcement and formed a bear wedge consolidation pattern in the $91.50-$100 zone that has not yet broken down. | On the long side, Abeona Therapeutics Inc. (ABEO) broke through prior resistance at $18.90 on Tuesday and sailed up 14%, or $2.45, closing at $19.95 on heavy volume of 2.4 million shares traded. On the short side, Hasbro, Inc. (HAS) lost 43 cents, closing at $96.19 on 644,100 shares traded Tuesday. After reaching an all-time high of $116.20 on July 21, price began falling with the entertainment company's 2Q earnings announcement and formed a bear wedge consolidation pattern in the $91.50-$100 zone that has not yet broken down. | On the long side, Abeona Therapeutics Inc. (ABEO) broke through prior resistance at $18.90 on Tuesday and sailed up 14%, or $2.45, closing at $19.95 on heavy volume of 2.4 million shares traded. After reaching an all-time high of $116.20 on July 21, price began falling with the entertainment company's 2Q earnings announcement and formed a bear wedge consolidation pattern in the $91.50-$100 zone that has not yet broken down. Harry Boxer is founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis, and live chart presentations. | On the long side, Abeona Therapeutics Inc. (ABEO) broke through prior resistance at $18.90 on Tuesday and sailed up 14%, or $2.45, closing at $19.95 on heavy volume of 2.4 million shares traded. The cloud OS stock broke out of a nearly 3-month consolidation formed in the $20-$25 zone. On the short side, Hasbro, Inc. (HAS) lost 43 cents, closing at $96.19 on 644,100 shares traded Tuesday. |
28098.0 | 2017-10-11 00:00:00 UTC | Are Options Traders Betting on a Big Move in Abeona Therapeutics (ABEO) Stock? | ABEO | https://www.nasdaq.com/articles/are-options-traders-betting-on-a-big-move-in-abeona-therapeutics-abeo-stock-2017-10-11 | nan | nan | Investors in Abeona Therapeutics Inc. ABEO need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 15 th 2017 $10 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Abeona Therapeutics, but what is the fundamental picture for the company? Currently, Abeona Therapeutics is a Zacks Rank #4 (Sell) in the Medical - Biomedical and Genetics industry that ranks in the Bottom 42% of our Zacks Industry Rank. Over the last 60 days, the current year Zacks Consensus Estimate has seen no upward or downward revision. The net effect has been taken by the Zacks Consensus Estimate going to a loss of 16 cents from a loss of 12 cents in that period.
Given the way analysts feel about Abeona Therapeutics right now, this huge implied volatility could mean there's a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Looking to Trade Options?
Each week, our very own Dave Bartosiak gives his top options trades. Check out his recent live analysis and options trade for the NFLXearnings report completely free. See it here: Trading Netflix's (NFLX) Earnings with Options or check out the embedded video below for more details:
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors in Abeona Therapeutics Inc. ABEO need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for Abeona Therapeutics, but what is the fundamental picture for the company? Currently, Abeona Therapeutics is a Zacks Rank #4 (Sell) in the Medical - Biomedical and Genetics industry that ranks in the Bottom 42% of our Zacks Industry Rank. | Click to get this free report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Investors in Abeona Therapeutics Inc. ABEO need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for Abeona Therapeutics, but what is the fundamental picture for the company? | Given the way analysts feel about Abeona Therapeutics right now, this huge implied volatility could mean there's a trade developing. Investors in Abeona Therapeutics Inc. ABEO need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for Abeona Therapeutics, but what is the fundamental picture for the company? | Given the way analysts feel about Abeona Therapeutics right now, this huge implied volatility could mean there's a trade developing. Investors in Abeona Therapeutics Inc. ABEO need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for Abeona Therapeutics, but what is the fundamental picture for the company? |
28099.0 | 2017-09-29 00:00:00 UTC | Bull bet on Abeona | ABEO | https://www.nasdaq.com/articles/bull-bet-abeona-2017-09-29 | nan | nan | Option traders are betting on a rise in shares of Abeona Therapeutics ( ABEO ) Friday. So far, 1,052 contracts of the Oct. 22.50 call have changed hands, against open interest of 142 contracts. All of today's volume has been at the high-end of the bid-ask spread, indicating that these new contracts were initiated from the buy side.
InvestorsKeyhole Trade Alert
IK-> The technicals for ABEO ($17.13 up $0.18) are bullish with an upward trend. The stock has support about $15.15. Look at the Nov. 10/12.50 bull-put spread for a 20-cent credit. That's an 8.7% return and the stock has to fall by 27.0% to cause a problem. [InvestorsKeyhole, various news and data services]
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Originally published on InvestorsObserver.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Option traders are betting on a rise in shares of Abeona Therapeutics ( ABEO ) Friday. InvestorsKeyhole Trade Alert IK-> The technicals for ABEO ($17.13 up $0.18) are bullish with an upward trend. All of today's volume has been at the high-end of the bid-ask spread, indicating that these new contracts were initiated from the buy side. | Option traders are betting on a rise in shares of Abeona Therapeutics ( ABEO ) Friday. InvestorsKeyhole Trade Alert IK-> The technicals for ABEO ($17.13 up $0.18) are bullish with an upward trend. [InvestorsKeyhole, various news and data services] The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Option traders are betting on a rise in shares of Abeona Therapeutics ( ABEO ) Friday. InvestorsKeyhole Trade Alert IK-> The technicals for ABEO ($17.13 up $0.18) are bullish with an upward trend. All of today's volume has been at the high-end of the bid-ask spread, indicating that these new contracts were initiated from the buy side. | Option traders are betting on a rise in shares of Abeona Therapeutics ( ABEO ) Friday. InvestorsKeyhole Trade Alert IK-> The technicals for ABEO ($17.13 up $0.18) are bullish with an upward trend. All of today's volume has been at the high-end of the bid-ask spread, indicating that these new contracts were initiated from the buy side. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.